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1.1. Chronic diseases: definition and burden 
 
Chronic diseases are defined as diseases of long duration and generally slow progression (WHO, 
2005a). Chronic diseases are commonly used as a synonym for non-communicable diseases, denoting 
diseases that are not passed from one person to another. However, some communicable diseases (i.e. 
infectious diseases) can be chronic too, for example HIV infection. In this PhD-thesis, chronic diseases 
will be defined as Chronic Non-Communicable Diseases (CNCDs). The World Health Organization 
(WHO) addresses four major CNCDs, considered to have the highest share in CNCD morbidity and 
mortality1, namely cardiovascular disease (mainly coronary heart disease and stroke), cancer, chronic 
respiratory diseases (such as chronic obstructive pulmonary disease, asthma, pulmonary hypertension) 
and diabetes (WHO, 2014a). Mental disorders, such as depression or anxiety disorders, are generally 
not included in the concept of CNCDs, although these disorders have a large impact on society as well, 
in terms of population health and public expenditure (Lokkerbol et al., 2013). The disease burden 
associated with mental disorders is largely attributable to disability rather than mortality (Figure 1). In 
Belgium, 20% of the population uses psychotropic drugs (Van Herck & Van de Cloot, 2013). Besides, 
although not directly related to mortality, mental disorders, particularly depression and schizophrenia, 
are the major determinant of suicide (Ferrari et al., 2014; Harris & Barraclough, 1998; WHO, 2004). Half 
of the people with suicidal thoughts suffer from a mental disorder (Nock et al., 2009). Because of their 
high burden, some health scientists argue for mental disorders to be classified as one of the main types 
of CNCDs (Ivbijaro, 2011; Ngo et al., 2013). Therefore, in this PhD-thesis, the concept of CNCDs also 
includes mental disorders, unless otherwise stated.  
CNCDs are major contributors to the global burden of disease (Vos et al., 2015; WHO, 2014a). The 
burden of disease concept can be described as the impact of a health problem on an individual or a 
population usually measured by mortality and morbidity (called health burden) or the financial impact 
(called economic burden).  
 
1.1.1. Health burden 
Many measures are available to assess the health of a population, such as disease prevalence, disease 
incidence, mortality, life-expectancy, etc. Summary measures of population health are measures that 
combine information on mortality and morbidity to represent the health of a particular population into 
one single number (Field & Gold, 1998). A wide array of summary measures have been proposed, for 
example disability-free life expectancy, disability-adjusted life expectancy, health-adjusted life 
expectancy, or disability-adjusted life years (Murray, Salomon, & Mathers, 2000). The WHO measures 
the global health burden using the summary measure of disability-adjusted life year (DALY)2. The 
European burden of disease in 2012 consisted of 314,387,085 DALYs, or 348 DALYs per 1,000 people, 
                                                          
1 Morbidity data indicate the number of persons in a population who become ill (incidence) or are ill at a given time 
(prevalence) (Centers for Disease Control and Prevention, 2016b) Mortality data indicate numbers of deaths by 
place, time or cause (WHO, 2016c) 
2 DALYs are calculated as the sum of years of life lost due to early mortality and years lived with disability due to 
the disease or its consequences. As such, the DALY concept includes life-expectancy, disease 
incidence/prevalence, disability weight and average duration of the condition until death.   
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of which about 81% was due to CNCDs (Vos et al., 2015; WHO, 2014a) (Figure 1a). When expressing 
the burden in terms of mortality, CNCDs account for 88% of all deaths in Europe (WHO, 2014b) (Figure 
1b).  
 
Figure 1a: Proportions of causes of DALYs in Europe, 201 2 
 
CNCDs: Chronic Non-Communicable diseases; Source: (WHO, 2014a)  
 
Figure 1b: Proportions of causes of deaths in Europe, 2012  
 
CNCDs: Chronic Non-Communicable diseases; Source: (WHO, 2014b)  
 
Overall, the figures for Belgium are in line with the European average. The global disease burden is 
slightly lower than the European average (295 versus 348 DALYs per 1,000 persons), but the proportion 
of CNCDs within the global disease burden (85%) is slightly higher (WHO, 2012b). As CNCDs (except 
for mental disorders) especially develop at older age and as population is ageing3, an increase in CNCDs 
                                                          
3 According to the projections of the Organisation for Economic Co-operation and Development (OECD), by 2050 
the number of people aged 65 years or over will have increased by one third, resulting in a proportion of about 25%-
30% of the total population  
Cardiovascular 
disease; 27%
Other CNCDs; 22%Cancer; 15%
Mental disorders; 11%
Suicide attempt; 2%
Chronic respiratory diseases; 
4%
Diabetes Mellitus; 2%
Communicable diseases and injuries; 17%
Cardiovascular disease; 
48%
Other CNCDs; 12%
Cancer; 22%
Mental disorders; 1%
Suicide; 1%
Chronic respiratory diseases; 
4%
Diabetes Mellitus; 2% Communicable diseases and injuries; 10%
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can be expected for the coming decades. Currently, about 17% of the population in Europe aged 65+ 
suffers from diabetes and 46% from heart or blood pressure problems (Eurostat, 2015a). According to 
the Belgian Health Survey in 2013 (Scientific Institute of Public Health, 2013), one third of the Belgian 
population aged between 30 and 100 suffers from a longstanding illness, chronic condition or handicap.  
 
1.1.2. Economic burden 
Beside morbidity and mortality due to diseases, the burden of disease concept should be completed 
with a consideration of the economic impact on society in general and more specifically on the public 
health budget. Generally, according to an estimation of the European Union, currently 70 to 80% of a 
country’s total health expenditure is spent on treating chronic diseases (European Union, 2014). 
Assessing the economic burden of disease more in detail implies exploring the financial consequences 
of the disease, for the patient, employers, government or the society at large. Results of such economic 
burden of disease studies provide insight into the overall magnitude of economic losses and the key 
cost drivers, informing policy makers on the priority-setting of health interventions. Research guidelines 
usually recommend to use the societal viewpoint in cost-assessment studies, meaning that costs for the 
society at large should be addressed, including medical costs, as well as costs borne outside the health 
care sector, such as productivity losses and patient travel expenses (Drummond, Sculpher, Torrance, 
O'Brien, & Stoddart, 2015; Jonsson, 2009). The report on the global economic burden of CNCDs, 
published by the World Economic Forum and the Harvard School of Public Health (Bloom et al., 2011), 
stated that CNCDs have a considerable financial impact of which cardiovascular disease and mental 
health disorders are the dominant contributors. The total cost of cardiovascular disease in Europe, from 
a societal perspective, was assessed at €214 billion in 2015 (€169 billion in 20034), of which 62% were 
health care costs, 21% costs due to productivity loss and 17% informal care costs (i.e. opportunity cost 
of unpaid care) (Leal, Luengo-Fernandez, Gray, Petersen, & Rayner, 2006). The cost of depression in 
Europe – currently one of the major mental disorders – has been estimated to be €146 billion in 2015 
(€118 billion in 20044) of which 36% health care costs and 64% costs due to productivity loss (Sobocki, 
Jonsson, Angst, & Rehnberg, 2006). The total cost of cancer in Europe in 2015 was estimated to be 
€139 billion (€126 billion in 20094), of which 40% were health care costs, 41% were costs due to 
productivity loss and 19% were informal care costs (Luengo-Fernandez, Leal, Gray, & Sullivan, 2013). 
Lung cancer had the highest share in the total cost due to cancer, followed by breast cancer, colorectal 
cancer and prostate cancer.  
 
From the figures on the health as well as economic burden of CNCDs, it can be stated that these 
diseases put a high burden on society. This disease burden is expected to increase in the coming years, 
as the health burden, and as such the associated cost is estimated to double by 2030 (Atun et al., 2013). 
  
                                                          
4 Adjusted for inflation based on the Harmonised Indices of Consumer Prices (Eurostat, 2016) 
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1.2. Prevention in the domain of public health 
 
Promoting interventions to prevent and control CNCDs is important in order to lessen their impact on 
population health as well as on the public budget (WHO, 2015a), and is the main mission in the field of 
public health. Public health is defined as “all organised measures (whether public or private) to prevent 
disease, promote health, and prolong life among the population as a whole. Its activities aim to provide 
conditions in which people can be healthy and focus on entire populations, not on individual patients or 
diseases.“ (WHO, 2016e).  
 
1.2.1. Classification of prevention interventions 
Public health prevention interventions to manage and control CNCDs can be classified in several 
categories. The original public health classification of disease prevention was established by the 
Commission on Chronic Illness (1957) and adopted by other organisations, such as the World Health 
Organization (WHO) (2016f). It classifies prevention as primary, secondary or tertiary. Primary 
prevention tries to avoid the occurrence of an event/disease by reducing exposure of individuals to risk 
factors or by increasing their resistance to them. Secondary prevention is designed to reverse or retard 
progression of an existing condition and tertiary prevention is the management of a disease to prevent 
progress or recurrence, by treatment and rehabilitation programs. Although the goals of these three 
types of prevention appear to be straightforward, in practice this distinction is not always clear and 
overlap is common.  
According to Gordon (1983) this classification depends on a clear identification of the biologic origin of 
the particular disease. While the relation between cause and development of acute infections and 
injuries may be obvious, this is not the case for CNCDs which currently constitute the major cause of 
disability and death. Therefore, he proposed an alternative classification more closely linked to the 
practical considerations related to the application of prevention interventions. His classification was 
based on a benefit-risk point of view in that the probability of getting a disease must be weighed against 
the cost and risks of the prevention intervention. Therefore, he proposed three categories, representing 
the population groups to whom the interventions were directed and for whom they were thought to be 
most optimal: universal, selective and indicated prevention (Figure 2). These levels denote preventive 
interventions that are oriented respectively towards the whole population, those who are at increased 
risk of a disease or health problem, and those who already show signs of developing a disease or health 
problem. Universal prevention is the most generally applicable type, which is desirable for everybody. 
This category comprises all those measures that can be implemented for the general public and which, 
in many cases but certainly not all, can be applied without much professional advice or assistance. An 
example is a school-based program for the promotion of an adequate diet, delivered to e.g. all 
preshoolers in the school, a policy measure such as a sugar tax, or a media campaign for the promotion 
of change in sedentary behaviour,…. Because of the balance of benefits against risks and costs, some 
prevention interventions are recommended for only a subgroup of the population which is based on 
specific characteristics such as age, sex, occupation or other characteristics related to an increased 
risk. These interventions can be classified as selective prevention. An example is a systematic screening 
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program with an age-restricted target population. A third category is indicated prevention, which applies 
to those persons who manifest a risk factor, condition or abnormality, that identifies them individually as 
being at high risk for development of a disease. Indicated prevention interventions are usually quite 
intense for the receiving person and can induce high costs per person. An example of indicated 
prevention is the management of hypertension or annual check-ups for patients in whom a skin cancer 
lesion has been removed. Gordon’s classification applied only to asymptomatic individuals. He defined 
prevention as “measures, actions, or interventions that are practiced by or on persons who are not, at 
the time, suffering from any discomfort or disability due to the disease or condition being prevented”. 
Nevertheless, in this thesis the view of the Institute of Medicine is adopted (Mrazek & Haggerty, 1994), 
in that indicated prevention interventions can apply to asymptomatic individuals with markers as well as 
to symptomatic individuals having minimal but detectable symptoms. For example, suicide prevention 
interventions might reduce the duration of the period one experiences early symptoms of suicidal 
thoughts and as such halt the progression of the severity of these thoughts to prevent the act of suicide.  
 
 
Figure 2: Classification of public health prevention interventions  
 
 
 
 
1.2.2.  Management and control of chronic non-communicable diseases 
Table 1 shows the age-standardised incidence and mortality rates for some important CNCDs in Europe 
and Belgium, of which the situation is worse in Belgium, compared to the European average. The (fatal) 
suicide rate, incidence- and mortality rate for breast cancer and colorectal cancer as well as the mortality 
rate for lower respiratory diseases is higher in Belgium than in Europe (Ferlay et al., 2013; OECD, 
2012d; WHO, 2012a), arguing for further prevention research and interventions. In Belgium, but also 
globally, health goals are being formulated and action plans are being developed with the aim of 
reducing the morbidity and mortality due to CNCDs (Centers for Disease Control and Prevention, 2016a; 
Vlaams Agentschap Zorg & Gezondheid, 2016; WHO, 2016b). These goals and action plans all mention 
two main strategies, namely focussing on the modifiable risk factors of CNCDs and early detection of 
the disease. 
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Table 1:  Age-standardised incidence and mortality rates in Belgium and Europe (per 100,000, in %), for the 
major CNCDs for which the rate was higher in Belgium than in Europe (2012) 
 
  
Suicide 
rate  
Breast 
cancer 
incidence 
rate 
Breast 
cancer 
mortality 
rate 
Colorectal 
cancer incidence 
rate 
Colorectal 
cancer mortality 
rate 
Chronic lower 
respiratory 
disease, 
mortality rate 
Belgium  17.4 147.5 29.5 M: 67.5; F: 43.4 M: 23.8; F: 15.3 46.2 
EU average 13.3 108.8 22.4 M: 59; F: 36.1 M: 23.8; F: 14.2 34.9 
Incidence rate: number of new cases of the disease in the particular population, during 2012, per 100,000 persons.  
Mortality rate: measure of the number of deaths, in the particular population, during 2012, per 100,000 persons 
M: Males; F: Females  
Source: (Ferlay et al., 2013; OECD, 2012d; WHO, 2012a) 
 
Focus on risk factors 
CNCDs are largely preventable through identifying and tackling the main modifiable risk factors, being 
health behaviours of which the most important are tobacco use, unhealthy diet, physical inactivity, 
sedentary behaviour, the harmful use of alcohol (WHO, 2015a), as well as exposure to ultraviolet (UV) 
radiation (as a risk factor for skin cancer) (Figure 3). It is estimated that if these main modifiable risks 
factors would be eliminated, about 80% of heart disease, stroke and type 2 diabetes as well as 40% of 
cancer could be prevented (WHO, 2005a). These health-related risk factors can lead to CNCDs directly, 
or indirectly through intermediate risk factors such as raised blood pressure or blood glucose, abnormal 
blood lipids, obesity and sunburn. There are an increasing number of studies suggesting that these 
modifiable health behaviours are also risk factors for common mental disorders (Akbaraly et al., 2009; 
Jacka, Mykletun, & Berk, 2012; Lucas et al., 2011; O'Neil et al., 2015; Pasco et al., 2008), although 
more research is necessary on the causality of health behaviours and mental disorders. In Figure 3 it is 
shown that the causes of CNCDs extend beyond the modifiable individual health behaviours and also 
include non-modifiable factors such as age, sex and the gene pool. Although there is agreement on 
inherited genes being a determinant of CNCDs, there is not yet a clear understanding to what extent the 
inherited gene pool plays a role in the onset of CNCDs (Billings & Florez, 2010; Cancer Research UK, 
2015; Maes, Neale, & Eaves, 1997; WHO, 2016a). Additionally, there are external factors such as socio-
economic (e.g. education, income), psychological (trauma, stress), cultural (religion), political (e.g. food 
taxes, price of natural resources such as sugar) and environmental characteristics (e.g. availability of 
walking trails), influencing the health of people (Magnusson, 2010). These external factors create the 
context in which people take health decisions, supporting or impeding healthy behaviour in the 
population. The impact of these different main risk factors makes prevention of CNCDs a complex task.  
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Figure 3: Main risk factors of chronic non-communicable diseases 
 
    Based on WHO report (World Health Organization, 2005b) 
 
In order to explore the current prevalence of the major modifiable health risk factors for CNCDs, Table 
2 presents the Belgian as well as the European prevalence of these risk factors (Eurobarometer, 2014; 
Eurostat, 2008b). Although the prevalence of overweight/obesity, smoking and vegetable consumption  
does not seem to be worse in Belgium compared to the European average, improvement is necessary. 
Besides, the prevalence of fruit consumption, alcohol consumption, physical activity and sedentary 
behaviour is shown to be worse in Belgium compared to the European average. According to the Belgian 
‘voedselconsumptiepeiling’ 2014-2015, children between 3 and 5 years already spend half of the day 
sitting (average of 6.5 hours a day) and this increases with age, reaching a peak in adolescence (De 
Ridder, 2016). From the same survey, the average fruit consumption was shown to have decreased 
compared to 2004 and is still below the norm of 250-375 grams per day (De Ridder, Lebacq, Ost, 
Teppers, & Brocatus, 2016). Globally, improvement of risk factors for CNCDs is necessary in order to 
manage the rise in CNCDs.  
 
Table 2:  Prevalence of risk factors for chronic diseases in Belgium and Europe (2008) 
  
Overweight/ 
obese 
Eating 
fruit ≤ 
once a 
week 
Eating 
vegetables 
≤ once a 
week 
Walking ≥10 
min/day for 
≤3 days per 
week 
Sitting ≥8h30 
on a usual day 
Smoking ≥  
once a day 
Drinking 
alcohol  
daily* 
Belgium  47.5% 8.3% 1.0% 57.0% 12.0% 35.7% 12.3% 
EU average 52.4% 6.2% 3.8% 39.0% 11.0% 37.3% 6.8% 
* portion not specified  
Prevalence of risk factors being worse in Belgium compared to the European average are shown in bold  
Source: (Eurobarometer, 2014; Eurostat, 2008b) 
 
 
Early detection 
Although the incidence of cancer might be reduced by identifying and modifying the main modifiable 
behaviours, these strategies cannot eliminate the majority of yet prevalent and irreversible but 
undetected cancers which are sometimes only diagnosed in late stages. Therefore, early detection, i.e. 
detection of a pre-cancerous or a cancerous lesion prior to the appearance of symptoms, could prevent 
disease progression and the associated health and economic consequences and thus is also a 
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cornerstone of cancer control (WHO, 2007). Early detection consists of two aspects, namely education 
to promote early diagnosis and screening. Information among health care providers and the general 
public is necessary to increase awareness and recognition of possible symptoms. Additionally, healthy 
individuals can be screened, using simple tests, in order to identify those who have the disease, but do 
not yet have clinical symptoms. Screening can consist of two strategies, namely screening based on 
symptoms or population-based screening of asymptomatic individuals to detect (pre-)cancerous lesions 
and to refer for diagnosis and treatment (WHO, 2007). Population-based screening programs can be 
organised for diseases eligible for screening according to the criteria of Wilson & Jungner (1968), such 
as when an effective test is available which is acceptable for the population, when the prevalence of the 
disease is high enough to justify the effort and costs of screening, when the natural progression of the 
condition is well understood and when facilities for diagnosis, treatment and follow-up are available. 
 
1.2.3.  Prevention on the policy agenda 
 
Investing in prevention 
Despite the reported burden of CNCDs, and the need for public health prevention programs, current  
health expenditure reveals that prevention is low priority for policy makers. Health systems are mainly 
focused on the (fragmented) care for the ill (Annemans, 2014). In Belgium, this is reflected in the average 
public expenditure on public health prevention programs being only 2% of the health budget, whereas 
the European average is 3% (OECD, 2012c). It would take about an extra €370 million per year of the 
Belgian health budget (Federale Overheidsdienst Budget en Beheerscontrole, 2016; Vlaamse Overheid, 
2016) to be spent on prevention in order to reach the average expenditure on prevention in Europe. This 
care-oriented focus may relieve short term pressures, but failing to invest in prevention will increase the 
cost for treatment services in the long run. A lack of public investment in prevention has multiple reasons. 
One of the major reasons is the nature of the benefits of prevention, which mostly only occur on the long 
term, whereas people, and especially policy makers (because of their legislative term), have an inherent 
preference for short term benefits. Prevention of CNCDs leads to immediate costs and delayed benefits. 
Moreover, successful prevention is largely invisible, as it is difficult to measure how many cases of a 
disease have been prevented. Secondly, there is a lack of research providing the (health) economic 
information on prevention interventions. The U.K. Clinical Research Collaboration analysed the 
distribution of the budgets across eight major health-related research activity groups and found that only 
5% of the funding is spent on prevention research (2015). However, several (recent) reviews (see 
paragraph 1.4.4. Cost-effectiveness of public health interventions) have shown a rise in the number of 
health economic evaluations of prevention programs in the past years. Another issue is that those who 
benefit from and those who bear the costs of prevention services are not always the same. This distortion 
emerges at the different policy levels but also between policy sectors. The current division of mandates 
in Belgium curbs an integrated and coordinated prevention policy. In Belgium, prevention is under the 
jurisdiction of the communities, while curative health care is regulated at the Federal level. This means 
that the costs of prevention and the benefits for the health care budget, due to increased population 
health, are situated on another legislative level. However, agreements between the different legislative 
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levels can be made, such as the co-financing of prevention programs. In case of the cancer screening 
programs in Flanders, the Flemish community and the Federal government have agreed that the 
Flemish community finances the organisation of the program (incl. the screening tests) and that costs 
of medical services related to and resulting from the program are funded by the Federal government 
(Federale Overheid, 2016). Lastly, budgets and interests are often in conflict with each other (Van Herck 
& Staelraeve, 2016). To what extent do schools for example need to invest financial resources in health 
promotion for children, in addition to their core education business, if the budget does not allow such 
convergence? There is a natural resistance to collaboration between policy departments, caused by a 
‘silo mentality’5. It is clear from previous points that the political structure of a country can affect the 
priority of prevention on the policy agenda.   
 
Health in all policies  
As shown in Figure 3, health is not only determined by health-related factors, but also by elements 
outside the health care sector. An effective health policy should involve all relevant policy areas at all 
government levels (European Commission, 2016). Health in All Policies (HiAP) is an approach that 
integrates health considerations at all levels of policy-making to improve the health of all communities 
and people (Leppo, Ollila, Pena, Wismar, & Cook, 2013). HiAP acknowledges that health is created by 
a multitude of factors beyond health care and, in many cases, beyond the scope of traditional public 
health activities. The HiAP-approach can be interpreted horizontally as well as vertically: on the one 
hand it implies that European, national, regional and local governments collaborate to take care of 
citizens’ health; on the other hand it implies including health considerations in policy making across 
different sectors that influence health, such as mobility, housing, education, employment, taxation, etc.  
Some HiAP-examples are: fall prevention by modifying the physical environment in residential care 
centres, or by giving an information session organised by the municipality; creation of parks and play 
forests in the city or town to improve sedentary behaviour, physical activity and increase mental 
wellbeing; financially rewarding schools or employers who are committed to improve the health of their 
students or employees; actions such as ‘met belgerinkel naar de winkel’ (organised by ‘Bond Beter 
Leefmilieu Vlaanderen’) in which every Flemish community can participate in order to promote shopping 
by bike instead of car; European legislation on health, implemented at national level, such as the 
guidelines for the quality of the screening program for breast cancer, food labelling , ... 
  
                                                          
5 A silo mentality is a mindset occurring when departments do not share information, goals, tools, priorities and 
processes with other departments. The silo mentality may contribute to a decreased performance and has a 
negative impact on the corporate culture. 
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1.3. Health budgets under pressure 
 
In 2013, public health expenditure6 (PHE) in Europe consisted of 6.5% of the gross domestic product 
(GDP) (OECD, 2015b). In Belgium the current public health care budget (i.e. at the Federal and 
community level, anno 2016) amounts to about €37 billion, which is 9% of the GDP. Since 2000, the 
PHE in Belgium, as a share of the GDP, has increased from 5.9% to 9%. This trend has mainly been 
nourished by a rise in the incidence of CNCDs as a consequence of changing health behaviour and 
population ageing -but also by technological progress, rising patient expectations and inefficient use of 
the health budget (Pammolli, Riccaboni, & Magazzini, 2012; WHO, 2015b). As such, the concern has 
been raised on the financial sustainability of the health care system. In the wake of the financial and 
economic crisis however, from 2009 on, health spending growth slowed down, in some countries even 
to negative growth figures (Figure 4). The crisis had a large negative impact on the availability of health 
system resources (Mladovsky et al., 2012), and as a response, several countries reported cuts in the 
national health budget, resulting in a slow-down or even fall in the health spending growth rate 
(Mladovsky et al., 2012; OECD, 2012b).  
 
Figure 4: Average annual growth in per capita public health spending in Europe, 2005-2014 
 
 (OECD, 2015b)  
 
The OECD reported the largest health budget cuts in 2009-2010 to be made in the sector of public 
health and prevention and of pharmaceuticals (McDaid et al., 2013; OECD, 2012c). Since 2010, PHE is 
slightly increasing again, and in recent years, increases in health spending are in line with overall 
economic growth (at a rate of about 1%), so that the health expenditure as a share of GDP remains 
stable (OECD, 2015a). However, as a response to cuts in the health budget, the European Commission 
published a report on “Investing in Health”, in order to inform and convince every country to invest in 
health (2013). Increases in health spending produce significant increases in health, particularly for 
increases in spending in prevention (Vavken, Pagenstert, Grimm, & Dorotka, 2012). Moreover, people 
                                                          
6 Public health expenditure consists of spending from government (central and local) budgets, external borrowings 
and grants (including donations from international agencies and nongovernmental organisations), and social or 
compulsory health insurance funds (The World Bank, 2016). Specific for the Belgian case PHE includes all direct 
health care spending by social security institutions, the federal government, the regions and communities, and local 
governments, including spending on disease prevention. 
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with better health are capable of producing more goods and services than those in poor health, leading 
to faster economic growth (European Commission, 2010b). An additional response to the difficulties in 
sustaining the health system came from the Institute for Health care Improvement, who developed a 
framework to address the objectives that should be pursued by the health care system, called the Triple 
Aim (2016). The Triple Aim stands for improving the health of populations, improving the patient 
experience of care (including quality and satisfaction) and reducing the per capita cost of health care. 
Indeed, the health care system should improve health within the limited budget, taking into account the 
quality of care. The policy emphasis should be on spending the money wisely (i.e. more efficiently), 
eliminating wasteful spending, encouraging personal responsibility for health and investing in prevention 
(Mladovsky et al., 2012; Moodie, 2013; Wanless, 2004). Consequently, policy makers need to make 
choices, towards the most efficient interventions and strategies (Drummond et al., 2015). Getting more 
value for money is crucial if countries are to ensure population health, under conditions of severe 
constraints on public budgets (Council of the European Union, 2010). 
 
1.4. Health economic evaluations 
 
In light of the pressure on health expenditure and budget constraints, policy makers have to make 
decisions on what interventions to offer and how the interventions should be provided in order to achieve 
an optimal health gain with available resources. This means that beside evidence on the efficacy and 
effectiveness7 of a health intervention, also information on the efficiency is necessary. Efficiency or cost-
effectiveness addresses the question whether it is worth implementing an intervention, compared to 
other interventions that could be implemented with the same budget (Annemans, 2008). Health 
economic evaluations are a valuable tool in the decision making process by informing on the efficiency 
of alternative health interventions and strategies, in terms of the incremental costs and health benefits 
of one intervention compared to another intervention or to the current standard (which can be no 
intervention). A health economic evaluation is defined as “the comparative analysis of alternative 
courses of action in terms of both their costs and consequences” (Drummond et al., 2015).  
1.4.1. Types of health economic evaluations 
Four general types of health economic evaluations exist: cost-minimisation analysis, cost-benefit 
analysis, cost-effectiveness analysis and cost-utility analysis. All four methods measure costs in the 
same way; the distinguishing feature of each is the way in which benefits are measured. Table 3 
summarises the characteristics of the four different types. Cost-minimisation analysis assumes -based 
on available evidence- the health effects of the alternatives to be equal, and therefore only considers 
the costs related to the analysed interventions (Drummond et al., 2015). In this way, the least costly 
intervention is the most efficient. Cost-benefit analysis measures costs as well as health benefits in 
monetary units. The outcome, expressed as net monetary gain/loss or as a ratio of benefits and costs, 
                                                          
7 Efficacy is achieved when the strategy leads to the intended health benefits in a controlled setting 
  Effectiveness is achieved when the strategy leads to the intended health benefits in real-life (Annemans, 2008) 
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can be compared between different alternative interventions. Cost-benefit analyses are not frequently 
performed, since the main challenge is valuing the benefits –such as deaths or disease prevented- in 
monetary units. Cost-effectiveness analysis compares interventions with the same objective. It 
measures the benefits of an intervention in natural units associated with the primary outcome (e.g., 
cases prevented, deaths prevented, life-years gained, decrease in BMI-units) and the costs in monetary 
units. The most common health economic evaluations are cost-utility analyses, which are a type of cost-
effectiveness evaluations and therefore usually called as such. Cost-utility analysis compares 
interventions with different objectives (i.e. across different pathologies). Guidelines on performing health 
economic evaluations usually advise to express health benefits as a generic measure such as disability-
adjusted life-years (DALYs) or quality-adjusted life-years (QALYs) (Cleemput, Neyt, Van de Sande, & 
Thiry, 2012). QALYs are more commonly used as generic outcome measure in reference to DALYs. 
QALYs are measured by utility weights which have a value between 0 (death) and 1 (perfect health). 
Belgian guidelines recommend to derive these utilities indirectly by specific pre-scored generic patient 
questionnaires. The most common and recommended questionnaire is the EuroQol Quality-of-Life 
instrument (EQ-5D) including five dimensions, namely mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, and three or five answer levels (from no problems to severe 
problems/unable) (EuroQol, 2016). The pre-scored EQ-5D value sets are elicited from the general 
population and are available for different countries. QALYs are calculated by multiplying the utility weight 
with the number of life years spent in a particular disease state. As such one QALY is equal to one year 
in optimal health. In this PhD-thesis, all included health economic evaluations were cost-effectiveness 
analysis, more specifically cost-utility analyses, expressing the health benefits in QALYs gained. Costs 
were included from a health care- as well as a societal perspective, encompassing medical costs as 
well as costs due to productivity loss. 
 
Table 3: Characteristics of the different types of economic evaluation   
Method 
Costs Effect + Advantages 
- Disadvantages measurements measurements 
Cost-
minimisation 
analysis 
Incremental costs  
in monetary units 
Health effects are not 
measured,  
since they are 
considered to be equal 
+ Simple and easy to understand 
- Should not be interpreted as a full economic 
evaluation 
Cost-benefit 
analysis 
Incremental costs  
in monetary units 
Incremental health 
effects in  
monetary units 
+ Allows comparison of interventions  across 
the entire economy 
- Difficult to place a monetary value on health 
outcomes* 
Cost-
effectiveness 
analysis 
Incremental costs  
in monetary units 
Incremental health 
effects in natural units  
(BMI-points lost, burns 
prevented, etc.) 
+ Easy to interpret and to communicate 
- Does not allow to compare interventions 
across different pathologies 
Cost-utility 
analysis 
Incremental costs  
in monetary units 
Incremental health 
effects in  
generic outcomes 
such as QALYs or 
DALYs 
+ Allows comparison of interventions across 
different pathologies 
- Generic outcome measure such as QALY 
may not capture all intervention outcomes 
such as those external to the health sector 
*In the health sector, market prices are often lacking. Surveys can be used to estimate hypothetical willingness-to-pay. 
QALYs: Quality-Adjusted Life-Years;   DALYs: Disability-Adjusted Life-Years. Source: (Drummond et al., 2015).   
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1.4.2. Incremental cost-effectiveness ratio 
The outcome of a cost-effectiveness analysis is calculated as the difference in costs between the 
evaluated intervention and the comparator, divided by the difference in health benefits, called the 
incremental cost-effectiveness ratio (ICER). The ICER is expressed as a cost per unit of health benefit 
gained. A new intervention usually induces an extra intervention cost, and can lead to extra costs or 
cost-savings in the medical costs and costs due to productivity loss (Figure 5). Depending on the size 
of the costs in these cost categories, the new intervention will induce an extra total cost in reference to 
the comparator, or lead to total cost savings. Figure 5 shows the example of an intervention leading to 
a total net cost.   
 
Figure 5: Visualisation of the incremental costs related to a new compared to a current health intervention 
 
 
Even in the case of an extra total cost, the new intervention can be cost-effective compared to the 
comparator arm. Figure 6 shows the quadrants of the cost-effectiveness plane, representing the 
combinations of possible outcomes of incremental costs and health effects. Interventions situated in 
quadrant A and C are easy to evaluate. If a new intervention induces less total costs than the comparator 
intervention and generates greater health benefits, then this new intervention is called dominant and 
thus obviously cost-effective (quadrant A) (Briggs, Sculpher, & Claxton, 2006). Interventions in quadrant 
C are not desirable as they cost more but do not lead to extra health benefit and will therefore be 
excluded from the decision process. Decisions on interventions situated in quadrant B and D are more 
difficult to make. Interventions situated in quadrant D are not only decreasing the total cost but also the 
health benefits. If the cost-savings are large enough to compensate for the health loss, such 
interventions can be cost-effective8. If the net health benefits of interventions in quadrant B compensate 
                                                          
8 Denoted with the term ‘decrementally’ cost-effective (Nelson, Cohen, Greenberg, & Kent, 2009). There is debate 
however on the threshold value in the south-west quadrant of the cost-effectiveness plane, namely whether or not 
it should be the same as in the north-east quadrant (Dowie, Kjer Kaltoft, Bo Nielsen, & Salkeld, 2015). 
+ =
consults, hospital, 
surgery, other drugs, 
tests …
New
New
Current
Current
Cost of intervention Other medical costs Total Cost+ Costs due to
productivity loss
New
Current
Current
New
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for the additional costs, then this new intervention can be cost-effective, depending on the societal 
willingness-to-pay threshold. If the ICER is below the threshold, the evaluated intervention is considered 
as cost-effective, i.e. offering good value for money (cf. the light blue surface in Figure 6). The lower the 
ICER, the better the cost-effectiveness. If the ICER is above the threshold, the intervention is not 
considered to be cost-effective and allocation of resources to this intervention is unlikely to increase 
efficiency.  
 
Figure 6: Four quadrants of the cost-effectiveness plane 
WTP:Willingness-To-Pay  
Interventions situated in the light-blue surfaces should be interpreted as cost-effective, dependent on the WTP-threshold.  
 
Some countries have an explicit threshold value or value range, such as the United Kingdom (£20,000 
to £30,000) but most countries, including Belgium, do not. There are three common approaches to 
determine a threshold of which the most common one is the approach proposed by the WHO, namely 
based on the GDP per capita (WHO, 2005b). In this PhD-thesis, an intervention was considered to be 
cost-effective if the ICER was below the threshold of one time the Belgian GDP per capita, set at 
35,000/QALY gained. However, this is a rather informal threshold and deviations, based on other criteria 
(see section 1.5.2.), are possible. Besides, by using a cost-effectiveness threshold based on the GDP 
per capita, it is assumed that the country is willing to pay up to that threshold for the health benefit, 
usually without any concrete evidence of that willingness to pay. Other approaches to determine the 
threshold are based on a benchmark intervention, by retrospective analysis of existing practice, or 
ranking interventions in a league table (Marseille, Larson, Kazi, Kahn, & Rosen, 2015). Considering a 
benchmark intervention to set the cost-effectiveness threshold has more local relevance than a 
threshold based on GDP. However, which benchmark intervention to choose is not straightforward; the 
Decrease in net health effects
Increase in net costs
Decrease in net costs
Increase in net health effects
New strategy more 
effective but more 
costly (Adopt?)
New strategy less
effective and more 
costly (Dominated)
New strategy less
costly but less
effective (Adopt?)
New strategy more 
effective and less
costly (Dominant)
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benchmark intervention may be a high or low outlier. It may for example have resulted from a political 
decision that does not reflect the current, true measure of societal willingness to pay for health benefits 
(Marseille et al., 2015). A league table lists all relevant health interventions based on their incremental 
cost-effectiveness ratio, with the best ratio on top and the worst ratio at the bottom of the ranking. The 
league table approach is based on the principle that health outcomes are maximised if selection of the 
options for implementation begins with the best ICERs, which are shown at the top of the league table 
and then moves down the list until the budget is exhausted. The disadvantage of a league table is that 
much information is needed on the cost-effectiveness of other interventions to prepare the table. 
However, this information is not always available.  
 
1.4.3. Cost-effectiveness models 
In order to predict long term costs and health effects associated with an intervention, most cost-
effectiveness analyses make use of modelling techniques. The most frequently used models are 
focusing on the average patient and are called cohort models. The two most common examples of 
cohort models are the decision tree and the Markov model. A decision tree is the simplest of both 
modelling techniques, representing disease prognosis, following an intervention, by a series of (mutually 
exclusive) pathways (Briggs et al., 2006). It estimates the likelihood of various outcomes, according to 
a certain probability, and applies associated costs and benefits for each pathway. The decision tree is 
suited to diseases where events occur over a discrete short time period. This method is however of 
limited use for more complicated diseases, with lengthy prognosis, or for events that are likely to recur 
over time, such as in the case of chronic diseases. It can however be used as a submodel in a larger 
model, e.g. to identify the number of cases detected by a screening program. A Markov model simulates 
disease progression, allowing to address more challenging problems (Briggs et al., 2006; Sun & Faunce, 
2008). This method is suited to model long term outcomes, where the timing of events is important and 
when events may happen more than once. Therefore, Markov models are particularly suited to evaluate 
chronic diseases (Briggs et al., 2006). A Markov model consists of a set of health states in which an 
individual can be at a certain point in time. The individual can only be in one health state at a time, and 
can transition to another state within a certain period, which is called the cycle length. The risk to move 
from one to another state is determined according to the transition probabilities, derived from clinical 
and epidemiological evidence. All individuals in a certain health state are assumed to have identical 
characteristics, meaning that the transition probabilities can only depend on the current health state and 
not on past health states (called the Markovian assumption).  Each health state is assigned costs and 
health effects (usually defined as QALYs). The length of the time horizon (i.e. the time span for which 
costs and effects should be measured or estimated), should be sufficiently long to capture all relevant 
differences in costs or outcomes between the compared interventions. Many public health interventions 
result in immediate costs, but may also lead to future health benefits and/or cost-savings. Due to time 
preference (i.e. future costs and benefits are valued less than current costs and benefits, as in the mean 
time we can benefit from them), future costs and health benefits should be recalculated to their present 
value, which is called discounting (Drummond et al., 2015). According to the Belgian guidelines, a 
discount rate of 1.5% is applied to future health benefits, and 3% to future costs (Cleemput et al., 2012). 
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The ICER is then the ratio of the difference in the summed costs and QALYs between the evaluated 
interventions at the end of the time horizon. 
 
1.4.4. Cost-effectiveness of public health interventions 
In the past 5 to 10 years, an increasing number of reviews on the availability of cost-effectiveness 
analyses of prevention interventions have been undertaken. Cohen et al. (2008) and Neumann et al. 
(2015) found that only 19%-35% of all analysed cost-effectiveness ratios were classified as preventive, 
while 65%-81% pertained to treatments. Additionally, Schwappach et al. (2007) showed in their review 
on the economic evidence of primary prevention of cardiovascular disease that 83% of the studies they 
retrieved analysed individual clinical prevention interventions (surgery, pharmacotherapy) and only a 
minority of the studies were about health promotion addressing a community of people (10%) and about 
screening (3%). Winn et al. (2016) found that the proportion of studies focusing on prevention of cancer 
has increased from an average of 4 studies per year between 1998 and 2006 to 21 studies per year 
between 2007 and 2011 and 24 studies per year in 2012 and 2013. Most of the studies they analysed 
were however focusing on individual-oriented treatment strategies (chemotherapy and post-diagnosis 
interventions), accounting for 71% of the evaluated strategies. Despite the more numerous economic 
evidence on treatments (drugs and medical technologies), there is evidence of increasing interest in 
analysing the cost-effectiveness of public health interventions in the last decade (Cobiac, Vos, & 
Veerman, 2010; Rush, Shiell, & Hawe, 2004; Schwappach, Boluarte, & Suhrcke, 2007; Winn, Ekwueme, 
Guy, Jr., & Neumann, 2016).   
The health benefits of prevention are intuitive, and policymakers and professionals often believe that 
prevention always saves money (Woolf et al., 2009). However, it is impossible to generalise about 
prevention interventions as if their results were all alike. In particular, the evidence does not support the 
commonly accepted idea that prevention always, or even usually, reduces medical costs -although it 
sometimes does (Cohen, Stolk, & Niezen, 2008; Goodell, Cohen, & Neumann, 2009; Russell, 2009; 
Russell, 2007). Moreover, as stated before, the question is not whether an intervention saves money, 
but whether it offers good value for money. Investing in cost-effective prevention strategies could 
increase the years lived in health while helping to control the growth in health care expenditure 
(European Commission, 2010b). Although Cohen et al. (2008) found that preventive interventions are 
not necessarily more cost-effective than treatment strategies, some promising results were found in 
other review studies. Owen et al. (2012) reviewed 200 cost-effectiveness estimates from 21 studies 
published between 2006 and 2010 (especially concerning smoking and physical activity) and found that 
the majority of studies (70.5%) had a cost-saving or very cost-effective result. Van Gils et al. (2011) 
confirmed this conclusion. Cobiac et al. (2010) evaluated the cost-effectiveness of 23 nutrition 
interventions and found that 72% of the reviewed interventions were cost-saving or cost-effective, 
especially interventions targeting the whole population (such as changing policies) rather than high-risk 
individuals. Chokshi & Farley (2012) showed that environmental interventions (i.e. interventions that act 
on persons indirectly by altering the physical or social environment, such as transfat bans) seem to be 
more cost-effective than clinical interventions (such as cancer screening) or non-clinical, person-
directed interventions (such as a suicide prevention helpline). Sassi et al. (2009) analysed the cost-
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effectiveness of 42 primary prevention programs, including food labelling, food advertising regulation, 
physician-dietician counselling, mass media campaigns, worksite interventions, school-based 
interventions, fiscal measures and food advertising self-regulation. They found that most interventions 
were cost-effective, with the two latter intervention strategies generating cost-savings. Although 
publication bias (i.e. overrepresentation of positive results in the literature) can play a role in these 
results, they seem to be promising.   
 
1.4.5. Uncertainty in cost-effectiveness analysis 
It is important to note that despite the value and the relevance of cost-effectiveness analyses, they 
include inherent uncertainties (Annemans, 2008). There are different sources of uncertainty, related to 
the structure of the model (structural uncertainty), uncertainty associated with parameters (parameter 
uncertainty), or uncertainty due to the choice of methods (methodological uncertainty) (Briggs et al., 
2006). Structural uncertainty refers to uncertainty about the extent to which a model adequately 
represents the health condition and intervention under evaluation. Parameter uncertainty is inherent in 
decision models as the true value of the input parameters is almost always unknown. Therefore, 
estimates of the true value are rather used and in case of lack of data assumptions have to be made. 
Additionally, several aspects of the underlying methods used in the particular cost-effectiveness analysis 
could be debated. Sources of methodological uncertainty are the perspective adopted in order to select 
the included costs (e.g. societal or health care payer perspective), (valuation of) health outcomes, 
duration of the intervention effect, length of time horizon, selection of discount rates and so on. (Bojke, 
Claxton, Sculpher, & Palmer, 2009). Jain et al. (2011) reviewed cost-effectiveness analyses published 
between 2000 and 2009 and found that almost 90% of the included articles addressed parameter 
uncertainty, while only 33% addressed methodological uncertainty and 8% addressed structural 
uncertainty. 
It is important to present results of the cost-effectiveness analysis in a transparent way, while exploring 
the uncertainty in key parameters and pay attention to validating the model and the model outcomes  
(Simoens, 2009). In order to improve the quality of cost-effectiveness analyses, the guidelines state that 
uncertainty should be explored by running sensitivity- and scenario analyses (Eunethta, 2015). In the 
studies included in this PhD, parameter values were varied one by one in one-way sensitivity analyses, 
to test the impact on the incremental cost-effectiveness ratio. In this way, the parameters with the 
greatest effect on the ICER as well as the magnitude of their effect can be determined. Another type of 
sensitivity analysis that was used to quantify uncertainty is probabilistic sensitivity analysis. This type of 
sensitivity analysis varies the values of all relevant parameters together, according to their probability 
distribution. Samples from these distributions are randomly drawn and generate a confidence interval 
around the ICER. Additionally, from a probabilistic sensitivity analysis a cost-effectiveness acceptability 
curve (CEAC) was drawn, to indicate the probability of the result being cost-effective considering a 
specific willingness-to-pay threshold. In a scenario-analysis, several methodological as well as structural 
assumptions were evaluated. In the review of Jain et al. (2011), 86% of the included articles conducted 
a one-way sensitivity analysis and 45% a probabilistic sensitivity analysis or a scenario-analysis. The 
use of CEACs increased over time from 3% in 2000-2003 to 36% from 2006 to mid-2009.  
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In addition to sensitivity- and scenario analyses, the validity of the model structure, input parameters, 
methodological assumptions as well as the outcomes of the studies included in this PhD, was assessed 
as much as possible by model validation. According to a report of the International Society for Pharmaco-
economics and Outcomes Research’s Task Force for Modeling Good Research Practice, model 
credibility can be enhanced by means of transparency and validation (Eddy et al., 2012; Husereau et 
al., 2013). Transparency is about clearly describing the model structure, calculations, parameters values 
and assumptions so that interested parties are able to understand the model and the results. Validation 
has been defined as the set of methods for judging a model’s accuracy in making relevant predictions 
(Eddy et al., 2012; Gray, Clarke, Wolstenholme, & Woodsworth, 2007). There are several types of 
validation: face validation, internal validation, cross-validation, outcome validation and predictive 
validation. Face validity represents the extent to which the model design corresponds to current 
(medical) evidence, as judged by experts. Internal validity addresses whether the model has been 
implemented correctly. Cross-validation implicates comparing the results of a model with other studies 
addressing the same research question to determine the extent to which they calculate similar results. 
Outcome validation consists of testing the outcomes of the comparator (which usually represents the 
current standard) with observed parameters. Predictive validation concerns the comparison of the 
predicted outcomes by the intervention arm with the outcomes observed in real-life. It refers to the ability 
of the model to make accurate predictions of future events. Despite the importance of validation in cost-
effectiveness analysis, and although validation is deemed important by many researchers, it is often 
omitted in the reporting of health economic modelling studies (de Boer, Frederix, Feenstra, & Vemer, 
2016; Koleva-Kolarova, Zhan, Greuter, Feenstra, & de Bock, 2015). Furthermore, there is no measure 
to decide how valid a model is. For example, the question of how close predictions of a model must be 
to observed data in real-life in order to be considered valid is impossible to answer (Eddy et al., 2012), 
although this should not affect the importance of model validation. The degree of accuracy also depends 
on the question that needs to be informed. For example, much less accuracy is needed to inform “Will 
this intervention increase or decrease costs?” than to answer “How much will this intervention cost?” 
(Eddy et al., 2012). The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
checklist has been developed to optimise reporting of health economic evaluations, but unfortunately 
no clear guidelines for the reporting of validation exercises are included in this checklist (Husereau et 
al., 2013). We will further elaborate on this topic in the general discussion of this PhD. 
 
1.5. Cost-effectiveness in policy 
 
1.5.1. Cost-effectiveness evidence informing policy 
Health economic evaluations cannot aid in the optimal use of the health budget unless research 
translates into policy. In the domain of health, the principles of evidence-based medicine are slowly 
spreading in the context of policy making. Nevertheless, the use of economic evidence has gained less 
importance than evidence on clinical effectiveness (Corbacho & Pinto-Prades, 2012; Eddama & Coast, 
2008; Merlo, Page, Ratcliffe, Halton, & Graves, 2015). In Belgium, the process for reimbursement of 
drugs is quite structured. The request for reimbursement is assessed by the Commission for Drug 
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Reimbursement. The evaluation is based on some key criteria (defined by law) including the cost-
effectiveness (next to added therapeutic value, the proposed price and reimbursement level, the medical 
need and the budget impact) (Federale overheidsdienst sociale zekerheid, 2001). However, decisions 
on public health interventions are much less structured and it is not clear to what extent cost-
effectiveness is used as a criterion. In Flanders though, prevention interventions seem to be increasingly 
tested for their cost-effectiveness (Van Herck & Staelraeve, 2016). Nonetheless, the systematic review 
of Eddama et al. (2008) describes an overall limited use of cost-effectiveness analysis in local decision-
making. Several studies explored the most important barriers for policy makers to make use of economic 
evidence in their decisions (Eddama & Coast, 2008; Eddama & Coast, 2009; Galani & Rutten, 2008; 
Merlo et al., 2015; Niessen et al., 2012; Oliver, Innvar, Lorenc, Woodman, & Thomas, 2014; Williams & 
Bryan, 2007). The main factors were described as the availability of relevant research in a timely manner 
(timing), the objective as well as perceived quality and transparency of the evidence, the clarity of its 
presentation, the extent to which it can be understood by the policy makers and the short term focus of 
policy makers. Policy makers often struggle to understand health economic analyses, mainly because 
of the language and concepts used in such analyses, and the presentational styles adopted. Moreover, 
commissioning cost-effectiveness research that can be delivered in a timely manner necessitates 
funding, which often is a barrier for policy makers. The review of Merlo et al. (2015) summarised some 
solutions to these barriers that were suggested in several studies: more cooperation between 
researchers and policy makers could positively influence the impact of economic evaluations on policy, 
training for policy makers could allow them to better interpret the design and results of economic 
evaluations and standardised formats for presenting the results of economic evaluations. 
 
1.5.2. Other important criteria in the decision making process 
Despite the value of cost-effectiveness evidence in the decision making process, it must be noted that 
cost-effectiveness is and should not be the only criterion for decision making. Multiple factors impact the 
decisions of policy makers (Thokala et al., 2016; Weintraub & Cohen, 2009), although the weight of 
these different factors is not transparent. Cost-effectiveness estimates should be used as a decision 
aid, not a decision rule (McDaid, Drummond, & Suhrcke, 2008). Only taking into account the cost-
effectiveness of an intervention or strategy might conflict with other policy goals. A recent systematic 
review on priority setting with explicit criteria to guide decision-making found that the following criteria 
emerged as being most common: effectiveness, cost-effectiveness, budget impact, medical need and 
equity (Cromwell, Peacock, & Mitton, 2015). This wider context is the focus of Health Technology 
Assessment (HTA), which is “the systematic evaluation of the properties and effects of a health 
technology9, addressing the direct and intended effects of this technology, as well as its indirect and 
unintended consequences, and aimed mainly at informing decision making regarding health 
technologies. HTA is conducted by interdisciplinary groups that use explicit analytical frameworks 
                                                          
9 A health technology is defined as an intervention that may be used to promote health, to prevent, diagnose or 
treat acute or chronic disease, or for rehabilitation.  Health technologies include pharmaceuticals, devices, 
procedures and organisational systems used in health care (International Network of Agencies for Health 
Technology Assessment, 2016). 
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drawing on a variety of methods” (International Network of Agencies for Health Technology Assessment, 
2016).  
Beside effectiveness and cost-effectiveness another important consideration when establishing 
priorities in the public sector is the budget impact of an intervention, denoting the impact of a positive 
policy decision on the health care budget. A cost-effectiveness analysis informs about the comparative 
value for money an intervention offers, whereas a  budget impact analysis helps to determine whether 
the health care payer can afford to implement a particular intervention (Cleemput et al., 2012), as it 
takes into account the total population to which the intervention would apply. A budget impact analysis 
is especially useful in the case of universal prevention, because of the large extent of the target 
population receiving the intervention. However, there is no clear reference as to what an acceptable 
budget impact is. This decision has to be made by the health care payer. In case the budget impact 
analysis estimates total cost savings by means of the intervention, a return on investment can be 
calculated, measuring the benefit for the payer resulting from the original intervention investment. The 
medical need of a new intervention is shaped by the morbidity and mortality caused by the health 
problem. Burden of disease studies can inform researchers and policy makers on the medical need. 
Burden of disease studies include studies on the total health burden to an individual or society because 
of a disease and studies on the financial impact of a disease to an individual or society. The latter studies 
are often called cost-of-illness studies. Cost-of-illness studies calculate the total costs of a particular 
disease with the aim of giving an idea of its economic burden. By measuring the health- and economic 
burden of a specific disease, such burden of disease studies can help health care decision makers to 
set up and prioritise health policies and interventions. According to Stolk et al. (2005) applying medical 
need as decision criterion means that “the relative efficiency criterion should be applied differently when 
the disease problem is more or less disabling, by varying the cost-effectiveness threshold in 
reimbursement decisions according to burden of disease”. Beside medical need, costs and benefits, 
another criterion likely to be of concern is the distribution of those benefits, reflecting equity issues. 
Questions related to this equity concern are: do all individuals with equal need have the same access 
to the intervention?, Does the intervention particularly benefit those with severe health conditions?, does 
the intervention particularly benefit the poor? (James, Carrin, Savedoff, & Hanvoravongchai, 2005).  
To conclude, it is possible that a prevention intervention, which has been shown to offer good value for 
money, does not receive public funding because it does not meet one or more of the above mentioned 
criteria. David Haslam, the chairman of the National Institute for Health and Care Excellence (NICE) 
stated it as follows: “One of the critical roles of the NICE committees I have tried to ensure is for them 
to use their judgement, not just to follow simple algorithms. If we had simple algorithms that could do 
this, we could replace everyone with a computer, but that’s not the point: we’re here to make complex 
judgements on behalf of society” (Pharmafile, 2014). In the United Kingdom a Value-Based approach 
was introduced, in order to create flexibility in the decision making (National Institute for Health and Care 
Excellence, 2014). If for example, a new technology increases the quality and length of life at the end 
of life, a higher willingness-to-pay threshold may be assumed. As such, the assumed threshold in cost-
effectiveness analyses is not rigid and the ICER should be interpreted as an extra source of information 
to the normative decision process. Of course, this list of abovementioned criteria in the decision-making 
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process is not exhaustive, and many other factors can influence policy decisions such as contextual 
factors (stakeholder interests and pressures), quality and strength of the evidence and complexity of the 
intervention (organisational requirements and capacity to implement) (Guindo et al., 2012). For example, 
sometimes it might be the case that a public health intervention is introduced before any strong evidence 
of (cost-)effectiveness is available, if leader opinion is strong or if there is pressure to focus on the ‘hot 
topics’ in health (Curtis, 2012; Specchia et al., 2015). However, this is not an argument against the use 
of cost-effectiveness evidence in health care decision making. A decision only based on cost-
effectiveness considerations is a wrong decision, but neglecting cost-effectiveness information in the 
decision making process is unethical. 
 
1.5.3. Transferability of cost-effectiveness results 
Information on the cost-effectiveness of a particular health technology is not always available on the 
short term, which might be a barrier for policy makers to inform their decision by cost-effectiveness 
evidence. Sometimes however, similar studies on the cost-effectiveness of the particular health 
technology in other countries might be transferable to the own context. Transferability refers to “the 
extent to which the results of a study, as they apply to a particular patient population and/or a specific 
context, hold true for another population and/or in a different context” (Briggs et al., 2006). The issue of 
transferability of cost-effectiveness studies from one country to another gains increasing interest, 
particularly in times of budget or time constraints. There are several reasons why cost-effectiveness 
results of similar interventions might differ between countries, such as demography and epidemiology 
of the condition, clinical practice, costs for treatment of a condition, etc. Consequently, health economic 
evidence cannot be considered to be always directly transferable between settings (Drummond et al., 
2009), although it might be possible taking certain aspects of the particular study into account.   
According to the model of Welte (2004), a study is not transferable if the relevant technology is not 
comparable to the one that will be used in the decision country; if the comparator is not comparable to 
the one that is relevant to the decision country or if the study does not possess an acceptable quality. 
In case these criteria are not met, the study might be transferable. In order to determine the level of 
transferability, the level of correspondence between the study country and the decision country on 
several transferability factors is to be estimated (Table 4). Finally, the likely effect of the factor on the 
cost-effectiveness result should be determined. When both the relevance of the factor and the 
correspondence between the countries is high, the transfer of the study result will be unbiased. After 
these three steps, it can be decided which adjustments are necessary to transfer the foreign studies. 
Table 4: Specific transferability criteria of Welte’s model  
Transferability characteristic Transferability factor 
Methodological characteristics  
perspective; discount rate; medical cost approach; productivity cost 
approach 
Health care characteristics absolute and relative prices; practice variation; technology availability 
Population characteristics 
incidence/prevalence; life expectancy; health-status preference; 
acceptance, compliance and incentives to patients; productivity and 
work-loss time; disease spread 
Source: (Welte, Feenstra, Jager, & Leidl, 2004) 
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1.6. Aims and outline of this study 
 
Action is necessary in order to control the burden of CNCDs on public health as well as on the public 
health care expenditure. Evidence on effectiveness and cost-effectiveness of prevention programs 
provides policy makers with information in order to make priorities and spend the budget wisely. Cost-
effectiveness analyses of public health interventions are increasingly performed, although not yet 
reaching the same levels as clinical individual-based interventions, such as drugs, devices and medical 
procedures. Nonetheless, cost-effectiveness analyses do have potential for public health interventions 
too. The main question that precedes a cost-effectiveness analysis of public health interventions is the 
same as for health care interventions, namely whether the intervention offers value for money. However, 
the use of cost-effectiveness evidence, especially of public health prevention interventions, has been 
estimated to be limited. This is mainly due to the availability, quality and transparency of such evidence, 
the clarity of its presentation and the extent to which policy makers understand such analysis. Therefore, 
the first aim of this thesis was to assess the cost-effectiveness of 8 public health interventions in the 
continuum of prevention, that hold some promise to reduce the health burden at a reasonable or lower 
total cost. However, cost-effectiveness analyses of public health interventions involve some 
uncertainties, mainly due to the particularities of the field (Weatherly et al., 2009). Uncertainty in the 
public health intervention analyses should be acknowledged, e.g. concerning the future benefits (how 
long does the effect maintain), attribution of long-term effects based on intermediate effects, use of 
QALY as outcome measure …The second aim was to inform researchers, health professionals as well 
as policy makers on the interpretation of cost-effectiveness results in light of uncertainty and the use of 
such information by reporting and reflecting on the main uncertainties that were encountered in the 
included cost-effectiveness analyses.  
 
The first part of this PhD-thesis consisted of a general introduction outlining the research background. 
The second part represents the different health economic evaluations within each prevention category. 
Each of the case studies are based on a paper which has been published or submitted for publication 
in a peer-reviewed journal. The first evaluated intervention is categorised as universal prevention and 
concerns the obesity problem. It is estimated that more than half (52%) of the adult population in the 
European Union are overweight or obese (OECD, 2012a). Additionally, around 1 in 3 European children 
aged 6-9 years old are overweight or obese (Wijnhoven et al., 2014). Childhood obesity is associated 
with a higher chance of obesity, premature death and disability in adulthood, especially due to 
cardiovascular disease, diabetes, and cancer (Acosta, Manubay, & Levin, 2008; Baker, Olsen, & 
Sorensen, 2007; Venn et al., 2007). The ToyBox intervention is a kindergarten-based, family-involved 
intervention to prevent obesity in early childhood (3.5 to 5.5 year-olds). It was implemented throughout 
2012-2013 in Belgium, Bulgaria, Germany, Greece, Poland and Spain. The intervention focused on four 
key health behaviours being physical activity, sedentary behaviour, snacking behaviour and drinking 
behaviour. As this intervention targeted the pre-schooler population, it could have been categorised as 
a selective prevention intervention as well. However, as almost all children between 3.5 and 5.5 attend 
pre-school, it is assumed that this intervention has the potential to reach the total population. Moreover, 
this intervention targeted pre-schoolers not because they have a particular higher risk to become obese 
GENERAL INTRODUCTION 
 
25 
 
adults compared to for example adolescents, but rather because it is important to learn healthy habits 
in young-aged children as it has been shown that childhood behaviour may track to adulthood 
(Busschaert et al., 2015; Craigie, Lake, Kelly, Adamson, & Mathers, 2011; Friedman et al., 2008).  
The subsequent interventions included in this PhD-thesis within the universal prevention category cover 
the prevention of skin cancer in Belgium. Skin cancer affects nearly 1 in 5 persons in Belgium. The 
global incidence of skin cancer -basal cell carcinoma, squamous cell carcinoma and melanoma- 
continues to increase, due to demographic factors (ageing of the population), but also due to 
environmental factors (such as the atmospheric ozone) and behavioural factors (such as going on 
holiday more often or getting a check-up more frequently). UV radiation is the most preventable cause 
of all major types of skin cancer. Avoiding excessive UV exposure, use of sunscreen and protective 
clothing are effective preventive measures. Therefore, we evaluated the cost-effectiveness and budget 
impact of the implementation of a comprehensive national sensitising prevention campaign in Belgium. 
This intervention strategy has been shown to prevent skin cancer by reducing the incidence of sunburn 
(Hill, White, Marks, & Borland, 1993). Not only natural but also artificial UV radiation can cause skin 
cancer. Lately, sunbed bans are a topic of debate in several countries and up to now only Australia and 
Brazil have recently implemented such a total ban. In this PhD-research, the cost-effectiveness of 
implementing a total ban on sunbed use in Belgium was evaluated.  
The next interventions are classified as selective prevention as it concerns three interventions that 
restrict their target population to those assumed to be at increased risk to develop cancer. Many cancers 
-believed to be about 40%- can be prevented, some others can be detected at an early pre-clinical (or 
in some cases even pre-cancerous) stage, when there is high potential for cure. The greatest proportion 
of cancer deaths in Europe are attributable to lung, breast, colorectal, and prostate cancer (Ferlay et al., 
2013). In Flanders, a population-based breast cancer screening program has been organised since 
2001 and a colorectal cancer screening program since 2013. The cost-effectiveness of these screening 
programs have never been evaluated before. That is why in this thesis, the cost-effectiveness and the 
budget impact of both programs were assessed. Up to now, only few studies exist on the early detection 
of skin cancer. Based on a skin cancer screening trial organised in 2014 in two comparable regions in 
Belgium (Hoorens et al., 2016), the cost-effectiveness and budget impact of a one-time skin cancer 
screening were evaluated. The study considered two screening interventions, namely a one-time total 
body examination and a one-time lesion-directed screening. In the cost-effectiveness analysis, the 
results of this one-time screening were extrapolated to the Belgian population. Although the total-body 
examination is a universal prevention intervention, it was evaluated together with the lesion-directed 
screening intervention in one study. Therefore, both evaluations will be reported in the section of 
selective prevention interventions.   
A final intervention evaluated in this thesis was categorised as indicated prevention, targeting high-
risk persons with suicidal thoughts. In 2012, suicide was reported to be the thirteenth leading cause of 
death in Europe (WHO, 2014b). The suicide rate in Belgium is almost one third higher than the European 
average (OECD, 2012d). However, currently there is a lack of studies providing evidence on the 
effectiveness and cost-effectiveness of interventions for suicide prevention (Scott & Guo, 2012), 
particularly suicide helplines (Krysinska & De Leo, 2007). The suicide helpline in Flanders, called ‘De 
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Zelfmoordlijn’, has been set up in 1979, first by telephone and since 2005 it also offers chat sessions. 
In our study, the cost-effectiveness and budget impact of this suicide helpline was calculated.  
 
The third and final part of this thesis comprises the general discussion which summarises and reflects 
on the included studies, in terms of health economic results as well as the experienced methodological 
challenges. These findings will be put in a broader perspective and recommendations for researchers, 
policy makers and other stakeholders who may be funding, participating in, or making use of economic 
evaluations are discussed.
 
 
 
 
  
  
 
 
 
 
 
Part 2: Original research studies: health economic 
evaluations in the continuum of prevention 
 
2.1.    Universal prevention interventions 
  
  
 
  
  
 
 
 
 
 
2.1.1. Establishing a method to estimate the cost-
effectiveness of a kindergarten-based, family-involved 
intervention to prevent obesity in early childhood. The 
ToyBox-study 
 
 
 
 
 
 
 
Based on: 
Pil L, Putman K, Cardon G, De Bourdeaudhuij I, Manios Y, Androutsos O, Lateva M, Iotova V,  Zych 
K, Góźdź, González-Gil EM, De Miguel-Etayo P, Geyer C, Birnbaum J, Annemans L; The ToyBox-
study group (2014). Establishing a method to estimate the cost-effectiveness of a kindergarten-based, 
family-involved intervention to prevent obesity in early childhood. The ToyBox-study. Obesity Reviews, 
15 Suppl 3, 81-89
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ABSTRACT 
Overweight and obesity in children are recognised as a major health problem. The ToyBox-intervention 
was developed with the aim of preventing obesity in pre-schoolers. Because it is increasingly important 
to inform policy makers not only on the effects of prevention interventions, but also on their costs and 
cost-effectiveness, our purpose was to establish a method to estimate the cost-effectiveness of the 
ToyBox-intervention. In order to estimate the long term impact of the ToyBox-intervention on health and 
societal costs, extrapolations of the intervention effect will be conducted to predict children’s weight 
status (based on the body mass index) at adult age. Effects of the adult weight status on the prevalence 
of obesity-related complications will be modelled through a Markov model, with a total time horizon of 
70 years and a cycle length of 1 year. The analyses will be performed separately for six European 
countries participating in the ToyBox-intervention, based on country-specific economic and 
epidemiological data. This study describes the methodological rationale and implementation of an 
analytic model to examine the cost-effectiveness of the ToyBox-intervention, in order to inform policy 
makers on the value for money of this intervention in the prevention of obesity in pre-schoolers. 
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INTRODUCTION 
The prevalence of overweight and obesity in pre-schoolers has substantially increased worldwide (De 
Onis, Blossner, & Borghi, 2010). Non-active lifestyles and non-healthy eating patterns have an important 
impact on this trend (Acosta et al., 2008; Liebman et al., 2003). Published literature has shown that 
obese children have a higher risk to be obese at adult age (Herman, Craig, Gauvin, & Katzmarzyk, 2009; 
Venn et al., 2007) and that obesity in children is associated with a higher risk for later chronic diseases 
such as heart disease (Baker et al., 2007). The trend of increasing prevalence of overweight and obese 
children and adults results in a rising societal impact due to higher health care costs and productivity 
loss (Konnopka, Bodemann, & Konig, 2011; Kwaliteitsinstituut voor de gezondheidszorg CBO, 2008). 
The ToyBox-study (short for ‘Multifactorial evidence based approach using behavioural models in 
understanding and promoting fun, healthy food, play and policy for the prevention of obesity in early 
childhood’) aimed to develop, implement and evaluate a kindergarten-based, family-involved 
intervention to prevent obesity in early childhood (Manios et al., 2012). Cost-effectiveness studies of 
health (care) programs are needed in order to inform policy makers on the value for money of a particular 
program (Cawley, 2007; Wang et al., 2008). Although the ToyBox-intervention effect is not yet 
evaluated, the current paper describes the design and data inputs of the health economic model used 
to estimate the long term costs and potential health effects of implementing the ToyBox-intervention, in 
the six intervention countries, namely, Belgium, Bulgaria, Germany, Greece, Poland and Spain. 
 
METHODS 
The ToyBox-intervention  
The ToyBox-intervention was a randomised cluster trial which was implemented throughout the 
academic year 2012–2013 in Belgium, Bulgaria, Germany, Greece, Poland and Spain (Manios et al., 
2012; Manios, 2012; Manios et al., 2014). The intervention targeted four key health behaviours, found 
to be associated with early obesity, in pre-schoolers aged 3.5-5.5 years old, namely drinking behaviour, 
snacking behaviour, physical activity and sedentary behaviour. Teachers from recruited kindergartens, 
assigned to the intervention group, were expected to make environmental changes in the 
classroom/kindergarten, such as installation of water stations and the ‘magic snack plate’, and to 
promote the four targeted energy balance-related behaviours (EBRBs) in the classroom/kindergarten, 
by for example implementing interactive classroom activities, for minimum 1 hour per week. Three 
training sessions were organised in order to provide detailed information to the teachers on how to 
implement the intervention (Androutsos et al., 2014b). Besides, parents were encouraged to apply 
relevant environmental and social changes at home, by means of newsletters, tip cards and posters that 
the children took home. More information on the design the study can be found in Manios et al. (2014). 
Alongside the intervention, a health economic evaluation will be conducted, estimating the long term 
costs and health benefits of the ToyBox-intervention.  
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Model structure 
The health economic model developed for the ToyBox-intervention is a combined model consisting of a 
decision analytic model to represent either the probability of improved EBRBs or improved weight status 
(based on body mass index (BMI)) and a Markov model simulating over a lifetime the occurrence of 
obesity-related complications with and without the intervention. The target population of the model 
consists of European pre-schoolers, between 3.5 and 5.5 years old. The difference in costs over a period 
of 70 years will be divided by the net effects (in quality-adjusted life years, QALYs) to obtain the primary 
outcome measure, the incremental cost- effectiveness ratio: (Costs intervention group – Costs control group) / 
(QALYs Intervention group – QALYs control group).  
There are three effect scenarios based on the possible anticipated consequences of the intervention: 
an effect either on the key EBRBs of the pre-schoolers targeted in the ToyBox-intervention (snacking 
behaviour, drinking behaviour, physical activity, sedentary behaviour), on anthropometric measures of 
the pre-schoolers or on both (Figure 1a). As chronic diseases start to develop at adult age, a long term 
extrapolation of the effect of the ToyBox-intervention on the pre-schoolers’ EBRBs or on the pre-
schoolers’ anthropometrics to the adult age is necessary. Currently no studies are available that 
investigated the direct association between pre-schoolers’ health behaviour and obesity-related 
diseases at adult age, hence the extrapolation needs to be made through adult weight status10. The 
effect scenario and the long term extrapolation make up the first part of the model. The second part of 
the model is a Markov model simulating the incidence of the main chronic diseases associated with 
obesity (type 2 diabetes, stroke, coronary heart disease (CHD), breast cancer, colorectal cancer) and 
mortality from the age of 30 years onwards (Figure 1b). For the first part of the model, tracking studies 
will be used that estimate the relationship between EBRBs or anthropometrics at pre-school age, on the 
one hand, and the weight status at adult age on the other hand. If anthropometric measures and/or 
healthy EBRBs in childhood improve as a consequence of the ToyBox-intervention, this will result in a 
shift in the prevalence of overweight or obesity at adult age. The relationship between weight status at 
adult age and obesity-related complications is obtained from the International Association for the Study 
of Obesity (2013). Hence, the impact on those obesity-related complications (and associated costs) at 
older age with the early childhood intervention can be calculated indirectly.  
Extrapolation to adult weight status 
First scenario: effect on weight status of the pre-schoolers 
A first approach is modelling the (possible) intervention effect on the weight status of the children (i.e. 
change in the proportions of pre-schoolers who are normal weight, overweight or obese11), whereby we 
make use of the tracking study of Venn et al. (2007) to estimate the proportions of pre-schoolers that 
will be normal weight, overweight or obese at adult age based on their pre-school weight post-
                                                          
10 According to the WHO norms: normal weight: <25 kg m2; overweight: 25.0-29.9 kg m2; obese: ≥30 kg m2 (WHO, 
2013). 
11 According to the cut-off values developed by Cole et al. (2000), adopted by the International Obesity Task 
Force  
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intervention. In this way the (possible) intervention effect on weight status can be extrapolated from pre-
schooler age to adult age. 
Second scenario: effect on pre-schoolers’ energy balance-related behaviours 
A second approach is the modelling based on change in the EBRBs. If the ToyBox-intervention would 
have an effect on the EBRBs of the children that are targeted in the ToyBox-intervention, two methods 
could be used to extrapolate the effect to the adult weight status (Figure 1a). Dependent on the available 
evidence in published literature, the effect on childhood behaviours can be extrapolated directly to the 
weight status at adult age, or indirectly via weight status at mid-term child age (De Coen, De 
Bourdeaudhuij, Verbestel, Maes, & Vereecken, 2013; Dubois, Farmer, Girard, & Peterson, 2007).  
 
Figure 1a: Model structure: extrapolation of the two possible intervention effects to the weight status at 
adult age (30-34 years) and the long term effect on the prevalence of the chronic diseases  
  
EBRB: Energy balance-related behaviour; Narrow arrows: intervention effect; broad arrows: modelling.  
 
Effect of the intervention: relative risk reduction 
The effect of the intervention in the total sample (on the EBRBs or on the weight status of the pre-
schoolers) will be extrapolated and modelled to the adult weight status. Hence, this intervention effect 
will be calculated as the relative risk reduction (RRR) in adult overweight/obesity in the intervention 
group, compared to the control group. This RRR will then be applied to the country-specific probabilities 
of the weight categories in the general adult population (Eurostat, 2008a), which is the starting 
population for the Markov model. 
Modelling to the disease states 
The Markov model includes the following states: ‘free-of- events’, type 2 diabetes, colorectal cancer, 
breast cancer (in females), stroke, CHD and death from any cause (Figure 1b). All events, except type 
2 diabetes, consist of a first year state and a follow-up state, as these follow-up states are associated 
with different quality-of-life levels and costs. The model has a 1-year cycle, i.e. transitions between 
states are allowed once a year. All individuals in the Markov model target population start the model in 
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the age-category 30-34 years in the free-of-events state. At the end of the first year, individuals remain 
event free or move to one of the event states, based on the weighted average disease incidences (cf. 
infra).  The first year in colorectal cancer, breast cancer, stroke and CHD are transitional states, i.e. one 
could only remain for one cycle in this state, after which one moves to the follow-up state or dies. 
Recurrence while being in follow-up is accounted for in the cost- and quality of life-measures. All 
individuals from the target cohort stay in the model until they die or until they reach the age of 100. Ten 
age categories are integrated in the model. Every age category and gender is associated with specific 
state transition probabilities. It should be taken into account that this model is a simplification of real life 
as suffering from more than one of the included chronic diseases at a time is not allowed in the model. 
 
Figure 1b: Model design: Markov model of health states and possible transitions between them during each 
1-year cycle. 
 
1 = first year after diagnosis; 1+ = follow-up year; CHD = coronary heart disease 
 
Transition probabilities  
Age- and gender-dependent transition probabilities to the disease states are calculated based on 
country-specific disease incidences (Appendix Table 1), mortality rates and relative risks of the different 
weight categories on a particular disease (Table 1). The same relative risk estimates for each disease 
are applied to all countries, assuming there is no interaction between the weight status of an adult person 
and that person’s country of residence on the associations (International Agency for Research on 
Cancer, 2002). Also, it was assumed that the relative risk estimates are the same for all age groups, 
except for breast cancer, where the distinction is made between premenopausal (<50 years) and 
postmenopausal breast cancer (>50 years). Based on these relative risk estimates, the disease 
Colorectal c 1+
CHD 1+
Stroke 1+
Breast c 1+
Diabetes
Colorectal c 1
Breast c 1
Stroke 1
CHD 1
DeathFree of events
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incidence associated with the different weight categories is calculated from the average country-specific 
disease incidence. The weighted averages of these specific incidences, making use of the Eurostat 
weight status probabilities (Eurostat, 2008a), is used as transition probabilities to the disease states. 
Hence, if the proportions in the adult weight status categories would change because of the ToyBox-
intervention, then the weighted average disease incidence will change. 
Table 1: Relative risks on chronic diseases for overweight and obese adults, in reference to normal weight 
adults, separately for males and females  
Disease 
Relative risk 
overweight obesity 
males females males females 
Diabetes 2.25 2.30 5.50 7.00 
Colorectal cancer 1.20 1.08 1.40 1.10 
Breast cancer 1.00  1.00  
 premenopausal (<50 years)  1.00  1.00 
 postmenopausal (≥50 years)   1.12   1.25 
Stroke 1.20 1.20 1.50 1.55 
Coronary heart disease 1.35 1.35 2.00 2.00 
     
  (International Association for the Study of Obesity, 2013) 
Cost data 
The health economic analysis will assume a societal perspective, i.e. including both the costs to the 
health care sector as well as costs related to productivity loss. Therefore, costs related to the disease 
states are split into direct medical costs for the health care sector and ‘indirect’ productivity related costs, 
the latter using the friction cost method, as explained further (Koopmanschap & van Ineveld, 1992). To 
calculate the cost of the intervention, all costs that are directly incurred by the intervention are included. 
The reference year of all costs is 2012, corresponding to the year of the start of the ToyBox-intervention. 
Intervention costs  
The country-specific cost of the ToyBox-intervention is calculated, based on the cost of the ToyBox 
material and delivery (cost of the design and production process not included), the cost of the teacher 
training sessions and other implementation attributable expenses such as transport to the kindergartens 
for trainings and the extra time spent by teachers on the intervention (beyond the class time, such as 
reading, preparing, talking to parents). In total three training sessions (conducted by the research staff) 
were organised for the teachers in order to train them for implementing the intervention as accurately 
as possible and to evaluate their experiences at different time points (Androutsos et al., 2014b). 
According to the method described by Kesztyus et al. (2013), costs for the development of the 
intervention materials as well as costs for the scientific evaluation are not included, and only costs that 
would be incurred by a repeated implementation are assessed. No costs were assigned to the control 
groups. 
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Each intervention class received one plastic box, including material for 25 pre-schoolers/families, 
namely, eight tip cards for the parents/caregivers (two per behaviour), nine newsletters for the 
parents/caregivers (one general + two per behaviour), four posters (one per behaviour), one binder with 
five types of handbooks for the teacher: one teacher general guide, four classroom activity guides, i.e. 
one for each of the targeted behaviours, and one hand puppet (De Craemer et al., 2014; Duvinage et 
al., 2014). A total cost for material boxes is assigned to every school, based on the amount and size of 
intervention classes per school.  
The costs related to the training sessions include direct travel costs to the venue of training sessions for 
teachers as well as trainers, time spent in travel, duration of the sessions and extra costs related to 
catering, renting the venue and possible incentives for teachers (Androutsos et al., 2014b). These costs 
were recorded via training session questionnaires by the ToyBox research staff and the teachers. 
Monthly diaries, filled out by the ToyBox research staff, captured the time ToyBox research staff spent 
on the preparation of the sessions. Time teachers spent on the training session (transport to and 
duration of the training) was calculated via ToyBox research staff’s and teachers’ training reports, filled 
out after every session by the teachers and the ToyBox research staff. Missing data of teachers on 
means of transport, amount of kilometers and time spent on transport were imputed using averages of 
the available information for that country. Average salary costs (gross salary + contribution of the 
employer) of kindergarten teachers and research staff (with on average 2-3 years of experience) were 
obtained from the partner countries. The salary cost related to classroom time of teachers was not 
included in the intervention as we assume that this is not extra invested time. However, the extra time 
teachers have spent on the ToyBox-intervention is captured in the cost calculation as well as the time 
teachers were at a training session (duration of the training and time spent on transport).  
To calculate other implementation-related costs, such as labour costs and transportation costs of 
teachers and research staff during the intervention months (besides training sessions), diaries and 
transport questionnaires were compiled and filled out by all research staff of each country. 
Transportation costs were based on the average refund for work-related car expenses. Process 
evaluation tools (teachers’ training evaluation forms and monthly logbooks) were used to assess the 
costs associated with the teachers (extra time spent and extra material bought) (Androutsos et al., 
2014a). Labour costs of teachers were based on the average gross salary. 
The country-specific cost of the intervention is expressed as an average cost per 1,000 pre-schoolers 
(Table 2). In total 68, 41, 126, 137, 63 and 47 intervention classes, respectively in Belgium, Bulgaria, 
Germany, Greece, Poland and Spain participated in the ToyBox-study. As explained before, every 
intervention class received a box of materials. The cost of the box was obtained from the manufacturer 
(AOK-Verlag) and amounted to €45.2 per box. Delivery cost of the material boxes ranged from €2.2 to 
€11.2 per school delivery. The work-related kilometer refund, used in the calculations of the transport 
cost, in Belgium, Bulgaria, Germany, Greece, Poland and Spain, was respectively €0.35, €0.15, €0.35, 
€0.2, €0.17 and €0.19 per kilometer. The price per one-way ticket of public transport was, respectively 
€1.2, €0.51, €2.5, €1.4, €0.88 and €1.25. The total cost related to the trainings sessions (transport and 
labor cost) for research staff and teachers was respectively €3,755 and €917 in Belgium, €488 and 
€1,332 in Bulgaria, €8,110 and €6,111 in Germany, €3,223 and €6,942 in Greece, €1,326 and €1,948 
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in Poland, and €815 and €844 in Spain. The greatest contributors to the total training session cost, per 
1,000 pre-schoolers, in Greece, Poland and Spain was the labor cost of the teachers, in Belgium and 
Germany the labor cost of the research staff, and in Bulgaria the extra costs -for extra materials and 
services during the training sessions. 
 
Table 2: Country-specific intervention costs (in 2012 euro) 
   Belgium Bulgaria Germany Greece Poland Spain 
Material boxes € 3,076 € 1,854 € 5,699 € 6,873 € 2,827 € 2,126 
Delivery of material boxes € 168 € 69 € 200 € 136 € 172 € 136 
Transport study staff for training sessions € 874 € 41 € 1,262 € 177 € 98 € 15 
Transport teachers for training sessions € 182 € 562 € 1,409 € 1,764 € 208 € 119 
Labor cost study staff for training sessions € 2,881 € 457 € 6,848 € 3,046 € 1,228 € 800 
Labor cost teachers for training sessions € 735 € 770 € 4,702 € 5,178 € 1,740 € 725 
Extra costs for training sessions € 16 € 1,473 € 126 € 801 € 0 € 0 
Labor cost study staff intervention months € 1,894 € 699 € 5,369 € 4,823 € 1,487 € 1,699 
Labor costs teachers intervention months € 3,272 € 714 € 10,905 € 8,538 € 484 € 2,642 
Transport cost study staff intervention months € 416 € 79 € 0 € 456 € 43 € 170 
Extra costs teachers intervention months € 564 € 350 € 2,211 € 1,661 € 25 € 1,116 
Number of kids receiving the intervention material 1243 1164 1343 3132 1584 1068 
Total cost per 1,000 pre-schoolers € 11,325 € 6,074 € 28,840 € 10,681 € 5,248 € 8,940 
 
 
Costs per disease state  
Costs per disease state in the model are derived from national and international sources, to obtain 
country-specific annual costs per person per disease state (Table 3). Direct medical costs as well as 
indirect economic costs (due to productivity loss) are captured in the model. To take into account the 
prevalence of diabetes in people with breast cancer or colorectal cancer, 23.8% of the total diabetes 
cost was added to the total cost of breast cancer and 38.2% of the total diabetes cost was added to the 
total cost of colorectal cancer (Sanchez Peralta, Oliveras-Lopez, Perez, Martinez, & Lopez-Garcia de la 
Serrana, 2012). To calculate indirect costs due to morbidity and mortality, the friction cost method is 
used. This method states that ‘disease may cause losses in production, but in general this loss will be 
confined to a period needed to adapt to the changed situation of work absence’ (Koopmanschap & van 
Ineveld, 1992). To calculate the cost of death, an average friction period length of 160 days, based on 
the report of Hakkaart-van Roijen and colleagues (2010), is multiplied by the average cost of one day 
absenteeism (Securex, 2010). The indirect cost per disease state is calculated based on the ratio of 
  38  
 
total and direct cost derived from Dutch literature (making use of the friction cost method). This ratio is 
applied to the disease states in every country. These indirect costs are only applied to productive age 
categories (30-65 years) and accounting for the average unemployment rate per country. As future costs 
and benefits are of less value than current cost and benefits, discounting future values to present values 
is applied. Annual discount rates of 3% and 1.5% are applied to future costs and effects respectively, 
as recommended by the Belgian Knowledge Centre for Health care (Cleemput et al., 2012). If costs for 
certain disease states were unavailable for some countries, they were imputed by the multiple imputation 
procedure in the statistical software program STATA, StataCorp, College Station, Texas, USA. 
Quality-of-life data  
QALYs are calculated by multiplying the utility level for a given condition (a health-related quality-of-life 
weight ranging between 0 and 1) with the numbers of years an individual lives with the particular 
condition. A utility of 1 is equal to perfect health, whereas 0 stands for death. Per country, age-specific 
EQ-5D utilities (i.e. quality-of-life indices used to calculate QALYs) per first year state and per follow-up 
year state were obtained from published literature (Table 4). The overall life satisfaction of people seems 
to be clustered in regions (Eurostat, 2015b), showing no big differences between the participating 
countries, except for Bulgaria. Therefore, if utilities for a certain state were not available for the particular 
country, published utilities from a nearby country were used. For Bulgaria, no utility data was available. 
Therefore, we used the utility data applied to the Belgian case, applying a ratio of 0.7 (Eurostat, 2015b). 
Sensitivity analyses  
One-way and probabilistic sensitivity analyses will be conducted to capture uncertainty in the main 
parameters. The individual effect of the intervention cost, total costs per disease state, the intervention 
effect, the relative risk of tracking for overweight and for obesity from childhood to adulthood, the relative 
risk of adult overweight and obesity on obesity-related diseases, disease incidence and the utilities per 
disease state will be evaluated in case of better or worse conditions of these parameters -defined by the 
confidence interval or ±30% variation in case confidence intervals were absent. A probabilistic analysis 
will vary these parameter values simultaneously by their own probability distribution. Cost data are 
assumed to be distributed according to a gamma-distribution, disease incidence and utilities according 
to a beta-distribution and relative risks according to a log-normal distribution (Briggs et al., 2006).  
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Table 3: Annual country-specific direct and indirect costs associated with the model diseases (per person).  
  Belgium1 Bulgaria2 Germany3 Greece4 Poland5 Spain6 
Direct cost diabetes € 3,038 € 1,790* € 3,038 € 1,502 € 1,574 € 2,938 
Indirect cost diabetes € 619 € 345 € 631 € 257 € 301 € 485 
Direct costs CRC € 25,451 € 4,375* € 31,008 € 24,677* € 7,038 € 27,395* 
Indirect costs CRC € 16,494 € 2,683 € 20,501 € 13,422 € 4,287 € 14,377 
Direct cost CRC FU € 8,596 € 2,536* € 6,452 € 6,310* € 7,038 € 12,158* 
Indirect cost CRC FU € 5,571 € 1,555 € 4,266 € 3,432 € 4,287 € 6,380 
Direct cost BC € 13,156 € 9,516* € 34,663* € 23,329* € 8,741 € 16,707 
Indirect cost BC € 8,648 € 5,837 € 22,917 € 12,689 € 5,324 € 8,768 
Direct cost BC FU € 3,171 € 7,843* € 11,223* € 9,182* € 8,741 € 3,001 
Indirect cost BC FU € 2,055 € 4,810 € 7,420 € 4,994 € 5,324 € 1,575 
Direct cost stroke € 11,531 € 881 € 21,227 € 5,780 € 2,989 € 6,151 
Indirect cost stroke € 854 € 54 € 1,403 € 314 € 182 € 323 
Direct cost stroke FU € 4,882 € 275 € 6,281 € 3,000 € 1,096 € 2,525 
Indirect cost stroke FU € 316 € 17 € 415 € 163 € 67 € 133 
Direct costs CHD € 6,001 € 1,368 € 5,975 € 6,418 € 1,394 € 5,325* 
Indirect cost CHD € 389 € 84 € 395 € 349 € 85 € 279 
Direct cost CHD FU € 1,658 € 474 € 1,019 € 3,000 € 465 € 2,072* 
Indirect cost CHD FU € 107 € 29 € 67 € 163 € 28 € 109 
Cost death € 44,800 € 4,684 € 45,163 € 26,159 € 11,734 € 28,798 
 
BC = breast cancer; CRC = colorectal cancer;  FU= follow-up; * Imputed costs  
1 (Annemans, Lamotte, Clarys, & Van den Abeele, 2007; Hakkaart-van Roijen, 2010; Lamotte, Annemans, Evers, & Kubin, 2006; Pacolet, De Coninck, Hedebouw, Cabus, 
& Spruytte, 2011; Securex, 2010; Steuten et al., 2007; Van Gelder & Annemans, 2011; Williams, Van, & Lucioni, 2002)  
2 (De Smedt et al., 2012; Kimman et al., 2011; Leal et al., 2006; Steuten et al., 2007)  
3  (Cook et al., 2004; Haug, Engel, Linder, & Verheyen, 2012; Kimman et al., 2011; Leal et al., 2006; Steuten et al., 2007; Williams et al., 2002)  
4 (Athanasakis et al., 2010; Fragoulakis, Kourlaba, & Maniadakis, 2012; Kimman et al., 2011; Leal et al., 2006; Steuten et al., 2007)  
5 (Carles et al., 2011; Dane i analizy, 2010; De Smedt et al., 2012; De Smedt et al., 2013; Kimman et al., 2011; Kinalska et al., 2003; Leal et al., 2006; Steuten et al., 
2007)  
6 (Ballesta, Carral, Olveira, Giron, & Aguilar, 2006; Carles et al., 2011; Kimman et al., 2011; Leal et al., 2006; Lopez-Bastida et al., 2012; Steuten et al., 2007) 
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Table 4: ranges of utilities per country, dependent on age, used to calculate the adjusted quality of life-
years.  
 Belgium1 Bulgaria2 Germany3 Greece4 Poland5 Spain6 
Free of events 0.68-0.84 0.48-0.59 0.86-0.94 0.65-0.92 0.76-0.94 0.67-0.94 
Diabetes 0.52-0.70 0.34-0.46 0.73-0.81 0.49-0.76 0.47-0.65 0.49-0.76 
CRC 0.45-0.63 0.29-0.41 0.49-0.57 0.42-0.69 0.40-0.58 0.33-0.60 
CRC FU 0.37-0.64 0.31-0.42 0.52-0.60 0.45-0.72 0.43-0.60 0.37-0.64 
BC 0.65-0.83 0.43-0.55 0.69-0.77 0.62-0.89 0.60-0.78 0.53-0.80 
BC FU 0.68-0.86 0.45-0.56 0.72-0.80 0.65-0.92 0.63-0.81 0.60-0.87 
Stroke 0.47-0.65 0.31-0.42 0.59-0.67 0.38-0.65 0.49-0.67 0.40-0.67 
Stroke FU 0.51-0.69 0.33-0.45 0.63-0.71 0.48-0.75 0.46-0.64 0.30-0.57 
CHD  0.54-0.79 0.27-0.38 0.66-0.74 0.53-0.80 0.41-0.59 0.47-0.74 
CHD FU 0.61-0.79 0.40-0.52 0.70-0.78 0.59-0.86 0.57-0.75 0.50-0.77 
 
CRC = colorectal cancer; BC = breast cancer; CHD = coronary heart disease; FU = follow up 
1 (De Smedt et al., 2013; Dorman, Dennis, & Sandercock, 2000; Heyworth, Hazell, Linehan, & Frank, 2009; Kimman et al., 2011; Kramer et al., 2012; 
Stouthard, Essink-Bot, & Bonsel, 2000; Scientific Institute of Public Health., 2013; Whynes, 2013; Wiering et al., 2010)  
2 Sources used for Belgium * 0.7 (based on the information from Eurostat (Eurostat, 2015b))  
3 (De Smedt et al., 2013; Haacke et al., 2006; Kimman et al., 2011; Kramer et al., 2012; Ose et al., 2009; Schweikert et al., 2009; Stouthard et al., 2000; 
Whynes, 2013; Wiering et al., 2010)  
4 (Dorman et al., 2000; Heyworth et al., 2009; Kimman et al., 2011; Kontodimopoulos et al., 2008; Spiraki, Kaitelidou, Papakonstantinou, Prezerakos, & 
Maniadakis, 2008; Stouthard et al., 2000; Whynes, 2013; Wiering et al., 2010)  
5 (De Smedt et al., 2013; Dorman et al., 2000; Golicki, Niewada, Jakubczyk, Wrona, & Hermanowski, 2010; Heyworth et al., 2009; Jegier et al., 2009; 
Kimman et al., 2011; Stouthard et al., 2000; Whynes, 2013; Wiering et al., 2010)  
6 (Cunillera et al., 2010; De Smedt et al., 2013; Kimman et al., 2011; Kramer et al., 2012; Lopez-Bastida et al., 2012; Mata Cases, Roset Gamisans, Badia 
Llach, Antonanzas Villar, & Ragel Alcazar, 2003; Moro-Valdezate et al., 2013; Stouthard et al., 2000; Whynes, 2013; Wiering et al., 2010) 
 
DISCUSSION 
The ToyBox-intervention is a kindergarten-based, family- involved intervention, focusing on pre-school 
snacking and drinking behaviour, physical activity and sedentary behaviour (Manios et al., 2014). 
Obesity prevention provides a major opportunity to improve population health. As health improvements 
usually require additional and scarce resources, novel interventions should be economically evaluated 
(Lehnert, Sonntag, Konnopka, Riedel-Heller, & Konig, 2012). The current paper described the methods 
and the data inputs for the cost-effectiveness analysis of the ToyBox-intervention. In the prevention of 
obesity, health benefits may slowly accumulate over time. The aim of the cost-effectiveness analysis is 
to estimate the long term impact of the ToyBox-intervention on the prevalence of obesity-related 
complications in comparison with current practice (i.e. no ToyBox-intervention). This will result in 
estimates of the long term costs or savings and health benefits in six European countries where the 
intervention was implemented, to inform policy makers about whether the intervention is worth the 
money. Extrapolations of the intervention effect to the adult age are necessary because, in general, 
chronic diseases start to develop at adult age. We tried to collect country-specific information on costs, 
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disease incidences and quality-of-life data. The intervention cost captures all expenses associated with 
implementing the intervention, including the cost for personnel and teachers, training sessions, 
transportation of training personnel and teachers, intervention materials and extra materials if 
necessary. The same method was used in other cost-effectiveness analyses of school-based prevention 
programs such as the study of Wang et al. (2008). The largest part of the intervention cost was due to 
personnel costs (labor cost of research staff and teachers), accounting for on average 58% of the total 
cost. Wang et al. observed a similar pattern, with 63% of the total intervention cost spent on personnel 
(2008). Differences in the cost for the material between countries (Germany and Greece versus Belgium, 
Bulgaria, Poland and Spain) were due to the fact that in Germany and Greece there were more partici-
pating classes, and in Germany these classes consisted on average of less pre-schoolers (on average 
11 versus 23 in the other countries). The higher costs for training sessions in Greece and Germany were 
due to the fact that the teachers had spent much time to the transportation to the training sessions in 
reference to the other intervention countries and because the researchers had spent more time per 
teacher to the training session and to transportation in reference to the other intervention countries. The 
higher other implementation-related expenses in Greece and Germany were caused by teachers and 
researchers spending more (extra) time to the intervention in reference to the other intervention 
countries. However, because there were more participating pre-schoolers in Greece than in Germany, 
the total intervention cost per 1,000 pre-schoolers is much lower in Greece in reference to Germany. 
The total intervention cost in Poland and Bulgaria was low in reference to the other countries, mainly 
because of the low personnel costs. Literature on country-specific direct medical costs of the included 
diseases in our model is very scarce. Therefore, many different sources and data sets had to be 
consulted and missing data had to be statistically imputed. It is possible that the disease costs in the 
countries included in our study captured different medical acts, but this was not always reported. 
However, the differences between the countries in the annual costs per disease state (Table 3) reflect 
the variations in per capita gross domestic product (GDP). Only for breast cancer there are no big 
differences in cost between Bulgaria and Poland, on the one hand, and Belgium, Germany and Greece, 
on the other hand. This could be due to the fact that other types of costs are included in the direct 
medical cost of breast cancer in the first two countries; however, this was not clearly reported. 
Until now, this is the first cross-European intervention aiming to prevent obesity in pre-schoolers and to 
assess its cost-effectiveness. The general method for calculating the cost-effectiveness of such a health 
promoting program, namely taking into account the generated health effect in the target group and the 
economic consequences for the society, and more specifically, the tracking method, namely the 
estimation of adult weight status based on childhood weight status/EBRBs, has been reported previously 
in cost-effectiveness analyses of overweight programs (Brown et al., 2007; Hagberg & Lindholm, 2005). 
However, our study design can guide and inform other cost-effectiveness analyses of childhood obesity 
prevention programs as it also accounts for the anticipated potential effect of the intervention on EBRBs. 
Nonetheless, there are some limitations to the analysis, due to its multicenter nature. First, as country- 
specific cost and quality-of-life data were not always available, some imputations had to be conducted 
for the direct cost of certain diseases. Second, a critical point in effectiveness and cost-effectiveness 
studies in the field of child health promotion is the use of BMI as a measure of child weight status, as it 
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does not distinguish between muscle mass and fat mass. In our health economic analysis of the ToyBox-
intervention, we need to rely on literature reporting the link between child overweight/obesity and adult 
overweight/obesity, and the association of adult overweight/obesity with morbidity. However, as 
literature describing the relation between waist circumference - argued to be a better measure for 
overweight and obesity - and morbidity is scarce, weight status (based on BMI) was used as an effect 
measure. Finally, if the ToyBox-intervention would have an effect on children’s EBRBs, some 
assumptions will have to be made concerning the extrapolation to adult age, as literature on the impact 
of EBRBs on later health and weight status is scarcer than literature on the impact of child weight status 
on later weight status. However, including more indirect relations into a model is associated with 
including more uncertainty. This uncertainty will be addressed in the cost-effectiveness analysis. 
CONCLUSION 
In summary, it is clear that early intervention efforts are needed to prevent obesity later in life. However, 
because financial resources are scarce, cost-effectiveness analyses are necessary to inform the choices 
of decision-makers. The aim of this study was to communicate an extensive description of the health 
economic model design and data inputs in order to better understand how the cost-effectiveness 
analysis of the ToyBox-intervention is performed and to guide other cost-effectiveness analyses of 
childhood obesity prevention programs.  
 
 
  
 
 
 
APPENDIX  
Appendix Table 1a: Age- and gender specific disease incidences in Belgium 
  BELGIUM 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.09% 0.14% 0.21% 0.31% 0.44% 0.59% 0.74% 0.86% 0.92% 0.88% 
Incidence colorectal cancerb 0.01% 0.01% 0.01% 0.03% 0.06% 0.11% 0.16% 0.27% 0.34% 0.49% 
Incidence strokec 0.03% 0.05% 0.07% 0.11% 0.17% 0.25% 0.37% 0.56% 0.84% 1.88% 
Incidence CHDd 0.01% 0.07% 0.07% 0.20% 0.20% 0.59% 0.59% 0.73% 1.11% 1.11% 
           
  BELGIUM 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.07% 0.10% 0.16% 0.23% 0.33% 0.45% 0.56% 0.65% 0.70% 0.64% 
Incidence colorectal cancerb 0.00% 0.01% 0.01% 0.03% 0.04% 0.08% 0.11% 0.16% 0.20% 0.38% 
Incidence breast cancerb 0.04% 0.09% 0.16% 0.25% 0.31% 0.34% 0.42% 0.41% 0.38% 0.37% 
Incidence strokec 0.03% 0.04% 0.06% 0.09% 0.13% 0.20% 0.29% 0.44% 0.66% 1.62% 
Incidence CHDd 0.01% 0.01% 0.01% 0.13% 0.13% 0.12% 0.12% 0.17% 0.51% 0.51% 
a Source: (Rijksinstituut voor Volksgezondheid, 2011a); b Source: (Belgian Cancer Registry, 2009); c Source: (Rijksinstituut voor Volksgezondheid, 2011b); d Source: (Van Herck et al., 2009) 
  
  
 
 
 
Appendix Table 1b: Age- and gender specific disease incidences in Bulgaria 
  BULGARIA 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.10% 0.15% 0.23% 0.34% 0.49% 0.65% 0.82% 0.95% 1.03% 0.97% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.03% 0.06% 0.12% 0.19% 0.26% 0.33% 0.35% 
Incidence strokec 0.34% 0.34% 0.34% 0.34% 0.34% 0.73% 0.73% 1.03% 1.03% 2.15% 
Incidence CHDa 0.01% 0.11% 0.11% 0.29% 0.29% 0.86% 0.86% 1.06% 1.61% 1.61% 
           
  BULGARIA 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.07% 0.11% 0.17% 0.26% 0.37% 0.49% 0.62% 0.72% 0.78% 0.71% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.03% 0.05% 0.08% 0.11% 0.15% 0.18% 0.20% 
Incidence breast cancerb 0.02% 0.02% 0.09% 0.12% 0.15% 0.17% 0.19% 0.20% 0.19% 0.19% 
Incidence strokec 0.09% 0.09% 0.09% 0.09% 0.09% 0.49% 0.49% 0.81% 0.81% 1.93% 
Incidence CHDa 0.02% 0.03% 0.02% 0.14% 0.09% 0.29% 0.19% 0.32% 0.63% 0.61% 
a Imputation based on diabetes prevalence; b (GLOBOCAN, 2008); c (Powles, Kirov, Feschieva, Stanoev, & Atanasova, 2002) 
 
  
  
 
 
 
Appendix Table 1c: Age- and gender specific disease incidences in Germany 
  GERMANY 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.41% 0.41% 0.41% 0.41% 0.41% 0.41% 0.41% 0.86% 0.86% 0.86% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.03% 0.06% 0.11% 0.17% 0.25% 0.33% 0.44% 
Incidence strokec 0.01% 0.03% 0.03% 0.13% 0.13% 0.37% 0.37% 0.58% 0.58% 1.25% 
Incidence CHDd 0.00% 0.04% 0.03% 0.23% 0.16% 0.87% 0.59% 0.76% 0.77% 0.73% 
           
  GERMANY 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.22% 0.22% 0.22% 0.22% 0.22% 0.22% 0.22% 0.33% 0.33% 0.33% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.02% 0.04% 0.06% 0.09% 0.12% 0.16% 0.27% 
Incidence breast cancerb 0.02% 0.02% 0.10% 0.16% 0.22% 0.28% 0.34% 0.36% 0.27% 0.34% 
Incidence strokec 0.01% 0.02% 0.02% 0.15% 0.15% 0.24% 0.24% 0.48% 0.48% 1.05% 
Incidence CHDd 0.01% 0.01% 0.01% 0.23% 0.15% 0.14% 0.10% 0.19% 0.37% 0.33% 
a (Meisinger, Doring, Thorand, Heier, & Lowel, 2006; Rathmann et al., 2009); b (GLOBOCAN, 2008); c (Palm et al., 2010); d Imputation based on stroke incidence  
  
  
  
 
 
 
Appendix Table 1d: Age- and gender specific disease incidences in Greece 
  GREECE 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.00% 1.15% 1.15% 1.29% 1.29% 2.37% 2.37% 3.38% 3.38% 2.26% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.01% 0.02% 0.04% 0.06% 0.09% 0.13% 0.23% 
Incidence strokec 0.02% 0.04% 0.04% 0.22% 0.22% 0.53% 0.53% 1.54% 1.54% 3.58% 
Incidence CHDd 0.03% 0.06% 0.06% 0.33% 0.33% 0.81% 0.81% 2.34% 2.34% 5.44% 
           
  GREECE 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.08% 0.85% 0.85% 1.44% 1.44% 2.48% 2.48% 2.19% 2.19% 3.59% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.01% 0.02% 0.03% 0.04% 0.05% 0.07% 0.17% 
Incidence breast cancerb 0.01% 0.01% 0.07% 0.08% 0.09% 0.11% 0.15% 0.16% 0.16% 0.26% 
Incidence strokec 0.01% 0.02% 0.02% 0.10% 0.10% 0.29% 0.29% 1.22% 1.22% 3.99% 
Incidence CHDd 0.02% 0.04% 0.04% 0.17% 0.17% 0.50% 0.50% 2.11% 2.11% 6.91% 
a (Panagiotakos, Pitsavos, Skoumas, Lentzas, & Stefanadis, 2008); b (GLOBOCAN, 2008); c (Truelsen et al., 2006); d (Panagiotakos, Pitsavos, Chrysohoou, Skoumas, & Stefanadis, 2008) 
  
  
 
 
 
Appendix Table 1e: Age- and gender specific disease incidences in Poland 
  POLAND 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.10% 0.15% 0.22% 0.33% 0.48% 0.64% 0.80% 0.93% 1.01% 0.95% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.02% 0.05% 0.10% 0.17% 0.25% 0.32% 0.37% 
Incidence strokec 0.02% 0.03% 0.03% 0.25% 0.25% 0.61% 0.61% 1.26% 1.26% 1.66% 
Incidence CHDd 0.00% 0.07% 0.07% 0.20% 0.20% 0.58% 0.58% 0.71% 1.08% 1.08% 
           
  POLAND 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.07% 0.11% 0.17% 0.25% 0.36% 0.48% 0.61% 0.71% 0.76% 0.70% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.02% 0.03% 0.05% 0.08% 0.11% 0.15% 0.20% 
Incidence breast cancerb 0.01% 0.01% 0.06% 0.10% 0.14% 0.18% 0.22% 0.21% 0.19% 0.17% 
Incidence strokec 0.01% 0.03% 0.03% 0.10% 0.10% 0.29% 0.29% 0.80% 0.80% 1.63% 
Incidence CHDd 0.01% 0.01% 0.01% 0.16% 0.11% 0.17% 0.12% 0.32% 0.62% 0.51% 
a Imputation; b (GLOBOCAN, 2008); c (Truelsen et al., 2006); d Imputation 
  
  
 
 
 
Appendix Table 1f: Age- and gender specific disease incidences in Spain 
  SPAIN 
Males 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.85% 0.85% 0.85% 1.02% 1.02% 1.02% 1.52% 1.52% 1.52% 1.52% 
Incidence colorectal cancerb 0.00% 0.00% 0.01% 0.03% 0.07% 0.12% 0.19% 0.27% 0.36% 0.46% 
Incidence strokec 0.02% 0.02% 0.02% 0.02% 0.02% 0.15% 0.15% 0.35% 0.35% 0.72% 
Incidence CHDd 0.00% 0.02% 0.02% 0.03% 0.02% 0.36% 0.24% 0.46% 0.47% 0.42% 
                     
 SPAIN 
Females 30-34y 35-39y 40-44y 45-49y 50-54y 55-59y 60-64y 65-69y 70-74y 75+ 
Incidence diabetesa 0.85% 0.85% 0.85% 1.02% 1.02% 1.02% 1.52% 1.52% 1.52% 1.52% 
Incidence colorectal cancerb 0.00% 0.00% 0.02% 0.03% 0.05% 0.07% 0.09% 0.13% 0.17% 0.24% 
Incidence breast cancerb 0.02% 0.02% 0.10% 0.15% 0.17% 0.20% 0.22% 0.20% 0.21% 0.21% 
Incidence strokec 0.01% 0.01% 0.01% 0.01% 0.01% 0.04% 0.04% 0.27% 0.27% 0.57% 
Incidence CHDd 0.01% 0.01% 0.01% 0.01% 0.01% 0.02% 0.02% 0.11% 0.21% 0.18% 
a (Valdes, Botas, Delgado, Alvarez, & Cadorniga, 2007); b (GLOBOCAN, 2008); c (Vega et al., 2009); d Imputation  
  
 
 
 
 
 
2.1.2. Cost-effectiveness analysis of a kindergarten-based, 
family-involved intervention to prevent obesity in early 
childhood. The ToyBox intervention 
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effectiveness analysis of a kindergarten-based, family-involved intervention to prevent obesity in early 
childhood. The ToyBox intervention. (Working Paper).  
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ABSTRACT 
 
Background: Childhood obesity not only affects the current health status, but also has an impact on 
health later in life. It is associated with chronic obesity-related diseases at adult age, which also affects 
the health care expenditure. Prevention should focus on early age children, in order to tackle the obesity 
challenge. Evaluating the cost-effectiveness of such interventions informs the decision of policy makers. 
In this study, the cost-effectiveness of the Toy-Box intervention was evaluated. 
 
Methods: A health economic model was developed consisting of a decision analytic model representing 
the intervention effect in the pre-schoolers and the projection of this intervention effect to adult age, 
followed by a Markov model simulating the occurrence of obesity-related complications in adults. Costs 
and quality-adjusted life-years were analysed over lifetime, in order to calculate the incremental cost-
effectiveness ratio. Sensitivity analyses were performed, taking into account uncertainty of the model 
parameters. 
 
Results: Assuming country-specific willingness-to-pay thresholds based on the gross domestic product, 
the ToyBox-intervention was estimated to be cost-effective in Spain (males: €21,719/QALY gained; 
95%CI: €2,646 – €178,296. Females: €10,568/QALY gained; 95%CI €476 – €87,298) and Poland (the 
latter only in females: €6,304/QALY gained; 95%CI: €1,277 – €44,637) and borderline cost-effective in 
Greek and Belgian females (respectively: €20,279/QALY gained; 95%CI: €5,663 – €140,325 and 
€37,422/QALY gained; 95%CI: €12,357 – €234,296). The analysis included quite a lot of uncertainty in 
several parameters. The parameters with greatest influence on the result were the parameters included 
in the extrapolation, the relative risk of obesity-related diseases, the effectiveness of the intervention, 
the intervention cost and the incidence in diabetes. More evidence on the link between pre-school health 
behaviours and chronic diseases at adult age, and a lower intervention costs would have resulted in a 
better incremental cost-effectiveness ratio.  
 
Conclusion: This health economic analysis has shown that the small health effects due to the ToyBox-
intervention are not always in balance with the extra costs induced. The cost-effectiveness of such 
intervention programs is dependent on the effectiveness of the intervention, the link between pre-school 
health behaviours and chronic diseases at adult age, and the intervention cost. Future paediatric obesity 
prevention interventions should not only focus on the intervention effect but also on the induced costs. 
Besides, more evidence on the tracking of pre-school behaviour or weight to the adult age is desirable 
to reduce uncertainty.  
 
  
 51 
 
INTRODUCTION 
Over the last decades, sweets, sugar-sweetened beverages (SSB) and fatty snacks together with a 
passive lifestyle have nourished the increasing prevalence of overweight and obesity in pre-school 
children worldwide (Acosta et al., 2008; De Onis et al., 2010; Liebman et al., 2003). This trend not only 
has an impact on the health of children now and later in life (Acosta et al., 2008; Baker et al., 2007), but 
also negatively affects society due to higher health care costs and productivity loss (Konnopka et al., 
2011; Kwaliteitsinstituut voor de gezondheidszorg CBO, 2008). With obesity being responsible for about 
0.7% to 2.8% of a country’s total health care expenditure (Withrow & Alter, 2011), the health and 
economic burden of paediatric obesity is substantial (Lobstein & Jackson-Leach, 2006). As most 
obesity-related health care costs are financed by the government, there is a strong motivation for policy  
makers to tackle the obesity epidemic. However, most of the health benefits of child obesity interventions 
do not emerge until adulthood, making health gains from the interventions difficult to observe, which 
impedes decisions to adopt such an intervention. Nonetheless, several obesity prevention programs for 
young children have been developed so far, with different designs and different outcomes (Laws et al., 
2014; Pitangueira, Rodrigues Silva, & Costa, 2015; Waters et al., 2011). The ToyBox-study (short for 
‘Multifactorial evidence-based approach using behavioural models in understanding and promoting fun, 
healthy food, play and policy for the prevention of obesity in early childhood’) aimed to develop, 
implement and evaluate a kindergarten-based, family-involved intervention to prevent obesity in early 
childhood (Manios, 2012). Modelling long term costs and benefits of the interventions is crucial, as to 
inform policy makers on the return on investment and to give advice on which interventions are worth 
implementing using public funding. In a previous publication, we informed on the design and data-inputs 
of the model to assess the cost-effectiveness of the ToyBox-intervention (Pil et al., 2014). In the current 
analysis, the cost-effectiveness of the ToyBox-intervention was evaluated by estimating the long term 
costs and effects in six European countries, namely Belgium, Bulgaria, Germany, Greece, Poland and 
Spain.  
 
METHODS 
 
The ToyBox-intervention  
The ToyBox-intervention was a randomised cluster trial which was implemented within the academic 
year 2012–2013 in Belgium, Bulgaria, Germany, Greece, Poland and Spain. The intervention targeted 
four key health behaviours in pre-schoolers aged 3.5-5.5 years old, namely drinking behaviour, snacking 
behaviour, physical activity and sedentary behaviour (for the design and implementation of the ToyBox-
intervention, see Manios et al. (2014)). By means of  Repeated Measures Anova analyses, the ToyBox 
research group investigated the effects of the intervention on the anthropometric measures and key 
health behaviours of the pre-schoolers, based on a sample of 4,964 pre-schoolers (4.7±0.4 years; 51.5% 
boys) from the six included countries (unpublished work). After the implementation period, some 
significant, albeit modest, effects of the ToyBox-intervention in the total sample were found on total SSB 
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consumption (soft drinks, pre-packed fruit juices, and sugared milk) (p < 0.001) and on screen time 
(including time spent on watching TV, and/or playing computer- and video games) (borderline significant 
p=0.06). These variables were were defined in two categories <=1h/weekday versus >1h/weekday and 
<=65ml/day versus >65ml/day, based on the categories as used by De Coen et al. (2013) (cf. infra) 
(Table 1). The effect was slightly higher in SSB consumption than in screen time, but both effects were 
simulated together in the analyses. No effect was found on the anthropometric parameters, vegetable 
and fruit consumption, snacking behaviour or physical activity.  
 
Table 1: Prevalence of pre-schoolers in the health behaviour categories  
  Adjusted baseline 
measurement 
Post-measurement 
  Intervention group control group 
    
Screen time    
<=1h/weekday 52.1% 52.2% 49.6% 
>1h/weekday 47.9% 47.8% 50.4% 
    
SSB consumption    
<= 65ml/day 35.8% 48.2% 40.5% 
>65ml/day 64.2% 51.8% 59.5% 
    
 
 
Model design  
The health economic model developed for ToyBox was a combined model consisting of a decision 
analytic model to represent the probability of improved energy balance-related behaviours in children 
and the projection of this intervention effect to adult age (see Figure 1a in chapter 2.1.1.), followed by a 
Markov model (See Figure 1b in chapter 2.1.1.) simulating the occurrence of obesity-related 
complications in adults (from the age of 30) over a lifetime. The same model was used for the 
comparator, ignoring the intervention effect. Over a lifetime, the difference in costs between both 
alternatives was divided by the net effects (in Quality Adjusted Life Years - QALYs), to obtain the primary 
outcome measure, the incremental cost-effectiveness ratio (ICER). The ICER was interpreted assuming 
the gross domestic product (GDP) per capita of the country as willingness-to-pay threshold (WHO, 
2005b). Since no literature was found to project the intervention effect on total SSB and screen time to 
adult obesity-related complications (i.e. the hard endpoints), an indirect calculation had to be made, 
through weight status (overweight/obese). First, based on a longitudinal study of De Coen et al. (2013), 
the intervention effect on screen time and total SSB at child age was projected to the child weight status 
two years later (mid-term). From the odds ratios they found in their study, we calculated the relative risk 
for screen time (categorised as >1h/weekday and ≤1h/weekday) to be 1.34 (95%CI 0.99 – 1.61), stating 
that pre-schoolers with 1 hour or more screen time per weekday are 34% more likely to be 
overweight/obese 2 years later in comparison to their peers with less than 1 hour screen time per 
weekday. Soft drink consumption (categorised as >65ml/day and ≤65ml/day) was associated with a 
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relative risk of 1.12 (95%CI: 0.89 –  1.31), stating that pre-schoolers with a soft drink consumption of 
>65ml/day are 12% more likely to be overweight/obese 2 years later in comparison to their peers with 
less than 65 millilitre soft drinks per day. Subsequently, this mid-term weight status of the children was 
extrapolated to adult weight status (at the age of 30) based on the relative risks calculated from the 
figures in the tracking study of Venn et al. (2007) (Table 2). This calculation was performed for the 
control as well as the intervention group. The estimated prevalence of overweight and obesity at adult 
age in case of the intervention was compared to the prevalence in the control group in order to calculate 
the relative risk reduction in overweight and obesity. Table 3 shows that, by means of the ToyBox 
intervention, which allows for a reduction in the number of children having more than 1 hour a day of 
screen time and a decrease in the number of children with more than 65ml SSB per day, it is expected 
that the prevalence of obesity in adult women relatively decreases with 2.07% (=0.91% + 1.16%). The 
association between adult weight status and obesity-related complications was obtained from the 
International Association for the Study of Obesity (2013) (Table 1, p.37 in this thesis). Finally, a risk 
reduction in the prevalence of overweight and obesity led to a risk reduction in the probability of obesity-
related complications. More detailed information on the design of the cost-effectiveness model can be 
found in Pil et al. (2014). In order to gain information on the budget impact of the intervention cost, a 
cohort-analysis was performed simulating the impact of adding a new cohort each year over a period of 
14 years (i.e. until the first cohort reaches the age of 18). Model validation is addressed in Appendix 
Table 1.  
 
Epidemiological and health-economic model inputs  
The prevalence of overweight and obesity in adults per country, was obtained by the Eurostat database 
(Eurostat, 2008a). Chronic disease incidences per country were obtained from the Globocan database 
(for cancer) (GLOBOCAN, 2012) and from published literature (Appendix Table 1, p.45-50 in this thesis). 
Costs were evaluated from a societal viewpoint, including direct health care costs related to the chronic 
disease states as well as indirect costs due to productivity loss, with reference year 2012 (Table 3, p.41 
in this thesis). The cost of the intervention captured all costs that were incurred by the implementation 
of the intervention. The average intervention cost was €11.8 per pre-schooler, but was included country-
specific in the model (see Table 2, p.39 in this thesis). QALYs were calculated using EQ-5D utilities, 
derived from literature data (Table 4, p.42 in this thesis). According to the Belgian guidelines, annual 
discount rates of 3.0% and 1.5% were applied to future costs and effects respectively (Cleemput et al., 
2012). Details on the intervention cost assessment and QALY calculation are explained in Pil et al. 
(2014). 
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Table 2: Relative risks for the tracking of overweight and obesity into adulthood (from the age of 30), in 
reference to normal weight children  
  Adult: Overweight     Adult: Obesity 
 males females males females 
Child 7-9y: Overweight 1.1  2.2  4.4  5.0 
Child 7-9y: Obesity 1.1  0.9 5.0 9.8 
Interpretation: e.g. a 7-9 year-old girl with overweight has a 5 times higher risk to become obese in adulthood in reference to a normal-weight 7-9 year old girl.  
Source: calculated from the study of Venn et al. (2007). The figures specific for 7 to 9-year olds were obtained by personal communication with the authors.  
 
Table 3:  Relative risk reductions in adult overweight and obesity due to the ToyBox-intervention  
         Screen time       Total SSB 
  males females males females 
Overweight 0.04% 0.23% 0.05% 0.30% 
Obesity 0.73% 0.91% 0.93% 1.16% 
Screen time: categorised as  >1h/weekday and ≤1h/weekday  
SSB: Sugar-sweetened beverages  
Total SSB: categorised as >65ml/day and ≤65ml/day   
 
Scenario- and sensitivity analysis  
As the Toybox-study lacks a long term follow-up analysis, the duration of the intervention effect is 
unclear. There is however some evidence for the tracking of physical activity, sedentary behaviour and 
diet from childhood to adulthood (Busschaert et al., 2015; Craigie et al., 2011; Friedman et al., 2008), 
because of which one could argue that the change to the more healthy behaviour due to the intervention 
would sustain into adulthood. On the contrary, there is also evidence for a waning intervention effect 
over time (Hoffman et al., 2011; Wen et al., 2015). Therefore, in order to sustain the original ToyBox-
intervention effect, we assumed a Toybox-similar intervention to be repeated annually in the base case 
model until the age of 18. Some scenarios concerning the intervention effect were explored for the 
Belgian case. A first scenario included a biennial implementation of a ToyBox-similar intervention 
instead of annually, assuming the intervention-effect to last for 2 years. In a second scenario the annual 
repetition of an intervention to sustain the effect of the ToyBox-intervention until the age of 30 instead 
of 18 was included.   
One-way- and probabilistic sensitivity analyses were conducted to capture uncertainty in the key 
parameters and to assess the effect of variation in the parameters on the ICER. In the one-way 
sensitivity analysis the individual effect of the intervention cost, total costs per disease state, the 
intervention effect, the relative risk of screen time and total SSB related to mid-term weight status, the 
relative risk of tracking for overweight and for obesity from childhood to adulthood, the relative risk of 
adult overweight and obesity on obesity-related diseases, disease incidences and the utilities per 
disease state was evaluated in case of better or worse conditions of these parameters -defined by the 
confidence interval or ±30% variation in case confidence intervals were absent. A probabilistic analysis 
varied the costs, utilities, disease incidences and the relative risks concurrently by their own probability 
distribution. Cost data were assumed to be distributed according to a gamma-distribution, utilities and 
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incidences according to a beta-distribution and the relative risks according to a log-normal distribution 
(Briggs et al., 2006).  
 
RESULTS 
Results were expressed over a period of 70 years, per 1,000 pre-schoolers per country, and for males 
and females separately (Table 4). Assuming the GDP per capita of the country as willingness-to-pay 
threshold (WHO, 2005b), the ToyBox-intervention, leading to less screen time during weekdays and 
less consumption of total SSB, was cost-effective in Spain and in Poland, the latter only in females. 
ICERS were €19,893/QALY and €9,094/QALY in Spanish males and females respectively and 
€5,758/QALY in Polish females. In Belgian and Greek females, the analysis showed a borderline cost-
effective result. In the other countries, the incremental cost-effectiveness ratio was above the assumed 
threshold. Although the intervention effect was assessed for the total sample, not separated according 
to gender, in all countries the result was better in females than in males. The worse cost-effectiveness 
results (in reference to the particular threshold) were found in Bulgaria and Germany. 
The scenario-analysis showed that a longer duration in the intervention effect, which would lead to the 
intervention being re-implemented biennially instead of annually, would decrease the (intervention) 
costs, while the health effects remain equal. Therefore, this would be a more cost-effective scenario 
(Table 5, results shown for Belgium), with an ICER below the threshold in females as well as males. If 
the intervention would have to be repeated until the age of 30 in order to sustain a stable effect 
throughout life, the intervention cost would increase and the result would be worse compared to the 
base case. One-way sensitivity analyses showed the most influential parameters, for the result in all 
countries, to be the relative risk of SSB and screen time on the mid-term weight status, the relative risk 
of obesity on obesity-related diseases, the cost of the intervention, the relative risk related to the tracking 
of overweight/obesity, the incidence of diabetes and the ToyBox-intervention effect on total SSB and 
screen time (see tornado diagrams in Figure 1, shown for the Belgian analysis). An increase in the value 
of these parameters resulted in a better cost-effectiveness result, except for the cost of the intervention, 
in which there was an opposite effect. Second order Monte Carlo analyses were performed to assess 
the effect of the uncertainty associated with the key parameters simultaneously. The probabilistic 
sensitivity analyses created credibility intervals around the mean estimate, which are shown in Table 4. 
The cost-effectiveness planes (Figure 2, shown for Belgium) display the simulated cost- and QALY-
points which are all situated in the north-east and north-west quadrants of the plane. The cost-
effectiveness acceptability curves depict the probability of the result being cost-effective considering 
different willingness-to-pay threshold (Figure 3, shown for females). The highest probabilities were found 
in the analysis for Poland and the lowest in the analysis for Germany. The probability of the result in 
each country being cost-effective considering the GDP as the threshold is shown in Table 4. These 
probabilities were highest for Spain, Belgium and Poland, and lowest for Bulgaria and Germany.  
Simulating the intervention cost for all Belgian pre-schoolers, until the original cohort of children reaches 
the age of 18 (i.e. for a period of 14 years on average), while every year a new cohort of 3 years-old  
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enters the model, would result in a total intervention cost of €105,031,189 million for the Belgian public 
payer. This equals €3 per year per child from the target group (3-6 year-olds, including annual inflow of 
new 3 year-olds). This is a maximum scenario, assuming a 100% participation rate to the program. 
  
 
 
 
Table 4: results of the cost-effectiveness analysis, expressed per 1,000 persons. 
  
GDP per capita 
∆ Costs ∆ QALYs ICER deterministic 
ICER probabilistic Cost-effectiveness 
(2012)* mean (95% CI) probability 
  males females males females males females males females males females 
Belgium € 34,400 € 117,355 € 113,209 2.2 3.1 € 52,847 € 36,304 
€ 54,103 € 37,422 
16.8% 43.2% 
(€16,880 - €372,878) (€12,357 - €234,296) 
Bulgaria € 5,650 € 64,324 € 58,951 1.7 3.8 € 38,194 € 15,527 
€ 38,779 € 16,087 
0.0% 1.0% 
(€13,769 - €238,372) (€5,535 - €110,784) 
Germany € 33,900 € 298,772 € 287,874 3.6 5.1 € 82,480 € 55,974 
€ 83,843 € 57,432 
1.9% 14.3% 
(€29,708 - €542,242) (€17,676 - €446,917) 
Greece € 17,100 € 107,238 € 97,388 3.2 5.1 € 33,298 € 19,417 
€ 33,771 € 20,279 
7.3% 37.3% 
(€11,138 - €226,433) (€5,663 - €140,325) 
Poland € 10,100 € 53,517 € 42,143 2.8 7.3 € 19,215 € 5,758 
€ 19,991 € 6,304 
9.4% 72.5% 
(€-11,287 - €145,332) (€1,277- €44,637) 
Spain € 22,000 € 72,551 € 57,457 3.7 6.3 € 19,893 € 9,094 
€ 21,719 € 10,568 
84.9% 78.4% 
(€2,646 - €178,296) (€476 - €87,298) 
 
∆: incremental; QALYs: Quality-adjusted life-years;  * (Council of the European Union, 2010) 
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Table 5: Results from scenario analysis for Belgium, expressed per 1,000 persons. 
  ∆ Costs ∆ QALYs ICER 
  males females males females males females 
Base case € 117,355 € 113,209 2.2 3.1 € 52,847 € 36,304 
Similar intervention biennially € 54,336 € 50,191 2.2 3.1 € 24,469 € 16,095 
Similar intervention annually until 30y € 181,221 € 177,075 2.2 3.1 € 81,607 € 56,785 
 
∆: incremental; QALYs: Quality-adjusted life-years 
 
 
Figure 1: Tornado diagrams for the one-way sensitivity analysis in males (A) and females (B), Belgium 
 
RR: relative risk; SSB: sugar-sweetened beverages  
Light-coloured bars show the result in case of a minimum value on the parameter, dark-coloured bars show the result in case of a maximum value on the 
parameter.  
 
 
RR: relative risk; SSB: sugar-sweetened beverages 
Light-coloured bars show the result in case of a minimum value on the parameter, dark-coloured bars show the result in case of a maximum value on the 
parameter. 
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€ 0 € 30.000 € 60.000 € 90.000 € 120.000
ToyBox effect on SSB [70%-130%]
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RR obesity on diseases [70%-130%]
RR screen time [73%-120%]
RR SSB [80%-117%]
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Figure 2: Cost-effectiveness planes for the analysis in Belgian males (A) and females (B), expressed per 
1,000 persons 
Black line through the cloud = willingness-to-pay threshold 
 
Figure 3: cost-effectiveness acceptability curve 
 
 
 
DISCUSSION AND CONCLUSION 
 
This article described the results of the cost-effectiveness analysis of the ToyBox-intervention for the six 
participating countries. The ToyBox-intervention resulted in modest effects on the total SSB 
consumption and screen time of the pre-schoolers. Consequently, this cost-effectiveness analysis 
showed only a minimal gain in QALYs per person, in all six countries. However, when this QALY-gain 
would apply to the total target population of pre-schoolers, a potentially large public health benefit could 
be achieved. However, in most of the analyses, the health benefit did not compensate for the extra costs 
related to the intervention. The probability of the intervention being cost-effective was the lowest in 
Bulgaria and Germany. This has probably to do with the intervention cost (which was high in Germany 
(Pil et al., 2014)), but also with assumed the willingness-to-pay threshold (which was very low in 
Bulgaria). The result for the Bulgarian analysis had the lowest probability of being cost-effective 
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considering the GDP per capita of the country as the threshold. However, Figure 4 shows that in case 
the threshold for Bulgaria would have been higher, the probability would not have been the lowest of all 
countries. Besides, results were better in females than in males, mainly because tracking of obesity from 
childhood into adulthood is stronger in females (Venn et al., 2007), which results in the relative risk 
reduction in overweight and obesity due to the intervention effect being larger in females. The analysis 
for Spain and for Polish females resulted in a good ICER, probably due to modest intervention cost and 
for Spain also because of the incidence of diabetes being quite high (compared to the other included 
countries). The value of these two parameters varied between the included countries and it was shown 
that uncertainty in these parameters had a high impact on the cost-effectiveness result.  
The intervention effect on the pre-schoolers’ EBRBs was extrapolated to the adult age since chronic 
diseases generally start to develop at adult age. Similar extrapolations from childhood to adulthood have 
been performed previously in cost-effectiveness analyses of childhood obesity programs (Brown et al., 
2007). Some intermediate extrapolations had to be made in our analysis, as no current literature 
describes the relation between child health behaviours and risk on chronic diseases in adulthood. 
However, such a causal chain induces extra uncertainty in the model, which needs to be explored in 
sensitivity analyses. The cost-effectiveness result was influenced by all included parameters in the 
model of which the most influential were the relative risks included in the causal chain (Figure 1a, chapter 
2.1.1.), the intervention cost and -effect and the incidence of diabetes. It is clear that a stronger relation 
between the EBRB at child age and the weight status at mid-term, would have resulted in better ICERs. 
This argues for more research on the relation between child health behaviour and weight status, or even 
better, between child health behaviour and adult weight status or adults risk on obesity-related diseases. 
Additionally, it was shown that when the intervention effect would sustain for 2 years, the cost-
effectiveness results would be better. This observation shows the importance of having more information 
on the duration of the intervention effects of the ToyBox-intervention, but also of similar interventions in 
general, in order to simulate the long term effects of such prevention interventions.   
Other cost-effectiveness analyses of obesity prevention interventions in children included for example 
the evaluation of an early childhood home visiting program in Sydney (Hayes et al., 2014), an after-
school program designed to prevent obesity among elementary school students (Wang et al., 2008) and 
a multicomponent through-school physical activity and nutrition program, delivered to all primary school 
children in a New Zealand region (Moodie, Carter, Swinburn, & Haby, 2010), which were all found to be 
cost-effective. In contrast, Moodie et al. (2011) evaluated an active transport program for primary school 
children and found that this intervention was not cost-effective. However, these interventions targeted 
primary school children instead of pre-schoolers and did not include long term costs and health effects. 
Our study assessed the impact on the long term costs and health effects of an international kindergarten-
based, family-involved intervention of obesity prevention in European pre-schoolers and therefore has 
added value to the previous published literature.  
Notwithstanding the value of our study, some limitations need to be addressed. First, in order to be able 
to use the relative risks assessed by De Coen et al., weight was included as the body mass index-
categories overweight and obesity. Adverse health consequences are positively correlated with the 
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severity of obesity (WHO, 2000), which leads to differences in quality of life among those experiencing 
different obesity severity. In our model, by using weight status categories, it was not possible to account 
for differences in the severity of obesity. Second, De Coen et al. found an effect of screen time and soft 
drink consumption on mid-term overweight/obesity. The effect on soft drink consumption was applied to 
total sugared-beverage consumption in our model, including not only soft drinks, but also pre-packed 
fruit juices and sugared milk. Moreover, there was only a trend in significance in the risks measured by 
De Coen et al., although we took the uncertainty in these parameters into account in the probabilistic 
sensitivity analysis. Third, it is possible that the ToyBox-intervention led to other health effects which 
were not captured in the effectiveness and cost-effectiveness analysis, such as change in parental 
health behaviours, empowerment, social contact, etc. Fourth, we did not perform sub-group analyses 
according to socio-economic status (SES) to account for variation in the cost-effectiveness of the 
intervention. It is possible that the intervention had another effect in pre-schoolers with a lower SES, 
resulting in different cost-effectiveness ratios between high- and low SES children. Additionally, 
published literature describes differences in the epidemiology of obesity-related disease according to 
SES, which could have an impact on the results (Fiscella & Tancredi, 2008; Manser & Bauerfeind, 2014; 
Marshall et al., 2015; Orsini, Tretarre, Daures, & Bessaoud, 2016; Rabi et al., 2006). Finally, it should 
be noted that the results could not be directly compared between the countries, as they are to be 
interpreted based on the assumed country-specific willingness-to-pay threshold.  
To conclude, the ToyBox-intervention was found to be only cost-effective in case of a modest 
intervention cost, a high incidence of diabetes and a beneficial willingness-to-pay threshold. Future 
interventions should bear in mind that intervention costs should be as low as possible, while maintaining 
a high effectiveness. Additionally, more research is necessary on the long term duration of the effect of 
prevention interventions and on the relation of pre-schooler health and later morbidity. 
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APPENDIX 
 
Appendix Figure 1: Cost-effectiveness planes for the analysis in males (A) and females (B)  
(costs and QALYs expressed per 1,000 persons) 
 
Bulgaria 
 
 
 
 
Germany 
 
 
 
Greece 
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Appendix Table 1: Model validation: average 1y predicted versus observed prevalence in the Belgian 
adult population  
  Diabetesa 
Colorectal  
cancerb 
Breast  
cancerb 
Strokea 
Coronary hearth  
diseasea 
females           
model 5.1% 0.4% 1.4% 1.4% 1.2% 
observed 5.9% 0.5% 2.4% 1.3% 1.9% 
            
males           
model 3.4% 0.3%   2.1% 3.0% 
observed 6.0% 0.5%   1.4% 2.8% 
a: 1y prevalence based on Health Interview Survey, 2008-2013 (Scientific Institute of Public Health., 2013)  
b: 1y prevalence based on the Belgian Cancer Registry, 2010 (Belgian Cancer Registry, 2010a; Belgian Cancer Registry, 2010b) 
 
Explanation Appendix Table 1:   
In order to validate the outcomes of the model for the Belgian analysis, the predicted average 1y-
prevalence of obesity-related diseases over 70 years in the control arm was compared with the observed 
1y-prevalence, based on Belgian data. The prevalence of diabetes (especially in males), colorectal and 
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breast cancer was slightly underestimated in the model. The prevalence of stroke and coronary heart 
disease (in males), was slightly overestimated. Despite the differences, the predicted data seems to 
approximate observed prevalence data.  
 
 
 
 
 
  
   
  
 
 
 
 
 
2.1.3. Burden of skin cancer in Belgium and the cost-
effectiveness of prevention by reducing ultraviolet 
exposure  
 
 
 
 
 
Based on: 
Lore Pil*, Isabelle Hoorens*, Katrien Vossaert, Vibeke Kruse, Isabelle Tromme, Niko Speybroeck, 
Lieve Brochez and Lieven Annemans (2016). Burden of skin cancer in Belgium and the cost-
effectiveness of prevention by reducing ultraviolet exposure. Preventive Medicine, 93: 177-182.  
* Shared first authorship
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ABSTRACT  
 
Background: Skin cancer (melanoma- and non-melanoma skin cancer) is one of the most rapidly 
increasing cancers worldwide.  
Objective: This study analysed the current and future economic burden of skin cancer in Belgium and 
the cost-effectiveness of two strategies in the prevention of skin cancer by reducing ultraviolet exposure.  
Methods: A retrospective bottom-up cost-of-illness study was performed, together with a Markov model 
in order to analyse the cost-effectiveness and the budget impact analysis of a comprehensive 
sensitisation campaign and a total ban on sunbeds in Belgium.  
Results: Total prevalence of skin cancer in Belgium was estimated to triple in the next 20 years. The 
total economic burden of skin cancer in 2014 in Belgium was estimated at €107 million, with a cumulative 
cost of €3 billion in 2034. The majority of this total cost was due to melanoma (65%).  Over a period of 
50 years, both prevention programs would lead to a gain in quality-adjusted life-years (sensitisation 
campaign: 1.39 QALY per 1,000 males and females; ban on sunbed use: 4.81 and 5.94 QALY per 1,000 
males and females respectively) and cost-savings (sensitisation campaign: €15,273 and €17,411 per 
1,000 males and females respectively;  ban on sunbed use: €19,886 and €20,384 per 1,000 males and 
females respectively). For every euro invested in the campaign, €3.6 would be saved on the long term 
for the health care payer.  
Conclusion: Policy makers and clinicians should promote ultraviolet protection strategies, as these are 
estimated to be dominant strategies. 
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INTRODUCTION 
Skin cancer is increasing globally (Arits, Schlangen, Nelemans, & Kelleners-Smeets, 2011; Flohil et al., 
2013a; Flohil, De Vries, Neumann, Coebergh, & Nijsten, 2011; Nikolaou & Stratigos, 2014), and affects 
nearly one out of five persons in Belgium. It is related to ultraviolet exposure, either naturally from the 
sun or artificially through solarium use. These risk factors are the strongest for non-melanoma skin 
cancer (NMSC) - defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) -, however 
meta-analyses also confirm the influence in development of melanoma skin cancer (MSC) (Boniol, 
Autier, Boyle, & Gandini, 2012; Elwood & Jopson, 1997). Several epidemiologic studies show an 
alarming global increase in the incidence of MSC and NMSC, due to the increasing age of the 
population, but also to altered risk seeking behaviour (De Vries, Van de Poll-Franse, Louwman, de Gruijl, 
& Coebergh, 2005; Diffey, 2004; Flohil et al., 2011; Hollestein, De Vries, & Nijsten, 2012; Marcos-
Gragera et al., 2010). Although NMSC is less aggressive than MSC, it has an important impact on the 
health expenditures because of the high prevalence (Stang, Stausberg, Boedeker, Kerek-Bodden, & 
Jockel, 2008). Consequently to this epidemic, the related health care costs are rising significantly. 
Current opinion in Europe states that the rise in health care spending is not sustainable in the future, so 
studies with a focus on estimating current expenditures on skin cancer and innovative ways to improve 
cost-effective health care and prevention are needed. However, despite the growing awareness of the 
magnitude of the skin cancer burden, such studies on this subject are scarce. Besides, currently, most 
studies on universal prevention focus on MSC or are performed in a high prevalent setting such as 
Australia (Gordon et al., 2009; Hirst, Gordon, Scuffham, & Green, 2012; Hirst, Gordon, Gies, & Green, 
2009; Shih, Carter, Sinclair, Mihalopoulos, & Vos, 2009).  For this reason the first objective of this study 
was to calculate the current and future health and economic burden of MSC and NMSC in Belgium. 
Estimating the total cost of skin cancer is particularly useful for measuring the potential cost savings 
from averting new skin cancer cases, emphasising the importance of skin cancer prevention. As such, 
this study also simulated the cost-effectiveness and budget impact of a hypothetical sensitisation 
campaign and a hypothetical total ban on sunbed use. 
 
METHODS 
Burden of skin cancer 
The health-related burden of skin cancer was estimated based on the registered prevalence of skin 
cancer lesions being in treatment, in intense follow-up or in long-term follow-up. (Belgian Cancer 
Registry, 2013; Integraal Kankercentrum Nederland, 2011). This current prevalence was projected to 
2034, taking into account the ageing of the population (since the cohort ages each cycle) and other skin-
cancer related trends such as going on holiday more often or getting a check-up more frequently, based 
on the estimated annual increase of skin cancer incidence (Flohil et al., 2013a; Hollestein et al., 2012; 
Hollestein et al., 2012). In order to estimate the total economic burden of skin cancer on society, a 
bottom-up cost-of-illness study was conducted, based on retrospective information from Belgian patient 
questionnaires being gathered from 1st March 2015 until  30th June 2015. Dermatologists and 
oncologists working in general and university hospitals, small (< 200 beds), medium (200-400 beds) or 
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big (> 400 beds) hospitals, as well as private practices were recruited in December 2014. These 
physicians were asked to give skin cancer patients the information about the study and to hand out the 
questionnaires to the patients. Eligible patients were those who were 18+, had a diagnosis of MSC, BCC 
and SCC maximum ten years ago and who presented to a participating physician between 1st March 
2015 and 30th June 2015. Patients were asked questions about their medical consumption for their skin 
disease during the last six months, as well as about their productivity loss and quality of life. Questions 
concerned the number of consultations, number and type of examinations, drug use, number of days 
absent from work and health-related quality of life (based on the EQ-5D-5L questionnaire). Ethics 
committee approval and patient informed consents were obtained. Based on the resource utilisation 
patterns for individuals with MSC, BCC or SCC and official Belgian unit costs (Rijksinsituut voor Ziekte- 
en Invaliditeitsverzekering (RIZIV), 2016), we calculated the cost per skin cancer stage per six months, 
separately for diagnosis and treatment, intense follow-up and long term follow-up. The current total 
societal cost was calculated by multiplying these direct costs per cancer stage with the prevalence of 
detected skin cancer (defined as patients in treatment as well as patients in follow-up) and by multiplying 
the cost per day absenteeism (Cleemput et al., 2012) with the number of days absent from work due to 
skin cancer (based on the patient questionnaires). In order to calculate the future cost of skin cancer in 
Belgium, a Markov model was composed (Microsoft Excel® 2013), with a time horizon of 20 years. All 
costs were computed at the 2014 euro price level and expressed separately as costs for the public 
health care payer, costs for the patient (co-payment) and costs due to productivity loss.  
 
Health economic evaluation of two universal prevention strategies 
A Markov state-transition cohort model was developed, examining the economic impact and the cost-
effectiveness of a hypothetical sensitising prevention campaign and a hypothetical total ban on sunbed 
use in reference to the current situation. A Markov model is a type of decision model based on a series 
of states that a person can occupy at a given point in time (Drummond et al., 2015). MSC as well as 
NMSC were included in the model, consisting of different disease states: undiagnosed skin cancer, 
diagnosis & treatment, follow-up and death (Appendix Figure 1), separated per skin cancer stage. The 
duration of the diagnosis & treatment phase was 6 months (= 1 cycle) for patients with BCC, SCC 0-II 
or MSC I-II and 1 year for patients with SSC III-IV or MSC III-IV. To assign a higher probability of skin 
cancer death in the first years after diagnosis in case of SCC IV and MSC IV, the follow-up phase was 
divided into intense- and long term follow-up, which lasted for 4 years, after which one moved into long 
term follow-up. Patients in follow-up remained in this state until the end of the model’s time horizon, or 
until they died. MSC and SCC stages were determined according to the 7th edition of the Tumour-Nodes-
Metastases-classification for malignant tumours (Sobin, Gospodarowicz, & Wittekind, 2009). Stages for 
BCC were defined as <1cm, 1-2cm, >2cm and aggressive histology. BCC and SCC patients were 
assigned a higher risk to develop an MSC lesion. All cohort members started the model in one of the 
model states, according to the baseline prevalence of BCC, SCC and MSC (Belgian Cancer Registry, 
2013; Integraal Kankercentrum Nederland, 2011). Transitions between the disease states were possible 
every six months. Health effects and costs of a cohort of Belgian adult males and females were 
simulated from a societal perspective, during a time horizon of 50 years. This time horizon included an 
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induction period (i.e. the period between risk factor exposure – being UV exposure – and the onset of 
skin cancer) of 20 years (based on expert opinion), and therefore had to be long enough in order to 
capture all relevant effects. Main outcomes included the incremental cost-effectiveness ratio (ICER), the 
total economic societal impact as well as the impact on the health care budget, and the estimated 
reduction in skin cancer incidence and mortality. The ICER was calculated by dividing the net costs by 
the net health benefits of the prevention program in reference to the current approach (i.e. absence of 
such a program). The budget impact analysis estimated the net cumulative cost of both prevention 
programs (and consequent examinations, treatment and follow-up) for the public health care payer over 
a period of 20 years. In order to calculate the societal economic burden and the health care budget 
impact, the model allowed each cycle new entrance of 18-year olds in the lesion-free state, who were 
subjected to the natural skin cancer progression.  
 
Intervention strategies 
1) Sensitisation campaign reducing risk of sunburn  
The hypothetical sensitisation campaign was defined as a comprehensive program such as the 
SunSmart campaign in Australia. SunSmart is a public education program which has been running in 
Australia (especially in the state Victoria) since 1987 (Hill et al., 1993). In the first implementation years, 
the major SunSmart communication strategy was a mass media campaign to raise awareness, to model 
preventive behaviour and to present ‘SunSmart’-behaviour as fashionable (Hill et al., 1993).  
The impact of a hypothetical comprehensive sensitisation campaign on skin cancer was modelled 
through an effect on being sunburned. Sunburn is an indicator of acute high sun exposure but no dose 
response for the number of sunburns leading to MSC has been clearly established (Shih et al., 2009). 
Published literature has shown the impact of ever being sunburned on the risk of MSC to be preventable 
by means of comprehensive prevention campaigns. Hill et al. (1993) evaluated the SunSmart campaign 
in Australia two years after its implementation and found an effect on reducing sunburns by 41% (RR 
0.59). The risk on developing MSC was estimated to be 59% higher for persons ever being sunburned 
during lifetime in reference to those never being sunburned (RR 1.59, 95%CI (1.37-1.83); Table 1) 
(Dennis et al., 2008). No evidence was found for the impact of sunburns on SCC (Veierod, Couto, Lund, 
Adami, & Weiderpass, 2014) or BCC. As there is no evidence on the duration of the effect, in our analysis 
the prevention campaign was implemented annually. 
 
2) Ban on sunbed use   
In this analysis, the hypothetical ban on public sunbed use was defined as a total ban. Boniol et al. 
(2012) found in their meta-analysis –based on 18 cohort studies- a relative risk of MSC of 1.25 (95%CI: 
1.09-1.43) for people who have ever versus those who have never used sunbeds (Table 1). The relative 
risk of SCC was 1.93 (Veierod et al., 2014) and for BCC no evidence on excess risk was found (Hirst et 
al., 2009; International Agency for Research on Cancer, 2007).  
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3) Comparator  
The comparator intervention is the current situation, namely without such a sensitisation campaign and 
without a total ban on sunbed use. As our cost-effectiveness analysis is an incremental analysis, it is 
assumed that only the extra costs of the strategies evaluated are considered in the analysis. It is 
assumed that the current local fragmented initiatives would still exist in case of a national sensitisation 
campaign.  
 
Table 1: input parameters related to the impact of the prevention strategies on health  
Parameter Mean (SE) 
Prevalence of ever sunburned; Belgiuma 90% 
RR of sunburn if campaignb 0.59 (0.11) 
RR of skin cancer if ever sunburned  
MSCc 1.59 (0.12) 
SCCd 1 
BCC 1 
  
Prevalence of ever used sunbed; Belgiume 47% 
RR of skin cancer if ever used sunbed  
MSCf 1.25 (0.09) 
SCCd 1.93 (0.43) 
BCCg 1 
 
RR: Relative risk 
a Expert opinion; b (Hill et al., 1993); c (Dennis et al., 2008); d (Veierod et al., 2014); e (Ipsos Public Affairs, 2013); f (Boniol et al., 2012); g (Hirst et al., 2009) 
 
 
Input data   
Prevalence of diagnosed MSC was derived from the Belgian Cancer Registry (2013) and of NMSC from 
the Dutch cancer registry (Integraal Kankercentrum Nederland, 2012a), since NMSC is more accurately 
registered in the Netherlands. A correction factor was applied to adapt the NMSC figures to Belgium, 
based on the ratio between the MSC mortality of both countries (factor: 0.51). Prevalence of 
undiagnosed skin cancer was derived from a previously organised screening trial including a Total Body 
Examination (TBE) and a Lesion-Directed screening (Hoorens et al., 2016) (see Chapter 2.2.3 for more 
information). Information on the probability of natural progression can be found in the appendix. Risk of 
recurrence in a treated lesion was accounted for in the model and risk of developing a subsequent lesion 
was included in the costs (Flohil et al., 2013b; Francken et al., 2008; Frost, Williams, & Green, 2000; 
Gandini et al., 2005; Leiter et al., 2012; Pomerantz, Huang, & Weinstock, 2015; Rees et al., 2014; Rowe, 
Carroll, & Day, Jr., 1992). The probability of spontaneous clinical detection was defined as the average 
prevalence of diagnosed skin cancer divided by the total prevalence (diagnosed and undiagnosed). All-
cause mortality risk was applied to all persons in the model (based on Belgian life tables), whereas 
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mortality from skin cancer was applied only to patients with MSC or SCC stage III or IV (Belgian Cancer 
Registry, 2014).  All epidemiologic and clinical input data are depicted in Appendix Table 1. The study 
was performed from the societal perspective, including direct medical costs as well as costs related to 
productivity loss because of morbidity and early mortality. Travel costs of patients were not included. 
Direct costs were identified as those medical health care resources consumed due to detection, 
diagnosis, treatment and follow-up, obtained from the 287 completed patient questionnaires. Indirect 
costs reflect the cost of absenteeism due to the management of the skin cancer. The cost for the 
sensitisation campaign was based the study of Shih et al. (2009) who estimated the annual future cost 
for the SunSmart intervention to be €0.17 per capita. Applied to the Belgian population, this would imply 
a total cost for the campaign of €1,525,998 per year. The possible associated costs of implementing a 
sunbed ban and financial consequences for the industry were not taken into account. Health effects of 
the universal prevention programs were defined as the impact on quality-adjusted life-years (QALYs) 
and skin-cancer related deaths. Stage-specific QALYs were based on the EuroQol 5 dimensions 
questionnaire (EQ-5D). The EQ-5D was included in the patient questionnaires, from which utilities were 
derived in combination with literature data (extra information and table in Appendix). Following Belgian 
guidelines, health effects were discounted at 1.5% and costs at 3% (Cleemput et al., 2012). 
Scenario and sensitivity analysis  
In the base case scenario an induction period of 20 years was assumed. However, since the duration 
of this period is not well documented, we varied it between 10 and 30 years. A second scenario consisted 
of the implementation of the combination of both a sensitisation campaign and a ban on public sunbed 
use. A one-way sensitivity analysis assessed the impact of variation in the key parameters one by one 
(according to the confidence interval (CI), or relative variation of ±30% in case no CI was available) in 
order to take into account uncertainty in the input variables. These parameters were the natural 
progression of skin cancer, prevalence and incidence data, effectiveness measures of the intervention 
strategies, disease-specific mortality, cost of the intervention, direct and indirect costs, utilities and the 
discount rate. A probabilistic sensitivity analysis (PSA) created credibility intervals around the 
deterministic ICER by running 5,000 (Monte Carlo) simulations according to the distribution of the 
parameters. Utilities and probabilities were varied according to beta-distributions, costs according to a 
gamma-distribution and relative risks according to a lognormal distribution (Briggs et al., 2006). 
 
RESULTS 
Burden of skin cancer 
Sample characteristics   
In total 16 dermatologists, nine oncologists and one general practitioner, employed in 10 different 
hospitals and six private practices participated in the study. In total, we received 287 completed patient 
questionnaires in a time span of four months. Response rates were 82.8% in dermatology patients and 
71.9% in oncology patients. The sample consisted of 56% women and 44% men. The median age-
category was 61-70 years old. Table 2 displays the stage distribution per cancer type.  
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Table 2: Distribution of study population according to skin cancer type and stage (N)  
 
  D&T Intense FU Long term FU Total 
BCC <1cm 19 17 15 51 
BCC 1-2cm 26 10 3 39 
BCC>2cm 8 1 0 9 
BCC aggressive 
hist. 
6 4 3 13 
SCC 0-I-II 7 11 10 28 
SCC III 0 2 0 2 
SCC IV 0 0 0 0 
MSC 0-I 15 43 42 100 
MSC II 5 7 3 15 
MSC III 8 8 3 19 
MSC IV 2 8 1 11 
Total 96 111 80 287 
 
D&T: Diagnosis and treatment; hist.: histology; FU: follow-up 
Duration D&T:   BCC, SCC 0-II, MSC I-II: 6 months (1 cycle)  
   SSC III-IV, MSC III-IV: 1 years (2 cycles)  
Duration intense FU:  BCC, SCC 0-II, MSC I-II: 1.5 year (3 cycles)    
   SSC III-IV, MSC III-IV: 4 year (8 cycles)  
Duration long term FU:   lifetime 
 
Epidemiology of skin cancer  
The model estimated the total number of skin cancers in 2014 in Belgium to be 137,117, of which the 
greatest part (70%) were BCC cases (males: 45,480; females: 50,390), 18.5% were SCC cases (males: 
12,278; females 13,066) and 11.5% were MSC cases (males: 6,239; females: 9,663). There were more 
female than male skin cancer patients, with a ratio of 1.13 to 1. This current prevalence is estimated to 
have tripled by 2034, to 397,213 skin cancer cases, of which 66% BCC (males: 101,932; females: 
160,221),  21.2% SCC (males: 39,280; females: 45,114) and 12.8% MSC (males: 16,706; and females 
33,960). The ratio of increase for MSC, SCC and BCC was respectively 3.2, 3.3 and 2.7. 
Cost of skin cancer and the potential impact of prevention  
For some patient groups (i.e. all stages of SCC and the more severe lesions of MSC) the response rate 
was low. To increase the power of the study, the direct cost was calculated based on guidelines 
produced by the European Dermatology forum (Euroderm) as well as dermatologist and oncologist 
expert opinions. For these groups with low sample, a care pathway was constructed that reflected 
current management patterns as accurate as possible. Also for large and aggressive BCCs, there was 
a low response rate. Therefore, the cost related to larger and aggressive BCCs was calculated from the 
cost related to a small BCC (<1cm) based on the ratios reported by Rogers & Coldiron (2009). Table 3 
shows the cost per skin cancer stage, expressed per six months. As already stated in previously 
published studies (Alexandrescu, 2009; Tromme, 2015), it is clear from the table that costs increase 
with tumour stage. There were almost no costs due to productivity loss in NMSC patients. The total 
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economic burden of skin cancer on society in 2014 in Belgium was estimated at €107 million, with direct 
costs being €78 million and indirect costs being €29 million (Table 4). The majority of this total cost was 
due to MSC (65%). Costs were slightly higher for females than for males. Costs due to productivity loss 
were ten times higher in MSC patients than in NMSC patients, whereas costs for the patient were higher 
in case of NMSC. The total discounted cost in 2034 amounted to €142 million; the total cumulative cost 
over a period of 20 years (up to 2034) was estimated at €3 billion and over 50 years €8 billion. The 
Markov model simulation over 50 years showed that of the total cumulative societal burden (including 
direct and indirect costs) of €8 billion, €228 million could be saved by a sensitisation campaign and €238 
million by a total ban on sunbeds, which is respectively 2.8% and 2.9% of the total societal burden (Table 
5). The budget impact analysis demonstrated that a campaign could save €142 million for the health 
care budget (i.e. about 0.35% of the current public health care budget), initial investment cost taken into 
account, and in case of a ban on sunbed use €167 million (i.e. about 0.45%), equalling a saving of about 
€0.32 and €0.38 per year per person of the target group. Every euro invested in the sensitisation 
campaign would save €3.6 to the health care payer on the long term. 
 
Table 3:  Cost (in 2014 €) per stage per six months, separated according to phase 
  D&T Intense FU Long term FU 
  
HC 
payer 
patient 
prod. 
loss 
HC 
payer 
patient 
prod. 
loss 
HC 
payer 
patient 
prod. 
loss 
BCC <1cm 196 34 0 119 22 0 82 46 0 
BCC 1-2cm 211 37 0 128 24 0 89 49 0 
BCC>2cm 227 40 0 137 26 0 95 53 0 
BCC aggr. hist. 227 40 0 137 26 0 95 53 0 
SCC 0-I-II 243 17 0 18 13 13 9 7 0 
SCC III 1,396 217 0 91 24 24 45 12 0 
SCC IV 1,659  262 0 91 24 24 45 12 0 
MSC 0-I 1,891 161 2,663 385 71 1,872 231 41 26 
MSC II 2,119 244 1,213 318 60 1,872 258 43 26 
MSC III 4,737 200 6,591 1,082 72  11,864 822 72 3,401 
MSC IV 51,034 344 6,591 6,758 147  16,688 1,401 141 3,401 
Death* - - - - - - - -  43,200 
D&T: Diagnosis and treatment; hist.: histology;  prod.: productivity  
* (Cleemput et al., 2012; Hakkaart-van Roijen, 2010) 
 
Cost-effectiveness of a hypothetical sensitisation campaign and a ban on sunbed use  
Impact on skin cancer mortality  
Based on the relative risks on skin cancer found in published literature (cf. supra), universal prevention 
of skin cancer would lead to a reduction in the prevalence of diagnosed SCC and MSC, by affecting the 
transition from ‘free of events’ to ‘undiagnosed lesion’. Our analysis showed that after 50 years, the 
sensitising campaign and the ban on sunbed use would lead to a reduction in the prevalence of 
diagnosed MSC stage I of 11.3% (absolute numbers: 10,954 in males and 15,053 in females) and 8.6% 
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(absolute numbers: 9,491 in males and 11,335 in females) respectively. The ban on sunbed use was 
shown to also reduce the prevalence of SCC with 22.7% (absolute numbers: 35,934 in males and 52,565 
in females). Due to this decrease in the prevalence of SCC and MSC, less tumours would progress to 
later stages, because of which a reduction in skin cancer mortality is to be expected. In our model, over 
a period of 50 years, 3,991 deaths were estimated to be avoided by means of an annual sensitisation 
campaign (1,593 in males and 2,398 in females) and 3,927 by means of a ban on public sunbed use 
(1,600 in males and 2,327 in females). 
Cost-effectiveness of universal skin cancer prevention  
Table 6 shows the results of the cost-effectiveness analysis of both prevention programs. Both programs 
would lead to a gain in QALYs and cost-savings, making them dominant prevention strategies. When 
both interventions would be implemented simultaneously, more QALYs could be gained and more costs 
could be saved than implementing only one of them.  
The effect of a shorter or longer induction period was tested and showed that the strategy of a ban on 
sunbed use remained cost-saving in case of a 10 year- or 30 year-period. A one-way sensitivity analysis 
of both prevention strategies showed the most influencing parameters to be the utility of skin cancer 
patients, the discount rate of costs and health effects, the direct cost of diagnosis and treatment of MSC 
stage III-IV, the relative risk of sunburn in case of a prevention campaign, the relative risk of MSC and 
SCC if sunbed use and the incidence of MSC, the incidence of MSC and the mortality of MSC stage III 
and IV (Figure 1). The higher the utility of skin cancer, the direct cost of MSC stage III-IV, the relative 
risk of MSC or SCC if sunbed use, the effect of the campaign of sunburn and the incidence of MSC, the 
better the cost-effectiveness. The higher the direct cost of MSC stage III-IV, the relative risk of MSC or 
SCC if sunbed use, the effect of the campaign of sunburn, the incidence and the mortality rate of MSC, 
the better the cost-effectiveness. The higher the utility of MSC and SCC and the discount rate, the worse 
the ICER(Figure 1). These planes show that all simulations are located in the south-east quadrant and 
hence are cost-saving, showing the robustness of the results. 
 
 
 
  
 
 
Table 4: Total current and future societal cost of skin cancer in Belgium, in 2014 euro (calculated with annual inflow) 
  MALES FEMALES TOTAL (incl. death) 
Total 
cumulative 
cost 
Total 
cumulative 
cost 
  MSC  NMSC MSC NMSC MSC NMSC TOTAL 2014-2034 2014-2064 
Health care payer € 17,574,784 € 12,791,731 € 20,289,465 € 13,983,486 € 37,864,249 € 26,775,217 € 64,639,466 € 1,909,776,064 € 5,243,814,688 
Patient € 893,220 € 5,102,829 € 1,293,760 € 5,683,730 € 2,186,979 € 10,786,559 € 12,973,539 € 341,834,700 € 993,608,874 
Productivity loss € 12,769,907 € 9,191 € 16,496,350 € 16,841 € 29,266,257 € 26,032 € 29,292,288 € 931,099,033 € 1,878,309,125 
Total € 31,237,910 € 17,903,750 € 38,079,575 € 19,684,057 € 69,317,485 € 37,587,808 € 106,905,293 € 3,182,709,797 € 8,115,732,687 
 
Table 5: Results from the economic impact analysis, showing cumulative costs over 50 years (calculated with inflow) 
  
Cost of 
intervention 
Cost for health 
care payer 
Cost for patient 
Cost 
productivity loss 
Total cost 
Total extra cost from 
societal perspective 
Total extra cost 
from health care 
payer perspective* 
No prevention strategy € 0 € 5,243,814,688 € 993,608,874 € 1,878,309,125 € 8,115,732,687     
Sensitisation campaign € 39,219,386 € 5,062,395,121 € 987,492,778 € 1,798,897,062 € 7,888,004,347 -€ 227,728,340 -€ 142,200,181 
Ban on sunbed use € 0 € 5,076,473,226 € 981,978,239 € 1,819,282,111 € 7,877,733,575 -€ 237,999,112 -€ 167,341,463 
*Health care payer perspective = government, excl. patient co-payment 
Table 6: Results from the cost-effectiveness analysis of universal prevention of skin cancer, expressed per 1,000 persons (calculated without inflow) 
  QALYs Costs Incremental QALYs Incremental costs ICER 
  males females males females males females males females males females 
No prevention strategy 18,876 20,856 € 669,861 € 977,368     
cost-saving 
Sensitisation campaign 18,877 20,857 € 654,587 € 959,957 1.39 1.39 -€ 15,273 -€ 17,411 
Ban on sunbed use 18,881 20,862 € 649,975 € 956,984 4.81 5.94 -€ 19,886 -€ 20,384 
Both interventions simultaneously 18,882 20,863 € 641,858 € 942,074 5.65 7.21 -€ 28,002 -€ 35,294 
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Figure 1a: One-way sensitivity analysis: tornado-diagram showing the most influencing parameters on 
the cost-effectiveness of a sensitizing prevention campaign in females 
 
Dark-coloured bars = maximum parameter value; light-coloured bars = minimum parameter value  
Range of variation in relative terms between brackets 
D&T: diagnosis & treatment; RR: relative risk 
 
Figure 1b: One-way sensitivity analysis: tornado-diagram showing the most influencing parameters on 
the cost-effectiveness of a total ban on sunbed use in females 
 
Dark-coloured bars = maximum parameter value; light-coloured bars = minimum parameter value  
Range of variation in relative terms between brackets 
D&T: diagnosis & treatment; RR: relative risk 
 
Figure 2: Cost-effectiveness planes displaying the results of the 5,000 simulations 
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DISCUSSION  
In order to perform the bottom-up cost analysis, individual skin cancer patient cost data were aggregated 
to the national level based on skin cancer epidemiologic data. Although a bottom-up approach is more 
time-consuming, it has the advantage of providing more detailed information on the incurred costs. 
Moreover, it has been shown that the self-reported health care use of responders to surveys does not 
differ significantly from the observed health care use in the total population and that such a survey is a 
valid instrument to estimate health care use, especially for general practitioner consultations and 
inpatient care (Agerholm, Bruce, Ponce De Leon, & Burström, 2015; Van der Heyden, De Bacquer, 
Tafforeau, Charafeddine, & Van Herck, 2016). Specialist consultations tend to be underestimated when 
self-reported, which makes the current cost-analysis rather conservative. The analysis on the burden of 
skin cancer showed that if the rising incidence trend continues, the skin cancer health burden in Belgium 
will triple within the next 20 years. In comparison, a recent study in the United States estimated MSC 
incidence rates to double from 2011 to 2030 (Guy et al., 2015). Tromme et al. have previously assessed 
the cost of MSC treatment by means of 145 hospital bills and 253 patient questionnaires from one 
hospital (Cliniques Universitaires St-Luc) (Tromme, 2015). The cost they calculated for treatment of 
MSC stage IV was lower than our result. Most probably, this has to do with the high cost of new treatment 
drugs for the management of melanoma stage IV, which were not yet used in the time Tromme et al. 
did their research. Besides, they didn’t include costs due to productivity loss. The current annual total 
cost for skin cancer in Belgium was estimated to be €107 million in this study (for a population of 8.8 
million Belgian adults), of which almost €65 million is to be paid by the health care payer (government), 
resulting in about 0.18% of the total public health care budget in Belgium. The result is comparable to 
other European studies. A Danish study (5.5 million inhabitants) found that in 2010 direct skin cancer 
cost accounted for €33.3 million or 0.2% of the Danish health care budget (Bentzen et al., 2013). In 
Sweden (9 million inhabitants in 2005) the total societal cost for MSC was €79.7 million and €36.2 million 
for NMSC in 2005 (Tinghog, Carlsson, Synnerstad, & Rosdahl, 2008). A bottom-up cost-of illness study 
in England calculated an annual direct cost of 106.4 million pound in 2008 (€124.7 million in 2015) for 
MSC and NMSC (Vallejo-Torres, Morris, Kinge, Poirier, & Verne, 2014). A top-down method generated 
a similar result. This is relatively low compared to the Belgian situation (direct cost estimated to be about 
€78 million) since there are almost 5 times more inhabitants in England. However, all these studies were 
performed some years ago, not yet taking into account the recent, more expensive therapies to treat 
metastatic MSC, which can bias the comparison with our study results. According to our results, MSC 
was responsible for 65% of the medical costs, in contrast to a study examining the hospitalisation costs 
of skin cancer in Germany (Stang et al., 2008). The latter study concluded that NMSC-related costs for 
hospitalisations were about twice the rates of MSC. Nonetheless, in Sweden and Denmark the 
proportion of cost due to MSC was similar to the Belgian proportion (resp. 68.7% and 59%, although the 
latter only included direct costs) (Bentzen et al., 2013; Tinghog et al., 2008). Additionally, the cost 
calculations were probably affected by the registration method. Only the first NMSC lesion was 
registered in the Dutch database. Although we tried to account for the risk of a recurrent and a 
subsequent lesion, the total NMSC-related cost tends to be underestimated in our study, which could 
have influenced the balance between MSC and NMSC-related costs. In comparison, the annual societal 
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cost of established arteriosclerotic cardiovascular disease in Belgium was €2,1 billion in 2004 (Vlayen 
et al., 2008), and all brain disorders combined accounted for €10.6 billion in 2004 (Schoenen, Gianni, 
Schretlen, & Sobocki, 2006), suggesting that the economic burden of skin cancer is relatively low. 
However, it is expected that the estimated total economic burden of skin cancer is an underestimation 
of the real cost of skin cancer, as only the first NMSC was registered in the epidemiologic data from the 
Dutch cancer registry (IKNL). Projections to 2034 showed an estimated annual discounted cost of €142 
million, and a total cumulative cost of €3 billion. This estimated future annual cost of 2034 is in line with 
other studies that made projections into the future. In England, a projection from 2008 to 2020 showed 
almost a doubling in the annual cost of skin cancer (106.4 million pound to 190.5 million pound) (Vallejo-
Torres et al., 2014).  
The results at hand showed that an on average €155 million of the health care budget could be 
redirected to other diseases by implementing a skin cancer prevention campaign or a ban on sunbeds 
in Belgium. Although a total ban on sunbed use would gain more health benefits, both interventions are 
cost-saving on the long term and thus dominant. However, the extra costs for the individuals as a 
consequence of the prevention campaign, such as extra sunscreen and sun-protecting clothing was not 
included in our model, since there is no accurate information on these costs in the control group (i.e. 
without intervention). Nonetheless, suppose an extra cost of €5 per adult would be assumed, then the 
sensitisation campaign would not be cost-effective anymore. The sensitivity analysis revealed that the 
higher the medical costs of treating metastatic MSC, the more cost-effective prevention would be, since 
the financial benefit of prevention would be higher. Recently, new expensive treatments for metastatic 
MSC were introduced and it is expected that in the future treatment costs will continue to rise, which 
further favours prevention interventions for MSC. However, a major challenge is to create the desired 
altered behaviour by implementing a prevention campaign. Consequently, a total ban on sunbed use 
could be a relatively more easy way to achieve a specific behaviour.  
To our knowledge, no similar cost-effectiveness analysis in combination with an economic burden-of-
illness and budget impact analysis of universal prevention of skin cancer has been performed up to now. 
Gordon & Rowell (2015) included seven studies in their review of the cost-effectiveness of - what they 
call- primary prevention. Although all studies had different designs and context, they concluded that skin 
cancer primary prevention programs or policies are consistently cost-effective and may even be cost-
saving for governments in the near future. In Australia, the SunSmart program has been evaluated twice, 
by Carter et al. (1999) and later on by Shih et al. (2009). We adopted the method of Carter et al., namely 
the evaluation of the effectiveness of the program on skin cancer incidence in an indirect way, by the 
effect on the prevalence of sunburns. Carter et al. included an induction period of 5 years for MSC and 
15 years for NMSC before the reduced incidence is realised. Their analysis resulted in the prevention 
of 4,300 deaths over 20 years, and net savings to government of AUD 103 million. The study of Shih et 
al. obtained similar results with a return of investment of AUD 3.6 per invested dollar. The major 
differences between the study of Shih et al. and our study are their measurement of the program 
effectiveness, namely directly on the skin cancer incidence, their final outcome in the economic analysis 
which were DALYs, the comparator of their analysis being a less intense program with less invested 
money and their perspective which was only from the health care payer. Additionally, the recent study 
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of Doran et al. evaluated the cost-effectiveness of the implementation of three skin cancer mass media 
campaigns in New South Wales (Australia) and found a return on investment of AUD 3.85 per invested 
dollar (Doran et al., 2016).  
Some limitations of our analysis should be acknowledged. First, since for some skin cancer stages the 
sample of returned patient questionnaires was too small, we had to rely on expert opinion and literature 
data to calculate the medical costs for these groups. The indirect costs were derived from the small 
sample data and could therefore be partly biased. However, the prevention strategies remained cost-
saving even without inclusion of productivity loss. Second, the simulation of the prevention programs is 
hypothetical; a trial-based analysis may be beneficial. Therefore, the effect of a prevention campaign 
was deduced from the Australian SunSmart program. However, it is not known if such a campaign would 
have a similar relative effect on sunburn in Belgium. A German study evaluating the effectiveness of 
skin cancer information campaigns during the last 16 years found a relative risk of 0.68 to get sunburned 
in presence of a campaign, which denotes a lower effectiveness of the campaign than the SunSmart 
campaign (Breitbart, Greinert, & Volkmer, 2006). However, the sensitivity analysis acknowledged this 
uncertainty and showed that the intervention would still be cost-saving in case of a lower effectiveness. 
Third, in Belgium there is no accurate registration of NMSC. Therefore, we relied on epidemiologic 
figures of the Dutch cancer registry, and applied a correction factor to it based on the incidence- as well 
as mortality rate of MSC in both countries (International Agency for Research on Cancer, 2012b). As 
already stated, it should be noted that only the first NMSC lesion was registered. Although we tried to 
account for subsequent and recurrent lesions in the model, it is expected that the real incidence, 
prevalence and costs of NMSC is larger than simulated by our model. Fourth, accurate information on 
the natural progression of skin cancer is not available. Therefore, in our model, the natural progression 
was estimated based on calibration. This is generally a more reliable approach than making 
assumptions on parameters based on limited studies. Lastly, it should be noted that the findings of this 
study cannot be directly transferred to other countries as some key parameters are context-specific such 
as the incidence of MSC and the medical costs for treatment and follow-up of advanced tumours. It is 
expected that in countries with a higher incidence of MSC, these evaluated prevention strategies would 
lead to higher cost-savings.  
 
CONCLUSIONS 
This analysis estimated the prevalence of skin cancer to triple in the next 20 years. A hypothetical 
sensitising campaign and a ban on sunbed use were shown to be two universal prevention strategies 
which can offer excellent value for money and even save money not only for the health care payer but 
also for society as a whole. These results can aid policy makers and clinicians to promote UV protection 
strategies on a long-term basis.  
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APPENDIX 
 
Appendix Table 1: Prevalence of undiagnosed lesions 
Parameter 
Input value 
18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
 BCC <1cm  M 0.015% 0.135% 0.377% 0.699% 1.528% 3.022% 3.809% 
 BCC <1cm  F 0.035% 0.150% 0.633% 0.799% 1.419% 2.033% 2.275% 
 BCC 1-2cm M 0.008% 0.075% 0.209% 0.387% 0.846% 1.674% 2.109% 
 BCC 1-2cm F 0.019% 0.083% 0.350% 0.443% 0.786% 1.126% 1.260% 
 BCC >2cm M 0.002% 0.021% 0.059% 0.109% 0.238% 0.470% 0.592% 
 BCC >2cm F 0.005% 0.023% 0.098% 0.124% 0.221% 0.316% 0.354% 
 BCC aggr. hist. M 0.011% 0.101% 0.282% 0.522% 1.141% 2.257% 2.844% 
 BCC aggr. hist. F 0.026% 0.112% 0.472% 0.597% 1.059% 1.518% 1.699% 
 SCC stage 0-II M 0.000% 0.001% 0.002% 0.013% 0.048% 0.268% 0.967% 
 SCC stage 0-II F 0.001% 0.002% 0.010% 0.033% 0.095% 0.222% 0.419% 
 SCC stage III M 0.000% 0.000% 0.000% 0.001% 0.006% 0.031% 0.112% 
 SCC stage III F 0.000% 0.000% 0.001% 0.004% 0.011% 0.026% 0.049% 
 SCC stage IV M 0.000% 0.000% 0.000% 0.000% 0.001% 0.007% 0.026% 
 SCC stage IV F 0.000% 0.000% 0.000% 0.001% 0.003% 0.006% 0.011% 
 MSC stage I M 0.065% 0.173% 0.328% 0.527% 0.805% 1.156% 1.132% 
 MSC stage I F 0.128% 0.311% 0.488% 0.543% 0.704% 0.767% 0.502% 
 MSC stage II M 0.019% 0.049% 0.094% 0.151% 0.230% 0.331% 0.324% 
 MSC stage II F 0.029% 0.070% 0.109% 0.122% 0.158% 0.172% 0.112% 
 MSC stage III M 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
 MSC stage III F 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
 MSC stage IV M 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
 MSC stage IV F 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 0.000% 
           
M: Males   F: Females  
Source: (Hoorens et al., 2016) 
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Appendix Table 2: Incidence and natural progression of skin cancer lesions 
Parameter 
Input value 
18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
INCIDENCE                
BCC Ma 0.001% 0.004% 0.013% 0.024% 0.053% 0.101% 0.107% 
BCC Fa 0.002% 0.006% 0.024% 0.029% 0.055% 0.075% 0.078% 
SCC Ma 0.000% 0.000% 0.001% 0.005% 0.018% 0.053% 0.123% 
SCC Fa 0.000% 0.000% 0.002% 0.006% 0.017% 0.038% 0.076% 
MSC I Mb 0.002% 0.004% 0.007% 0.010% 0.013% 0.019% 0.017% 
MSC I Fb 0.005% 0.011% 0.017% 0.016% 0.015% 0.017% 0.009% 
         
NATURAL PROGRESSION        
BCCc 12.5% 
SCC stage 0-II => IIId 1.0% 
SCC stage III => IVe 7.0% 
MSC I => II/IIIe 0.4% 
MSC II => IIIe 1.7% 
MSC II => IVe 1.5% 
a (Integraal Kankercentrum Nederland, 2011); b (Belgian Cancer Registry, 2013); c (Kirkup & De Berker, 1999); d (Smoller, 2006);  e calibration 
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Appendix Table 3: Risk of metastases, of developing MSC after NMSC and mortality rates 
Parameter 
Input value 
18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
PROGRESSION TO METASTASES, 
AFTER TREATMENT 
       
SCCa 0.23% 
MSC stage I  => MSC stage IIIb  0.07% 
MSC stage I  => MSC stage IVb 0.07% 
MSC stage II  => MSC stage IIIb 0.47% 
MSC stage II  => MSC stage IVb 0.47% 
MSC stage III  => MSC stage IVb 2.26% 
         
RELATIVE RISK OF DEVELOPING 
MSC AFTER DIAGNOSES OF NMSC  
       
MSC after BCCc     3.28    
MSC after SCCc 3.62 
         
MORTALITY RATES  
Mortality due to  skin cancer  (first year)        
MSC stage IVd 26.66% 
SCC stage IVe 23.70% 
Mortality due to  skin cancer  (follow-up)        
MSC stage IVd M: 12.45%   F: 7.65% 
SCC stage IVf M: 6.33%   F: 9.71% 
Mortality due to other causesg        
Male 0.04% 0.05% 0.12% 0.33% 0.76% 1.97% 3.85% 
Female 0.01% 0.02% 0.04% 0.13% 0.30% 0.71% 2.46% 
 
M: male;  F: female  
a (Rowe et al., 1992); b (Leiter et al., 2012); c (Rees et al., 2014); d (Belgian Cancer Registry, 2014)  corrected for new therapies; e (Council of the European 
Union, 2010); f (Hollestein et al., 2012); g Belgian life tables 2012  
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Health-related quality of life: utilities 
Undiagnosed BCC, SCC stage 0-II and MSC stage I were assigned the same utility as the population 
norm, which is 0.81 (Scientific Institute of Public Health., 2013). The utility for undiagnosed SCC stage 
III-IV and MSC stage III-IV was calculated as the average of the population norm and the utility for 
diagnosis and treatment. The sample size of completed patient questionnaires for SCC and MSC stage 
II-III and IV was too small to have sufficient sample power, so the utilities of these stages (diagnosed) 
were calculated based on the ratio of the utilities in these stages compared to stage I, as described by 
Tromme et al. (2014). The utility for BCC patients, who are in treatment or intense follow-up is derived 
from the study of Gaulin et al. (2015). The utility for patients in long term follow-up for BCC, SCC 0-II 
and MSC 0-I and II was defined to be the same as the population norm, since it is assumed that once 
the lesion has been excised, the quality-of-life will return to baseline on the long term.  
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Appendix Table 4: utilities assigned to the model states 
Parameter 
Input value  
18-29y 30-39y 40-49y 50-59y 60-69y 70-79 79+ 
General populationa 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
BCC undiagnosedad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
D&T BCCb  0.869 0.822 0.811 0.769 0.767 0.746 0.630 
intensive FU BCCb  0.869 0.822 0.811 0.769 0.767 0.746 0.630 
Long term FU BCCad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
SCC 0-II undiagnosedad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
SCC III undiagnosed 0.710 0.663 0.652 0.610 0.608 0.587 0.471 
SCC IV undiagnosed 0.730 0.683 0.672 0.630 0.628 0.607 0.491 
SCC 0-II D&Tc 0.611 0.564 0.553 0.511 0.509 0.488 0.372 
SCC III D&T 0.529 0.482 0.471 0.429 0.427 0.406 0.290 
SCC IV D&T 0.569 0.522 0.511 0.469 0.467 0.446 0.330 
SCC 0-II intense FUc 0.786 0.739 0.728 0.686 0.684 0.663 0.547 
SCC III intense FU 0.699 0.652 0.641 0.599 0.597 0.576 0.460 
SCC IV intense FU 0.781 0.734 0.723 0.681 0.679 0.658 0.542 
SCC 0-II long term FUad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
SCC III long term FU 0.785 0.738 0.727 0.685 0.683 0.662 0.546 
SCC IV long term FU 0.878 0.831 0.820 0.778 0.776 0.755 0.639 
MSC I undiagnosedad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
MSC II undiagnosedad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
MSC III undiagnosed 0.751 0.704 0.693 0.651 0.649 0.628 0.512 
MSC IV undiagnosed 0.774 0.727 0.716 0.674 0.672 0.651 0.535 
MSC I D&Tc 0.761 0.714 0.703 0.661 0.659 0.638 0.522 
MSC II D&T 0.654 0.607 0.596 0.554 0.552 0.531 0.415 
MSC III D&T 0.610 0.563 0.552 0.510 0.508 0.487 0.371 
MSC IV D&T 0.658 0.611 0.600 0.558 0.556 0.535 0.419 
MSC I intense FUc 0.780 0.733 0.722 0.680 0.678 0.657 0.541 
MSC II intense FU 0.774 0.727 0.716 0.674 0.672 0.651 0.535 
MSC III intense FU 0.688 0.641 0.630 0.588 0.586 0.565 0.449 
MSC IV intense FU 0.769 0.722 0.711 0.669 0.667 0.646 0.530 
MSC I long term FUad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
MSC II long term FUad 0.891 0.844 0.833 0.791 0.789 0.768 0.652 
MSC III long term FU 0.785 0.738 0.727 0.685 0.683 0.662 0.546 
MSC IV long term FU 0.878 0.831 0.820 0.778 0.776 0.755 0.639 
False positive result on screeningd 0.884 0.837 0.826 0.784 0.782 0.761 0.645 
 
a (Scientific Institute of Public Health., 2013)  
b (Gaulin, Sebaratnam, & Fernandez-Penas, 2015)  
c patient questionnaires  
d assumption 
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Natural evolution of skin cancer 
Information on the natural evolution of undiagnosed melanoma tumours is lacking. Therefore, model 
calibration was applied by manually searching for the best combination of parameter values, as to match 
the modelled outputs to the observed evidence on the outputs, in this case the number of melanoma 
deaths. In Belgium, every year about 450 people die from skin cancer. Over 20 year this would mean 
about 9,000 deaths (without taking the rising trend in incidence into account). Since SCC lesions are 
under registered in Belgium, the actual number of deaths is estimated to be higher. The output of the 
model, in terms of number of skin cancer deaths after 20 year, was matched to this expected 9,000 
deaths based on estimation of the natural progression. When this natural progression from MSC stage 
I was set at 0.4% and from MSC stage II at 1.7% (to stage III) 1.5% (to stage IV), the output of the model 
showed 11,100 deaths over 20 years, which is in line with the estimated number of deaths in reality. 
Natural progression of BCC was derived from the study of Kirkup et al. (1999), showing an evolution of  
1 cm per 3.8 years or 1.2 mm per 6 months. The transition risk from SCC stage 0-II to stage III or IV 
was estimated as 0.5% per 6 months (Smoller, 2006). 
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Appendix Figure 1: Visualisation of the Markov model 
BCC: Basal cell carcinoma;  SCC: Squamous cell carcinoma; FU: Follow-up; D & T: Diagnosis and treatment. Light-coloured states correspond to undiagnosed cancer 
  
a) Markov model for BCC lesions 
 
*FU is divided in intense FU (3 cycles) and long term FU  
From BCC one can also develop a melanoma lesion 
 
 
 
 
b) Markov model for SCC lesions 
 
 
*FU is divided in intense FU (3 cycles) and long term FU      
** FU is divided in intense FU (8 cycles) and long term FU  
From SCC one can also develop a melanoma lesion 
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c) Markov model for MSC lesions 
 
*FU is divided in intense FU (3 cycles) and long term FU      
** FU is divided in intense FU (8 cycles) and long term FU  
 
 
 
 
  
 
 
  
  
 
 
 
 
 
Part 2: Original research studies: health economic 
evaluations in the continuum of prevention 
 
 
2.2.    Selective prevention interventions 
  
  
 
  
  
 
 
 
 
 
2.2.1. Cost-effectiveness and budget impact analysis of the 
population-based screening program for breast cancer  
 
 
 
 
 
 
 
Maaike Fobelets*, Lore Pil*, Koen Putman, Jeroen Trybou & Lieven Annemans. Cost-effectiveness 
and budget impact analysis of the population-based screening program for breast cancer. Journal of 
Medical Screening. (Paper submitted).  
* Shared first authorship 
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ABSTRACT 
Introduction Belgium has the highest incidence of breast cancer (BC) in Europe. A biennial 
mammography population-based screening program for women aged 50 to 69 years has been 
organised in Flanders (Belgium) since 2001. An economic analysis was performed to evaluate the cost-
effectiveness of the current BC screening program in order to assess whether continuation of the current 
screening program is efficient.  
Methods A screening decision tree and a state-transitional Markov model were developed to calculate 
the costs and health effects over a period of 20 years. Medical and non-medical costs, quality-adjusted 
life-years and mortality were estimated in order to determine the incremental cost-effectiveness ratio of 
the screening program, compared to no screening program. A budget impact analysis estimated the 
impact of the screening program on the healthcare budget. 
Results Assuming a threshold value of €35,000/QALY gained, the BC screening program in Flanders 
was predicted to be cost-effective with an ICER of €28,428/QALY and a mortality reduction of 14.0% 
over a period of 20 years. The parameters with the highest influence on the ICER were the utility of BC 
stage I treatment and follow-up, absenteeism due to a mammography and the natural progression of 
BC. The budget impact analysis indicated that, beside the organisational cost, the screening program 
induces extra costs for both patient and health care payer. 
Conclusion The current population-based BC screening program is cost-effective in Flanders and 
appears to be effective in reducing BC mortality, despite the possible adverse effects and the induced 
treatment costs related to the biennial mammography screening program 
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INTRODUCTION 
No other European country recorded a higher incidence of breast cancer (BC) than Belgium, namely 
147.5 cases per 100,000 women (International Agency for Research on Cancer, 2012a). The BC 
screening program in Flanders was introduced in 2001 after a long history of opportunistic screening. 
Today, women of 50 to 69 years are invited biennially for a screening mammography, in accordance 
with the European guidelines for BC screening and diagnosis (Perry et al., 2008). Over the last decade, 
several cost-effectiveness studies on BC screening have been published, all focussing on certain 
aspects of breast cancer screening. Some evaluated the BC screening program as currently 
implemented in the particular country (Arrospide et al., 2016; Carles et al., 2011; Pharoah, Sewell, 
Fitzsimmons, Bennett, & Pashayan, 2013), others evaluated different screening intervals (Gocgun et 
al., 2015; Mittmann et al., 2015; Rojnik, Naversnik, Mateovic-Rojnik, & Primiczakelj, 2008), different 
screening techniques (Melnikow et al., 2013; Wang, Merlin, Kreisz, Craft, & Hiller, 2009) or different age 
limits (Rafia et al., 2016; Rashidian, Barfar, Hosseini, Nosratnejad, & Barooti, 2013). However, few of 
these studies have looked at the budget impact of BC screening. Moreover, possible drivers of the 
results, such as the impact of the uncertainty associated with anxiety due to a false-positive result as 
well as productivity losses have rarely been included. In addition, results of these published cost-
effectiveness studies from other jurisdictions cannot be directly transferred to the situation in Flanders, 
as country- or region-specific demographic, epidemiologic as well as screening-related parameters 
should be taken into account. Since a health economic analysis of the current population-based BC 
screening program in Flanders has never been performed in the past, the aim of this study was to assess 
the overall cost-effectiveness and budget impact of the program, taking into account the uncertainty in 
the above mentioned parameters and with the aim to explore all possible drivers of the result. 
 
METHODS 
Screening strategy   
The organised BC screening program consists of a biennial mammography screening for women of 50 
to 69 years, of which 50.2% participated in 2013. Women with a history of BC (less than ten years ago) 
and women who underwent an opportunistic mammography less than two years ago are not invited to 
the screening program. All screening mammograms undergo double reading by two independent 
radiologists. In case of discordant double reading results, arbitration by a third radiologist is used to find 
a consensus. After a positive test result extra diagnostic tests such as a breast ultrasound are 
performed; after a negative test result, the woman will be re-invited after two years. An estimated 15% 
of the target group participates in spontaneous opportunistic screening instead of participating in the 
organised the screening program.  
Model design  
A Markov model with a 20-year time horizon and a one-year cycle length was developed consisting of 
several disease states categorised according to the Tumour-Node-Metastasis-staging (Sobin et al., 
2009). The following states were included in the Markov model: unidentified ductal carcinoma in situ 
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(DCIS); unidentified BC stage I, II, III or IV; identified BC stage I, II, III or IV in treatment; intense follow-
up (year 1 to 4) of these stages; and long-term follow-up (year 4+) (Appendix Figure 1). The comparator 
of the screening program was the natural history of BC in the presence of the above mentioned 15% 
spontaneous opportunistic screening. At the start of the model, persons in the target population were 
free of lesions or had an unidentified lesion. BC could be detected through the population-based 
screening program, spontaneous opportunistic mammography or clinically, based on symptoms. 
Annually, cancer-free people could develop a tumour, people with an unidentified tumour could be 
detected, diagnosed and receive treatment and in the next years progress to follow-up. The treatment 
phase lasted one year after which women progressed to the follow-up phase (separated into intense FU 
and long term FU). During treatment and follow-up, women could still progress to regional metastasis 
(stage III) or to distant metastasis (stage IV). Mortality was incorporated as BC-related mortality, only 
applied to women with BC stage III or IV, and as mortality from other causes. The cost-effectiveness of 
the screening program was evaluated by calculating the incremental cost-effectiveness ratio (ICER), 
defined as the ratio of difference in costs to the difference in effectiveness between intervention and 
comparator. The budget impact analysis estimated the net cumulative cost of the screening program 
(and consequent examinations, treatment and follow-up) for the healthcare payer (i.e. government) over 
a period of 20 years, while accounting for an annual inflow of new 50 year olds. 
Epidemiological and clinical inputs  
Epidemiologic data were based on a combination of the best available data from the Belgian Cancer 
Registry, life tables and data from published literature (Appendix Table 1-4). Annual progression 
probabilities were calculated by converting sojourn times12, based on tumour size, into annual 
progression probabilities assuming a basic Poisson process (Harris & Hellman, 1996; Tan et al., 2013). 
Risk of metastases was retrieved from the study of Siponen et al (2013). Disease-specific mortality was 
obtained from the Belgian Cancer Registry (2014) and mortality from other causes was extracted from 
the Flemish life tables. Model parameters related to the screening program were obtained from the 
Flemish Government (Table 1) (Centrum voor Kankeropsporing, 2013).  
Health-Economic inputs  
All cost calculations were performed from a societal perspective (medical unit costs and days 
absenteeism are presented in Appendix Table 5-6). Direct medical costs for screening, diagnosis and 
treatment were based on Belgian data (Broe. Indirect costs of productivity loss were calculated based 
on the friction cost method (Hakkaart-van Roijen, 2010). The number of days off work due to BC were 
multiplied with the average cost per working day (Cleemput et al., 2012), weighted for the employment 
rate, proportion of full-time equivalents and applied to women younger than 65 years. Costs were 
indexed to year 2014 by using the Health Index (Federale Overheidsdienst Economie KM, 2015). Health 
effects were calculated as quality-adjusted life years (QALYs), by using (EQ-5D index) utilities,  
expressing the quality of life with a range from 0 (death) to 1 (perfect health). The utilities for the different 
                                                          
12 The sojourn time is the time between the onset of the disease (preclinical phase) and the manifestation of 
clinical symptoms (clinical phase) 
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health states were age- and gender specific, derived from Flemish as well as international published 
data (Appendix table 7). A utility loss reflecting the psychological stress due to a false-positive screening 
result was considered in the model, although there is still debate on the magnitude of this impact 
(Cockburn, Staples, Hurley, & De, 1994; Johnston, Brown, Gerard, O'Hanlon, & Morton, 1998). 
According to Johnston et al. (1998), the utility related to a false-positive result is similar to the utility of a 
true positive result. In our model, the utility of an identified DCIS of BC stage I is about 10% less than 
the utility of the general population. Therefore a 10% disutility related to a false-positive result was 
assumed, for a duration of one month. Following the Belgian guidelines, health effects were discounted 
at 1.5% and costs at 3% (Cleemput et al., 2012). 
 
Table 1: Screening-related parameters from the Flemish screening program 
Model parameter 
Input value 
50-59y 60-69y 
Participation rate screening 49.40%  51.5% 
Participation rate extra examinations (after pos. screening result) 91.70% 91.70% 
Proportion of screening population with diagnostic mammography* 15.00% 15.00% 
Sensitivity screening program  for DCIS 83.00%  83.00% 
Sensitivity screening program  for invasive BC 69.10%  69.10% 
Specificity screening program   98.30%  98.30% 
BC: Breast cancer   DCIS: Ductal carcinoma in situ  
Source: Annual report Flemish cancer screening, 2013 (Centrum voor Kankeropsporing, 2013) 
* expert opinion 
 
Sensitivity and scenario analysis  
A one-way and probabilistic sensitivity analysis was conducted to identify the uncertainty of parameters 
and the robustness of the results. The following parameters were included in the one-way sensitivity 
analysis: costs of the screening program, direct medical costs, days off work due to BC, time off work 
due to the mammography, incidence of undiagnosed BC stage I, BC mortality rates, test characteristics 
(screening- and diagnostic mammography), screening participation rate per age group, utilities, 
participation to further examinations, percentage opportunistic screening, risk on symptoms and BC 
progression rates. Parameters were varied based on standard error estimates of the literature (if not 
available ±30% ranges were used). Probability distributions were defined for costs (gamma distribution), 
utilities, test characteristics of the mammography, participation rate per age-category (beta distribution) 
and days off work (normal distribution). A probabilistic sensitivity analysis was performed by running 
5000 2nd order Monte Carlo simulations and a cost-effectiveness acceptability curve (CEAC) was drawn 
to inform policy makers on the probability of cost-effectiveness given a certain cost-effectiveness 
threshold (i.e. willingness to pay). Moreover, the following scenarios were tested: a public health care 
payer perspective (i.e. exclusion of costs related to productivity loss and costs to be paid by the patient), 
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worst and best case scenario of the utility of a false-positive result, in which the worst case was an equal 
value to the utility of BC stage I in treatment and the best case was an equal value to the utility of no 
abnormal lesion, and a time horizon of 50 years instead of 20 years. In the scenario with a time horizon 
of 50 years, an annual inflow of new 50-year olds was included, as after 20 years the original cohort is 
not eligible for screening anymore. 
Model outcome validation   
The modelled mammography screening resulted in an average annual positivity rate of 2.23% and 
detection rate of 0.51% over a period of 20 years. These results are in line with the positivity rate of 
2.10% and detection rate of 0.55% of the current BC screening program (Centrum voor 
Kankeropsporing, 2013). Besides, the distribution of the cancer prevalence according to the tumour 
stage over 20 years in the screening arm was compared to the stage distribution of tumours in 2010 
(Belgian Cancer Registry, 2010a). This stage distribution was 40%, 36%, 17% and 7% from stage I to 
IV in the model, and 43%, 37%, 14% and 7% in real-life, which means that overall estimated stage 
distribution seemed to approximate the observed stage distribution.  
 
RESULTS 
Base case (deterministic)  
Over 20 years, the screening program yielded 0.007 QALY per woman of 50 years and older, against 
an incremental cost of €206 (Table 2), resulting in an incremental cost-effectiveness ratio of 
€28,428/QALY. Assuming a cost-effectiveness threshold of €35,000/QALY gained (i.e. GDP per capita 
Belgium) this result shows that the Flemish BC screening program is expected to be cost-effective. The 
benefit of the screening program is shown in Appendix Figure 2; more early-stage tumours were 
detected in reference to advanced tumours. The incidence of BC stage IV in the presence of the 
screening program was predicted to decrease by 14.5% during the 20-year period, in comparison to the 
situation without screening program. Additionally, over 20 years a mortality reduction of 14.2% was 
expected due to the screening program. The budget impact analysis showed that the screening program 
generates more costs for the health care payer (i.e. government) compared to no screening program 
(Table 3). Over a period of 20 years, the screening program resulted in a net cumulative cost of 
€492,239,887, or €31 per year per woman from the target group (50-69 year-olds). 
Sensitivity and scenario analysis  
The results of the one-way sensitivity analysis are depicted in Appendix Figure 3. The most influential 
parameters were the utility of treatment of BC stage I, the utility of follow-up, absenteeism due to having 
a mammography, the natural progression of BC and the incidence of BC stage I. A higher utility related 
to the treatment of BC stage I and the follow-up of BC in general, as well as a higher incidence rate of 
BC stage I would lead to a better ICER. Higher natural progression rates would also favour the ICER. 
In the base case no productivity loss was applied to undergoing a mammography, assuming the time 
women lost due to the mammography screening would be compensated. When applying 2 to 4 hours 
productivity loss, the ICER would deteriorate to a range of €43,284/QALY to €58,141/QALY. Increasing 
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the participation rate for screening, usually perceived as one of the key indicators, with 30% relatively 
(i.e. from 51% to 66%), only slightly ameliorated the ICER. Results from the Monte Carlo simulations, 
which are mainly plotted in the north-east quadrant of the incremental cost-effectiveness plane (Figure 
1), confirmed that the BC screening program induced more costs but was more effective compared to 
no screening. The probabilistic sensitivity analysis resulted in an ICER of €31,377/QALY (95%CI: 
€21,973 -54,977/QALY) and a mortality reduction of 14.0% (95%CI: 11.1% – 16.6%). The cost-
effectiveness acceptability curve showed that biennial mammography screening was cost-effective in 
82.9% of all simulations, given a willingness-to-pay threshold of €35,000/QALY gained (Figure 2). In 
case of assuming a public health care payer perspective the ICER slightly worsened (Table 2).  In the 
worst case scenario concerning the utility related to a false-positive result, the cost-effectiveness result 
would deteriorate to €86,486/QALY, in the best case scenario, the ICER ameliorated to €27,042/QALY. 
Extending the time horizon to 50 years (incl. annual inflow) resulted in a better ICER, namely 
€13,060/QALY.   
 
Table 2: Results of the cost-effectiveness analysis, with several scenarios  
Scenario Δ Cost (€) Δ QALY ICER (€/QALY) 
Mortality 
reduction 
Base case deterministic € 206 0.007 € 28,428 14.20% 
Public health care payer perspective € 215 0.007 € 29,828 14.20% 
Time horizon 50 years  
(incl. new inflow) 
€ 219 0.017 € 13,060 17.80% 
Utility false positive: best case € 206 0.008 € 27,042 14.20% 
Utility false positive: worst case € 206 0.002 € 86,468 14.20% 
Base case probabilistic € 195 0.008 € 31,377 14.10% 
(95%CI) (€149-€305) (0.002-0.010) (€21,973-€54,977) (11.1%-16.6%) 
 
Δ cost: total cost with screening program minus total cost without screening program  
Δ QALY: total Quality Adjusted Life Years (QALY) with screening program minus total QALY without screening program  
ICER: Incremental cost-effectiveness ratio  
Mortality reduction: mortality due to BC without screening program (i.e. non-invited) minus with screening program (i.e. invited) 
 
Table 3: Results of the budget impact analysis (over 20 years) 
  Cost health care payer 
Costs for 
organisation of 
screening 
Total extra cost 
With screening program € 1,424,621,725 € 53,830,610 
€ 492,239,887 
Without screening program € 986,212,448 € 0 
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Figure 1: Cost-effectiveness plane 
 
QALYs Quality-Adjusted Life Years 
Black line: assumed threshold of €35,000/QALY 
 
Figure 2: Cost-effectiveness acceptability curve 
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DISCUSSION 
Due to a predicted stage shift in breast cancers, namely a reduction of 14.5% in advanced tumors, the 
screening program was estimated to reduce breast cancer mortality by 14.2% over 20 years. In the 
Netherlands, a similar reduction in advanced tumours of 12.1% was found after the first eight years of 
screening program implementation (Fracheboud et al., 2004). Our study showed that biennial 
mammography screening in Flanders is cost-effective with a probability of 82.9%, regarding a 
willingness-to-pay of €35,000/QALY. In published literature, studies showing better ICERs were found 
(Carles et al., 2011; Rojnik et al., 2008), other studies estimated worse ICERs (Mittmann et al., 2015; 
Pharoah et al., 2013). Making direct comparisons between cost-effectiveness studies is difficult though, 
since results are dependent on the input data as well as model design. However, some similarities could 
be recognised in the conceptualisation and results of our study and the study of de Gelder et al. (2009). 
Their cost-effectiveness study of the Swedish mammography screening program included a realistic 
participation rate, opportunistic screening and local demographic and epidemiologic data as input 
parameters for the model. Their study resulted in an ICER of €15,601/QALY gained and a mortality 
reduction of 13% with 80% biennial mammography screening and 20% opportunistic screening. The 
number of QALY gained per woman in this study is low; in the current screening program, the gain in 
QALY is 0.007 per woman aged 50+, which means an extra 3 days. When calculating the QALY gained 
for the total population cohort, 9,236 QALY (with inflow: 16,532) are gained in case of a screening 
program compared to no screening program, showing the beneficial impact of BC screening on public 
health. Beside the benefit in health simulated by our model, the population-based screening program 
also induced a net cost. The result of the budget impact analysis showed that the screening program 
generates a net cumulative cost of €492 million for the public health care payer, what can be explained 
by the screening program inducing more examinations, treatment and follow-up. To compare, the budget 
impact of the Flemish colorectal cancer screening program was estimated to amount €118 million (Pil, 
Fobelets, Putman, Trybou, & Annemans, 2016), which shows the financial impact of the BC screening 
program to be substantial. However, the cost-effectiveness result showed that this invested budget 
offers value for money. The results of the sensitivity analyses showed the importance of mammograms 
being performed as scheduled, avoiding waiting times, and consequent costs related to productivity 
loss. Additionally, the lower the quality of life related to BC stage I, the worse the cost-effectiveness of 
screening. Screening detects particularly BC stage I lesions, which might never have been detected in 
case there would be no screening program. The natural progression of BC also highly influences the 
result. The higher the progression rate, the faster the lesions evolve to a more severe BC state, which 
favours the screening program. This parameter however is difficult to assess, since no accurate data is 
available. The annual probabilities were calculated based on the sojourn times described by Tan et al. 
(Harris & Hellman, 1996; Tan et al., 2013). A higher incidence of undiagnosed BC stage I would result 
in a better cost-effectiveness of screening, which means that it would be useful to detect subgroups with 
high incidence rates. It was shown that an increase in participation rate would not influence the ICER to 
a great extent, illustrating that increase in participation rate should not be the only focus of policy makers. 
As in most health economic models, the result from a public health care payer (i.e. exclusion of costs 
due to productivity loss and cost to be paid by the patient) was slightly worse. Screening leads to a 
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slightly higher cost to the patient (as more tumours are detected and treated), which is compensated for 
by a high reduction in productivity loss due to prevention of severe tumours. This makes the screening 
program more interesting from societal perspective in reference to the public health care payer 
perspective. Extending the time horizon of the model to 50 years ameliorated the ICER to a great extent, 
as the benefits of screening are taken into account for a longer time period. However, it should be noted 
that longer time horizons induce more uncertainty (O'Mahony, Newall, & Van Rosmalen, 2015). Despite 
the change in the incremental cost-effectiveness ratio when simulating different scenarios, all four 
scenarios resulted in an ICER below the assumed threshold of €35,000/QALY gained. This is the first 
time that the long term costs and health effects of the BC screening program in Flanders have been 
evaluated.  A major strength of the study is that not only the benefits of BC screening were captured in 
the model, as in most models (Koleva-Kolarova et al., 2015), but also the negative aspects, such as the 
mental consequences of a false-positive screening result on quality of life and overdiagnosis, which is 
implicitly included in the model as all detected tumours were assumed to be treated. However, more 
research is needed on the negative effects of the screening itself and of a false-positive result on the 
quality of life, as our analysis showed that this latter parameter affected the cost-effectiveness result. 
Risk of radiation-induced BCs due to the mammographic screening program was not included in the 
model, since other studies have shown this risk to be very small. Two studies evaluating the impact of 
biennial screening from the age of 50 showed a lifetime risk of radiation-induced BC of 0.010% to 
0.014% and radiation-induced BC death of 0.0010% to 0.0016% (Hauge, Pedersen, Olerud, Hole, & 
Hofvind, 2014; Yaffe & Mainprize, 2011). Additionally, productivity loss due to cancer treatment was 
taken into account in the model. Productivity loss due to the screening test was considered in the 
sensitivity analysis. The importance of including these costs was shown in the sensitivity analysis since 
absenteeism due to having a mammography was one of the most influential drivers for the ICER. 
Furthermore, a budget impact analysis was performed as a part of a comprehensive economic 
assessment alongside the cost-effectiveness analysis, intended to inform policy makers about the health 
care expenditure as a consequence of implementing the screening program. Notwithstanding the 
strengths of our study, it needs to be taken into account that the health benefits of cancer screening due 
to the stage-shift and mortality reduction as predicted in our model, are still subject of controversy in 
published literature. Current observational studies provide inconclusive evidence on this predicted 
stage-shift (Autier et al., 2011; Bleyer & Welch, 2012; de Glas et al., 2014; Lousdal, Kristiansen, Moller, 
& Stovring, 2014; Weigel, Heindel, Heidrich, Heidinger, & Hense, 2016), so more clinical evidence is 
necessary to check this prediction. In addition, randomised controlled trials investigating the mortality 
reduction by systematic screening provide inconsistent results on the mortality reduction due to 
systematic screening. A Cochrane review reported a mean mortality reduction of 19% (95% CI 13–26%) 
based on seven trials (10% if only based on the tree optimal trials) (Gotzsche & Jorgensen, 2013), while 
other researchers believe that early detection by mammography produces no benefit in terms of 
reduction in mortality and incidence of metastasised tumours (Autier, Boniol, Gavin, & Vatten, 2011; 
Jorgensen, Zahl, & Gotzsche, 2010; Miller et al., 2014). Besides, some limitations of our study should 
be addressed. First, the used progression rates were based on tumour size and metastasis since rates 
on the TNM-staging were not available to our knowledge. Second, including in situ tumours in the 
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Markov model is a subject of discussion, since not all detected DCIS will progress to a further cancer 
stage. We decided to include DCIS in the model, although this increased the costs and decreased the 
quality of life but resulted in a more accurate model of the natural history of BC. Third, this model was 
an evaluation of the Flemish screening program, based on biennial screening. The model did not allow 
to compare with other screening frequencies. Although biennial screening has previously been shown 
to be the most cost-effective option (Rashidian, Barfar, Hosseini, Nosratnejad, & Barooti, 2013), further 
studies are recommended to evaluate other screening frequencies in the Flemish program such as 
triennial screening. Finally, it is possible that not all aspects of the impact of breast cancer on the health-
related quality of life was incorporated in the QALY-measure, for example sleep deprivation, dignitiy, 
etcetera. If such aspects would have been captured by the QALY-measure, the cost-effectiveness of 
screening might have been better.  
 
CONCLUSION 
According to the cost-effectiveness threshold of €35,000/QALY, this economic evaluation illustrates the 
cost-effectiveness of the biennial population-based screening program for BC – with a probability of 
82.9%. We should be aware though that the techniques for screening and treatment of cancer are 
evolving continuously and that population-based screening programs need to be evaluated on a regular 
basis. Additionally, studies which continue to evaluate the current BC program are necessary to test the 
predictions made by this model. 
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APPENDIX 
 
Appendix Table 1: Epidemiological parameters used as input for the prevalence’s at start of the model  
Model parameter Input value 
  50-59y 60-69y 70+y 
Prevalence non-identified DCIS 0.06% 0.05% 0.02% 
Prevalence non-identified BC stage I 0.16% 0.20% 0.13% 
Prevalence non-identified BC stage II 0.11% 0.14% 0.17% 
Prevalence non-identified BC stage III 0.04% 0.05% 0.07% 
Prevalence non-identified BC stage IV 0.01% 0.02% 0.04% 
 
BC: Breast cancer   DCIS: Ductal carcinoma in situ   
Source: Prevalences Flanders 2010 (Belgian Cancer Registry, 2010a) 
 
Appendix Table 2: Annual transition probabilities of natural progression 
Model parameter Input value  
Progression from DCIS to BC stage I 15%  
Progression from BC stage I to BC stage II 27%  
Progression from BC stage II to BC stage III 35%  
Progression from BC stage III to BC stage 
IV 
55%  
 
BC: Breast cancer   DCIS: Ductal carcinoma in situ  
Source: based on sojourn times as described in Tan et al. (Harris & Hellman, 1996; Tan et al., 2013) 
 
 
Appendix Table 3: Risk of metastases in the first 4 years and in long term follow-up  
Model parameter 
Input value intense FU  Input value long term FU 
regional distant regional distant 
BC stage I 0.26% 1.38% 0.08% 0.43% 
BC stage II 0.64% 3.40% 0.20% 1.07% 
BC stage III 0.64% 3.40% 0.20% 1.07% 
BC stage IV   3.40%   1.07% 
 
BC: Breast cancer    
Source: (Siponen, Joensuu, & Leidenius, 2013)
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Appendix Table 4: Annual mortality rates 
Model parameter Input value 
    50-59y 60-69y 70+y 
BC-related mortality, year of diagnosis*        
  Stage III 1.40% 2.50% 6.80% 
  Stage IV 21.20% 19.30% 32.30% 
BC-related mortality, FU year 1-4y*        
  Stage III 3.77% 4.32% 7.59% 
  Stage IV 20.48% 21.88% 25.27% 
BC-related mortality, FU year 4+y**        
  Stage III 2.58% 2.95% 5.18% 
  Stage IV 13.99% 14.94% 17.26% 
 
BC: Breast cancer   DCIS: Ductal carcinoma in situ   
* Source: Belgian Cancer Registry 2004-2012 (Belgian Cancer Registry, 2014) 
** Mortality reduction of 68% 5 years after diagnosis 
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Appendix Table 5: Medical unit costs in € 2014 price 
Model parameter Input value  
 Health care payer 
Patient  
(co-
payment) 
Total 
Medical cost diagnosis     
Screening mammography € 60 € 0 € 60 
diagnostic mammographya  € 113 € 25 € 138 
DCIS € 429 € 45 € 474 
BC stage I € 613 € 64 € 677 
BC stage II € 952 € 100 € 1,051 
BC stage III € 1,462 € 153 € 1,615 
BC stage IV € 1,634 € 172 € 1,806 
Medical cost treatment    
DCIS € 4,978 € 523 € 5,500 
BC stage I € 7,111 € 746 € 7,858 
BC stage II € 11,047 € 1,160 € 12,206 
BC stage III € 16,970 € 1,781 € 18,752 
BC stage IV € 18,972 € 1,992 € 20,964 
Medical cost follow-up 
(first 4 years after treatment) 
   
DCIS € 524 € 55 € 579 
BC stage I € 749 € 79 € 827 
BC stage II € 1,163 € 122 € 1,285 
BC stage III € 1,787 € 188 € 1,974 
BC stage IV € 1,998 € 210 € 2,207 
 
BC: Breast cancer   DCIS: Ductal carcinoma in situ  
Source: (Broekx et al., 2011) 
*Average cost for mammography by radiologist and obstetrician (Rijksinsituut voor Ziekte- en Invaliditeitsverzekering (RIZIV), 2016)
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Appendix Table 6: Days off work due to BC treatment or follow-up 
Model parameter Input value 
Productivity loss during treatment (days/year)  
stage I 17  
stage II 25  
stage III 35  
stage IV 55  
DCIS 12 
  
Productivity loss during intense follow-up (days/year)*  
stage I 7  
stage II 15  
stage III 25  
stage IV 45  
DCIS 2  
  
Productivity loss death** 160 
 
Source: based on estimation of on average 40 days per year in Broekx et al. (Broekx et al., 2011) 
*Assumption of 10 days per year less than in the treatment phase  
**Source: (Hakkaart-van Roijen, 2010)
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Appendix Table 7: Utilities per BC stage, by age category 
Model parameter Input value  
  50-59y 60-69y 70+y 
No abnormal lesion 0.81  0.793  0.694  
False-positive result  0.80 0.79 0.69 
DCIS identified  0.72 0.70 0.60 
DCIS non-identified  0.77 0.75 0.65 
BC stage I identified  0.72 0.70 0.60 
BC stage I non-identified  0.77 0.75 0.65 
BC stage II identified  0.56 0.54 0.44 
BC stage II non-identified  0.69 0.67 0.57 
BC stage III identified 0.32 0.30 0.20 
BC stage III non-identified 0.57 0.55 0.45 
BC stage IV identified  0.19 0.17 0.07 
BC stage IV non-identified  0.50 0.48 0.38 
Follow-up DCIS* 0.81 0.79 0.69 
Follow-up BK I* 0.81 0.79 0.69 
Follow-up BK II* 0.74 0.72 0.61 
Follow-up BK III* 0.39 0.38 0.32 
Follow-up BK IV* 0.21 0.20 0.17 
  
Source: (Kimman et al., 2011; Schleinitz, DePalo, Blume, & Stein, 2006; Scientific Institute of Public Health., 2013)  
*Assumption: average utility for follow-up was divided according to stage based on distribution of utility of identified lesions 
  
 
 
 
Appendix Figure 1: Markov model 
BC = Breast cancer; D&T = diagnosis and treatment; FU = Follow-up.  
From the state of treatment or follow-up regional metastasis (Stage III) or distant metastasis (stage IV) can occur, after which one transitions to the treatment phase of this stage.  
Death from BC is only possible for a person with BC stage III or stage IV.
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Appendix Figure 2: Distribution of identified tumours after 20 years in the model, in women aged 50+  
 
BC: Breast cancer   DCIS: Ductal carcinoma in situ 
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Appendix Figure 3: Tornado-diagram showing the results of the one-way sensitivity analysis  
Between brackets: range of variation in relative terms  
Opp.: Opportunistic   BC: Breast cancer   DCIS: Ductal carcinoma in situ 
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2.2.2. Cost-effectiveness and budget impact analysis of a 
population-based screening program for colorectal cancer  
 
 
 
 
 
 
 
 
Based on: 
Lore Pil, Maaike Fobelets, Koen Putman, Jeroen Trybou & Lieven Annemans. (2016). Cost-
effectiveness and budget impact analysis of a population-based screening program for colorectal 
cancer. European Journal of Internal Medicine, 32: 72–78.
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ABSTRACT 
 
Background: Colorectal cancer (CRC) is one of the leading causes of cancer mortality in Belgium. In 
Flanders (Belgium), a population-based screening program with a biennial faecal immunological test 
(FIT) in women and men aged 56–74 has been organised since 2013. This study assessed the cost-
effectiveness and budget impact of the colorectal population-based screening program in Flanders 
(Belgium).  
 
Methods: A health economic model was conducted, consisting of a decision tree simulating the 
screening process and a Markov model, with a time horizon of 20 years, simulating natural progression. 
Mortality and incidence, total costs, and quality-adjusted life-years (QALYs) with and without the 
screening program were estimated in order to determine the incremental cost-effectiveness ratio of CRC 
screening. Deterministic and probabilistic sensitivity analyses were conducted, taking into account 
uncertainty of the model parameters.  
 
Results: Mortality due to CRC and CRC incidence were predicted to decrease over 20 years. Assuming 
a threshold of €35,000/QALY gained, the colorectal screening program in Flanders was found to be 
cost-effective with an ICER of €1,582/QALY in males and €3,327/QALY in females. The probability of 
being cost-effective given a threshold of €35,000/QALY was 100% and 97.3%, respectively. The budget 
impact analysis showed the extra cost for the health care payer to be limited. 
 
Conclusion: This health economic analysis has shown that despite the possible adverse effects of 
screening and the extra costs for the health care payer and the patient, the population-based screening 
program for CRC in Flanders is cost-effective and should therefore be maintained. 
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INTRODUCTION 
Colorectal cancer (CRC) is the fifth leading cause of death in Europe. From a national perspective, it is 
the third most prevalent cancer in Belgian men and the second most prevalent cancer in Belgian women 
(Stichting Tegen Kanker, 2015b). Annually, 8500 people in Belgium are diagnosed with CRC (Stichting 
Tegen Kanker, 2015a) and about 3000 persons die from the disease. In light of this burden, program-
based cancer screening has been recommended by various international organisations (European 
Commission, 2010a; U.S.Preventive Services Task Force, 2008; Von Karsa et al., 2003). However, in 
times of limited budgets, policymakers require clinical and health-economic evidence in order to spend 
the available resources in the most optimal way. Several studies have illustrated that detection of pre-
cancerous lesions (adenomas) and early-stage cancers results in significant health benefits, although 
observational studies provide inconsistent results on the magnitude of these benefits (Faivre et al., 2004; 
Hardcastle et al., 1996; Kronborg, Fenger, Olsen, Jorgensen, & Sondergaard, 1996; Ventura et al., 
2014; Zorzi et al., 2015). The CRC screening policy recommended by the European Commission is the 
Faecal Occult Blood test for men and women aged 50-74 with a screening interval of maximum 2 years 
(European Commission, 2010a). Since 2013, a biennial CRC population-based screening program has 
been organised in Flanders, the northern region of Belgium, inviting men and women between 56 and 
74 years old to be screened by means of the faecal immunological test (FIT). The FIT seems to be a 
cost-effective alternative to the older and low-sensitivity Guaiac Faecal Occult Blood test (Sharp et al., 
2012; Telford, Levy, Sambrook, Zou, & Enns, 2010). However, up to now, the value for money of the 
recent Flemish CRC screening program has not yet been evaluated. Therefore, the purpose of this study 
was to analyse the cost-effectiveness as well as the budget impact of the population-based CRC 
screening program in Flanders. The result of this analysis is an important source of information for policy 
makers in order to make evidence-based choices concerning the screening policy for CRC. 
 
METHODS 
Screening strategy  
The health economic model assessed the costs and effects of the Flemish CRC screening program and 
compared these costs and effects to those expected in the absence of an organised screening program. 
In the Flemish CRC screening program a FIT is mailed to the target population as a self-test with simple 
instructions. The stool needs to be pierced with a small included stick and mailed back for testing. The 
stool is then analysed by means of the one-sample OC-sensor test13, using a haemoglobin cut-off value 
of 75 nanogram/millilitre. At each FIT-screening round, men and women attending the screening may 
have either a (false) negative result or a (false) positive result which will lead to further examination with 
colonoscopy. After a negative colonoscopy, one is not invited to the screening program for the next 10 
years. After a positive colonoscopy, the patient is treated accordingly. 
                                                          
13 The OC-sensor test (Eiken) is a quantitative immunological fecal occult blood test, an automated analyzer 
testing the hemoglobin in stool samples. 
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General model description  
The health economic model consisted of a decision tree, simulating the screening process, and a state-
transitional Markov model simulating the natural progression of the disease, over a period of 20 years, 
for the Flemish population aged 50 and older. The population was distributed in age-categories of five 
years and simulated until they reached the age of 100 or until death. Several disease states were 
comprised in the model, categorised as unidentified lesions (i.e. not yet detected and diagnosed by a 
physician) and identified lesions (i.e. detected and diagnosed) (Figure 1). At the start of the model, 
according to observed 2011 prevalence figures and the screening yield, the total population was 
distributed over the state of ‘free of any abnormal lesion’, ‘unidentified polyp’ (defined as non-
adenomatous polyp, low-risk adenomatous polyp14 or high-risk adenomatous polyp), or ‘unidentified 
invasive CRC’, assuming that all existing lesions were unidentified by start. Furthermore, the model 
presumed all cancers to arise from pre-existing adenomas. Adenomas could only be detected by means 
of organised or spontaneous screening since it was assumed that these lesions are not associated with 
symptoms. Non-adenomatous and low-risk adenomatous polyps could naturally regress every year. 
However, all polyps detected by screening were removed by polypectomy (resection). CRC stages were 
determined according to the 7th edition of the Tumour-Nodes-Metastases classification for malignant 
tumours (Sobin et al., 2009). The population transitioned through the states on an annual basis, based 
on age- and gender-specific transition probabilities estimated from national epidemiologic data and 
published literature. From the stages treatment or follow-up, one could develop regional metastases 
(stage III) or distant metastases (stage IV) and go back into treatment. From stage III and stage IV, one 
could die from CRC and from all stages one could die from other causes than CRC. CRC could be 
detected by means of the screening program, spontaneous opportunistic screening in case one was not 
invited or did not participate in the screening program, or it could be clinically detected (based on 
symptoms). In case of detection, in either way, it was assumed that the tumour was treated in the same 
year of detection. In the year following treatment, the patient progressed to the follow-up state which 
was separated into a temporary intense follow-up state (first 4 years) and a long term follow-up state 
(next years), because of more intense follow-up due to a higher risk of death in the first years after 
treatment. 
Epidemiological and clinical inputs   
Epidemiologic input data were collected from the Belgian Cancer Registry. The prevalence of 
unidentified CRC at start of the model was defined as the total prevalence of CRC, namely, the 
prevalence of registered CRC diagnoses (most recent available data, but before the screening program 
was implemented) (Belgian Cancer Registry, 2010b), supplemented with the yield of the screening 
program (2014). Since at the moment of the analysis, test characteristics of the screening were not yet 
systematically measured, we relied on published literature to estimate the sensitivity and specificity of 
the FIT and colonoscopy. The incidence of polyps was derived from the study of Brenner et al. (2014), 
as diagnosis of polyps is not registered in Belgium. However, a correction factor to the Belgian situation 
was applied, based on CRC incidence of both countries (GLOBOCAN, 2012). Prevalence at start of the 
                                                          
14 1 or 2 small tubular adenomatous polyps with low-grade dysplasia; serrated polyps <10mm or without dysplasia 
  
115 
 
model and transition probabilities between the disease states are depicted in the Appendix Table A1-
A4. All screening-related data were obtained from the Flemish government (Centrum voor 
Kankeropsporing, 2013) (Table 1). Annual constant screening uptake rates were applied over the years, 
meaning that participation was not linked to disease incidence or progression. 
Figure 1: Markov model depicting the natural progression of CRC and the possible transitions.  
 
CRC = colorectal cancer; D&T = diagnosis and treatment; FU = Follow-up.   
From the state of treatment or follow-up regional metastasis (stage III) or distant metastasis (stage IV) can occur, after which one transitions to the treatment 
phase of this stage. Death from CRC is only possible for a person with CRC stage III or stage IV. Dotted lines correspond to transitions which are only possible 
in case of systematic or opportunistic screening. 
 
Health-economic inputs   
Health effects of the screening program are represented as the impact on CRC mortality and on the 
quality of life of patients. The combination of these effects is expressed as quality-adjusted life-years 
(QALY), calculated by means of (EQ-5D index) utilities during the lifespan of the model population. 
Utilities express the quality of life with a value between 0 (death) and 1 (perfect health). The utilities 
used in the model are age- and gender-specific and were derived from Flemish as well as international 
published data (Appendix Table 5). A false-positive FIT result was assumed to be associated with a 
utility loss of 10% for three months in reference to the general population utility, because of the related 
psychological stress (Cullen, Schwartz, Lawrence, Selby, & Mandelblatt, 2004). The utility for patients 
in follow-up was calculated as the average of the utility for patients with a detected tumour and patients 
with an undetected tumour. 
The cost-effectiveness analysis was conducted from a societal perspective, including direct medical as 
well as indirect costs due to productivity loss because of morbidity, or premature death. All costs in the 
model were calculated in euro with 2014 as reference year. Medical costs were separated into costs for 
detection and diagnosis, costs for treatment, and costs for follow-up. The medical costs for detection 
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and diagnosis were calculated per stage based on official Belgian costs of medical procedures. The 
medical costs for treatment and for follow-up were derived from the Belgian report of Pacolet et al. 
(2011) and made stage-specific based on the ratios of the study of Tilson et al. (2012). For the treatment 
cost of stage IV, a correction was applied to take into account the new and more expensive therapies 
(panitumumab, cetuximab) that emerged in the last few years. 
Cost due to productivity loss were estimated according to the friction cost method (Hakkaart-van Roijen, 
2010). The number of days off work were multiplied by the cost for one day absenteeism estimated 
previously by the Belgian Health Care Knowledge Centre (Cleemput et al., 2012). A productivity loss of 
160 days was assigned to deceased people (Hakkaart-van Roijen, 2010). These costs due to 
productivity loss were only applied to the productive age-categories of 50-65 years, taking into account 
the proportion fulltime equivalents and the unemployment rate. Future costs were discounted with 3% 
and health effects with 1.5%, according to the Belgian guidelines for health economic analyses 
(Cleemput et al., 2012). Appendix Table 6 shows the costs for diagnosis, treatment, and follow-up. 
 
Table 1: Screening-related parameters 
Model parameter Input value   
  56-60y 61-70y 71-74y 
  males females males females males females 
Participation rate screening* 43.90% 43.10% 51.20% 50.20% 45.30% 44.50% 
Adherence to colonoscopy  
(after positive FIT)* 
82.20% 82.20% 95.80% 95.80% 84.80% 84.80% 
% of screening population with  
spontaneous opportunistic screening* 
6.17% 7.21% 6.34% 6.93% 5.53% 5.94% 
Sensitivity screening FIT for  
polyps and low-risk adenomas** 
5.70% 
Sensitivity screening FIT for  
polyps and high-risk adenomas** 
34.20% 
Sensitivity screening FIT for CRC** 73.00% 
Specificity screening program**   97.00% 
 
CRC: colorectal cancer   DCIS: ductal carcinoma in situ  
*Source: Annual report Flemish cancer screening, 2013 (Centrum voor Kankeropsporing, 2013)  
** Source: (Goede et al., 2013; Kovarova et al., 2012; Wilschut et al., 2011) 
 
Outcome parameters  
Over a period of 20 years, the difference in total costs was divided by the difference in total effects 
resulting in an incremental cost- effectiveness ratio expressed as a cost per QALY gained. The budget 
impact analysis measured the net cumulative cost of the screening program for the public health care 
payer (including the cost of consequent examinations, treatment, and follow-up) over a period of 20 
years. To calculate the budget impact, an annual inflow of new 50-year-old persons was assumed. As 
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shown by previous studies, CRC screening is expected to result in a decrease in the incidence and 
mortality of CRC. Both were calculated as the difference between the invited and non-invited cohort. 
Scenario and sensitivity analyses  
Several additional scenarios were tested. In the first scenario, 50- to 55-year olds were included in the 
screening program as recommended by the European guidelines (European Commission, 2010a). In 
the second scenario the costs for the patient and the costs due to productivity loss were excluded (i.e. 
public health care payer perspective) and in the third scenario the minimum value of the utility in case 
of a false-positive result was set to the utility of CRC stage I in treatment and the maximum value to the 
utility of no abnormal lesion (worst case – best case). In a final scenario the time horizon of the model 
was extended to 50 years instead of 20 years. In the scenario with a time horizon of 50 years, an annual 
inflow of new 50-year olds was included, as after 20 years the original cohort is not eligible for screening 
anymore. Both one-way and probabilistic sensitivity analyses were conducted to take into account 
uncertainty in the input parameters and to test the robustness of the results. The one-way sensitivity 
analysis included the cost of the screening program, medical costs, days off work, utilities, test 
characteristics of the FIT and colonoscopy, participation rate per age-category, percentage performed 
colonoscopies after referral, prevalence of non-identified polyps, incidence of low-risk adenomatous 
polyps, positivity rate of the screening program, natural progression rates, mortality rates and the dis-
count rate. These parameters were varied based on standard error estimates or based on ±30% ranges 
in case standard errors were not available. In order to perform the probabilistic sensitivity analysis (PSA), 
probability distributions were defined for the costs (gamma distribution), utilities (beta distribution), test 
characteristics of the FIT and colonoscopy (beta distribution), prevalence and incidence of low-risk 
adenomatous polyps (beta distribution), participation rate per age-category (beta distribution), and days 
off work (normal distribution). A cost-effectiveness plane was plotted to visualise the values of the 5000 
2nd-order Monte Carlo simulations. As to provide information on the proportion of simulations with a cost-
effective result, given a certain willingness-to-pay threshold, a cost-effectiveness acceptability curve 
(CEAC) was drawn.  
 
RESULTS 
Base case  
Over a period of 20 years, the screening program is expected to reduce CRC mortality by 23% in males 
and 19% in females and the incidence of invasive CRC (i.e. stage III-IV) by 26.6% in males and 21.5% 
in females. In the first years of the model, more tumours were detected in persons invited for screening 
than in controls, while in later years, more tumours were found in the control cohort (Appendix Figure 
1). Additionally, 0.012 QALY were gained per male aged 50+ and 0.005 QALY per female aged 50+, 
against an incremental cost of €19 and €18, respectively. The incremental cost-effectiveness ratio of 
the CRC screening program, in reference to no screening program, was €1,582/QALY in males and 
€3,327/QALY in females (Table 2). Over a period of 20 years, the screening program resulted in a net 
cumulative cost of €63,084,518 in males, and €54,528,777 in females, totaling the extra cost over 20 
years to €117,613,295 (Table 3), or €5 per year per person in the target group (56-74y).
  
 
 
 
Table 2: Results of the cost-effectiveness analysis, with several scenarios 
Scenario Δ cost (€) Δ QALY  ICER (€/QALY) Mortality reduction 
  males females males females males females males females 
Base case det. 19 18 0.012 0.005 1,582 3,327 23% 19% 
Public health care payer perspective 32 24 0.012 0.005 2,666 4,800 23% 19% 
Incl. 50-55 year olds 16 18 0.013 0.006 1,211 3,169 25% 20% 
Utility false positive: best case 19 18 0.013 0.006 1,444 2,860 22% 19% 
Utility false positive: worst case 19 18 0.005 -0.002 4,212 negative 22% 19% 
Time horizon 50 year -1596 -70 0.070 0.033 cost-saving 25% 20% 
Base case prob. 17 16 0.011 0.005 1,681 4,484 20% 19% 
(95% CI) (-15 – 57) (-5 – 48) (0.007 – 0.014) (0.001 – 0.007)  (-1,317 – 6,601)  (-3,254 – 18,163) (16% – 23%) (15% – 22%) 
 
Δ cost: total cost with screening program minus total cost without screening program. 
Δ QALY: total QALY with screening program minus total QALY without screening program.  
ICER: Incremental cost-effectiveness ratio. 
Mortality reduction: mortality due to CRC without screening program (i.e. non-invited) minus with screening program (i.e. invited). det.: deterministic prob.: probabilistic.  
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Table 3: Results of the budget impact analysis  
 Cost health care payer  
Cost for organisation of 
screening 
Total extra cost 
males     
With screening program € 1,046,716,220 € 28,901,310 
€ 63,084,518 
Without screening program € 1,012,533,012 € 0 
      
females     
With screening program € 787,561,407 € 29,235,862 
€ 54,528,777 
Without screening program € 762,268,492 € 0 
 
 
Scenario and sensitivity analyses  
Results of the different scenarios are shown in Table 2.  When opting to invite 50- to 55-year olds to the 
screening program (in line with the European guidelines but not currently implemented), there was only 
a marginal increase in net QALYs and decrease in net costs, resulting in a slightly better ICER. Excluding 
costs due to productivity loss worsened the result to a small extent. The worst scenario was found if the 
quality of life in females in case of a false-positive would be similar to that in case of diagnosis and 
treatment for CRC stage I. Then the positive effect of screening on the quality of life would be 
overshadowed by the negative effect. Extending the time horizon to 50 years instead of 20 years -
including annual inflow- altered the outcome markedly as the result became cost-saving. All scenarios 
were in favour of the CRC screening program.  
Results of the one-way sensitivity analysis present the influence of the parameters on the cost-
effectiveness result. The parameters with the highest impact were the sensitivity of the FIT for high-risk 
polyps, the natural progression of CRC, the risk on symptoms, the specificity of the FIT, the prevalence 
of unidentified high-risk polyps, the adherence to colonoscopy after referral, and the sensitivity of 
colonoscopy for high-risk polyps. When the value of these parameters was varied to the maximum, then 
the incremental cost-effectiveness ratio ameliorated, except for the risk on symptoms. Consequently, 
the opposite was true when the value of these parameters was varied to the minimum. Importantly, in 
all simulations, the result remained cost-effective, demonstrating the robustness of the result in the base 
case scenario. A change in the participation rate -one of the main features of a screening program- did 
not considerably influence the result. Tornado diagrams are shown in Appendix Figure 2. 
A PSA with 5,000 Monte Carlo simulations was performed, generating credibility intervals (CI) around 
the point estimate of the ICER. Over a period of 20 years, the PSA resulted in an incremental cost- 
effectiveness ratio of €1,681/QALY (95% CI €-1,317 to €6,601/QALY) in males and €4,484/QALY (95% 
CI €- 3,254 to €18,163/QALY) in females (Table 2). The cost-effectiveness planes display the result of 
the simulations (Figure 2). Most of the simulations were situated in the north-east quadrant of the graph, 
meaning that the screening program resulted in health benefits but against an extra cost, as shown by 
the cost-effectiveness results. In the analysis for males all points and in the analysis for females almost 
all points are situated below the willingness-to-pay threshold of €35,000/QALY gained which shows the 
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robustness of the result being cost-effective. In some of the simulations, the screening program was 
expected to result in health benefits and cost-savings (south-east quadrant). However, in females, some 
simulations also resulted in a loss of health benefits due to the screening program (north-west quadrant). 
The CEAC (Figure 3) depicts the probability for the biennial FIT to be cost- effective in case of a 
willingness-to-pay threshold ranging from €5,000 to €55,000/QALY. The Flemish CRC population-based 
screening program has a probability of 100% and 97.3% to be cost-effective in males and females, 
respectively, given a threshold of €35,000/QALY. 
Figure 2: cost-effectiveness plan for males (left) and females (right) 
Black line: willingness-to-pay threshold of €35,000/QALY gained 
 
Figure 3: Cost-effectiveness acceptability curve 
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Model validation  
Results of the health economic analysis were internally validated with respect to the observed results 
from the actual screening program. Estimated average positivity rates derived by the model were lower 
than field results (5% versus 10%). Two arguments can be proposed. First, the prevalence and 
incidence of polyps is uncertain. These input figures could be underestimated in the model, leading to 
lower estimated positivity rates. Second, the test-characteristics of the FIT were not derived from the 
Flemish screening program as they are not available yet. It could be that the test-characteristics used 
in the model, differ from the ones in the screening program. However, we chose not to calibrate the 
parameters based on these results as the observed positivity rate of 10% is the one observed in the first 
screening round only. It is expected that future screening rounds will result in a lower yield. Moreover, 
the first screening round only included people aged over 66 years, while in the model, people aged 56-
66 years were also invited. To compare, the pilot screening study in one Flemish province in 2009 had 
a positivity rate of 5.3%, and also the study of Hol et al. (2009) - using the same FIT and hemoglobin 
cut-off value—showed a positivity rate of 5.7% in the Dutch trial, which are both closer to our estimations. 
The false-positive rate in the actual screening program was not determined yet at the time of this 
analysis. We calculated a false-positive rate of the FIT of on average 2.2%. Besides, the distribution of 
the cancer prevalence according to the stage over 20 years in the absence of the screening program 
was compared to the stage distribution of tumours in 2010 (Belgian Cancer Registry, 2010b). These 
were 25%, 31%, 29% and 15% from stage I tot IV in the model, and 21%, 32%, 30% en 17% in real-life, 
showing the predicted distribution to approximate the observed. 
 
DISCUSSION 
The health economic evaluation showed that the Flemish population-based CRC screening program 
with a biennial FIT is highly cost-effective, considering a threshold of €35,000/QALY gained. These 
results are in concordance with studies from other countries (Hassan et al., 2011; Heresbach, Chauvin, 
Grolier, & Josselin, 2010; Lejeune, Dancourt, Arveux, Bonithon-Kopp, & Faivre, 2010; Sharp et al., 2012; 
Wilschut et al., 2011), although these studies may have included different values for the screening 
parameters such as for participation rate or other parameters. Consequently, the use of different 
methodologic approaches and different model designs to assess the cost-effectiveness ratios, makes 
study results difficult to compare directly. In our analysis, the population-based CRC screening program 
yielded a rather small number of QALYs per person, but when interpreted on the population level, it 
leads to a considerable benefit for the Flemish population aged over 50 years of 20,451 QALYs (or with 
inflow: 26,047 QALYs). This health benefit is higher than in the Flemish BC screening program (Fobelets 
M*, Pil L*, Putman K, & Annemans L, 2016). The gain in QALYs is a reflection of the predicted decrease 
in incidence and mortality of CRC. This argues for the early detection and treatment of polyps (and 
tumours) leading to aversion of new and more advanced CRC tumours. However, it must be taken into 
account that these findings were not yet proven by randomised controlled trials (RCTs) or observational 
studies, as the screening program is only been running from 2013. Hewitson et al. (2007) evaluated in 
their meta-analysis the combined results from three RCTs that used biennial screening with the Guaiac 
Faecal Occult Blood test and showed a 15% mortality reduction (RR 0.85, CI: 0.78-0.92) with an average 
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follow-up of 17 years and an average participation rate of 61%. As the sensitivity of the FIT is shown to 
be better compared to the Guaiac Faecal Occult Blood test (Brenner & Tao, 2013; Guittet et al., 2007), 
it is expected that the reduction in CRC incidence and mortality due to FIT will be higher. Few 
observational studies up to now have evaluated these FIT health benefits though. Ventura et al. (2014) 
showed a mortality reduction of 41% over a period of 11 years (with 40% participation). However, these 
results are calculated for invited participants versus invited non-participants, while in our study an invited 
cohort (with an average participation rate of 44%) was compared to a non-invited cohort, which makes 
comparison with the results of Ventura et al. difficult. Comparing screened persons versus non-screened 
persons should indeed show better results, as in Ventura et al. Another recent Italian study showed a 
mortality reduction of 24% over 16 years (with participation of about 50%) (Zorzi et al., 2015). This result 
is better than the expectations based on our model. However, based on the few available observational 
studies evaluating FIT today, it is difficult to validate the predictions of our model yet. More real-life 
evidence is necessary. However, the CRC population-based screening program was predicted not only 
to result in a health gain but also to induce a net cost. The result of the budget impact analysis showed 
that over 20 years, the screening program would lead to a net cumulative cost of €118 million for the 
government. It can be deducted that the screening program induces more examinations, treatment, and 
follow-up, leading to higher costs for the health care payer. However, the cost-effectiveness result 
showed that this invested budget offers value for money. Besides, compared to the total extra cost due 
to the BC screening program (€492 million), the budget impact can be assessed as limited (Fobelets M* 
et al., 2016). The cost-effectiveness result in our analysis was better for males than for females, which 
can be explained by the higher prevalence of non-identified polyps and CRC tumours at the start of the 
model and higher incidence of polyps in males than in females. Hence, screening can attain a greater 
benefit in males in terms of earlier detection and treatment and mortality reduction. The more favourable 
result by introducing the age-category 50-55 in the screening program could be explained by the fact 
that when a tumour is detected early in these persons, more healthy life-years could be gained since 
persons in this age-category have a higher average quality of life than older persons. Extending the time 
horizon to 50 years instead of 20 years altered the cost-effectiveness result quite markedly. Over a 
period of 50 years the CRC screening program would be cost-saving. The one-way- and probabilistic 
sensitivity analyses demonstrated the test-characteristics of the FIT, the natural progression of CRC, 
the risk on symptoms, the prevalence of high-risk polyps and patient adherence to be the most 
influencing parameters, although the conclusion based on the cost-effectiveness result remains the 
same. The Flemish CRC population-based screening program has a probability of 100% and 99.6% to 
be cost-effective in males and females respectively. 
It is the first time that both costs and benefits of the CRC screening program in Flanders have been 
analysed thoroughly. Not only the benefits of screening were captured in the model but since there has 
been a lot of debate concerning the negative aspects of population-based screening, we have tried to 
include the impact of a false-positive screening result on quality of life in terms of psychological harms 
as well. However, anxiety that could possibly be induced by receiving the mailing kit and by participating 
in the screening, regardless of the test result, was not included since we are not able to estimate this 
parameter because of the lack of scientific evidence. The risk of overtreatment was implicitly included 
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in the model. Polyps that are detected are removed at the same time, by means of polypectomy, 
regardless of whether this polyp would have caused any harm. These costs are included in the model. 
Direct costs related to colorectal cancer, used in our model, were derived from the study of Pacolet et 
al. (2011), and were based on the ‘All Patient Refined-Diagnostic Related Groups’-classification. The 
basis for this classification consists of the main diagnosis in combination with surgery procedures, the 
age and sex of the patient, and occurrence of complications. This means that the cost associated with 
the risk of bowel perforation or bleeding as a consequence of colonoscopy, is implied in the cost 
estimates. 
Nonetheless, some limitations of our analysis should be addressed. First, the incidence and prevalence 
of adenoma is uncertain, since these data are not registered in the Belgian cancer registry. For the 
adenoma incidence we had to rely on data from the German screening colposcopy register as provided 
by Brenner et al. (2014). A correction was applied in reference to the ratio between CRC incidence in 
Germany and in Belgium. However, in case of multiple adenoma only the largest was recorded, which 
results in an underestimated incidence rate. Moreover, the prevalence of adenoma identified in the 
opportunistic circuit in Belgium is unknown so we could only rely on the number of adenoma identified 
in the screening program (2014). These shortcomings possibly resulted in an underestimation of the 
incidence and prevalence of adenoma and thus an underestimation of the yield of the screening 
program. Consequently, the result of our analysis is rather a conservative estimate of the cost-
effectiveness ratio. Second, evidence about the test-characteristics of the FIT and colonoscopy in the 
Flemish population is not available yet as the screening program has only been implemented since 
October 2013. Therefore, numbers from published literature were used. One-way sensitivity analysis 
showed the test-characteristics of the FIT to have the highest influence on the cost-effectiveness result. 
This should be kept in mind when interpreting the results. We used published test-characteristics, but 
information on the test-characteristics of the screening program should be available soon. Third, due to 
a lack of information on the natural progression of CRC, these progression rates had to be derived from 
U.S. studies which estimated these rates based on calibration to observed data (Hur, Chung, Schoen, 
& Gazelle, 2007; Pickhardt et al., 2007). Fourth, all CRC were assumed to arise from a prior adenoma. 
In reality, although negligible, there is a small percentage of CRC tumours that do not arise from a pre-
existing adenoma. Fifth, separate analyses for low-SES subgroups were not performed in this study. In 
these subgroups, CRC mortality is expected to be higher, although CRC incidence might be lower 
(Manser & Bauerfeind, 2014). This difference in epidemiology, together with a predicted lower screening 
uptake, can influence the cost-effectiveness of CRC screening in these groups. Lastly, it should be noted 
that screening parameters such as participation rate as well as unit costs of detection, treatment, and 
follow-up are context-specific limiting the direct transferability of the results across different countries. 
However, we believe that this positive health economic evaluation can inspire policy makers 
internationally and stimulate them to make similar evaluations.   
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CONCLUSION 
In this health economic analysis, the cost-effectiveness and budget impact of the population-based CRC 
screening program in Flanders was evaluated. Results of the analysis show that, despite the possible 
adverse effects of screening, and the induced costs for the health care payer and patient, the population-
based screening program for CRC in Flanders is very cost-effective and should be maintained. 
Policymakers could decide to also include 50- to 55-year-old males and females in accordance to the 
European guidelines. Although there is currently few long term real-life evidence on the effectiveness of 
FIT in terms of reduction in CRC incidence and -mortality, modelling should be used to estimate the 
cost-effectiveness of a screening program and the potential impact of changes in policy. Additionally, 
we should be aware that the techniques for screening and treatment of cancer are evolving continuously, 
emphasising the need to frequently evaluate the population-based screening programs. 
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APPENDIX  
Appendix Table 1: Epidemiological parameters used as input for the prevalence at start of the model 
Model parameter Input value 
    50-55y 56-59y 60-69y 70-74y 74+ 
prevalence non-identified non-adenomatous 
polyps * 
males 2.95% 2.95% 3.80% 4.40% 4.50% 
  females 1.60% 1.60% 2.10% 2.70% 3.30% 
prevalence non-identified low-risk polyps* males 3.90% 3.90% 4.98% 5.80% 6.01% 
  females 2.10% 2.10% 2.80% 3.58% 4.31% 
prevalence non-identified high-risk polyps* males 2.00% 2.00% 2.56% 2.97% 3.08% 
  females 1.08% 1.08% 1.43% 1.84% 2.21% 
prevalence non-identified CRC Stage I*/** males 0.25% 0.28% 0.61% 0.33% 0.84% 
  females 0.11% 0.11% 0.27% 0.20% 0.60% 
prevalence non-identified CRC Stage I*/** males 0.12% 0.14% 0.42% 0.23% 0.76% 
  females 0.04% 0.06% 0.16% 0.14% 0.60% 
prevalence non-identified CRC Stage II*/** males 0.10% 0.13% 0.31% 0.23% 0.52% 
  females 0.05% 0.08% 0.23% 0.15% 0.48% 
prevalence non-identified CRC Stage IV*/** males 0.07% 0.08% 0.24% 0.10% 0.26% 
  females 0.02% 0.05% 0.18% 0.10% 0.19% 
*    Derived from yield screening program, 2014    
** Prevalence Flanders 2010 (Belgian Cancer Registry, 2010b) + yield screening program 2014 
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Appendix Table 2: Annual transition probabilities of natural progression 
Model parameter Input value 
    50-55y 56-59y 60-69y 70-74y 74+ 
Annual risk to develop non-adenomatous 
polyps1 
males 1.74% 1.67% 1.74% 1.59% 1.30% 
  females 1.01% 1.09% 1.16% 1.16% 0.87% 
Annual risk to develop low-risk polyps1 males 2.40% 2.30% 2.40% 2.20% 1.80% 
  females 1.40% 1.50% 1.60% 1.60% 1.20% 
Progression from low- to high-risk polyps2 males 4.24% 4.00% 4.00% 4.10% 3.70% 
  females 4.00% 3.60% 3.70% 4.70% 3.70% 
Progression from high-risk polyp to CRC 
stage I2 
males 2.60% 3.10% 3.80% 5.10% 5.20% 
  females 2.50% 2.70% 3.80% 5.00% 5.60% 
Progression from CRC stage I to CRC stage 
II3 
males 30.00% 30.00% 30.00% 30.00% 30.00% 
  females 30.00% 30.00% 30.00% 30.00% 30.00% 
Progression from CRC stage II to CRC stage 
III4 
males 45.00% 45.00% 45.00% 45.00% 45.00% 
  females 45.00% 45.00% 45.00% 45.00% 45.00% 
Progression from CRC stage III to CRC stage 
IV4 
males 50.00% 50.00% 50.00% 50.00% 50.00% 
  females 50.00% 50.00% 50.00% 50.00% 50.00% 
Natural regression of non-adenomatous and 
low-risk polyps5 
males 2.00% 2.00% 2.00% 2.00% 2.00% 
  females 2.00% 2.00% 2.00% 2.00% 2.00% 
CRC: colorectal cancer 
1 (Brenner, Altenhofen, Stock, & Hoffmeister, 2014)     2 (Brenner et al., 2007)     3 (Pickhardt et al., 2007)     4 (Hur et al., 2007)     5 Expert opinion dr. Luc 
Colemont 
 
Appendix Table 3: Annual mortality rates 
  Year of diagnosis* FU year 1-4* FU year 4+ ** 
CRC Stage III    
males 11.60% 7.60% 5.20% 
females 12.50% 7.90% 5.40% 
CRC Stage IV    
males 37.10% 30.60% 20.90% 
females 41.70% 31.70% 21.60% 
* (Belgian Cancer Registry, 2014)  
** Assumption:  Same trend in mortality risk after 5y as described for breast cancer (Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., 2005), i.e. 
from year 5 on, mortality risk is one third lower than in first follow-up years.   
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Appendix Table 4: Risk of metastases in the first 4 years and in long term follow-up  
  
Input value intense FU  Input value long term FU 
regional distant regional distant 
CRC stage I 0.67% 0.89% 0.21% 0.28% 
CRC stage II 1.42% 3.12% 0.44% 0.98% 
CRC stage III 1.81% 7.04% 0.56% 2.20% 
CRC stage IV   29.57%   9.26% 
 
 
Appendix Table 5: Utilities  
Model parameter Input value 
  Males Females 
  50-54j 55-56j 60-69j 70-74j 75+ 50-54j 55-56j 60-69j 70-74j 75+ 
No abnormal lesion* 0.86 0.83 0.84 0.86 0.75 0.82 0.81 0.80 0.79 0.67 
False-positive result** 0.84 0.81 0.82 0.84 0.73 0.80 0.79 0.78 0.77 0.65 
Non-identified adenoma*** 0.78 0.74 0.76 0.77 0.66 0.73 0.72 0.71 0.70 0.58 
Identified adenoma*** 0.78 0.74 0.76 0.77 0.66 0.73 0.72 0.71 0.70 0.58 
CRC stage I  non-identified***  0.78 0.74 0.76 0.77 0.66 0.73 0.72 0.71 0.70 0.58 
CRC stage I  identified*** 0.69 0.66 0.67 0.69 0.69 0.65 0.64 0.63 0.62 0.50 
CRC stage II  non-identified***  0.78 0.74 0.76 0.77 0.66 0.73 0.72 0.71 0.70 0.58 
CRC stage II  identified *** 0.69 0.66 0.67 0.69 0.69 0.65 0.64 0.63 0.62 0.50 
CRC stage III  non-identified***  0.72 0.69 0.70 0.72 0.72 0.68 0.67 0.66 0.65 0.53 
CRC stage III  identified *** 0.58 0.55 0.56 0.58 0.58 0.54 0.53 0.52 0.51 0.39 
CRC stage IV non-identified*** 0.21 0.17 0.19 0.20 0.20 0.16 0.15 0.14 0.13 0.01 
CRC stage IV  identified*** 0.21 0.17 0.19 0.20 0.20 0.16 0.15 0.14 0.13 0.01 
Follow-up CRC I year 1-4** 0.74 0.70 0.71 0.73 0.62 0.69 0.68 0.67 0.66 0.54 
Follow-up CRC II year 1-4** 0.74 0.70 0.71 0.73 0.62 0.69 0.68 0.67 0.66 0.54 
Follow-up CRC III year 1-4** 0.65 0.62 0.63 0.65 0.54 0.61 0.60 0.59 0.58 0.46 
Follow-up CRC IV year 1-4** 0.21 0.17 0.19 0.20 0.09 0.16 0.15 0.14 0.13 0.01 
Follow-up CRC I year 4+** 0.78 0.74 0.76 0.77 0.66 0.74 0.72 0.71 0.70 0.58 
Follow-up CRC II year 4+** 0.71 0.68 0.69 0.71 0.60 0.67 0.66 0.65 0.64 0.52 
Follow-up CRC III year 4+** 0.67 0.64 0.65 0.67 0.56 0.63 0.62 0.61 0.60 0.48 
Follow-up CRC IV year 4+** 0.45 0.41 0.43 0.44 0.34 0.41 0.39 0.38 0.37 0.25 
Waiting state after neg. 
colonoscopy** 
0.86 0.83 0.84 0.86 0.75 0.82 0.81 0.80 0.79 0.67 
 
*(Scientific Institute of Public Health., 2013) 
** Assumption;   
 ***(Cronin et al., 2013; Ness, Holmes, Klein, & Dittus, 1999) 
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Appendix Table 6: Unit costs in €, 2014 prices 
Model parameter Input value 
  
Health care  
payer 
Patient Total 
Medical cost diagnosis1      
Non-adenomatous polyps and low-risk 
adenoma 
€ 375 € 18 € 393 
High-risk adenoma € 375 € 18 € 393 
CRC I € 424 € 33 € 457 
CRC II € 424 € 33 € 457 
CRC III € 556 € 36 € 592 
CRC IV € 556 € 36 € 592 
Medical cost treatment, first year2      
CRC I € 11,399 € 1,409 € 12,808 
CRC II € 20,217 € 2,499 € 22,716 
CRC III € 27,902 € 3,449 € 31,351 
CRC IV € 33,258 € 4,111 € 37,369 
Medical cost follow-up (first 4 years after 
treatment)2 
     
CRC I € 7,756 € 408 € 8,165 
CRC II € 5,859 € 308 € 6,167 
CRC III € 3,972 € 209 € 4,181 
CRC IV € 11,611 € 611 € 12,223 
Medical cost follow-up, (4+)2       
CRC I € 180 € 21 € 202 
CRC II € 180 € 21 € 202 
CRC III € 3,972 € 209 € 4,181 
CRC IV € 11,611 € 611 € 12,223 
Cost of productivity loss      
Cost per day absenteeism3   € 261 
Number of days off work4     
CRC I 51 
CRC II 51 
CRC III 84 
CRC IV 148 
Death (based on friction cost method5) 160 
 
1 Based on official Belgian nomenclature prices     2 (Pacolet et al., 2011)     3 (Cleemput et al., 2012)     4 (Hauglann, Saltyte, Fossa, Tveit, & Dahl, 2014)     
5 (Hakkaart-van Roijen, 2010) 
  
 129 
 
Appendix Figure 1a: Absolute number of identified tumours per year, in males aged 50+ (with inflow) 
 
 
Appendix Figure 1b: Absolute number of identified tumours per year, in females aged 50+ (with inflow) 
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Appendix Figure 2a: Tornado-diagram showing the results of the one-way sensitivity analysis (males) 
 
Range of variation in relative terms between brackets 
D&T: diagnosis & treatment; FU: Follow-up 
Dark-colored bars: maximum parameter value.   Light-colored bars: minimu parameter value. 
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Appendix Figure 2b: Tornado-diagram showing the results of the one-way sensitivity analysis (females) 
 
Range of variation in relative terms between brackets 
D&T: diagnosis & treatment; FU: Follow-up 
Dark-colored bars: maximum parameter value.   Light-colored bars: minimu parameter value. 
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ABSTRACT  
Importance: Several  epidemiologic studies  show  an  alarming  global  increase  in  the incidence  of  
melanoma  and  non-melanoma  skin  cancer. Consequently the related health care costs are rising 
significantly.  
Objective: To examine the cost-effectiveness of two population-based screening methods, namely a 
one-time total body examination and a one-time lesion-directed screening, as well as their budget impact 
and the impact on skin cancer epidemiology.   
Design: A Markov model with a time horizon of 20 years analysed the cost-effectiveness (societal 
perspective) and budget impact (public health care payer perspective) of two population-based 
screening programs in Belgium, compared to the situation in the absence of a screening program 
(considering a threshold of 35,000/QALY gained) 
Participants: In the health economic model, the total Belgian population aged 18+ was assumed to be 
invited for the screening program.  
Main outcomes and measures: The impact of the screening program on skin cancer epidemiology 
and the cost per quality-adjusted life-year (QALY) gained of the two screening programs, compared to 
no screening program were evaluated, as well as the budget impact, expressed as the net costs for the 
health care payer over 50 years.  
Results: Both screening strategies produced a gain in QALYs, resulting in incremental cost-
effectiveness ratios of €31,360/QALY (€23,251/QALY – €41,468/QALY) in males and €18,051/QALY 
(€13,493/QALY – €23,019/QALY) in females for TBE and €34,170/QALY (€25,586/QALY – 
€44,831/QALY) in males and €18,999/QALY (€13,725/QALY  – 25,139/QALY) in females for LDS. 
Additionally, a 4% decrease was predicted in the incidence rates of stage III&IV MSC at population level, 
in reference to the comparator. Skin cancer mortality was expected to decrease slightly due to the 
screening program with 5.6% in case of TBE and 1.0% in case of LDS, compared to no screening 
program. The budget impact analysis demonstrated that over a period of 20 years a one-time screening 
would induce an extra cost for the health care payer of €36 million in case of TBE or €6 million in case 
of LDS, respectively €4.1 or €0.7 per adult.  
Conclusion and relevance: These results can be interpreted as cost-effective at a willingness-to-pay 
threshold of €35,000/QALY gained. Based on these results a TBE in general adult population (especially 
in the females; in males the results were less explicit) is the most cost-effective screening strategy and 
is predicted to result in a reduction of mortality over 20 years. 
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INTRODUCTION 
 
The global skin cancer incidence is currently assessed to be between 2 and 3 million non-melanoma 
skin cancers and 132,000 melanoma skin cancers each year. It is estimated that one in every three 
cancers diagnosed is a skin cancer (WHO, 2016d). Despite the health burden, and despite the idea that 
early detection can lead to better cure rates and reduce the costs of disease, few  studies have assessed 
the effectiveness and cost-effectiveness of screening strategies (Gordon & Rowell, 2015). Screening is 
a prevention strategy by which early detection changes the prognosis by a shift in stage distribution to 
earlier stages. However, these few currently available studies mainly addressed melanoma skin cancer 
(MSC) (Beddingfield, 2002; Freedberg, Geller, Miller, Lew, & Koh, 1999; Girgis, Clarke, Burton, & 
Sanson-Fisher, 1996; Gordon & Rowell, 2015; Losina et al., 2007), while non-melanoma skin cancer 
(NMSC) is also responsible for a large part of the direct medical health care costs of skin cancer (Stang 
et al., 2008), At this point, no evidence exists that population-based screening by means of a whole 
body examination is cost-effective (Bigby, 2010). In this study we compared the cost-effectiveness of 
two population-based screening strategies organised as a pilot study in Belgium, namely a one-time 
standard total body examination (TBE) versus a one-time lesion-directed approach (LDS) (Hoorens et 
al., 2016). The LDS approach, in which participants are seen with only a specific lesion of concern 
meeting certain pre-set criteria, was shown to result in lower participation rates but similar skin cancer 
detection rates as in TBE. In reference to TBE, LDS was time-saving for the physician. Details on the 
results of these two screening methods are described elsewhere (Hoorens et al., 2016).  
In addition to the cost-effectiveness analysis, a budget impact analysis of both screening strategies was 
performed to evaluate the impact on the public health care budget. 
 
 
METHODS 
 
Screening strategies 
The modelled screening strategies were based on a skin cancer screening trial which has been 
organised in Belgium in 2014, comparing TBE to LDS in two socio-demographically comparable regions 
(Hoorens et al., 2016). The TBE was organised in a community of 9325 inhabitants (Wichelen, East-
Flanders, Belgium) during a 5-day screening (March 14-18, 2014). All inhabitants 18 years and older 
received a personal invitation. The LDS was organised in a comparable community in terms of genetic 
background, socioeconomic status, culture, and geographic area (Nevele, East-Flanders, Belgium) 
(April 22 and 25-27, 2014), of which the inhabitants (9,484) were invited for a free-of-charge skin cancer 
check for a specific lesion meeting or more of the following listed criteria: ABCD rule (A, asymmetry; B, 
borders; C, colours; and D, differential structures), ugly duckling sign, new lesion lasting longer than 4 
weeks, or red non-healing lesions. All participants (1668 TBE and 248 LDS) were screened by a team 
of six dermatologists using both naked-eye inspection and dermoscopy. In case of a suspicious lesion, 
the patient received a referral letter for his or her general practitioner or a dermatologist. As expected, 
the participation rate was higher in the TBE region compared to the LDS region (17.9% versus 3.3%, P 
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= < 0.01). Skin cancer yield did not differ significantly between both groups (2.3% TBE versus 3.2% 
LDS, P = 0.40). Further details on the design of this trial can be found in Hoorens et al. (2016). 
 
Model structure 
The Markov model was developed in Microsoft Excel® 2013, complemented with Visual Basic, and 
incorporated MSC as well as BCC and SCC. It consisted of different disease states: undiagnosed skin 
cancer, diagnosis & treatment, follow-up and death, separated per skin cancer stage. The same model 
design has been used before to estimate the cost-effectiveness of a skin cancer sensitisation campaign 
and a total ban on sunbed use. More information on the design of the model can be found in (Pil et al., 
2016a) (Chapter 2.1.3. in this PhD thesis). All Belgian adult males and females were assumed to be 
invited for the single screening program. Modelled clinical outcomes of the screening were pathologically 
confirmed skin cancer, a false positive result or a (false) negative result. It was assumed that persons 
with an undiagnosed lesion who chose not to participate in the screening program or persons with a 
false negative result could have their lesion diagnosed by spontaneous clinical detection in the same 
cycle. Spontaneous clinical detection was also possible in the comparator (i.e. current situation). The 
duration of the diagnosis & treatment phase was 6 months (= 1 cycle) for patients with BCC, SCC 0-II 
or MSC I-II and 1 year for patients with SSC III-IV or MSC III-IV.  To assign a higher probability of skin 
cancer death in the first years after diagnosis in case of SCC IV and MSC IV, the follow-up phase was 
divided into intense- and long-term follow-up, which lasted for 4 years, after which one moved into long-
term follow-up. Patients in follow-up remained in this state until the end of the model’s time horizon, or 
until they died. MSC and SCC stages were determined according to the 7th edition of the Tumour-Nodes-
Metastases-classification for malignant tumours (Sobin et al., 2009). Stages for BCC were defined as 
<1cm, 1-2cm, >2cm and aggressive histology. BCC and SCC patients were assigned higher risk to 
develop an MSC lesion. Risk of a recurrent lesion was included in the model, risk of subsequent similar 
lesion (for all cancer types) was accounted for in the costs, since the effect of a subsequent lesion on 
the quality of life has not yet been described in current literature. All cohort members started the model 
in one of the model states, according to the baseline prevalence of BCC, SCC and MSC (Belgian Cancer 
Registry, 2013; Integraal Kankercentrum Nederland, 2011). The Markov model served two aims, namely 
to evaluate the incremental cost-effectiveness ratio (ICER) (calculated as the net costs divided by the 
net health effects) from a societal perspective and considering a willingness-to-pay threshold of 
35,000/QALY gained, as well as the budget impact, over a period of 20 years. The budget impact 
analysis estimated the net cumulative cost of the screening program (and consequent examinations, 
treatment and follow-up) for the public health care payer over a period of 20 years, while allowing new 
entrance of 18-year olds each cycle in the lesion-free state, who were subjected to the natural 
progression of skin cancer.  
 
Model inputs  
Screening-related input parameters 
Screening-related input parameters are depicted in Table 1. We did not derive the test-characteristics 
of the dermoscopy from the screening trial, as only expert dermatologists were involved, which can bias 
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the test-characteristics. Therefore, the study of Chevolet et al. (2015) was used, in which the test-
characteristics of the dermoscopy used by well-trained and less-trained dermatologists were calculated. 
Averages of these values were used in our model.  
 
Epidemiological and clinical data  
The epidemiologic and clinical data used for the model have been described in our previous study (Pil 
et al., 2016b) (see Appendix p.84-89 in this PhD-thesis).  
 
Costs and health effects  
Costs included the cost of screening, direct medical costs and costs due to productivity loss, expressed 
separately for the health care payer and for the patient. The total cost of the screening per screenee 
was calculated at €4.9 in the TBE group and €1.8 in the LDS group. This included the costs for the 
invitation, poster and flyers, the cost for renting a public place for screening, the cost for using medical 
equipment and the cost of total time spent by the dermatologists. The difference in cost was mainly due 
to the difference in duration of the two screening methods (TBE 5 times longer than LDS). Direct costs 
for treatment and follow-up and indirect costs due to productivity loss -because of screening participation 
(derived from the screening study), morbidity or early mortality- were calculated based on a medical 
consumption questionnaire returned by 287 Belgian skin cancer patients, multiplied by official Belgian 
unit costs (Cleemput et al., 2012; Rijksinsituut voor Ziekte- en Invaliditeitsverzekering (RIZIV), 2016).  
Health effects of the screening were represented as the impact on quality-adjusted life-years (QALYs), 
which include the impact on the quality of life as well as the life-expectancy as a result of the stage shift.  
Direct and indirect costs as well as EQ-5D utilities are described in our previous skin cancer study (Pil 
et al., 2016b) (see Table 3 on p.75 in this thesis). Following the Belgian guidelines, health effects were 
discounted at 1.5% and costs at 3% (Cleemput et al., 2012). 
 
Scenario- and sensitivity analysis 
Several scenarios were tested: screening from the age of 40 years instead of 18 -since skin cancer 
tumours usually do not arise frequently in younger persons-, public health care payer perspective 
(exluding the costs due to productivity loss and the costs for the patient), extending the time horizon to 
50 years instead of 20 years and screening every five or two years during a period of 20 years instead 
of only once (and assuming a time horizon of 50 years and with constant screening uptake rates, not 
linked to disease incidence or progression). Sensitivity of the results to changes in individual parameters 
was assessed by means of a deterministic one-way sensitivity analysis and a probabilistic sensitivity 
analysis. In order to test the parameters’ influence on the result, parameters were varied guided by the 
confidence interval (CI), or varied by ±30% of their original value in case a CI was not available. A 
probabilistic sensitivity analysis created a credibility interval around the cost-effectiveness ratio by 
running 5,000 Monte Carlo simulations according to the distribution of the input parameters. Utilities and 
probabilities were varied according to a beta-distribution and costs according to a gamma-distribution. 
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Table 1: Screening-related input parameters 
Parameter 
Input value 
 
18-29y 30-39y 40-49y 50-59y 60-69y 70-79y 79+y 
Participation rate1          
TBE males 8.80% 13.60% 14.20% 20.50% 24.10% 18.30% 5.40% 
 
TBE females 14.50% 20.10% 20.30% 24.00% 27.10% 18.60% 4.60% 
LDS males 1.50% 2.10% 2.20% 3.80% 5.90% 3.70% 2.60% 
LDS females 1.80% 3.30% 3.70% 2.70% 5.50% 2.70% 0.90% 
           
Test characteristics2          
sensitivity dermoscopy BCC 83% 
 
SCC 83% 
MSC 74% 
specificity dermoscopy BCC 87% 
SCC 87% 
MSC 89% 
1 (Hoorens et al., 2016)     2 (Chevolet et al., 2015) 
 
 
RESULTS 
 
Impact on skin cancer epidemiology 
Over a period of 20 years, the model estimated the one-time screening to result in a 4% decrease in the 
incidence rates of MSC stage III & IV at population level, in reference to the comparator. Moreover, both  
screening programs were estimated to have a positive, although modest, impact on mortality from skin 
cancer, with an absolute reduction of 628 deaths in case of TBE (273 in males and 355 in females) and 
118 in case of LDS (57 in males and 61 in females). This corresponds to a relative mortality reduction 
of about 5.6% in case of TBE and 1% in case of LDS, in reference to the comparator. 
 
Cost-effectiveness 
Base case 
Both screening strategies resulted in a gain in QALYs over a period of 20 years (Table 2). Incremental 
health effects and costs were in good balance, leading to incremental cost-effectiveness ratios of 
€33,072/QALY in males and €18,687/QALY in females for TBE and €34,836/QALY in males and 
€19,470/QALY in females for LDS, which can be interpreted as a moderate cost-effective result 
assuming a willingness-to-pay threshold in Belgium of €35,000/QALY gained (Nationale Bank van 
België, 2015; WHO, 2005b). 
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Table 2: Results of the cost-effectiveness analysis, over a period of 20 years, per 1,000 persons 
 
  Incremental QALYs Incremental Costs  ICER 
  males  females males  females males  females 
TBE 0.20 0.34 € 6,465 € 6,383 € 33,072 € 18,687 
LDS 0.04 0.05 € 1,391 € 977 € 34,836 € 19,470 
TBE: total body examination; LDS: lesion-directed screening 
QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio 
 
Table 3: Results of the scenario analysis 
  
TBE LDS   
(€/QALY gained) (€QALY gained) 
  males females males females 
ICER base case 33,072 18,687 34,836 19,470 
Screening from 40 years 35,622 21,841 36,348 23,485 
Public health care payer 
perspective 
20,016 12,300 20,784 12,887 
Time horizon 50 years  9,253 5,722 10,262 5,549 
Screening every 5 years*  11,811 6,060 12,758 5,671 
Screening every 2 years*  12,180 6,021 12,404 5,436 
ICER probabilistic 31,360 18,051 34,170  18,999 
(95% CI) (23,251-41,468) (13,493-23,019) (25,586-44,831) (13,725-25,139) 
 
TBE: total body examination; LDS: lesion-directed screening 
QALY: quality-adjusted life-year; ICER: incremental cost-effectiveness ratio; prod. loss: productivity loss  
* during 20 years, but with a time-horizon of 50 years 
 
Scenario- and sensitivity analysis 
Results from the scenario-analysis are presented in Table 3. A one-time screening from the age of 18 
remained the most cost-effective strategy. From a public health care payer perspective, omitting the 
costs for the patient and the costs due to productivity loss, the result was better than from a societal 
perspective. Screening every two or five years had a lower cost-effectiveness ratio, but since the time 
horizon was set at 50 years for this scenario -as 20-year time horizon would not capture the effect of 
screening in e.g. year 18-  it should be compared to the scenario of a one-time screening with a time 
horizon of 50 years. The one-way sensitivity analysis showed the most influencing parameters in the 
analysis for males to be the natural progression of MSC, the utility related to MSC, the prevalence of 
undiagnosed MSC and BCC, the direct cost BCC long term follow-up and the direct cost of MSC III and 
IV (Figure 1, tornado diagram shown for TBE). A higher value on these parameters led to a more cost-
effective result, except for the prevalence of undiagnosed BCC and the direct cost of BCC follow-up, in 
which the effect was the opposite. Variation in these parameters resulted in ICERs exceeding the 
€35,000/QALY gained threshold in males; in females only the variation in the natural progression of 
MSC led to an ICER exceeding the threshold. The probabilistic sensitivity analysis created credibility 
intervals around the deterministic result. The cost-effectiveness planes, which are depicted in Figure 2, 
show that most simulations are located in the north-east quadrant and are below the willingness-to-pay 
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threshold of €35,000/QALY gained, although for the simulation in males part of the values are situated 
above the threshold. The cost-effectiveness acceptability curves (Figure 3) show that regarding a 
willingness-to-pay threshold of €35,000/QALY gained, the probability of screening being cost-effective 
is 79.7% and 59.9% for TBE and LDS in males and 100% in females. 
 
Figure 1: Tornado diagrams with results of the one-way sensitivity analysis (for TBE) 
a) TBE in males 
 
b) TBE in females 
 
MSC: melanoma skin cancer; BCC: basal cell carcinoma: SCC: squamous cell carcinoma 
D&T: Diagnosis and treatment; FU: follow-up 
Light grey bars: minimum value of parameter; Dark grey bars: maximum value of parameter 
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Figure 2: Cost-effectiveness planes displaying the 5,000 simulations     
 
Willingness-to-pay threshold of €35,000/QALY is displayed in the graphs 
 
Figure 3: Cost-effectiveness acceptability curves 
 
 
 
Budget impact 
The budget impact analysis presented in Table 4, showed that over a period of 20 years a one-time 
screening would induce an extra cost for the health care payer of €36 million in case of TBE or €6 
million in case of LDS, respectively €0.2 and €0.03 per year per person in the target group (18+).  
 
Table 4: Results of the budget impact analysis, over a period of 20 years 
  
Cost of 
intervention 
Health care payer Total cost Total net cost 
Control  € 0 € 1,909,776,064 € 1,909,776,064   
TBE  € 7,308,319 € 1,938,193,177 € 1,945,501,496 € 35,725,432 
LDS € 463,275 € 1,915,431,360 € 1,915,894,635 € 6,118,570 
TBE: total body examination; LDS: lesion-directed screening 
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Model validation 
The results of the skin cancer screening analysis resulted in detection rates similar the ones observed 
in the screening trial (Hoorens et al., 2016) (Appendix Table 1). Besides, the distribution of the cancer 
prevalence according to the tumour types over 20 years in the absence of the screening program was 
69.9% BCC, 18.5% SCC and 11.6% MSC, which is in line with the observed 70% - 20% - 10% 
distribution (Integraal Kankercentrum Nederland, 2012b). 
 
DISCUSSION  
 
Over a period of 20 years, this analysis showed that a one-time TBE was estimated to lead to a gain of 
2,380 healthy life-years in the total population (8.8 million) and a one-time LDS to 397 healthy life-years. 
In addition, TBE was projected to reduce skin cancer mortality by 5% over 20 years. However, currently 
no prospective studies support a reduction in skin cancer mortality due to screening. According to Boniol 
et al., the transient decrease in mortality in Schleswig-Holstein followed by return to pre-screening levels 
could reflect a temporal modification in the reporting of death causes (Boniol, Autier, & Gandini, 2015; 
Katalinic et al., 2012). In addition, no decrease in MSC mortality has been documented since the nation-
wide skin cancer screening was introduced in Germany in 2013 (Katalinic, Eisemann, & Waldmann, 
2015). Due to the screening cost, and the extra costs for treatment and follow-up, implementing a one-
time screening costs extra money for the health care payer. Nevertheless, the balance between 
incremental costs and health effects is shown to be beneficial, both for TBE and LDS (ratio below the 
accepted threshold of €35,000/QALY gained), although in the case of males both screening strategies 
tend to this threshold limit. However, the probability of the screening’s cost-effectiveness result being 
below the considered threshold was 80% in TBE and 60% in LDS. The incremental cost-effectiveness 
ratio for TBE was better than for LDS, which can be explained by the low participation rate in the LDS 
screening arm (Hoorens et al., 2016). Since the skin cancer detection rates were comparable in both 
screening arms and since LDS screening was time-saving, it could be worthwhile to investigate how 
participation in this type of screening could be increased. If the same participation rates of TBE would 
be attained in LDS, then LDS would be more cost-effective than TBE. Screening in females was clearly 
more cost-effective than in males, because of the higher prevalence and incidence of skin cancer in 
females in Belgium. Screening from the age of 40 instead of 18 only slightly deteriorated the cost-
effectiveness result, probably because younger persons have a higher quality of life, which means that 
screening could gain more health benefits in younger persons, and because older persons have a higher 
risk to die from other causes than skin cancer, which disadvantages the beneficial effect of screening. 
Suppose the time horizon of the model would be extended to 50 years, then the cost-effectiveness ratio 
would be better than with a 20-year time horizon, as the benefit of the screening probably continues for 
a longer period than 20 years. The choice to implement the screening program repeatedly would be 
cost-effective, but a one-time screening would still be the most cost-effective strategy. When assuming 
a public health care payer perspective, omitting the extra costs for the patient and the costs due to 
productivity loss, screening becomes more cost-effective as those extra costs for the patient are not 
taken into account, lowering the total incremental cost. Sensitivity analysis showed that the natural 
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progression of skin cancer had the highest influence on the cost-effectiveness outcome, arguing for 
further research on the natural progression of skin cancer. Another important influencing parameter was 
the cost of MSC III and IV (for diagnosis and treatment). It is possible that the cost for treating MSC III 
and IV will keep on rising due to new (combinations of) drugs and other technologies, which would result 
in screening becoming more cost-effective. Also the prevalence of undiagnosed BCC and MSC was 
highly influential: a higher prevalence of undiagnosed MSC would lead to higher health benefits 
compensating for the extra costs, which would make the screening more cost-effective. However, in 
case of a higher prevalence of undiagnosed BCC, screening would become less cost-effective, as 
detecting and treating BCC does not lead to benefits in quality of life and lead to extra costs. Although 
treating small BCC lesions is less expensive than treating more advanced BCC lesions, it seems from 
this study that the extra costs for treating the BCC lesions would become too high. Furthermore, since 
a better sensitivity of dermoscopy leads to a better cost-effectiveness result (10th most influencing 
parameter), training initiatives for dermoscopy are recommended.  
Other studies on the cost-effectiveness of skin cancer screening have been conducted especially in the 
U.S. and Australia and only included MSC. Most of these studies expressed the cost-effectiveness of 
MSC screening to no screening in cost per life-year saved. These studies showed that screening men 
over 50 years biennially by general practitioners resulted in a ratio of $12.137/life-year saved (AUD) 
(Girgis et al., 1996). A one-time screening by dermatologists in a self-selected population resulted in 
$51,481/life-year saved (USD) (Beddingfield, 2002) and in a high-risk population in $39.600/life-year 
saved (USD) (Freedberg et al., 1999).  One study calculated the cost per QALY gained of a visual one-
time screening from the age of 50 to be $10,100/QALY gained (USD) (~ €9,256/QALY gained) (Losina 
et al., 2007). When implemented biennially the ICER rose to $80,700/QALY (~ €73,882/QALY) and if 
annually to $586,800/QALY (~ €537,220/QALY). Our results supports this latter result of better cost-
effectiveness in case of one-time screening. However, it is difficult to compare studies directly because 
of different screening setting (visual screening versus dermoscopy screening, composition of the 
screening team), different epidemiological backgrounds (cf. incidence of MSC higher in Australia than 
in Belgium) and different model design. 
This is the first time that the costs and benefits of a skin cancer screening program have been analysed 
in detail. Not only the benefits of screening were captured in the model, but the impact of a false-positive 
screening result on quality of life in terms of psychological harms was included as well. However, in our 
model, the screening examination itself did not have an impact on the quality-of-life. The study of Collins 
et al. (2011) showed that screening (in general) does not appear to have an adverse emotional impact 
in the longer term and they stated that up to now too few studies have assessed the short term emotional 
impact of screening. The study of Hoorens et al.(2016) questioned the anxiety of the screenees right 
after the screening, but baseline levels were not available so no conclusions on the quality-of-life right 
before and after the screening could be deducted from this study. Beside the strengths of our analysis, 
some limitations should also be addressed. Firstly, in Belgium there is no accurate registration of NMSC. 
Therefore, we relied on epidemiologic results of the Dutch cancer registry, since they have a more 
systematic registration of NMSC. Secondly, accurate information on the natural progression of skin 
cancer is not available. Therefore, in our model, the natural progression was estimated based on 
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calibration. This is generally a more reliable approach than making assumptions on parameters based 
on limited studies. Lastly, it may be noted that screening parameters such as participation rate, test 
characteristics, as well as unit costs of detection, treatment and follow-up and epidemiologic parameters 
are context-specific limiting the direct transferability of the results across different countries. However, 
we believe that not only the mean result, but also the results from the sensitivity and scenario-analysis 
can be informing for other countries. 
 
CONCLUSION 
 
Based on this study, skin cancer screening was shown to be moderately cost-effective at a willingness-
to-pay threshold of €35.000/QALY gained, especially in females. Based on these results a total-body 
examination in the general adult population (with particular focus on females) is the most cost-effective 
screening strategy from a societal viewpoint and projected to result in a mortality reduction over 20 
years. The study indicates an important opportunity to collect observational data in support of the 
mortality reduction.  
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APPENDIX 
 
Appendix Table 1: Model validation: observed versus calculated cancer detection rates from the screening 
 Observed Calculated 
  males females males females 
SCC 0-II 0.060% 0.060% 0.067% 0.061% 
SCC III 0.007% 0.007% 0.007% 0.007% 
SCC IV 0.002% 0.002% 0.003% 0.002% 
MSC I 0.480% 0.480% 0.482% 0.478% 
MSC II 0.102% 0.080% 0.103% 0.075% 
 
Observed: parameter values observed in the screening trial   
Calculated: estimated parameter values based on the model
  
 
 
 
  
  
 
 
 
 
 
Part 2: Original research studies: health economic 
evaluations in the continuum of prevention 
 
 
2.3.    Indicated prevention interventions 
 
  
  
 
  
  
 
 
 
 
 
2.3.1. Cost-effectiveness of a helpline for suicide 
prevention 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on:  
 
Lore Pil, Kirsten Pauwels, Ekke Muijzers, Gwendolyn Portzky & Lieven Annemans. Cost-
effectiveness of a helpline for suicide prevention. (2013). Journal of Telemedicine and 
Telecare 19 (5). p.273-281  
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ABSTRACT 
Background: The cost-effectiveness and budget impact of a suicide helpline in Belgium was evaluated, 
consisting of a telephone- and a chat service.  
Methods: An age- and gender-dependent Markov model with a ten-year time horizon and a one-year 
cycle length was developed, assuming a societal perspective, to predict cumulative costs and quality-
adjusted life-years (QALYs) in the helpline users. The model included six transition states: the initial 
state (at risk), first attempt, re-attempt, follow-up, suicide and death from other causes. Data on the 
effect of the helpline and costs associated with model states were obtained from the literature. One-way 
and probabilistic sensitivity analyses were performed to capture uncertainty. In addition, the budget 
impact of the helpline was analysed.  
Results: Over ten years, the telephone- as well as the chat service could avoid about 36% of suicides 
and attempts in this high-risk population. In males, 0.063 QALYs (95% confidence interval, CI 0.030-
0.097) and 0.035 QALYs (95%CI -0.026-0.096) were gained by users of the telephone- and chat service 
respectively. The corresponding values for females were 0.019 QALYs (95%CI -0.015-0.052) and a 
QALY-neutral result of -0.005 (95%CI -0.071 -0.062). There were net societal savings of respectively 
€2,382 (95%CI 1,953-2,859) and €2,282 (95%CI 1,855-2,758) per person in male users; €2,171 (95%CI 
1,735-2,664) and €2,458 (95%CI 1,945-3,025) in female users. At the population level, €1,452,022 could 
be saved for the public health service (national health insurance), mainly due to the telephone service.  
Conclusion: The analysis predicted that both means of telemedicine for suicide prevention in Flanders 
are cost-saving, and have a modest effect on QALYs. 
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INTRODUCTION 
 
Suicide is an important public health problem in Flanders (Belgium). The annual suicide rate is nearly 
twice as high as the European average (Vlaams Agentschap Zorg en Gezondheid, 2012b; WHO, 
2012c). Every day more than three people commit suicide and 26 people attempt suicide in Flanders 
(De Jaegere, Wittouck, Portzky, & Van Heeringen, 2009). There is an urgent need to reduce the 
incidence of suicidal thoughts, utilising evidence-based prevention interventions and policy action 
(Jacka & Reavley, 2014). A suicide helpline is one type of such prevention interventions, targeting high-
risk individuals with (minimal) signs of suicidal thoughts and plans and aiming to reduce the suicidal 
state of the helpline user. The conventional telecommunication medium for suicide prevention is a 
telephone service, but new communication channels like the Internet can also be used (Krysinska & De 
Leo, 2007; Luxton, June, & Kinn, 2011). In Flanders, the suicide helpline De Zelfmoordlijn has provided 
a crisis service since 1979, first by telephone, and since 2005 by online chat sessions as well. Unlike 
chat rooms, the chat service of De Zelfmoordlijn allows people to have an individual conversation with 
a trusted person. In 2011, 3785 people contacted the helpline seeking personal help. In this study, a 
cost-effectiveness analysis and budget impact analysis of the Flemish suicide helpline was conducted. 
METHODS 
 
Model structure  
The analysis was based on an age- and gender-dependent state transition Markov model, predicting 
life events for users of the suicide helpline in 2011. The target population consisted of 3785 unique 
users of the suicide helpline, who call/chat for themselves, of which 2418 women (64%) and 1367 
men (36%). In women there were 1840 telephone- and 578 chat service users, in men 1201 
telephone- and 166 chat service users. Mean age of the population was 37 years (range 12 to 91 
years), with 21 years in the chat service group and 42 years in the telephone service group. 
Predictions were made from the contact with the helpline over a period of ten years for two scenarios: 
a scenario in which the suicide helpline was present and a scenario in which the suicide helpline was 
absent. Six states, which we considered the most important in the suicidal process of an individual, 
were included in the model: the initial state (i.e. at risk for suicide), first attempt, follow-up, re-attempt, 
suicide and death from other causes (Figure 1). Transitions between these states were allowed once 
a year. All individuals in the target population started the model in the initial state (i.e. people who 
seek for personal help and who had not made an attempt before), consisting of helpline users with no 
to mild suicidal thoughts as well as users with moderate to strong suicidal thoughts (i.e. those who 
are categorised in one of the three most severe states of the suicidal process). This categorisation 
was based on information registered by the Centre for Prevention of Suicide (Table 1) (2012). During 
the first year after the contact, individuals could move to another state - i.e. they could attempt suicide, 
commit suicide or die due to another cause- or remain in the initial state. From the second year 
onwards, transitions to more states were possible: making a re-attempt or moving to the follow-up 
state (i.e. state one moves to after an attempt). The attempt state was a transitional state, i.e. 
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individuals only remained in this state for one cycle, after which they moved to follow-up, re-attempt, 
suicide or death (from another cause). All individuals stayed in the model for ten years. At the start of 
the model, they were distributed among 14 age categories. Analyses were performed separately for 
males and females, and for both telephone- and chat services. The analysis assumed a societal 
perspective, using the friction cost method for assessing the cost due to productivity loss (Hakkaart-
van Roijen, 2010; Koopmanschap & van Ineveld, 1992). The difference in costs over ten years was 
divided by the net effects in quality-adjusted life-years (QALYs), in order to obtain the primary outcome 
measure, the incremental cost-effectiveness ratio (ICER). Annual discount rates of 3% and 1.5% were 
applied to future costs and effects respectively, as recommended by the Belgian Knowledge Centre 
for Health care (Cleemput et al., 2012). In order to estimate the budget impact, net costs during one 
cross-sectional year were simulated by repeating the model outcomes in one cohort for subsequent 
annual cohorts. 
 
Figure 1:  Markov model of health states and possible transitions during each 1-year cycle.  
 
 
The ellipses represent the possible states and the arrows correspond to transition probabilities 
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Table 1: proportion of suicidal thoughts in the helpline users at baseline and after an attempt (= follow-
up)  
  Telephone Chat 
  males females males females 
No to mild suicidal thoughtsa 53.6% 52.2% 44.9% 40.8% 
Moderate to strong suicidal thoughtsa 46.4% 47.8% 55.1% 59.2% 
No to mild suicidal thoughts at follow-upb 81.2% 81.2% 81.2% 81.2% 
Moderate to strong suicidal thoughts at follow-upb 18.8% 18.8% 18.8% 18.8% 
 
a (Centrum ter Preventie van Zelfdoding, 2012); b (De Jaegere, Wittouck, Portzky, & Van Heeringen, 2010)  
Follow-up: only three days after attempt (cf. De Jaegere et al., 2010). These prevalences at follow-up are only used to estimate the utility associated with the follow-up 
state. 
Transition probabilities  
The age- and gender-dependent transition probabilities between the model states were derived from 
published literature, official Flemish databases and data from the Flemish Centre of Suicide 
Prevention, the latter specific for the target population (Table 2). The annual risk of attempting suicide 
for the first time was calculated as a weighted average of the risk of helpline users with no to mild 
suicidal thoughts, (ranging from 0.012% to 0.36%; gender- and age-specific, based on suicide 
statistics of the Flemish population (Boffin et al., 2010; Vlaams Agentschap Zorg en Gezondheid, 
2012b)) and helpline users with moderate to strong suicidal thoughts, (ranging from 5.6% to 8.5%; 
gender- and age-specific (May et al, 2012)) (Table 2). May and colleagues (2012) found in their ten-
year follow-up study that two thirds of those individuals with suicidal thoughts who made an attempt, 
made that attempt in the first 2.5 years after baseline measurement and one third between year 2.5 
and year 5. Based on this study, transition probabilities to the attempt state were varied according to 
the time one remains in the initial state. Probabilities of making an attempt from the study of May et 
al. (2012) were used for years 1-3 and years 4-5. After 5 years, the average Flemish population risk 
was assigned to the individuals who still remained in the initial state (Boffin, Bossuyt, & Van Casteren, 
2010; De Jaegere et al., 2010). The annual risk to commit suicide was calculated in the same way 
(May, Klonsky, & Klein, 2012). These transition probabilities for making an attempt and committing 
suicide were age-adjusted according to the Flemish suicide statistics (Vlaams Agentschap Zorg en 
Gezondheid, 2012b). The annual risk of committing a non-fatal re-attempt within the first year after 
the first attempt was derived from the study of Tejedor et al. (1999) and amounted to 6.5% per year. 
In the subsequent eight years after the first attempt this risk decreased to 1.7% per year. The annual 
probability to complete a fatal re-attempt during the period of 10 years was 1.3% (Tejedor, Diaz, 
Castillon, & Pericay, 1999). These risks were made gender- and age-adjusted based on the age 
distribution of attempts and suicides in the Flemish population. The annual risk of dying from another 
cause was obtained by Flemish life tables (Vlaams Agentschap Zorg en Gezondheid, 2012a). 
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Table 2: Ranges of annual transition probabilities (in %), dependent on gender, age and telephone- or 
chat-service group (2010), and base-case annual costs per model disease state (2012 values).  
  Females (%) Males (%) 
First attempt year 1-31 2.70-5.19 1.86-4.65 
First attempt year 4-51 1.32-2.60 0.91-2.30 
First attempt year 6-102 0.03-0.36 0.01-0.25 
Suicide year 1-31 0.06-2.25 0.22-3.23 
Suicide year 4-51 0.03-1.10 0.11-1.58 
Suicide year 6-101 0.00-0.03 0.00-0.05 
Non-fatal re-attempt year 13 4.84-7.39 3.43-7.17 
Non-fatal re-attempt year 2-103 1.24-1.9 0.88-1.84 
Fatal re-attempt3 0.11-3.28 0.4-5.05 
Death (from other causes) 0.01-6.00 0.01-8.85 
  Direct costs (€) Indirect costs (€) 
Initial state4  - 1,526 
(Re-)Attempt5 2,933 43,434 
Follow-up6 89 1,526 
Suicide7 2,600 60,537 
 
1 (Boffin et al., 2010; Centrum ter Preventie van Zelfdoding, 2011; De Jaegere et al., 2010; May et al., 2012; Vlaams Agentschap Zorg en Gezondheid, 
2012b).     2 Flemish population risk (Boffin et al., 2010; De Jaegere et al., 2010; Vlaams Agentschap Zorg en Gezondheid, 2012b)     3 (Boffin et al., 2010; 
De Jaegere et al., 2010; Tejedor et al., 1999)     4 Average number of days absenteism + (Securex, 2010)     5 (Corso, Finkelstein, Miller, Fiebelkorn, & 
Zaloshnja, 2006; Securex, 2010; Verschraegen, 2007)     6 (Corso et al., 2006; Securex, 2010)     7 (Corso, Mercy, Simon, Finkelstein, & Miller, 2007; 
Securex, 2010) 
Cost data  
Direct and indirect costs associated per model state are shown in Table 2 (2012 values). The direct 
cost of a suicide attempt is the weighted sum of Belgian costs assigned to hospitalisation (92%) and 
general practitioner consultations (8%) (Corso et al., 2006; Verschraegen, 2007). Because of lack of 
data on the annual cost of suicide in Belgium or Europe, an estimation of the direct cost of suicide 
was derived from the American study of Corso et al. (2007) (converted to euro using the purchasing 
power parity and indexed to 2012). This cost includes ambulance transport, medical examiner costs, 
emergency department, inpatient hospitalisation and/or nursing home costs. The direct medical cost 
associated with the follow-up was based on the ratios for long term medical costs from the study of 
Corso et al. (2006), which were 30%  and 14% of the costs due to an attempt, for admitted and non-
admitted cases respectively. Costs due to productivity loss were calculated by multiplying the unit cost 
of one day of absenteeism (€280) (Securex, 2010) with the average annual days of absenteeism per 
working individual both in general (5.7) (Securex, 2010) as well as specifically due to a suicide attempt 
(assumed to be 162, weighted average of full-time and part-time working individuals (Algemene 
Directie Statistiek en Economische informatie, 2011; Draper, 1994) or suicide (assumed to be one 
year, weighted for of full-time and part-time working individuals). The friction cost method assumes 
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the costs to lost productivity due to suicide only to be applied in the year in which the suicide was 
committed (Hakkaart-van Roijen, 2010). Because not all individuals in the model were at productive 
age during the ten years, the indirect costs were not applied to age categories under 20 years and 
age categories from 60 years on (as the average age of retirement in 2011 was 62 years). The total 
cost of 'De Zelfmoordlijn' for 2011, including salaries, transport costs of personnel, compensation for 
the trained volunteers, operation costs and costs of telephony and instant messaging, equals 
€218,299. This cost was divided by the total number of people reached by the helpline (5054; including 
those who made use of the helpline for the benefit of others), and amounted to €43 per person. This 
cost was added once per individual, namely at the point where the individuals start in the model. 
Quality of life data 
The total cohort started the model in the initial state, which consists of helpline users with moderate to 
strong suicidal thoughts and users with no to mild suicidal thoughts. The utilities associated with the 
initial state were calculated as the weighted average of the utility related to suicidal thoughts and the 
utility in the general Belgian population. An average EQ-5D utility for suicidal thoughts (0.64,  95%CI: 
0.33-0.95) and a suicide (re-)attempt (0.54, 95%CI: 0.29-0.79) were derived from the study of Van 
Spijker et al. (2011). In Belgium, utilities in the general population are currently only available as scores 
on a visual analogue scale (Szende & Williams, 2004). To convert these scores to EQ-5D index utilities, 
both were plotted per health state. A linear relation was assumed between them, so the best fitting 
regression line was used to calculate the EQ-5D index values. Utilities associated with the follow-up 
state were calculated as the weighted average of the utility related to the general Belgian population 
and to suicidal thoughts, based on the proportion of the target population with suicidal thoughts at follow-
up (De Jaegere, Wittouck, Portzky, & Van Heeringen, 2010). The age-dependent base-case utilities are 
shown in Table 3. 
 
Table 3: Age-dependent base-case utilities per state; initial state utilities separated according to gender 
Age Initial state telephone Initial state chat Attempt Follow-up 
  female male female male female/male female/male 
10-17 0.777 0.780 0.757 0.764 0.578 0.829 
18-29 0.753 0.755 0.733 0.74 0.559 0.803 
30-39 0.727 0.729 0.708 0.715 0.54 0.775 
40-49 0.726 0.728 0.707 0.714 0.539 0.774 
50-59 0.699 0.701 0.68 0.687 0.519 0.745 
60-69 0.686 0.688 0.668 0.674 0.509 0.731 
70-79 0.615 0.617 0.599 0.605 0.457 0.656 
80+ 0.611 0.613 0.595 0.601 0.454 0.652 
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Relative risk reduction: effect of the intervention  
Studies supporting the effectiveness of telephone- and chat services in suicide prevention are scarce 
(Gould, Kalafat, Harrismunfakh, & Kleinman, 2007; Krysinska & De Leo, 2007; Scott & Guo, 2012). The 
main barriers for conducting randomised controlled follow-up studies in suicide prevention are the 
principles of anonymity and confidentiality. Currently no effectiveness study of the Flemish suicide 
helpline has been performed. Lester (1997) found some evidence for the effectiveness of suicide 
prevention centers in the U.S. Gould et al. (2007), conducted a pre- and post-test immediately before 
and after a call to a U.S. crisis hotline, to assess the proximal effect. Before the call, 43% of the users 
had a moderate to strong intent to die (3 or more on a 5-point scale). After the call, this proportion had 
decreased to 25%, which shows a relative risk reduction of 40.98%. The relative risk reduction 
calculated by Gould et al. was applied to our Flemish suicide helpline. This could be justified by two 
main arguments. First, both the suicide helpline in our study and the US suicide helplines work in a 
similar way (e.g. both are staffed by trained volunteers who keep call records) (Kalafat, Gould, Munfakh, 
& Kleinman, 2007). Second, the proportion of individuals in the study of Gould et al. with a moderate to 
strong intent to die (43%) approximates the number of people with moderate to strong suicidal thoughts 
in our model (47%) [265]. Assuming the suicide helpline can lower the amount of individuals with 
moderate to strong suicidal thoughts, suicidal acts can be prevented since the risk of making an attempt 
or committing suicide is based on the proportion of individuals with suicidal thoughts. Fukkink and 
Hermans (2009) investigated the effect of the telephone- and chat service of a child helpline in the 
Netherlands. They found a positive effect of the helpline, but there were no significant differences in 
effect sizes between the telephone- and chat service. Hence, in our model the same relative risk 
reduction was used for the chat- as for the telephone service, which means that both should have an 
equally strong impact on the amount of suicidal thoughts and thus on suicides and suicide attempts. 
The effect of the intervention was applied in the first five years after the call, after which no further effect 
was applied. 
Sensitivity analyses 
One-way and probabilistic sensitivity analyses were carried out to capture uncertainty in the key 
parameters. The effect of costs, utility of suicidal thoughts, utility of making an attempt, incidences of 
attempts and suicides in suicidal individuals, the relative risk reduction and the discount rate on net costs 
and net QALYs was evaluated in case of better or worse conditions of these parameters, defined by an 
increase or decrease of 30%. A probabilistic analysis varied costs, utilities and the relative risk reduction 
by their own probability distribution. Cost data were assumed to be distributed according to a gamma-
distribution, utilities according to a beta-distribution and the relative risk reduction according to a log-
normal distribution (Briggs et al., 2006). Several scenario analyses were conducted in order to assess 
the effect of different methodological choices. In the first scenario we evaluated the effect of a continuing 
risk over the 10 years to make a first attempt instead of a decreasing risk, assuming individuals to remain 
equally suicidal during the years they remain in the initial state. In a second scenario analysis the effect 
of decreasing the utilities of the follow-up state to the level of utilities of the initial state was investigated. 
In a third scenario the effect of using the human capital method instead of the friction cost method was 
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assessed, applying the cost due to productivity loss for a lifetime and in a final scenario the change in 
the ICER was explored when excluding the costs due to productivity loss.  
 
RESULTS 
Base-case analysis 
It was estimated that over a period of 10 years about 36% of suicides and first suicide attempts would 
be avoided in the population of high-risk helpline users by means of the telephone service as well as by 
means of the chat service of the suicide helpline. This represents 205 attempts and 33 suicides. In 
relative terms, 16 suicides and 47 first suicide attempts would be prevented in 1,000 males with the 
telephone service and 10 suicides and 60 first suicide attempts with the chat sessions. In 1,000 females 
the telephone service would lead to the prevention of 6 suicides and 54 first suicide attempts, while 2 
suicides and 68 first suicide attempts would be avoided by the chat sessions. In the situation where the 
helpline is available, female users of the telephone service would gain 0.019 QALYs, but in the chat 
service there was almost a neutral result (-0.007) (Table 4). The telephone service seems to lead to 
more health gains than the chat service, especially in male users. An increase of 0.064 and 0.046 QALYs 
respectively was found in males. Differences in costs between the chat- and telephone service were 
less clear. Total costs would decrease by €2,171 and €2,457 in female users of telephone- and chat 
service respectively, and by €2,366 and €2,272 respectively in males. Differences in costs between the 
chat- and telephone service are less clear. These outcomes for one cohort were repeated for 
subsequent annual cohorts in order to simulate the costs and effects during one cross-sectional year. It 
was estimated that over a period of 10 years, the suicide helpline in Flanders would save €1,452,022 
for the public health service (national health insurance) (equaling €4 per year per contact person); 
€1,188,519 through the telephone service and €263,503 through the chat service. 
  
 
 
Table 4: Results in the base case and sensitivity analyses, expressed in net QALYs and net costs over a period of 10 years   
  Results in users of the telephone service  Results in users of the chat service  
 males females males females 
  net QALYS net costs net QALYS net costs net QALYS net costs net QALYS net costs 
Base case deterministic* 0.064 € -2,366 0.019 € -2,171 0.046 € -2,272 -0.007 € -2,457 
Continuing risk of 
attempt/suicide 
0.070 € -2,470 0.020 € -2,266 0.053 € -2,185 -0.010 € -2,340 
Utilities FU = initial state 0.077 € -2,366 0.035 € -2,171 0.069 € -2,272 0.024 € -2,457 
Human capital method 0.064 € -5,801 0.019 € -3,105 0.046 € -4,404 -0.007 € -3,002 
Excl. productivity loss 0.064 € -165 0.019 € -171 0.046 € -204 -0.007 € -219 
Base case probabilistic 0.064 € -1,222 0.019 € -1,088 0.045 € -1,192 -0.008 € -1,237 
95% CI (0.057–0.084) (€-2,498–€-1,995) (0.013–0.038) (€-2,307–€-1,790) (0.036–0.074) (€-2,401–€ -1,908) (-0.018–0.023) (€-2,608–€-2,050) 
 
*Base case = decreasing risk on attempt in year 4-5 and from year 6-10, effect of helpline continuing for 5 years, utility related to follow-up calculated as the average of the utility of the general Belgian population and the utility associated with suicidal thoughts 
FU: Follow-up 
 
  159  
 
Sensitivity- and scenario analyses 
One-way sensitivity analyses, for male and female users of the telephone- and chat service, assessed 
the effect of uncertainty in parameters on net QALYs and net costs (Figure 2, tornados shown for male 
users). The uncertainty in the risk of making an attempt, the utility associated to a suicide attempt, the 
relative risk reduction due to the helpline and the prevalence of suicidal thoughts had the highest 
influence on the QALY gain, although the impact was only minimal. A higher risk of making an attempt,  
a higher relative risk reduction and a higher prevalence of suicidal thoughts in the target population 
would result in a higher QALY gain, whereas a higher utility associated with an attempt would result in 
a lower QALY gain. The net cost result was mostly influenced by the risk of making an attempt, the 
relative risk reduction due to the helpline, the prevalence of suicidal thoughts and the indirect costs due 
to productivity loss. However, the impact was only minimal. 
A scenario analysis with a continuing risk of making a first attempt or conducting suicide instead of a 
decreasing risk after being in the initial state for some years resulted in slightly higher QALY gains and 
cost-savings (Table 3). A second scenario took into account the fact that the utilities for the follow-up 
state are quite uncertain since the follow-up period was only 3-4 days after the attempt. As we assume 
that the degree of suicidal thoughts will increase with time since the attempt, a scenario was simulated 
in which the utilities of the initial state were applied tothe follow-up state. The results changed in a 
positive way: the base case gain in QALYs increased to 0.077 and 0.069 in males for telephone and 
chat service respectively, and to 0.035 and 0.024 in females for telephone and chat service respectively. 
Applying the human capital method instead of the friction cost method generated higher cost savings, 
especially in males. Omitting costs due to productivity loss would worsen the result, although there would 
still be cost-savings. 
Second order Monte Carlo analyses were performed to assess the effect of the uncertainty associated 
with the risk of making an attempt, the relative risk reduction, utilities and costs simultaneously. The 
cost-effectiveness planes show that cost and QALY points are mainly situated in the south-east quadrant 
of the cost-effectiveness plane, except in the case of female users of the chat service (Figure 3). In the 
analysis for female users of the chat service, only 33% of the simulations showed a gain in QALYs, in 
contrast to the 99% probability of a QALY gain in male users of the chat service. Based on the 
probabilistic sensitivity analyses, credibility intervals (95%) were generated (Table 4).  
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Figure 2 Tornado diagrams of one-way sensitivity analyses on net costs and net QALYs for A) male users 
of telephone service and B) male users of chat service  
 
 
 
Light-coloured bars show the result in case of a minimum value on the parameter; dark-coloured bars show the effect in case of a maximum value on the  
parameter. Values were varied with ±30%. Relative range in values is shown between brackets. 
Prev.: Prevalence 
 
 
 
Figure 3:  Cost-effectiveness planes for: (a) male users of telephone service (b) male users of chat service 
(c) female users of telephone service (d) female users of chat service 
 
 
 
 
 
A) B)
A) B)
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DISCUSSION  
Telemedicine for suicide prevention purpose, like the Flemish suicide helpline, empowers individuals by 
providing accessible prevention services. This cost-effectiveness analysis has shown that the suicide 
helpline in Flanders leads to a small gain in QALYs and cost-savings for the health care payer as well 
as for society at large. The dominance of the helpline is most clear for male users of the telephone 
service, not because of the service itself (as the same relative risk reduction occurred with both the 
telephone- and the chat service) but because the risk of committing suicide is higher in adult males than 
females (23.5/100,000 versus 8.3/100,000 (Vlaams Agentschap Zorg en Gezondheid, 2012b)). The 
model estimated that over ten years the helpline can avoid about 36% of suicides and suicide attempts 
in males as well as females. A budget impact analysis revealed important savings for the public health 
service. For each euro invested in the suicide helpline, the national health insurance gains almost €7 
especially by means of the telephone service. The greater societal savings in an average female user 
of the chat service in comparison with a female user of the telephone service can be explained by the 
fact that the direct medical cost of an attempt is higher than the direct medical cost of suicide (€2,933 
against €2,600 respectively). As productivity costs were only assigned to the age categories between 
20 and 60 years, there are a lot of females in the chat service group (whose mean age is 21 years) who 
do not bring along productivity costs. Since more attempts than suicides are prevented in the chat 
service group (in absolute figures), especially in females, this can explain the higher savings due to the 
chat service compared to the telephone service in females. In males, the ratio between avoided attempts 
and avoided suicides is smaller. On the other hand, the greater societal savings in male users of the 
telephone service in comparison with female users of the telephone service can be explained by the 
fact that males are more likely to commit suicide than females and that older people are more prone to 
commit suicide than younger people (Vlaams Agentschap Zorg en Gezondheid, 2012b). 
The QALY impact of the suicide helpline was rather small. The lower gain in QALYs for the chat service 
than for the telephone service was due to the fact that more suicides are prevented in the telephone 
group, since this group contains older people (mean age 42 years) than in the chat service group (mean 
age 21 years), who are more likely to commit suicide than younger people. As preventing suicides leads 
to the highest gain in QALYs, this can explain the difference between the chat- and telephone service 
group. On the other hand, males gain more QALYs than females because males are at higher risk to 
commit suicide than females. It is clear that differences in the telephone service and chat service 
concerning health gains and cost-savings are due to the demographic and suicidal characteristics of the 
helpline users. These characteristics also explain the fact that the helpline did not have an effect on the 
quality of life in female users of the chat service.  
To validate our results, the model has been subjected to comparison with suicide probabilities in other 
scientific literature. In our model, there is a risk of 29.4% in the telephone service group and 37.4% in 
the chat service group of ever making a first suicide attempt in 10 years. In Kessler, Borges & Walters 
(1999) the lifetime probability of making an attempt was 37.9%. In Zahl & Hawton (2004) patients who 
already made a first attempt were followed for an average of 11.4 years. Of them, 2.6% committed 
suicide, 89.7% remained in the follow-up state, and 7.7% died from other causes. In our model, the 
distribution over the states after 10 years is as follows: 2.34% (telephone service) and 1% (chat service) 
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committed suicide; 12.3% (telephone service) and 13.2% (chat service) made a first attempt ever in 
those 10 years; 1.6% (telephone service) and 1.8% (chat service) ever made a re-attempt; 55.8% 
(telephone service) and 62.3% (chat service) were or still are in the follow-up state; 25.9% (telephone 
service) and 21.4% (chat service) have remained in the initial state and 2.1% (telephone service) and 
0.3% (chat service) died from other causes.  
Some international research about the effectiveness of suicide prevention interventions has already 
been carried out, although most of the studies were of poor methodological quality (Scott & Guo, 2012). 
Since there is a scarcity of health economic evaluations of suicide helplines and since there are a lot of 
differences in analysis methods and assumptions, comparison of our results with other national or 
international studies is difficult. Many researchers, including ourselves, conclude that a great deal of 
research remains to be done on the cost-effectiveness of suicide prevention interventions (Kirkwood, 
Stamm, Hudnall, & Blampied, 2010; Krysinska & De Leo, 2007; Mishara & Daigle, 2000). However, Sari 
et al. (2008) and Zaloshnja et al. (2003) showed that some suicide prevention interventions have 
favorable cost-to-benefit ratios. The present study had certain limitations. First, the relative risk reduction 
included in our study was derived from an American suicide helpline (Gould et al., 2007) which 
resembled the helpline in our analysis. However, there is uncertainty in this parameter, as Gould and 
his colleagues did not make use of a control group in their study. Second, the length of one cycle in our 
model is one year. In reality it is possible that an individual makes an attempt and a re-attempt in the 
same year. Hence, in our model, the re-attempt will be postponed, which may bias the results in favor 
of our suicide helpline. Third, relative incidence rates for suicide in suicidal persons and for re-attempts 
were not available for Belgium, so information from the U.S. (May et al., 2012) and Spain (Tejedor et 
al., 1999) was used. Fourth, an annual cost of suicide per patient was not available in Europe, so we 
had to make use of data from the U.S. although the U.S. has a very different health care system. Fifth, 
the model was based on some assumptions in the literature concerning age-related incidences 
(Corcoran, Keeley, O'Sullivan, & Perry, 2004; Scoliers, Portzky, van, & Audenaert, 2009). Re-attempt 
incidences were not specified for different age-groups so calculations were based on the assumption 
that the relative age-dependent incidences of attempts in the Flemish population were also applicable 
to re-attempts. The same assumption was applied to calculate age-specific utilities. The age-distribution 
of the utilities for general health was used to make other utilities age-adjusted. A strength is that 
information specific to the target group was obtained to build the model. This leads to more accurate 
outcomes. Finally, the Markov model depended on age, gender and medium and every age-category, 
gender and medium had its own state transition probabilities. 
 
CONCLUSION 
The present cost-effectiveness study suggests that both the telephone- and the chat service of the 
Flemish suicide helpline may lead to cost savings as well as small health benefits (especially for adult 
male users of the telephone service) over a period of ten years. Differences concerning health gain and 
cost-savings between both services were mainly due to the characteristics of the users. The budget 
impact shows that the helpline also has great annual benefits for the public health service. Both the 
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telephone- and chat service of the suicide helpline are therefore likely to be cost-effective for suicide 
prevention in Flanders and should be continued. More suicide research is necessary mainly on the 
effectiveness of the Flemish suicide helpline in reducing the suicidal state of the person.  
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3.1. Introduction 
 
Although cost-effectiveness analysis is mainly used to evaluate clinical health care interventions, it has 
potential for evaluating public health prevention interventions as well. However, the use of cost-
effectiveness evidence in policy, especially of public health prevention interventions, has been estimated 
to be limited. This is mainly due to the availability, quality and transparency of such evidence, the clarity 
of its presentation and the extent to which policy makers understand such analysis.   
The first aim of this PhD-thesis was to assess the cost-effectiveness of 8 public health interventions in 
the continuum of prevention, that hold some promise to reduce the health burden at a reasonable or 
lower total cost. These findings will be summarised below in section ‘3.2.1. Health economic results’. 
The second aim of this PhD-thesis was to inform researchers as well as policy makers on the 
interpretation of cost-effectiveness results and the use of such information by reporting and reflecting 
on the main uncertainties that were encountered in the included cost-effectiveness analyses. In section 
‘3.2.2. Main methodological challenges’, we discuss the uncertainties that frequently emerged while 
performing the cost-effectiveness analyses and while interpreting the results. In the third section of this 
discussion part, the use of the study results is discussed in light of the uncertainty and in the final section, 
recommendations for research practice, publich health practice and policy are proposed.  
  
3.2. Main findings and discussion 
  
3.2.1. Health economic results 
Universal prevention interventions: the ToyBox-intervention and skin cancer prevention 
The first intervention, classified as universal prevention, was the ToyBox-intervention, aiming to prevent 
obesity in pre-schoolers. The ToyBox-intervention led to less screen time during weekdays and a lower 
total sugar-sweetened beverage consumption in pre-schoolers. Considering a willingness-to-pay 
threshold similar to the GDP per capita of the particular country, the intervention was shown to be cost-
effective in Spain for males and females (ICER of €21,719/QALY (95%CI €2,646 - €178,296/QALY) in 
males and €10,568/QALY (95%CI €476 - €87,298/QALY) in females) and in Polish females (ICER: 
€6,304/QALY (95%CI €1,277 - €44,637/QALY). The probability of the ICER to be below the assumed 
threshold was 85%, 78% and 73% respectively. In Belgian and Greek females, the intervention was 
borderline cost-effective, with a probability of 43.2% and 37.3% for the ICER to be below the threshold.  
Results were generally better in females than in males, mainly because tracking of obesity from 
childhood into adulthood is stronger in females (Venn et al., 2007). This resulted in the relative risk 
reduction in adult overweight and obesity, based on the intervention effect, being larger in females. The 
probability of the intervention being cost-effective was the lowest in Bulgaria and Germany. This is 
probably due to the intervention cost which was high in Germany (€29,325 per 1,000 pre-schoolers), 
but also due to the willingness-to-pay threshold which was very low in Bulgaria (€5,650/QALY gained). 
Additionally, it was shown that when the intervention effect would sustain longer than the assumed one 
year, the cost-effectiveness results would be better. The key parameters influencing the cost-
effectiveness result were the parameters related to the causal chain of the model design, the intervention 
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cost and –effectiveness and the incidence of diabetes. Sensitivity- and scenario analyses stressed the 
need for more research on the relation between child health behaviour and weight status, or even better, 
between child health behaviour and adult weight status or adult risk on obesity-related diseases. More 
information is also needed on the sustainability of the intervention effect of the ToyBox-intervention, but 
also of similar interventions in general, in order to simulate the long term effects of such prevention 
interventions. 
The second study assessed the health and economic burden of skin cancer currently and in the future, 
in order to investigate the need for prevention. The cost-effectiveness and budget impact analysis 
evaluated the impact of prevention on this burden. Two hypothetical universal prevention interventions 
were evaluated, namely a comprehensive sensitisation campaign and a total ban on sunbed use. 
Results of the burden of skin cancer analysis estimated a current prevalence of about 140,000 skin 
cancer diagnoses. This prevalence was estimated to triple in the coming 20 years, based on a rising 
trend in incidence and on ageing of the population. The cost per skin cancer type and stage per six 
months was assessed by means of a retrospective bottom-up cost analysis. The current annual total 
cost of skin cancer (i.e. cost for detection and diagnosis, treatment, follow-up and productivity costs of 
MSC, BCC and SCC patients in 2014) in Belgium was estimated to be €107 million of which the greatest 
part is funded by the public health care payer. The cumulative cost in the next 20 years was estimated 
at €3.2 billion. Results of the cost-effectiveness and budget impact analysis of a hypothetical 
sensitisation campaign or a total ban on sunbed use in Belgium showed that both interventions are 
predicted to lead to a gain in QALYs and to be cost-saving on the long term. Implementing one of both 
strategies would save on average €155 million on the long term for the public health care payer. The 
return on investment associated with the implementation of a sensitisation campaign was estimated at 
€3.6 per euro invested. Main influencing parameters were the effect of the campaign on sunburn, the 
relative risk on skin cancer in case of sunbed use, the utility related to skin cancer, the incidence of skin 
cancer and the medical costs due treatment of advanced MSC. Higher values on these parameters 
resulted in higher cost-savings. 
 
Selective prevention interventions: population-based screening program for colorectal cancer, breast 
cancer and skin cancer 
The cost-effectiveness analysis of the breast cancer screening program in Flanders (with a biennial 
mammography for women aged 50-69y) predicted the screening to gain QALYs, by a reduction in breast 
cancer mortality of 14% and a reduction in the incidence of breast cancer stage IV by 14%, in reference 
to no screening program. The result of the budget impact analysis showed that the screening program 
led to a net cumulative cost of €492 million over 20 years. Despite the extra cost, the probabilistic ICER 
was €31,377/QALY gained (95%CI: €21,973 – €54,977/QALY gained), with an 83% probability of being 
below the threshold. 
The cost-effectiveness analysis of the colorectal cancer screening program in Flanders (with a biennial 
faecal immunological test for persons aged 56-74y) showed that, over a period of 20 years, the program 
was predicted to increase the total quality of life in the population aged 50+, due to a decrease in CRC 
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mortality by 21% and a reduction in the incidence of invasive CRC by about 24% (as all detected polyps 
are removed), compared to no screening program. The impact of the screening program on the health 
care budget, estimated at an extra €118 million over 20 years, was partly compensated for by the health 
benefits, resulting in an ICER way below the informal threshold of €35,000/QALY gained, namely 
€1,681/QALY gained (95%CI: €-1,317 – €6,601/QALY gained) in males and €4,484/QALY gained 
(95%CI: €-3,254 – €18,163/QALY gained) in females. The probability of the screening program being 
cost-effective was 100% and 97.3% in males and females respectively.  
A one-time total body examination (TBE) as well as a one-time lesion-directed screening (LDS) were 
both predicted to gain a small amount of QALYs in the total population on the long term, by means of a 
stage-shift from more advanced to less advanced lesions and a predicted relative mortality reduction of 
5% in case of TBE (i.e. 630 deaths less over 20 years). Due to the screening cost and the extra costs 
for treatment and follow-up, implementing the screening strategy would induce an extra €36 million in 
case of TBE or €6 million in case of LDS for the public health care payer, over a period of 20 years. 
Nevertheless, the balance between costs and health effects was shown to be below the threshold of 
€35,000/QALY gained, although in the case of males both screening strategies tended to this threshold 
limit (€31,360/QALY gained  (95%CI: €23,251 – €41,468/QALY gained) in TBE and €34,170/QALY 
gained  (95%CI: €25,586 – €44,831/QALY gained) in LDS). The probability of TBE and LDS being below 
the €35,000 threshold was 79.7% and 59.9% respectively in males and 100% in females. The cost-
effectiveness result was clearly better in females than in males because of the higher prevalence and 
incidence of skin cancer in females in Belgium. Similarly, the result was better in TBE than in LDS 
because of the lower participation rate in LDS. Since LDS was less time-consuming for the 
dermatologist, but produced the same yield as TBE, increasing the participation rate of LDS to the level 
of TBE would result in LDS being more cost-effective than TBE. Some scenarios from a practical 
viewpoint were tested, including repeated screening strategies, and showed a one-time screening from 
the age of 18 to be the most cost-effective strategy, although screening from the age of 40 did not 
drastically change the results. 
Some common main influencing parameters were identified in these four screening strategies, namely 
the natural progression of cancer, the test-characteristics of the screening test, the prevalence of 
undiagnosed lesions and the utility related to treatment and follow-up of early-stage tumours. The higher 
the value of these most influencing parameters found in all studies, the better the cost-effectiveness. 
One exception was the prevalence of undiagnosed basal cell skin cancer (BCC). If the prevalence of 
such lesions is higher, then screening would not be cost-effective anymore. Derived from this study, we 
assume that screening for BCC might not offer good value for money. Screening for BCC does not affect 
the quality of life, but it does safe some money as treating small BCC lesions is less expensive than 
treating bigger lesions. However, when there are many BCCs to treat, the costs for treatment and follow-
up seem to be too high, undermining the effect of early detection on the cost side. In our study the 
screening included all skin cancer lesions, but it might be that screening for melanoma only would be 
more cost-effective. However, from a practical viewpoint, screening only for melanoma lesions is an 
unrealistic scenario. Some specific influencing parameters per disease area were identified as well. The 
GENERAL DISCUSSION 
  
170 
 
adherence to colonoscopy after referral was an important influencing parameter in the study of colorectal 
cancer, absenteeism due to having a mammography in the study of breast cancer screening and the 
direct and indirect cost of MSC stages III and IV in the skin cancer screening study.  
 
Indicated prevention intervention: the suicide helpline 
The cost-effectiveness analysis of the suicide helpline in Flanders evaluated two services which both 
aim to reduce the acute suicidal state of the helpline user, namely the telephone service and the more 
recent chat service. Both services were predicted to reduce the number of suicides and first suicide 
attempts over a period of 10 years by 36% (33 suicides and 205 attempts). The impact on quality of life 
was small to absent, and was most noticeable in male users of the telephone service. However, all 
strategies resulted in cost-savings for the health care payer as well as for society. Differences in the 
model outcomes of the chat- versus telephone users were due to the profile of the users, as the 
effectiveness was assumed to be the same for both services. Suicide happens more in males than in 
females (23.5/100,000 versus 8.3/100,000 respectively), while the prevalence of suicide attempts is 
higher in females compared to males (182/100,000 versus 143/100,000 respectively). As preventing 
suicide gains more health benefit and saves more money (mainly due to productivity loss) than 
preventing an attempt, the suicide helpline is more cost-saving in males than in females. Similarly, the 
prevalence of suicide is higher in older than in younger persons. Older persons make more use of the 
telephone service than the chat service, which makes the telephone service more cost-saving than the 
chat service. These reasons also explain why the chat-service does not lead to a health gain in females. 
Different scenarios and variation in the value of the parameters showed no big difference in the cost-
savings. 
 
To summarise, Figure 7 gives an overview of where the interventions are situated in the cost-
effectiveness plane, based on the mean incremental costs and QALYs. Figure 7a shows that all 
interventions are situated in the east quadrants, showing an increase in QALYs, except for the chat 
service of the suicide helpline in female users. Some intervention strategies are situated in the south-
east quadrant of the cost-effectiveness plane, namely the suicide helpline strategies and the universal 
prevention strategies for prevention of skin cancer. These are the strategies that were estimated to lead 
to health effects and cost-savings and are therefore called dominant strategies. The majority of the 
interventions strategies however are situated in the north-east quadrant (Figure 7b, showing this 
quadrant enlarged), which means that these interventions induced not only a gain in QALYs, but also 
extra total costs. However, most interventions were found to have a good balance between the gained 
health effects and extra costs, leading to an ICER below the assumed willingness-to-pay threshold of 
€35,000/QALY gained. There was one exception, namely the ToyBox analysis in Belgian males (17% 
probability of being cost-effective at a threshold of €35,000/QALY gained) and females (43% probability 
of being cost-effective). This intervention was however shown to be cost-effective in Spain and Poland. 
Nevertheless, these results should be interpreted in light of their uncertainties, which are described in 
the next sections.  
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Figure 7a: Cost-effectiveness plane displaying the incremental cost-effectiveness ratios of all included 
interventions  
 
 
 
Figure 7b: Enlargement of one quadrant of the cost-effectiveness plane displaying the incremental cost-
effectiveness ratios of the included interventions  
 
F: females; M: males; BC: breast cancer; TBE: total-body skin cancer examination; LDS: lesion-directed skin cancer screening; CRC: colorectal cancer 
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3.2.2.  Main challenges  
While performing the evaluations included in this thesis, some main challenges have emerged. They 
will be discussed in this paragraph, classified according to the three main sources of uncertainty in cost-
effectiveness research as explained in the general introduction of this thesis, namely structural 
uncertainty, parameter uncertainty and methodological uncertainty. Some challenges in the use of cost-
effectiveness in policy decisions as addressed in the general introduction will be discussed shortly as 
well. In the following paragraphs the uncertainties we encountered in our studies are described as well 
as the ways we explored and reported these uncertainties in order to increase the model credibility 
(marked by paragraph indents).  
Structural uncertainty: indirect evidence  
All cost-effectiveness studies included in this thesis provided predictions on the long term cost and 
quality of life based on indirect evidence. Public health interventions often take a long time to 
demonstrate effect (Drummond, 2007; Kelly, McDaid, Ludbrook, & Powell, 2005; Marsh, Phillips, 
Fordham, Bertranou, & Hale, 2012; Weatherly et al., 2009). Therefore, studies assessing the 
intervention effectiveness usually focus on intermediate outcomes which can be observed in shorter 
time periods (e.g. lower blood pressure, higher consumption of fruits and vegetables, number of cancers 
detected, prevalence of depressive symptoms...). This brings about two challenges, namely that long 
term predictions need to be made based on indirect (short term) evidence and that the long term 
predictions cannot yet be tested based on real-life data. Intermediate outcomes have to be extrapolated 
to long term final endpoints relevant to health economic evaluations, using a modelling approach. For 
example in the case of the ToyBox-intervention (Chapter 2.1.1.- 2.1.2.), up to now there are no long 
term studies showing the impact of a school-based intervention focusing on health behaviours on the 
onset of chronic diseases in adulthood. In case of cancer screening (Chapter 2.2.), up to now few real-
life evidence is available on the impact of screening on mortality and cancer incidence. Some studies 
have been performed, especially concerning breast cancer, but these show inconclusive evidence, 
aiming for further research. As it takes a long time before any health effects emerge, such long term 
studies are difficult to perform, time-consuming, costly and therefore almost impossible. As such, the 
effect of a public health intervention is commonly indirectly projected to the long term final endpoints by 
means of a chain of evidence structure (Ades, 2003; Claxton, Sculpher, & Culyer, 2007). Linking 
intermediate to long term health outcomes may be a more frequent research issue in appraising public 
health interventions than in conventional economic analyses of health care interventions (Claxton et al., 
2007). In the evaluation of the ToyBox-intervention (Chapter 2.1.1.- 2.1.2), an extrapolation was made 
from childhood health behaviour to the weight status two years later, subsequently from childhood 
weight status to adult weight status based on tracking studies and finally from adult weight status to 
chronic disease endpoints. Also the evaluation of the prevention of skin cancer by means of a 
sensitisation campaign (Chapter 2.1.3.), made use of an intermediate endpoint. The prevention 
campaign was modelled to have an impact on skin cancer incidence through the effect on sunburn. The 
long term health effect of the screening programs evaluated in this thesis (Chapter 2.2.) was modelled 
through early detection of lesions leading to a stage shift in the cancer epidemiology from more severe 
lesions to less severe lesions. Because of this stage shift, a mortality reduction and increase in quality 
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of life is expected. The cost-effectiveness study of the suicide helpline in Flanders modelled the effect 
on attempts and suicide, through the effect on the prevalence of severe suicidal thoughts (Chapter 
2.3.1.). Hence, all studies included a causal chain of evidence, the one being longer and more complex 
than the other, to establish how a public health intervention causes an outcome and to predict the 
population health outcome resulting from an intervention (McDaid et al., 2008; Threlfall et al., 2015). 
Despite their usefulness in modelling studies, such causal chains create uncertainty. The length of this 
causal chain between interventions and outcomes was described as one of the key challenges for 
economic evaluations of public health interventions (Kelly et al., 2005; Kelly et al., 2010; McDaid, Sassi, 
& Merkur, 2015). Providing indirect evidence on the long term is based on modelling assumptions which 
can influence the cost-effectiveness result and thus lead to different policy decisions (Drummond & 
Sculpher, 2005). The more indirect relations included in the model, the longer the causal chain and the 
more uncertainty incorporated in the model.  
All models used for the evaluation included in this thesis have been constructed with or revised by 
clinical experts in the field to assure the model includes all aspects of reality considered important 
by experts. The model should represent reality as simply as possible, while capturing underlying 
essentials of the disease process and interventions (Eddy et al., 2012). This process increased the 
face validity of our models, including the causal chain.   
In order to validate the causal chain internally, we verified individual equations to make sure that all 
the calculations included in the causal chain were performed correctly. An example of such 
verification is extreme value analysis, such as erasing the intervention effect, assuming all utilities 
to be the same, using sensitivity analysis to detect illogical changes in the result when varying input 
parameter values, etc.   
Furthermore, uncertainty in the main building blocks of the causal chain, namely the linking 
parameters, was tested by one-way sensitivity analysis. In the ToyBox-analysis (Chapter 2.1.2), it 
was shown that the link between the weight status of the pre-schoolers and the mid-term weight 
status based on the health behaviour was one of the most important influencing parameters. Also 
the tracking parameters and the relative risk of obesity on the incidence of obesity-related diseases 
had a main influence on the results. Stronger causality would have led to better cost-effectiveness 
results. In the case of the skin cancer sensitisation campaign (Chapter 2.1.3.), it was shown that the 
influence of the campaign on the prevalence of sunburn had an impact on the result, but it did not 
change the conclusion. The result remained cost-saving and was robust for change in this 
parameter. Finally, we want to mention that already validated models may exist to investigate a 
particular research question. For example, in the case of cancer screening some models have been 
built and thoroughly validated, such as the models from the seven research groups in the Cancer 
Intervention and Surveillance Modelling Network (CISNET) to evaluate cancer control interventions. 
One of these models is the Microsimulation Screening Analysis (MISCAN) model from Erasmus 
University Medical Center (The Netherlands) (Habbema, van Oortmarssen, Lubbe, & van der Maas, 
1985; Loeve, Boer, van Oortmarssen, van, & Habbema, 1999). However, to use the models built by 
these research groups is expensive and it is not clear to what extent all complex mathematic 
calculations are transparently described for every researcher to be used.  
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Parameter uncertainty: data input  
A second and related important challenge that we faced in our studies was parameter uncertainty. 
Parameter uncertainty generally arises in two ways. Firstly, there is uncertainty due to sample variation 
around the parameter estimates and secondly, there is uncertainty on which input values to include, and 
where to find the information on the parameter estimates. It is this second type of parameter uncertainty 
that is addressed in this paragraph. In all studies we faced a lack of detailed data. The type of missing 
data depended on the different types of studies. For example, in Chapter 2.1.2, the cost-effectiveness 
of the ToyBox-intervention was evaluated in six participating countries. As such, this analysis required 
international data. Data concerning the costs and quality of life related to an obesity-related disease and 
the incidence of such diseases was not always available and had to be imputed. In Chapter 2.1.3., the 
aim was to evaluate the cost-effectiveness of a hypothetical comprehensive skin cancer sensitisation 
campaign in Belgium. Although small and fragmented campaigns have been implemented in Belgium, 
no effectiveness data is available. Alternatively, we had to rely on published effectiveness data in other 
countries. Unit costs and health effects of skin cancer in Belgium have recently been investigated 
(Tromme, 2015; Tromme et al., 2014). However, these data only included melanoma and as new 
expensive treatment options have emerged in the last years, we apprehended these data to be outdated. 
Therefore, patient questionnaires were composed in order to assess health care consumption, drug use, 
quality of life and impact on the job situation of patients with BCC, SCC of MSC. These questionnaires 
were completed by 287 Belgian skin cancer patients. However, this is a time-consuming exercise (and 
even then not including a sufficient number of patients) which was not always possible to perform in the 
other evaluations included in this thesis. For example, in the case of the suicide helpline analysis 
(Chapter 2.3.1.), we had to rely on published data from the U.S. for the medical cost due to suicide. The 
cancer screening studies (Chapter 2.2) faced some similar caveats in the data inputs. Firstly, there was 
a lack of data mainly concerning the natural progression of the tumours. Secondly, the epidemiology of 
adenomas (in the colorectal cancer screening model) and non-melanoma skin cancer in 
Belgium/Flanders is currently unknown. However, as there are plans to start a colonoscopy register in 
Flanders, there should be more information on the epidemiology of adenomas in the future. Currently, 
these data were based on a German adenoma study (Brenner, Altenhofen, Stock, & Hoffmeister, 2013; 
Brenner et al., 2014). Non-melanoma skin cancer rates were derived from the Dutch cancer registry 
(Integraal Kankercentrum Nederland, 2011), as, in contrast to Belgium, in the Netherlands these 
tumours are systematically registered. However, these data only included the first lesion, which could 
have affected our results. 
Consulting (clinical) health experts was not only relevant to validate the structure of the model but 
also to discuss the best available data sources. Uncertainty in data input was mainly tested by one-
way as well as probabilistic sensitivity analysis. The one-way sensitivity analysis revealed the 
impact of the uncertainty in the particular parameters by varying the value of these parameters. 
The probabilistic sensitivity analysis showed uncertainty in the parameters by creating credibility 
intervals around the mean ICER estimate.  
In the breast cancer screening model (Chapter 2.2.1.), the natural progression was calculated by 
means of a Poisson regression analysis, based on estimates from Tan et al. (2013). In the 
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colorectal screening model (Chapter 2.2.2.), the natural progression rates were derived from the 
study of Hur et al. (2007) who calculated these rates based on calibration with the observed stage 
distribution. Also in our model, the estimated stage distribution approximated the observed stage 
distribution, so the progression rates as estimated by Hur et al. were adopted in our model. Natural 
progression rates for skin cancer (Chapter 2.2.3.) were calibrated based on the estimated skin 
cancer deaths in Belgium.  
Additionally, some validation checks applied to structure uncertainty as well as parameter 
uncertainty: (1) the outcomes predicted by the comparator arm in our models (which usually 
represents the current standard) were compared with observed outcomes (outcome validation). In 
the cancer screening program analyses the model outcomes were tested according to the observed 
prevalence and cancer deaths (Chapter 2.2). Comparison of expected cancer deaths according to 
the model with those observed was only possible in the skin cancer analysis as in the model of 
colorectal cancer and breast cancer, there were only undiagnosed lesions at the start of the model. 
In the evaluation of the ToyBox-intervention (Chapter 2.1.2.), the prevalence of obesity-related 
diseases as predicted by the model based on disease incidence and the transition probabilities was 
compared to the observed prevalence. Although some slight differences were shown, the predicted 
outcomes approximated the observed outcomes. In the case of the suicide helpline, outcome 
validation was more difficult as the target population only consisted of a high-risk group, which 
could not be compared to the total population (Chapter 2.3.1). As such, prevalence of suicide or 
suicide attempt could not be compared to the national or regional prevalence. (2) When possible, 
the predicted outcomes by the intervention arm were compared with the outcomes observed in 
real-life, in order to test whether the model makes accurate predictions of future events (predictive 
validation). For example, in case of the screening analyses (Chapter 2.2), the positivity rate 
predicted by the model was compared to the one observed. However, as stated before real-life 
data may not always be available at the moment of the analysis, which makes predictive validation 
difficult. Moreover, as already stated before, long term longitudinal studies are almost impossible 
to undertake because of the long term that needs to be bridged, which makes it costly, time- and 
energy consuming and difficult to control for other factors that can affect the outcome (Edwards, 
Charles, & Lloyd-Williams, 2013; Fischer et al., 2013; Kelly et al., 2005; Kelly et al., 2010; Marsh et 
al., 2012; Threlfall et al., 2015; Weatherly et al., 2009). (3) Also, all outcomes of the original 
research studies included in this thesis have been compared to other published research studies 
addressing a similar research question (cross validation). Nevertheless, comparison may be 
impeded by transferability issues: a great deal of our model inputs are country-specific (such as 
participation rate in screening), limiting the ability of direct comparison with other studies (see 
paragraph 3.2.3.).  
Furthermore, we want to stress the importance of good quality databases. In 2006, the Belgian Health 
care Knowledge Centre issued a report with an inventory of available databases in health care (Federaal 
Kenniscentrum voor de gezondheidszorg, 2006). The conclusion was that Belgium has many registries 
and databases, collecting detailed data. However, some substantial gaps were identified. Content-wise, 
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the lack of data on outpatient treatment, about technology used in health care and non-reimbursed 
health care consumption were addressed. Concerning the practical organisation, the fragmentation of 
the databases was denounced, as well as the accessibility of the databases to secondary users, which 
is hampered by legal conditions and procedures such as privacy laws. Anno 2016 these gaps are still 
present. There is need for centralisation of clinical patient data and for linking databases in order to 
create integrated databases (Camberlin et al., 2013). Such databases could contain not only clinical 
data such as the diagnosis, but also resource use, costs and demographic information. Although there 
are some initiatives to integrate data, such as linking data from the Intermutualistic Agency15 and the 
Belgian Cancer Registry (Camberlin et al., 2013; Maetens et al., 2016), more initiative on the linking of 
databases could be useful for scientific research. The Belgian government recognises these needs. In 
the coalition agreement of the federal government (2014) the development of an efficient data system 
is recognised as an objective. The goal is "developing a centralised health information system that fills 
the gaps in the knowledge landscape and coordinates the registration and management of data, ....". 
An e-Health action plan 2013-2018 was agreed upon, which involves a cooperation agreement between 
the federal government and the regions. This includes among other things the development of 
streamlined data registration and exchange between states, but also the (re)-evaluation of existing 
financial incentives for data-processing of health care providers. An additional important plan is to work 
on a legal basis for obtaining anonimised aggregated data for public and private research purposes.  
Methodological uncertainty: Choice of methods  
Methodological uncertainty relates to the methodological choices that need to be made. The 
methodological choices we encountered were mainly associated with technical aspects of an analysis, 
such as what health effects to include, what perspective to take, how long the time horizon should be 
and the duration of the intervention effect. Equity issues are also described in this section.  
A. Health effects  
The most challenging question on what effects to include in our analyses was not about the health 
effects but rather about the harms that could emerge by the intervention. Public health interventions aim 
to deliver an overall population health gain. Thereby, it seems to be accepted that some individuals will 
not benefit, or may even experience a degree of harm. However, lately there has been a lot of debate 
concerning the negative aspects of population-based screening. As stated in the review of Koleva-
Kovarova et al. (2015), most screening models only include health benefits. To address this issue, we 
tried to incorporate some disadvantages of screening in our analysis (Chapter 2.2). As such, we included 
the possible impact of a false-positive screening result on quality of life in terms of psychological harms 
in the screening models (Cullen et al., 2004). Anxiety that could possibly be induced by the screening 
invitation was not included, as this has not yet been explored in currently published research. The risk 
of overtreatment (and associated costs and health effects) was implicitly included in the model, as it was 
assumed that all detected lesions were treated. Risk of radiation-induced breast cancers due to the 
                                                          
15 The Intermutualistic Agency is an instance collecting and analysing administrative data from the seven Belgian 
health insurers. This agency does not dispose of medical patient data.  
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mammographic screening program was not included in the model, since other studies have shown this 
risk to be very small (Hauge et al., 2014; Yaffe & Mainprize, 2011). The risk of bowel perforation or 
bleeding as a consequence of a colonoscopy, is implied in the cost estimates (derived from Pacolet et 
al. (2011)). Capacity constraints, impeding tests or examinations to be performed immediately after one 
another, were included as the period patients are assumed to experience a disutility due to a false 
positive result. It should be noted that there was a problem of waiting times in the first year after 
enrolment of the colorectal cancer screening program (Vlaams Agentschap Zorg & Gezondheid, 2014), 
but now these waiting times should have declined to a minimum. Including negative aspects is especially 
important when assessing wide-range interventions (such as universal or selective prevention 
interventions), as these interventions reach a lot of persons and can therefore induce potentially large 
harms. 
By means of a scenario-analysis the effect of using different values for the disutility due to a false-
positive screening result was tested. For example in the analysis for breast cancer screening, it was 
shown that the worst case scenario for the utility associated with a false positive result, i.e. equal 
value to the utility associated with a detected stage I breast cancer lesion, would have a high impact 
on the cost-effectiveness result. The ICER would deteriorate from about €28,000/QALY to 
€86,000/QALY, which shows the importance of including this potential harm and the need for more 
research on this topic. When varying the utility associated with a false-positive result in the study of 
colorectal cancer screening, to the utility of detected CRC stage I, no gain in QALYs in females was 
realised anymore. From our research, we conclude that more research should be performed on these 
negative aspects of screening in order for researchers to include them in the cost-effectiveness 
analysis, as it has been shown that these disadvantages can have a great impact on the cost-
effectiveness result.  
Another possible harm of prevention interventions is stigma. Health professionals try to achieve that 
health risks and unhealthy behaviour is perceived as negative, as undesirable (Raad voor 
Volksgezondheid en Samenleving, 2016) Therefore, it is possible that targeting people with for example 
obesity, or a mental disorder stigmatises these groups, making them feel inferior and helpless (MacLean 
et al., 2009). Also, interventions specifically targeting low-income families could be perceived as 
stigmatising and humiliating. Focusing on promoting health behaviour, instead of a negative focus on 
unhealthy behaviour could counteract stigma. Stigma is especially a risk of selective and indicated 
prevention strategies, as such interventions target high-risk groups. Stigma could lead to lower 
participation rates, decreasing the effectiveness of the intervention or even lead to opposite effects of 
the intervention. Therefore, public health interventions, as well as the cost-effectiveness analysis, should 
take this possible harm of stigma into account. In our analyses, we did not take into account the potential 
harm of stigma due to the intervention, as no information on this topic was available. In case of the 
ToyBox-study (Chapter 2.1.2.), the risk of stigma could be interpreted as rather small as the positive 
behaviour was reinforced. However, the content of the sensitising skin cancer prevention campaign 
(Chapter 2.1.3.) should be screened for stigmatising messages. In case of the cancer screening 
programs (Chapter 2.2.), stigma in the high-risk groups receiving an invitation could lead to a lower 
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participation rate. However, currently there is no information on this topic. In case of the suicide helpline, 
stigma might have led to the fact that persons feeling stigmatised do not make use of the helpline, 
although the presence of such a helpline should not be stigmatising itself as it is anonymous.  Hence, 
more research is necessary on the stigmatising level of public health interventions, how to measure it, 
and how to take this into account in the cost-effectiveness analysis.  
In addition, it needs to be mentioned that the QALY-outcome does not measure all potential health 
effects. What about shame (eg. in skin diseases), dignity (eg. Incontinence), sleep deprivation,…?. 
Another limitation of the QALY-outcome is that it does not capture the costs and benefits of a public 
health intervention that go beyond the health sector  (Drummond, 2007; Edwards et al., 2013; Squires, 
Chilcott, Akehurst, Burr, & Kelly, 2016; Weatherly et al., 2009). For example, providing a healthy 
breakfast at school free of charge may not only lead to an improvement in health but may generate 
additional effects on social and educational development, which are generally not captured by the 
QALY-concept.  Alternative approaches are available (such as cost-consequence analysis, in which all 
outcome dimensions are prioritised and weighed, or the capability approach16), but all have limitations 
and are not yet used frequently in health economic analyses.   
B. Costs   
What costs to include in the cost-effectiveness analysis is dependent on the perspective the analysis 
assumes. A health care payer perspective only takes into account the costs to be paid by the public 
health care payer whether or not supplemented with the costs for the patient. A societal perspective 
takes into account other costs outside the health care sector, mainly the costs due to productivity loss. 
Furthermore, there a two methods to value productivity loss, namely the friction cost method and the 
human capital method. Both have advantages as well as shortcomings, but we used the friction cost 
method as this is the most conservative one. The friction cost method assumes that a long term absent 
employee will be replaced (Koopmanschap & van Ineveld, 1992). Therefore, in case of long term 
absenteeism or in case of death, productivity loss should only be accounted for during the period it takes 
to replace an employee (assumed to be 160 days (Hakkaart-van Roijen, 2010), instead of during the 
total period until the person retires or would have been retired (i.e. human capital method).  
By means of several scenario-analyses the effect of using a health care payer perspective or a 
societal perspective was explored, as well as the effect of assuming the friction cost method or the 
human capital method. From the scenario analyses, we derived that the incremental cost-
effectiveness ratio is usually better if a societal perspective is assumed (see Chapter 2.2 and Chapter 
2.3.1.). However in case of the cancer screenings, if productivity loss would be applied to undergo 
the screening test, then the result would be worse from a societal perspective. In our cost-
effectiveness analyses a societal perspective was assumed as this perspective provides a more 
complete picture. The budget impact analyses however, were performed from the public health care 
payer perspective in order to estimate the impact on the health care budget. In the analysis of the 
suicide helpline (Chapter 2.3.1) the result was tested based on both productivity loss valuation 
                                                          
16 For more information, see Mauskopf et al. (1998) and Coast et al. (2008) 
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methods. The analysis showed that in the case of the human capital method, the net costs would 
have been twice as low in males, due to the savings in productivity loss and about one third lower in 
females. Additionally an extra analysis was performed to evaluate the impact on the result in case 
the period of absenteeism would be shorter than assumed in the analysis, namely 76 days 
(Bouwmans, Vemer, Van Straten, Tan, & Hakkaart-van, 2014) due to an attempt, instead of 162 days 
and 160 days due to suicide (i.e. average friction period (Hakkaart-van Roijen, 2010)) instead of 226 
days. Table 5 shows that this adaptation would lead to lower costs due to productivity loss which 
would results in the net costs per person being halved in reference to the base case. However, the 
conclusions would not change.  
Table 5: Impact on the ICER of the suicide helpline, assuming shorter periods of absenteeism 
  Results in users of the telephone service  Results in users of the chat service  
 males females males females 
  net QALYS 
net 
costs 
net 
QALYS 
net 
costs 
net 
QALYS 
net 
costs 
net 
QALYS 
net 
costs 
Base case  0.064 € -2,366 0.019 € -2,171 0.046 € -2,272 -0.007 € -2,457 
Change in 
prod.loss  
0.064 € -1,239 0.019 € -1,092 0.046 € -1,205 -0.007 € -1,243 
 
C. Time horizon  
The question of how long to run the model simulation is important for several reasons. In public health 
interventions, effects usually only appear on the long term. According to the Belgian guidelines, “the 
time horizon of the model should be long enough to capture all relevant possible effects on the 
outcomes” (Cleemput et al., 2012). In this sense, a life-time horizon seems the best option in case of 
public health interventions. However, a long time horizon inevitably comes at the costs of increasingly 
uncertain estimates (O'Mahony et al., 2015), as the impact of future trends in epidemiology of diseases 
and innovation in medical technologies cannot be predicted. Additionally, the longer the time horizon, 
the greater the effect of discounting on the cost and health outcome, what could underrate the impact 
of the intervention. On the other hand a long time horizon could lead to an overestimation of the benefits 
of the intervention.  
In the analysis of the ToyBox-intervention (Chapter 2.1.2.) as well as in the analysis of a sensitisation 
campaign and ban on sunbed use (Chapter 2.1.3.) a long time-horizon was included, because an 
induction period17 needed to be taken into account. We assumed the induction period for skin cancer 
to be 20 years, which means that the impact of prevention on the incidence of undiagnosed skin 
cancer was only implemented from year 20 on. In the Toybox-study, the intervention effect was 
extrapolated to the adult age, in that the incidence of chronic diseases was affected by the preschool 
health behaviour. Consequently, an induction period was implicitly included in the model. Because 
of these time lags between the implementation of the intervention and expected health effects, the 
time horizon needed to be long enough to capture those effects. In case of screening, the effect 
should be notable earlier, therefore the effects were modelled over a time period of 20 years. 
                                                          
17 The induction period is defined as the period between causal action and disease initiation (Rothman, 1981) 
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However, in a scenario-analyses this time horizon was extended to 50 years in order to explore the 
effect on the cost-effectiveness result. This analysis showed that assuming a longer time horizon 
resulted in a better incremental cost-effectiveness ratio. In the study of the suicide helpline (Chapter 
2.3.1) the budget impact was estimated over a period of 10 years, which showed a cost-saving 
effect. When calculating the return on investment the intervention cost was only included once. 
However, when we assume this intervention cost to be applied for each cohort in the budget impact 
analysis, while the benefits in 10 consecutive cohorts are captured, the return on investment would 
have been lower than described in the study, namely €2.4 instead of €6.7 per invested euro. 
D. Duration of intervention-effect  
Another time-related issue is the duration of the intervention effect. In the case of the ToyBox-study 
(Chapter 2.1.2.), as well as the analysis of the suicide helpline (Chapter 2.3.1), no evidence on the 
duration of the effect was available.  
Based on a waning effect found in other early childhood obesity prevention interventions, we 
assumed the ToyBox-study to be repeated annually in order to sustain the intervention effect. 
However, in a scenario-analysis, the ICER was explored in case the intervention effect would sustain 
for two years, meaning that the intervention would only need to be re-implemented every two years. 
As expected, this had a positive result on the ICER. In the case of the suicide helpline, the 
intervention effect was also assumed to decrease in time and after five years no continuing effect 
was included anymore. However, we wanted to explore the impact on the ICER if the helpline would 
only have a short-term impact. Therefore, an extra scenario was evaluated with an effect during one 
year instead of five years. The results below in Table 6 show that the gain in QALYs and the cost-
savings would be lower. However, the main conclusion would not have changed.     
 
Table 6: Impact on the ICER of the suicide helpline, assuming an effect during 1 year 
  
Results in users of the telephone 
service  
Results in users of the chat service  
 males females males females 
  
net 
QALYS 
net 
costs 
net 
QALYS 
net 
costs 
net 
QALYS 
net 
costs 
net 
QALYS 
net 
costs 
Base case  0.064 € -2,366 0.019 € -2,171 0.046 € -2,272 -0.007 € -2,457 
Effect helpline 1y  0.019 € -1,162 0.006 € -1,148 0.025 € -1,066 -0.003 € -1,255 
 
E. Equity  
Although tackling inequalities in health is an important goal in many public health interventions, 
economic evaluations focus mainly on the efficiency of interventions, while equity considerations are 
rather ignored (Cookson, Drummond, & Weatherly, 2009; Drummond, 2007; Sassi, Archard, & Le, 2001; 
Weatherly et al., 2009). For example, one feature of a cost-effectiveness analysis is that a QALY has 
equal weight, regardless of the recipient. Also in our studies included in this PhD-thesis, no equity 
considerations were included. Total health benefit from an intervention was calculated as the sum of all 
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QALYs without equity weighting or separation between subgroups based on socio-economic status 
(SES). 
Cookson et al. (2009) proposed some approaches to take into account equity considerations in a health 
economic evaluation: a review of background information on equity supplementing the cost-
effectiveness analysis, a health inequality impact assessment generating quantitative evidence about 
the impact of the intervention health inequality (e.g. the variation between sub-groups based on socio-
economic status, age, gender), an analysis of the opportunity cost of equity to estimate the health 
sacrifice related to the equity consideration (e.g. QALYs forgone by pursuing the equitable option 
compared with the QALY maximizing option), and equity weighting of health outcomes, i.e. setting 
quantitative weights on health gains accruing to different people in different circumstances in order to 
adjust the health outcome for equity considerations. However, these methods seem not to be frequently 
integrated in cost-effectiveness analysis (Johri & Norheim, 2012).  
There is an example of equity weighting of health outcomes for certain clinical treatments in the UK 
decision process. Since 2009, the National Institute for Health and Clinical Excellence (NICE) has 
introduced a rule in their advice to the National Health System (NHS) in order to introduce more flexibility 
in the decision and to promote access to end-of-life treatments. The advice implies that some treatments 
may exceed the cost-effectiveness threshold of £30,000 per QALY gained, on the condition that the 
treatment is intended for patients with a short life-expectancy (less than 24 months), extends the life-
expectancy with at least three months in comparison with the current NHS treatment, and applies only 
to a small patient population. When these conditions are met, the commission considers the effect of 
giving more weight to QALYs gained in the later stages of terminal illness, assuming that the extention 
of life is experienced at the same quality of life as a healthy person of the same age, and the size of the 
extra weight that should be given for the cost-effectiveness of the treatment to fall below the threshold. 
 
Use of cost-effectiveness in policy decisions 
As stated in the general introduction of this PhD-thesis, it is not clear to what extent cost-effectiveness 
is used as a criterion in decisions on public health prevention interventions, although it seems to be used 
in a limited way. Main pullbacks were the availability of relevant research in a timely manner and the 
extent to which cost-effectiveness evidence can be understood by policy makers, and the quality and 
transparency of the evidence (Eddama & Coast, 2008). How to explore and improve the quality and 
transparency of the evidence has been discussed in the previous sections. The extent to which the cost-
effectiveness evidence can be understood by policy makers, is related to this quality and transparency 
issue. Policy makers often struggle to understand health economic analyses, mainly because of the 
language, concepts and calculations used in such analyses. 
 
Collaboration with policy makers provided added value in performing the study on breast- and 
colorectal cancer screening (Chapter 2.2.1 and 2.2.2). From this collaboration with policy makers, 
we learned that there should be better access to health economic evaluations, but providing evidence 
alone is not sufficient. We not only made our breast- and colorectal cancer model available for the 
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engaged policy makers, but also involved these persons in every step of the model composition, 
such as the input data and model assumptions. In this way, they fully understood the assumptions 
and calculations made and they can make adaptations in case newer data becomes available. This 
collaboration also rendered more insight in what is important for policy makers, e.g. on what 
parameters and outcomes they focus, and what parts of the analysis are the most difficult to 
understand or to interpret.  
As also stated in the general introduction, the availability of relevant research in a timely manner can be 
improved by evaluating the transferability of study results from one country to another.  
Despite the lack of data we encountered (see paragraph 3.2.2.), the models in our analyses used 
local data as much as possible. The study on the cost-effectiveness of a total ban on sunbed use, 
included the Belgian prevalence of sunbed use in 2013 (Ipsos Public Affairs, 2013). Costs and quality 
of life data were obtained by questionnaires from 287 Belgian skin cancer patients. Screening 
parameters in the study of skin cancer screening were derived from a trial implemented in two Belgian 
cities. The evaluation of breast- and colorectal cancer screening adopted the design of the screening 
program in the model. Frequency of screening, as well as the specific screening test (such as the 
OC sensor FIT test with a cut off value of 75ng/ml) and age range of the target population can vary 
between countries. In case of the suicide helpline, the prevalence of suicidal thoughts was obtained 
from the data registered by the ‘Centrum ter Preventie van Zelfdoding’. Nevertheless, it is entirely 
acceptable that cost-effectiveness findings vary by setting as background parameters, such as levels 
of clinical experience, disease severity and prices, may differ. However, if researchers or policy 
makers want to transfer our study results to their country, they need to explore to what extent our 
results are transferable to their current situation.  
Not only the transferability of our studies should be questioned, but also of the studies that were used 
to provide input for our model in case Belgian data was not available. For example, in case of suicide 
helpline evaluation, important input data from other countries –such as the effectiveness of the 
helpline and the cost related to suicide- had to be imported as Belgian data was not available. 
However, the U.S. effectiveness study which provided input for our model concerned a helpline with 
a very similar organisation and similar target population in terms of prevalence of suicidal thoughts, 
which increased the transferability of those results to our study. Moreover, suppose the relative risk 
reduction in suicidal thoughts would not 41% but only 20%, the Flemish suicide helpline would still 
be dominant (althought the cost-savings would be halved). If the effectiveness would be higher than 
41%, the cost-savings would logically be higher. In this respect, adopting the effectiveness of the 
suicide line from the U.S. study has no major impact regarding the conclusion of our study, i.e. that 
the Flemish suicide helpline is a dominant intervention. Moreover, it is expected that the effect of the 
U.S. helpline is underestimated because the persons with the strongest suicidal thoughts were not 
included in the study because during such a call no attention was given to the risk assessment. 
Additionally, the effectiveness of a public awareness campaign for the prevention of skin cancer was 
based on the effectiveness of the Australian SunSmart campaign. Although the epidemiology of skin 
cancer in Australia differs from Belgium and their skin cancer prevention already has a long history, 
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we adopted this effectiveness measure in relative terms (relative risk) and from the first years it was 
implemented. A German study evaluating the effectiveness of skin cancer information campaigns 
during the last 16 years found a relative risk reduction of 32%, which is lower than the 41% found by 
the SunSmart campaign. This uncertainty was included in the sensitivity analyses and it was shown 
that the effectiveness of the campaign was one of the main influencing parameters. However, even 
in case of a lower effectiveness, the intervention was shown to be still cost-saving. 
 
3.3. Interpretation of study results in light of uncertainty 
 
Cost-effectiveness analyses contain inherent uncertainties, which are normal and not completely 
avoidable. It is always the aim to reduce the degree of uncertainty and especially to explore and describe 
the uncertainty in the ways mentioned before. As researchers, we perform the cost-effectiveness 
assessment and give advice, but the final decision is to be made by the policy makers. As such, it is up 
to the policy makers to decide –based on the cost-effectiveness result but also on other criteria, see 
general introduction- whether the particular prevention intervention should be implemented (and 
reimbursed) or not. That is why researchers need to report in a transparent way, describing the 
uncertainties in the model and the impact of uncertainty on the result. In this section, we interpret the 
study results described in 3.2.1., in light of the uncertainties described in 3.2.2.. Which study results do 
show strong evidence and which results should be interpreted with more caution?   
As was shown, the analysis of the ToyBox-intervention includes quite a large level of uncertainty. The 
main uncertainties were related to the extrapolation of the effects from childhood to adulthood, and the 
duration of the intervention effect. This study should therefore be interpreted as a push for more research 
concerning these uncertainties and an introduction to similar cost-effectiveness research in pre-schooler 
obesity prevention interventions.   
The study of universal prevention of skin cancer comprised two parts, first an estimate of the number of 
skin cancers in 2014 and 20 years later, along with the cost of cancer in Belgium in 2014 and 20 years 
later, and secondly the cost-effectiveness analysis of two universal prevention strategies. The 
information on the prevalence and costs were based on the skin cancer epidemiology in Belgium and 
the Netherlands and the annual trend in incidence shown in published literature. Information on the 
health care consumption of skin cancer patients was obtained from a Belgian patient population through 
own data collection. The results of the first part contain useful information on the trend in skin cancer 
and the increase in the number of skin cancers and as such the associated cost, showing the need for 
skin cancer prevention. With the information from the second part of the study, we have to be more 
careful since it concerns two hypothetical prevention strategies in Belgium. With this analysis, we 
particularly wanted to demonstrate the cost-effectiveness potential of these universal cancer prevention 
strategies in terms of health and financial terms. As these are hypothetical interventions, it is advisable 
to first conduct further research on what the effectiveness of such measures is or may be in a Belgian 
context. Especially the sensitivity analysis in this study was highly informative as it showed that the 
incidence of melanoma plays a role in the cost effectiveness of such strategies. The higher the 
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incidence, the more cost-effective prevention is. If we expect an increase in the number of skin cancers 
(based on an estimates from the first part of the study), we can assume that prevention will become 
even more beneficial. Also, the higher the cost of treatment for melanoma, the more cost-effective 
prevention becomes. The latter is particularly useful in light of the new, more expensive treatments that 
recently entered the market.   
The next two studies include the cost-effectiveness analysis of the population-based screening 
programs for breast cancer and colon cancer in Flanders. As these screening programs are already 
implemented, the screening-related data could be used in the analysis. Based on the results of these 
two studies and similar studies in literature, we concluded that the current screening programs are cost-
effective and should be continued. However, further research is needed on the long-term impact of 
screening on mortality and the incidence of new tumours (in the further stages), in order to verify whether 
the model predictions are correct.  
A one-time skin cancer screening was shown to be a cost-effective strategy, especially in women; a 
total body examination showed a slightly better result on cost-effectivenss than the lesion-directed 
screening (which was only due to the participation rate). However, more information on the natural 
progression of skin cancer as well as a systematic registration of NMSC lesions in Belgium would 
improve the cost-effectiveness research. By means of this study we were able to make 
recommendations for skin cancer prevention in the future, though more research on skin cancer 
screening to confirm our results (and the most efficient target group and screening interval) is desirable. 
Concerning all three cancer screening interventions, it should be stated that further research should also 
inform on the possible negative effects of screening, for example, the emotional distress of a false 
positive result and lost work time due to the screening. Currently only few articles report very general 
on emotional distress because of screening. More knowledge on this topic is important as negative 
effects of the screening could worsen its cost-effectiveness. The largest uncertainty in the study of the 
suicide helpline was the lack of information on the effectiveness of the suicide helpline in Flanders and 
the lack of information about the cost of a (fatal) suicide attempt. On the other hand, based on the results 
of the sensitivity analysis, we can say that the Flemish suicide helpline is a cost-effective, and even 
dominant strategy. However, if we want more clarity on the magnitude of the cost savings, it is necessary 
first to have more information on the effectiveness of the Flemish suicide helpline and the cost of a (fatal) 
suicide attempt in Flanders/Belgium. 
 
3.4. Recommendations for future practice 
 
In this PhD thesis, we tried to stress the promise and relevance of health economic evaluations of 
prevention interventions in public health for managing and controlling the health care budget. A variety 
of interventions in the continuum of chronic disease prevention have been evaluated during this 
research. All but one intervention showed cost-effective results, and some were even dominant. This 
shows that (1) public health prevention interventions can have a positive influence, not only on 
population health but also on the health care budget and (2) that even those interventions that lead to a 
total extra cost for the health care payer, can still be cost-effective and should be considered in policy 
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decisions. The included cost-effectiveness studies shared some main challenges, some being specific 
to the field of public health prevention interventions, such as providing indirect evidence, the choice of 
time horizon, duration of the intervention-effect, and some being related to cost-effectiveness analysis 
in general, such as the lack of data, choice and valuation of costs to include, harms of the intervention, 
etcetera. By our research we informed reseachers, health professionals and policy makers on the 
uncertainties related with these challenges, by exploring the impact they can have on the cost-
effectiveness result. In this way, we stressed the importance of sensitivity analyses and validation 
efforts, as well as the importance of transparency. Based on the findings in this PhD-thesis, we formulate 
some recommendations for researchers and health professionals as well as policymakers. 
 
3.4.1. Recommendations for researchers performing cost-effeciveness analyses 
Based on our studies included in this PhD-thesis, some recommendations can be made for researchers 
performing cost-effectiveness analyses in order to increase the quality as well as improve the use and 
interpretation of cost-effectiveness results for other researchers, health professionals and policy makers. 
First of all, researchers performing cost-effectiveness analyses should be aware of the uncertainty 
frequently faced in performing such analyses. Cost-effectiveness analyses of public health prevention 
interventions often provide indirect evidence. Researchers should analyse the main building blocks of 
the causal chain providing the indirect evidence and describe the uncertainty associated with those 
building blocks. Parameter uncertainty is a second main challenge. Solutions to lack of data could be 
collecting own data, statistical imputation of data or imputation of data from other countries. Besides, 
not only the positive health effects of prevention interventions should be included in the cost-
effectiveness analysis; researchers should also include potential harms of the intervention in the 
analysis. Furthermore, methodological choices such as the duration of the intervention effect, the 
perspective of the analysis, the time horizon of the model etcetera should be adressed and explored. 
Additionally, the uncertainties induced by those challenges should be examined. This can be done by 
performing one-way and probabilistic sensitivity analysis as well as scenario-analysis. 
In order to increase the quality of a cost-effectiveness analysis, researchers need to improve the 
transparency by clearly describing the model structure, parameters values, assumptions and 
calculations included in the modelling analysis so that interested parties are able to understand the key 
drivers of the model, as well as strengths and limitations of the analysis. Transparent analyses are easier 
to understand, which increases the value and the use of the analysis for other researchers and health 
professionals and which increases the likelihood of policy makers to make use of the cost-effectiveness 
information provided by the analysis. Reporting validation efforts is desirable to assess the validity of 
the model, in order to increase policy makers' and other stakeholders’ confidence in the analysis and its 
outcomes. Researchers should be aware that mean (base case) cost-effectiveness results provide 
relevant information, but results from sensitivity analyses and model validation exercises are even more 
informing.  
Moreover, in order to enhance the recognisability and uptake of cost-effectiveness evidence from 
prevention interventions by health professionals as well as policy makers, researchers should cooperate 
with relevant stakeholders, before, during or after performing the analysis. This could be achieved by 
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selecting a stakeholder group, representing clinical and health economic experts as well as data 
registries and policy makers where possible. This group could provide advice on the model structure, 
the data input, the interpretation and diffusion of results. However, a pitfall to collaboration with relevant 
stakeholders could be the independency of the researcher. Researchers need to be aware that the more 
intense the collaboration, the greater the conflict-of-interest threat.  
Additionally, in order to increase the uptake of cost-effectiveness evidence from prevention interventions 
by health professionals and policy makers, health economic researchers need to educate stakeholders 
on the relevance of cost-effectiveness analysis to policy and practice, on how such analyses are 
performed, what uncertainties can be involved and how the results should be interpreted. This could be 
effectuatued for example by organising health economic information sessions for health professionals 
when participating in a joint project or by organising seminars targeted at public health policy makers as 
well as lunch meetings with health professionals. 
 
3.4.2. Recommendations for health professionals 
Study results from cost-effectiveness analyses are interesting for health professionals as well, mainly in 
developing and implementing interventions. While developing a prevention intervention, health 
professionals should keep in mind the factors with the highest impact on the cost-effectiveness, shown 
from studies such as those included in this PhD research. More specifically, health professionals should 
think about the potential harms of the intervention and include modules in the intervention to be able to 
capture the effect of such potential harms on the participant’s quality of life and participation/compliance. 
This could be explored for example in a questionnaire to the participants. Additionally, collecting 
information on the participant’s quality of life in intervention trials could be useful to estimate the value 
of intermediate outcomes to the participants. Other common factors highly influencing the cost-
effectiveness result in the evaluated studies, which health professionals could take into account were 
the effectiveness of the intervention (as well as the duration of the effect) and in some cases the cost of 
the intervention. Therefore, we recommend health professionals to conduct more longitudinal research 
with a follow-up in the long term. Besides, we advise health professionals to keep the intervention cost 
as low as possible, while maintaining the effectiveness of the intervention. Input from published cost-
effectiveness studies can provide tips and tricks on how to achieve this. Besides, it was shown that up 
to now equity issues are seldom included in cost-effectiveness analyses. In order to improve the 
incorporation of equity issues, health professionals could take into account heterogeneity by conducting 
subgroup analyses while evaluating the intervention effect. 
 
3.4.3. Recommendations for policy makers 
Firstly, we want to stress that policy makers should keep in mind that even those interventions that do 
not result in total cost-savings, can still be desirable dependent on the balance between health effects 
and extra total costs which is assessed against the willingness-to-pay threshold. Additionally, policy 
makers should facilitate the use of cost-effectiveness as a means of identifying the most valuable 
preventive services by funding research producing cost-effectiveness evidence, by assessing the 
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transferability of international cost-effectiveness studies, by having health economic training in order to 
better understand cost-effectiveness analyses, by disseminating results of cost-effectiveness studies to 
relevant stakeholders and by using such evidence as information when making a policy decision 
(Goodell et al., 2009). Besides, policy could support health economic research not only by funding 
research, but also by investing in improving and integrating databases and by facilitating access to those 
data for research aims. Furthermore policy makers have to take into account that cost-effectiveness 
analyses of public health intervention simulating costs and health effects over the long term are generally 
based on short-term data and therefore the calculations resulting from the modelling are predictions, 
which include uncertainty. Whether a model is sufficiently valid or accurate for a particular application 
must be determined by those who use its results (Eddy et al., 2012). According to Threlfall et al. (2015), 
the important question is not whether it is scientific to make decisions based on predictions, but how 
much uncertainty the policy maker is willing to accept. It is assumed that in case of prevention within 
public health, more uncertainty is allowed, as long term evidence is more difficult to assess. In practice, 
policy makers cannot wait for independent external validation data before a decision is made. However, 
if data becomes available the model predictions should be tested against this data. Finally, policy makers 
should be more transparent in the decision making criteria and the relative importance of the different 
criteria in each decision. 
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Appendix 
 
1. EQ-5D questionnaire 
 
Zet bij iedere groep in de lijst hieronder een kruisje in het hokje achter de zin die het best past bij uw eigen 
gezondheidstoestand vandaag.      Met “ik”wordt de patiënt bedoeld! 
 
MOBILITEIT  
Ik heb geen problemen met rondwandelen       
Ik heb een beetje problemen met rondwandelen      
Ik heb matige problemen met rondwandelen       
Ik heb ernstige problemen met rondwandelen       
Ik ben niet in staat om rond te wandelen      
ZELFZORG  
Ik heb geen problemen met mijzelf te wassen of aan te kleden    
Ik heb een beetje problemen met mijzelf te wassen of aan te kleden    
Ik heb matige problemen met mijzelf te wassen of aan te kleden     
Ik heb ernstige problemen met mijzelf te wassen of aan te kleden    
Ik ben niet in staat mijzelf te wassen of aan te kleden   
DAGELIJKSE ACTIVITEITEN (bijv. werk, studie, huishouden, gezins- en vrijetijdsactiviteiten)  
Ik heb geen problemen met mijn dagelijkse activiteiten    
Ik heb een beetje problemen met mijn dagelijkse activiteiten    
Ik heb matige problemen met mijn dagelijkse activiteiten     
Ik heb ernstige problemen met mijn dagelijkse activiteiten    
Ik ben niet in staat mijn dagelijkse activiteiten uit te voeren   
PIJN/ONGEMAK  
Ik heb geen pijn of ongemak          
Ik heb een beetje pijn of ongemak         
Ik heb matige pijn of ongemak         
Ik heb ernstige pijn of ongemak         
Ik heb extreme pijn of ongemak        
ANGST/DEPRESSIE  
Ik ben niet angstig of depressief         
Ik ben een beetje angstig of depressief        
Ik ben matig angstig of depressief         
Ik ben erg angstig of depressief         
Ik ben extreem angstig of depressief        
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Via deze meetschaal willen we weten hoe goed of slecht uw algemene 
gezondheidstoestand VANDAAG is. Deze meetschaal (te vergelijken met een 
thermometer) is genummerd van 0 tot 100. 
100 staat voor de beste gezondheid die u zich kunt voorstellen. 
0 staat voor de slechtste gezondheid die u zich kunt voorstellen. 
Plaats een X op de meetschaal om aan te geven hoe uw gezondheid VANDAAG is.  
Noteer nu het getal dat u aangeduid hebt op de meetschaal in het onderstaande 
vakje.  
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2. Questionnaire used in the studies on skin cancer prevention, in order to estimate the 
costs, utilities and productivity loss: 
 
 
Studie naar medische consumptie, levenskwaliteit en werksituatie van personen met huidkanker 
 
 
A) Inleiding 
 
Beste patiënt, dank om mee te werken aan deze studie. U bent geselecteerd om deze vragenlijst in te vullen via uw 
behandelende arts. Graag willen wij een aantal vragen stellen over uw levenskwaliteit en nagaan hoe vaak u gebruik 
gemaakt hebt van medische zorgen tijdens de afgelopen 6 maanden en hoe uw woon-werk-situatie eruit ziet. 
De studie wordt uitgevoerd in het kader van een doctoraat aan de universiteit van Gent, in samenwerking met de dienst 
Dermatologie van het UZ Gent. U mag deze vragenlijst zelf invullen; als dit niet kan, mag uw arts,  een verpleegkundige, 
een verzorger of een familielid die nauw bij de uw zorg betrokken is, helpen om de vragenlijst mee in te vullen. 
 
B) Algemene vragen 
 
1. Op welke datum vult u deze vragenlijst in? 
 
 
dag         maand      jaar 
 
 
2. Wat is uw leeftijd?:         
…………jaar 
 
 
3. Wat is uw geslacht? (kruis aan):            
Man        Vrouw 
 
 
4. Wat is uw hoogste diploma?   
 Lagere school     Middelbaar onderwijs    Hoger onderwijs     Universitair diploma  
 
 
5. Via welke arts kreeg u deze vragenlijst mee (naam)?  
 
………………………………………………………………………….. 
 
6.  Welke van de volgende diagnose werd bij u vastgesteld (kruis aan) 
(BCC: basocellulair carcinooom; SCC: spinocellulair carcinoom) 
 
 BCC <1cm                  SCC stadium III (regionale uitzaaiing) 
 BCC 1-2cm              SCC stadium IV (gemetastaseerde uitzaaiing) 
 BCC >2cm      Melanoom stadium 0 (in situ) 
 BCC, agressieve histologie    Melanoom stadium I (T1-2a, N0, M0) 
 Multipele BCC     Melanoom stadium II (T2b-4b, N0, M0) 
 SCCstadium 0 (Bowen)    Melanoom stadium III(T1-4, N1-3, M0) 
   Spinocellulair carcinoom stadium I of II    Melanoom stadium IV(T1-4, N, M1) 
 
 
7. Op welke locatie werd deze diagnose vastgesteld? 
 Scalp          Voorhoofd 
 Wangen         Neus 
 Oren     Thorax 
 Onderarmen    Handen 
 Onderbenen    Voeten 
 Andere: _________ 
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8. Op welke datum werd deze diagnose gesteld? (m.a.w de datum van de uitslag van de biopsie)  
  
 
dag        maand        jaar 
 
 
 
 
In het verdere verloop van de vragenlijst zullen we naar deze diagnose verwijzen als ‘uw huidaandoening’ 
 
 
 
 
 
C) Levenskwaliteit 
Zet bij iedere groep in de lijst hieronder een kruisje in het hokje achter de zin die het best past bij uw eigen 
gezondheidstoestand vandaag.      Met “ik”wordt de patiënt bedoeld! 
 
MOBILITEIT  
Ik heb geen problemen met rondwandelen       
Ik heb een beetje problemen met rondwandelen      
Ik heb matige problemen met rondwandelen       
Ik heb ernstige problemen met rondwandelen       
Ik ben niet in staat om rond te wandelen      
ZELFZORG  
Ik heb geen problemen met mijzelf te wassen of aan te kleden    
Ik heb een beetje problemen met mijzelf te wassen of aan te kleden    
Ik heb matige problemen met mijzelf te wassen of aan te kleden     
Ik heb ernstige problemen met mijzelf te wassen of aan te kleden    
Ik ben niet in staat mijzelf te wassen of aan te kleden   
DAGELIJKSE ACTIVITEITEN (bijv. werk, studie, huishouden, gezins- en vrijetijdsactiviteiten)  
Ik heb geen problemen met mijn dagelijkse activiteiten    
Ik heb een beetje problemen met mijn dagelijkse activiteiten    
Ik heb matige problemen met mijn dagelijkse activiteiten     
Ik heb ernstige problemen met mijn dagelijkse activiteiten    
Ik ben niet in staat mijn dagelijkse activiteiten uit te voeren   
PIJN/ONGEMAK  
Ik heb geen pijn of ongemak          
Ik heb een beetje pijn of ongemak         
Ik heb matige pijn of ongemak         
Ik heb ernstige pijn of ongemak         
Ik heb extreme pijn of ongemak        
ANGST/DEPRESSIE  
Ik ben niet angstig of depressief         
Ik ben een beetje angstig of depressief        
Ik ben matig angstig of depressief         
Ik ben erg angstig of depressief         
Ik ben extreem angstig of depressief        
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Via deze meetschaal willen we weten hoe goed of slecht uw algemene gezondheidstoestand 
VANDAAG is. Deze meetschaal (te vergelijken met een thermometer) is genummerd van 0 tot 100. 
100 staat voor de beste gezondheid die u zich kunt voorstellen. 
0 staat voor de slechtste gezondheid die u zich kunt voorstellen. 
Plaats een X op de meetschaal om aan te geven hoe uw gezondheid VANDAAG is.  
Noteer nu het getal dat u aangeduid hebt op de meetschaal in het onderstaande vakje.  
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D) Huidig gebruik van medische verzorging 
 
In de volgende vragen wordt met “u” de patiënt bedoeld, ongeacht wie deze vragen invult. 
 
 
I.  Hospitalisatie 
 
1. Bent u naar de dagkliniek geweest de afgelopen 6 maanden, in verband met uw huidaandoening? 
 Neen 
 Ja  Hoeveel dagen in totaal? ………….. 
 
2. Heeft u in een ziekenhuis verbleven de afgelopen 6 maanden, in verband met uw huidaandoening? 
 Neen 
 Ja  Hoeveel dagen in totaal? ............. 
 
*dagkliniek: u wordt opgenomen maar mag diezelfde dag nog naar huis  
 
3. Indien ‘Ja’ op vraag 1 en/of  vraag 2, gelieve in te vullen hoeveel keer u welk vervoersmiddel hebt gebruikt, 
hoeveel van uw tijd dit transport in beslag nam, hoeveel kilometer de rit was (indien met auto) en de kostprijs 
van het ticket (indien openbaar vervoer) 
(bv. U bent drie keer in het ziekenhuis of dagkliniek geweest, waarvan 2  keer met de auto en 1 keer met openbaar 
vervoer  + een stukje te voet  dan vult u 2 keer in in het vakje na auto, 1 keer in het vakje na openbaar vervoer en 1 
keer in het vakje naast te voet) 
  
Vervoersmiddel Aantal keer 
Gespendeerde tijd aan dit 
transport per keer (heen 
en terug) 
Aantal km per 
keer (heen en 
terug) 
Kostprijs ticket 
per keer (heen 
en terug) 
Auto (als chauffeur of als 
passagier) 
……... keer als chauffeur ……u …..min ...……km    
 ……u …..min ...……km  
……... keer als passagier .…..u …..min  ………km    
Openbaar vervoer ……... keer …….u …..min     €……..  
Te voet of met de fiets ……... keer ..….u …..min       
 
 
II.  Consultaties 
 
Toelichting 
Wij willen graag weten met welke dokters of zorgverleners u in de afgelopen 6 maanden een afspraak/consultatie had in 
verband met uw huidaandoening. Het gaat om afspraken voor uzelf.  
 
 
Welke afspraken tellen mee? 
* Controles in verband met uw huidaandoening 
* Afspraken/consultaties omdat u een lichamelijke of psychische klacht had in verband met uw huidaandoening 
* Afspraken/bezoeken waarbij de dokter bij u thuis kwam in verband met uw huidaandoening 
* Afspraken voor een (kleine) ingreep in verband met uw huidaandoening 
 
Wat telt niet mee? 
* Afspraken voor een ander, bijvoorbeeld voor uw kind 
*  Telefoontjes om een afspraak te maken  
 
Weet u niet precies hoeveel consultaties het waren? Schrijf dan op hoeveel het er ongeveer waren 
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Hoeveel keer  
had u een  
consultatie?  
(de afgelopen  
6 maanden) 
Waar had u deze consultatie(s) de afgelopen 6 maanden? 
   
     
Consultatie 
in spreek-  
kamer van de 
 arts 
Consultatie 
thuisbezoek 
Consultatie  
tijdens een 
hospitalisatie  
Consultatie in het  
ziekenhuis (zonder 
gehospitaliseerd te zijn)  
Consultatie 
spoedgevallen 
     Dermatoloog             
    Huisarts             
        Oncoloog       
    Radioloog             
     Plastisch chirurg             
      
Andere  
specialist  
specificeer: 
……………………… 
            
 
 
1. Indien u minstens 1 consultatie had de laatste 6 maanden, gelieve in onderstaande tabel in te vullen hoeveel 
keer u welk vervoersmiddel hebt gebruikt om naar de consultatie te gaan, hoeveel van uw tijd dit transport 
in beslag nam, hoeveel kilometer de rit was (indien met auto) en de kostprijs van het ticket (indien openbaar 
vervoer) 
(bv. U hebt drie keer een consultatie gehad, waarvan u er 2  keer met de auto heen ging en 1 keer met openbaar 
vervoer  + een stukje te voet  dan vult u 2 keer in in het vakje na auto, 1 keer in het vakje na openbaar vervoer en 
1 keer in het vakje naast te voet) 
 
Vervoersmiddel Aantal keer 
Gespendeerde tijd aan dit 
transport per keer (heen 
en terug) 
Aantal km per 
keer (heen en 
terug) 
Kostprijs ticket 
per keer (heen en 
terug) 
Auto (als chauffeur of als 
passagier) 
……... keer als chauffeur ……u …..min ...……km    
 ……u …..min ..……km  
……... keer als passagier .…..u …..min  ………km    
Openbaar vervoer ……... keer …….u …..min     €……..  
Te voet of met de fiets ……... keer ..….u …..min       
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III.  Onderzoeken & Behandeling 
Heeft u de voorbije 6 maanden testen, chirurgische ingrepen, onderzoeken of andere niet-medicamenteuze interventies 
(bv. bloedtransfusie) ondergaan in functie van diagnose en behandeling van uw huidaandoening?  
 
1) ONDERZOEKEN TER DIAGNOSE EN/OF OPVOLGING (kruis aan (meerdere opties mogelijk)+ geef weer 
hoeveel keer) 
   Dermoscopie. Aantal keer: ……………………………. 
  Biopsie. Aantal keer:……………………………………….. 
  Echografie lymfeklieren. Aantal keer:……………… 
  Echografie buik. Aantal keer:…………………………… 
  CT-scan longen. Aantal keer:……………………………. 
  CT-scan buik. Aantal keer:……………………………….. 
  CT-scan lever. Aantal keer:………………………………. 
  CT-scan hersenen. Aantal keer:……………………….. 
  MRI-scan hersenen. Aantal keer:…………………….. 
  PET-scan. Aantal keer:…………………………………….. 
  RX Thorax. Aantal keer:…………………………………….. 
  Andere, specificeer aub: ………………………………… 
  Geen 
 
2) BEHANDELING (kruis aan (meerdere opties mogelijk) + geef weer hoeveel keer) 
  Chirurgisch wegnemen van een huidplekje . Aantal keer:……………………………………..  
  Curettage (wegschrapen) al dan niet in combinatie met dichtschroeien. Aantal keer: …………… 
  Bevriezing (cryotherapie). Aantal keer:…………………………………….. 
  Laser. Aantal keer:…………………………………….. 
  Fotodynamische therapie (behandeling met bijtende crème en lamp). Aantal keer:……………….  
  Behandeling met een bijtende crème (bijvoorbeeld Aldara, Picato, Efudix)  Is een medicijn, dus gelieve dit ook te 
vermelden bij de vraag naar gebruik van medicatie. Aantal keer:…………………………………….. 
  Bestraling (radiotherapie). Aantal keer:…………………………………….. 
  Chirurgisch verwijderen lymfeklier (enkel de sentinel/wachtpost-klier(en)). Aantal keer:……………. 
  Chirurgisch verwijderen lymfeklieren (gehele klierstation) . Aantal keer:…………………………………….. 
  Immunotherapie (behandeling met medicijnen die de eigen weerstand tegen kankercellen versterken, bijvoorbeeld 
interferon, interleukine)  Is een medicijn, dus gelieve dit ook te vermelden bij de vraag naar gebruik van medicatie. 
Aantal keer:…………………………………….. 
  Algemene chemotherapie (bij gemetastaseerd melanoom, SCC)  Is een medicijn, dus gelieve dit ook te vermelden 
bij de vraag naar gebruik van medicatie. Aantal keer:…………………………………….. 
  Andere, specificeer aub: ………………………………………………………………………………………………… 
 
 
 
 
 
  
 
 
 
  
 
IV.  Medicatie 
Gelieve op deze pagina alle geneesmiddelen te noteren die u genomen heeft/neemt gedurende de voorbije 6 maanden, voor de verzorging en behandeling van uw huidaandoening 
en de klachten die ermee gepaard gaan, en voor de verzorging van de eventuele nevenwerkingen van de behandeling. Zalf/crème dient hier ook vermeld te worden. 
GENOMEN GENEESMIDDEL VOOR UW HUIDAANDOENING (NIET VOOR ANDERE GEZONDHEIDSKLACHT!) 
 Naam van het product, dosis (indien zalf dan niet in te vullen) en de vorm (zalf, pil, capsule, siroop, injectie) 
AANTAL  
 
Hoeveel keer per dag? 
PERIODE 
 
Hoeveel dagen heeft u dit product  
de laatste 6 maand gebruikt?  
 (max = 180) 
Naam product Dosis die u neemt 
per keer 
Vorm van het product 
(zalf, pil, capsule, siroop, injectie) 
  
Voorbeeld:  Nurofen Voorbeeld: 400 mg Voorbeeld: pil Voorbeeld: 3 Voorbeeld: 14  
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E) Werk-situatie 
 
1. Kruis aan wat uw werksituatie was vóór diagnose van uw huidaandoening (meerdere mogelijk): 
 
 Ik was gepensioneerd  
 Ik was huisvrouw/huisman  
 Ik werkte voltijds  
 Ik werkte deeltijds. Aantal uren per week: …………………………………………. 
 Ik was in ziekteverlof  
 Andere: ……………………………………………………………………………………………… 
 
2. Is uw werksituatie veranderd door uw huidaandoening? 
 Neen 
 Ja  
 
Indien JA op vraag 2: Kruis aan wat uw huidige werksituatie is. Indien Neen op vraag 2, ga dan verder naar 
vraag 3. 
 Ik ben vervroegd op pensioen gegaan door mijn huidaandoening  
 Ik ben ontslagen of heb ontslag genomen (door mijn huidaandoening)  
 Ik ben in ziekteverlof (door mijn huidaandoening)  
 Ik ben huisvrouw/huisman (door mijn huidaandoening) 
 Ik werk deeltijds (door mijn huidaandoening). Aantal uren per week: _____________ 
 
3.  Bent u in de afgelopen 6 maanden afwezig geweest van uw werk omwille van de huidaandoening? 
 Neen 
   Ja, ik ben ….. werkdagen afwezig geweest 
   Ja, ik ben reeds  ….. werkdagen afwezig, en ben het nog steeds 
 
 
4. Heeft u, door uw huidaandoening, extra, betaalde huishoudhulp nodig gehad de afgelopen 6 maanden? 
Bijvoorbeeld thuiszorg, hulp voor het poetsen of boodschappen doen  
! Indien u bijvoorbeeld een poetsvrouw heeft, maar niet omwille van uw huidletsel, gelieve dan ‘neen’ aan te kruisen. 
 
  Neen 
 Ja  Aantal weken: _________________ 
              Aantal uur per week: ___________ 
 
 
 
Dit was de laatste vraag. Hartelijk dank voor uw medewerking aan deze studie! 
Indien u vragen hebt, dan mag u contact opnemen met 
Lore Pil 
Lore.Pil@UGent.be - 0478/657125 
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Summary 
 
Chronic non-communicable diseases (CNCDs) are the largest contributors to the population health 
burden and it is expected that their incidence will keep on rising in the next decades, mainly due to 
ageing of the population and changing health behaviours. Not only population health is affected by these 
CNCDs, but also the health budget. It is estimated that 70% to 80% of the health budget is spent on the 
treatment of CNCDs. Health care costs as well as costs due to productivity loss are putting the public 
budget under huge pressure. As such, the concern has been raised on the financial sustainability of the 
health care system. The World Health Organization recommends to promote public health interventions 
that prevent and control CNCDs in order to lessen their global health and economic impact. 
Governments should invest in prevention interventions that offer good value for money, by considering 
cost-effectiveness evidence in the decision-making process. However, the use of cost-effectiveness 
evidence, especially of public health prevention interventions, has been estimated to be limited. This is 
mainly due to the availability, quality and transparency of such evidence, the clarity of its presentation 
and the extent to which policy makers understand such analyses.   
Therefore, the first aim of this PhD-thesis was to assess the cost-effectiveness of 8 public health 
interventions in the continuum of CNCD prevention, that hold some promise to reduce the health burden 
at a reasonable cost or even at a lower total cost. Universal prevention interventions included in this 
PhD research comprised the prevention of obesity in pre-schoolers, as well as a sensitisation campaign 
and a total ban on sunbed use to prevent skin cancer. The evaluation of interventions categorised as 
selective prevention consisted of a biennial mammography screening program for the early detection of 
breast cancer, a biennial faecal immunological test for the early detection of colorectal cancer, a total-
body examination and a lesion-directed screening for the early detection of skin cancer. Finally, the 
indicated prevention intervention was a suicide helpline for the prevention of suicide. All analysed 
interventions showed potential for increasing population health while controlling the health care budget. 
These interventions were found to result in incremental cost-effectiveness ratios being below the 
assumed threshold of €35,000/QALY gained, which means that public investment in these interventions 
would offer good value for money. However, the strength of the evidence was stronger in some studies 
than in others, dependent on the inherent uncertainties that should be taken into account while 
interpreting these cost-effectiveness results. It needs to be stated that cost-effectiveness analyses 
include inherent uncertainties concerning the model structure (structural uncertainty), availability of data 
(parameter uncertainty) and the methodological choices (methodological uncertainty), some being 
specific to the field of public health prevention interventions, such as providing indirect evidence, the 
choice of time horizon, duration of the intervention-effect, the use of QALYs as outcome measure, and 
some being related to cost-effectiveness analysis in general, such as the lack of data, choice and 
valuation of costs to include, harms of the intervention, etcetera.  
Our second aim was to inform researchers as well as policy makers and other stakeholders on these 
uncertainties and their impact on the interpretation of cost-effectiveness results. This was performed by 
reporting and reflecting on the main uncertainties that we encountered in the included cost-effectiveness 
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analyses. By interpreting the study results in light of these uncertainties, it was shown that the results of 
the study on prevention of pre-schooler obesity should be interpreted with caution as there is still a lot 
of uncertainty on the duration of the intervention effect and the extrapolation of the effect in pre-schoolers 
to adulthood, both influencing the cost-effectiveness result. The universal prevention interventions to 
prevent skin cancer were hypothetical interventions. Although the results were promising (both were 
predicted to be dominant) and seemed quite robust, it is advisable to first conduct further research on 
what the effectiveness of such measures is or may be in a Belgian context. As it es expected that the 
incidence of skin cancer and the cost of treating skin cancer will increase in the future, it was shown that 
prevention of skin cancer would become more cost-effective. The screening programs on breast- and 
colorectal cancer are already implemented in Flanders. As such, screening-related data was obtained 
from these existing programs. Both programs were found to be cost-effective and therefore advised to 
be continued. However, further research is needed on the quality of life related to these cancers and to 
a false-positive result as both influence the cost-effectiveness of screening. Also, more information on 
the long-term impact of screening on mortality and the incidence of new tumours (in the further stages) 
is desirable, in order to verify whether the model predictions are correct. Furthermore, as the screening 
techniques as wel as treatment therapies are continuously evolving, frequent evaluation is necessary. 
A one-time skin cancer screening was shown to be a cost-effective strategy, especially in women; a 
total body examination showed a slightly better result on cost-effectivenss than the lesion-directed 
screening (which was only due to the participation rate). However, more information on the natural 
progression of skin cancer as well as a systematic registration of NMSC lesions in Belgium would 
improve cost-effectiveness research, as the sensitivity analysis showed that screening for basal cel 
carcinoma might not offer good value for money in case of a high prevalence. By means of this study 
we were able to make recommendations for skin cancer prevention in the future, though more research 
on skin cancer screening to confirm our results (and the most efficient target group and screening 
interval) is desirable. The largest uncertainty in the study of the suicide helpline was the lack of 
information on the effectiveness of the suicide helpline in Flanders and the lack of information about the 
cost of a (fatal) suicide attempt. On the other hand, based on the results of the sensitivity analysis, we 
can say that the Flemish suicide helpline is a cost-effective, and even dominant strategy. However, if 
we want more clarity on the magnitude of the cost savings, it is necessary first to have more information 
on the effectiveness of the Flemish suicide helpline and the cost of a (fatal) suicide attempt in 
Flanders/Belgium. From our studies, we concluded that uncertainty in cost-effectiveness studies offers 
interesting information, in addition to the mean result, that should be reported transparently in order for 
the results to be interpreted in light of these uncertainties. In this way, we stressed the importance of 
scenario- and sensitivity analyses and validation efforts. 
By our research we informed several stakeholders who may be performing, funding, participating in, or 
making use of economic evaluations and formulated some recommendations for future practice and 
policy. Researchers performing cost-effectiveness analyses need to be aware of the included 
uncertainties and explore the impact on the result. Mean (base case) cost-effectiveness results provide 
relevant information, but results from sensitivity analyses and model validation exercises are even more 
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informing. Furthermore, in order to enhance the quality of the cost-effectiveness evidence researchers 
should cooperate with relevant stakeholders, before, during or after performing the analysis. This could 
be achieved by selecting a stakeholder group, representing clinical and health economic experts as well 
as data registries and policy makers where possible. Also, to increase recognisability and uptake of of 
cost-effectiveness evidence from prevention interventions by health professionals and policy makers, 
health economic researchers need to educate stakeholders on the relevance of cost-effectiveness 
analysis to policy and practice, on how such analyses are performed, what uncertainties can be involved 
and how the results should be interpreted. This could be effectuatued for example by organising health 
economic information sessions for health professionals when participating in a joint project or by 
organising seminars targeted at public health policy makers as well as lunch meetings with health 
professionals. Study results from cost-effectiveness analyses are interesting for health professionals as 
well, mainly in developing and implementing interventions. While developing a prevention intervention, 
health professionals should keep in mind the factors with the highest impact on the cost-effectiveness, 
shown from studies such as those included in this PhD research. More specifically, health professionals 
should think about the potential harms of the intervention and include modules in the intervention trial 
to be able to capture the effect of such potential harms on the participant’s quality of life and 
participation/compliance. Besides, collecting information on the participant’s quality of life is also 
recommended to increase our knowledge on the value of intermediate outcomes to the participants. 
Other common factors highly influencing the cost-effectiveness result in the evaluated studies, which 
health professionals could take into account, were the effectiveness of the intervention (as well as the 
duration of the effect) and in some cases the cost of the intervention. More longitudinal research with a 
follow-up in the long term is advised. Besides, it was shown that up to now equity issues are seldom 
included in cost-effectiveness analyses. In order to improve the incorporation of equity issues, health 
professionals could take into account heterogeneity by conducting subgroup analyses while evaluating 
the intervention effect. Policy makers should facilitate the use of cost-effectiveness evidence as a means 
of identifying the most valuable preventive services by funding research producing such evidence, by 
assessing the transferability of international cost-effectiveness studies, by having health economic 
training in order to better understand cost-effectiveness analyses, by disseminating results of cost-
effectiveness studies to relevant stakeholders and by using such evidence as information when making 
a policy decision. Besides, policy could support health economic research not only by funding research 
projects, but also by investing in improving and integrating databases and by facilitating access to those 
data for research aims. Furthermore, policy makers have to be aware that cost-effectiveness analyses 
include uncertainty. Whether a model is sufficiently valid or accurate for a particular application must be 
determined by those who use its results. The important question is not whether it is scientific to make 
decisions based on predictions, but how much uncertainty the policy maker is willing to accept. It is 
assumed that in case of prevention within public health, more uncertainty is allowed, as long term 
evidence is more difficult to assess. Finally, policy makers should be more transparent in the decision 
making criteria and the relative importance of the different criteria in each decision.  
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Samenvatting 
 
Chronische niet-overdraagbare ziektes (CNOZs) zijn de grootste oorzaken van ziekte en sterfte op 
populatieniveau. Er wordt verwacht dat de incidentie van deze ziektes zal blijven stijgen in de komende 
decennia, voornamelijk als gevolg van de vergrijzing van de bevolking, maar ook door veranderingen in 
de levensstijl van de bevolking. Niet alleen de volksgezondheid wordt beïnvloed door deze CNCDs, 
maar ook het budget van de gezondheidszorg. Er wordt naar schatting 70% tot 80% van het 
gezondheidsbudget gespendeerd aan de behandeling van CNOZs. De kosten voor de gezondheidszorg 
mede als de kosten omwille van productiviteitsverlies zetten de overheidsbegroting onder enorme druk. 
Als gevolg van deze trend wordt de financiële houdbaarheid van de gezondheidszorg in vraag gesteld. 
De Wereldgezondheidsorganisatie adviseert om in te zetten op preventieve interventies die 
kosteneffectief zijn, i.e. waarde voor hun geld bieden, om de impact van CNOZs op de volksgezondheid 
en het gezondheidsbudget te beheersen. Kosteneffectiviteitsanalyses informeren beleidsmakers over 
de verhouding tussen de kost en gezondheidswinst van interventies. Echter, het gebruik van informatie 
over de kosteneffectiviteit van interventies in besluitvorming, in het bijzonder van preventieve 
interventies ter bevordering van de volksgezondheid, wordt ingeschat als zijnde beperkt. Dit is 
voornamelijk te wijten aan de beschikbaarheid van dergelijke informatie, de kwaliteit en transparantie 
ervan en de mate waarin de beleidsmakers dergelijke analyses begrijpen.  
Daarom was een eerste doelstelling van dit proefschrift om de kosteneffectiviteit te evalueren van acht 
interventies in het continuüm van CNOZ-preventie, die de gezondheid trachten te bevorderen door te 
focussen op de belangrijkste CNOZs. Interventies die in dit proefschrift in de categorie van universele 
preventie werden gecategoriseerd omvatten de preventie van overgewicht en obesitas bij kleuters, 
evenals een sensibiliseringscampagne en een totaal verbod op zonnebankgebruik ter preventie van 
huidkanker. Interventies binnen de selectieve preventie bestonden uit een tweejaarlijkse 
mammografiescreening voor de vroegtijdige opsporing van borstkanker, een tweejaarlijkse fecale 
immunologische test voor de vroege opsporing van dikkedarmkanker, een onderzoek van het totale 
lichaam en een vlekjesscreening voor de vroegtijdige detectie van huidkanker. Tenslotte bevatte de 
categorie van geïndiceerde preventie de evaluatie van een hulplijn ter preventie van zelfmoord. Alle 
interventies toonden potentieel in het verbeteren van de volksgezondheid en het controleren van de 
uitgaven aan gezondheidszorg. Deze interventies hadden een incrementele kosteneffectiviteitsratio die 
onder de veronderstelde drempelwaarde van €35.000 per gewonnen levensjaar lag, wat betekent dat 
overheidsinvestering in deze interventies extra gezonde levensjaren zou bieden tegenover een matige 
kostprijs of soms zelfs kostenbesparingen. Echter, de sterkte van het resultaat verschilde van studie tot 
studie, afhankelijk van de inherente onzekerheden in de analyses waarmee rekening moet gehouden 
worden bij het interpreteren van de resultaten. Het moet worden vermeld dat 
kosteneffectiviteitsanalyses onzekerheden bevatten met betrekking tot de structuur van het model 
(structurele onzekerheid), beschikbaarheid van invoergegevens (parameter onzekerheid) en de 
methodologische keuzes (methodologische onzekerheid). Sommige van deze onzekerheden gelden 
specifiek voor kosteneffectiviteitsanalyses van preventie interventies, zoals het aanleveren van indirect 
bewijs, de keuze van de tijdshorizon, de duur van de interventie-effect, het gebruik van QALYs als 
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uitkomstmaat. Andere onzekerheden gelden voor kosteneffectiviteitsanalyses in het algemeen, zoals 
het gebrek aan gegevens, de keuze en de waardering van kosten, includeren van nadelen van de 
interventie, etcetera.   
Het tweede doel van dit proefschrift was om zowel onderzoekers als beleidsmakers en andere 
belanghebbenden te informeren over deze onzekerheden en hun invloed op de interpretatie van 
kosteneffectiviteit resultaten. Onzekerheden die werden vastgesteld tijdens het uitvoeren van de 
analyses werden gerapporteerd en de invloed ervan op het resultaat van de analyse werd onderzocht. 
Zo werd aangetoond dat de resultaten van de studie omtrent preventie van obesitas bij kleuters met 
enige voorzichtigheid geïnterpreteerd moeten worden, aangezien er nog veel onzekerheid is over de 
duur van het interventie-effect en de extrapolatie van het effect in kleuters naar volwassen leeftijd, 
dewelke beide de kosteneffectiviteit sterk beïnvloeden. De universele interventies ter preventie van 
huidkanker waren hypothetische interventies. Hoewel de resultaten van de analyse veelbelovend zijn 
(beide werden voorspeld dominant te zijn op lange termijn) en vrij robust bleken, is het aanbevolen om 
eerst verder onderzoek te voeren naar de effectiviteit van dergelijke maatregelen in een Belgische 
context. Aangezien verwacht wordt dat de incidentie van huidkanker en de kost om het te behandelen 
zal stijgen in de toekomst, werden deze scenario’s geanalyseerd en werd aangetoond dat deze trends 
de nood aan dergelijke preventieve interventies verhogen en de kosteneffectiviteit ervan verbeteren. De 
screening programma’s naar borst- en dikkedarmkanker zijn reeds geïmplementeerd in Vlaanderen, 
waardoor de screening-gerelateerde data van deze bestaande programma’s kon verkregen worden. 
Beide bevolkingsonderzoeken werden geëvalueerd als zijnde kosteneffectief en daardoor aanbevolen 
om verdergezet te worden. Echter, meer onderzoek is nodig naar de kwaliteit van leven gerelateerd aan 
deze kankers en aan een vals-positief resultaat op de screeningstest, aangezien beide de 
kosteneffectiviteit van screening sterk blijken te beïnvloeden. Ook is meer informatie welkom omtrent 
de langetermijn impact van screening op de mortaliteit en incidentie van nieuwe tumoren (in de verder 
gevorderde stadia), om de voorspellingen van het model op lange termijn te toetsen. Bovendien is 
frequente evaluatie van de bevolkingsonderzoeken aangeraden aangezien de screeningstechnieken en 
behandelingen van deze kankers voortdurend evolueren en de kosteneffctiviteit van screening 
beïnvloeden. Een éénmalige huidkankerscreening bleek kosteneffectief te zijn, vooral bij vrouwen; een 
gehele lichaamsinspectie toonde een lichtjes betere kosteneffectiviteit dan een vlekjesscreening (maar 
dit was enkel te wijten aan de lagere participatiegraad in deze tweede groep). Meer informatie over de 
natuurlijke progressie van huidkanker evenals een systematische registratie van niet-melanome letsels 
in België zou onderzoek bevorderen, aangezien de sensitiviteitsanalyse aantoonde dat screening naar 
basaalcelcarcinoom minder waarde voor z’n geld zou bieden in geval van een hogere prevalentie. Door 
middel van deze studie konden we aanbevelingen doen over huidkankerscreening in de toekomst, 
hoewel verder onderzoek nodig is om deze resultaten te bevestigen en om de meest efficiënte 
doelgroep en screeninginterval te determineren. De grootste onzekerheid in de studie over de 
zelfmoordlijn wat het gebrek aan informatie over de effectiviteit van de zelfmoordlijn in Vlaanderen en 
het over de kost van een (fatale) zelfmoordpoging. Anderzijds kunnen we op basis van de resultaten 
van de sensitiviteitsanalyse met vrij veel zekerheid concluderen dat de Vlaamse zelfmoordlijn 
kosteneffectief en zelfs dominant blijkt te zijn. Echter, indien we een meer accuraat beeld over de 
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grootte-orde aan kostenbesparingen willen, is het nuttig om eerst meer informatie te hebben over de 
effectiviteit van de hulplijn in Vlaanderen en kost van een fatale poging. Door middel van de resultaten 
van onze studies, kunnen we concluderen dat de onzekerheid in de kosteneffectiviteit studies 
interessante informatie oplevert die transparant moet worden vermeld, zodat de resultaten in het licht 
van deze onzekerheden kunnen worden geïnterpreteerd. Op deze manier werd het belang van 
sensitiviteits- en scenario-analyses belicht, evenals van validatie-oefeningen.  
De resultaten die voortvloeien uit dit proefschrift kunnen verschillende belanghebbenden informeren die 
kosteneffectiviteitsanalyses uitvoeren, financieren of ervan gebruik maken. Verschillende 
aanbevelingen werden geformuleerd. Onderzoekers, die kosteneffectiviteitsanalyses uitvoeren, moeten 
zich bewust zijn van de onzekerheden in de kosteneffectiviteitsanalyses en de impact ervan op het 
resultaat evalueren. Het gemiddelde resultaat (basis-scenario) van een kosteneffectiviteitsanalyse biedt 
relevante informatie, maar de resultaten van de sensitiviteitsanalyses en modelvalidatie zijn nog 
informatiever. Bovendien, om de kwaliteit van de kosteneffectiviteitsresultaten te verbeteren moeten 
onderzoekers samenwerken met relevante belanghebben, vóór, tijdens of na het uitvoeren van de 
analyse. Dit kan worden bewerkstelligd door het selecteren van een groep van belanghebbenden, die 
zowel klinische als gezondheids(economische) experten maar ook verantwoordelijken van dataregisters 
vertegenwoordigt. Om ook de herkenbaarheid en het gebruik van de resultaten van 
kosteneffectiviteitsanalyses door andere onderzoekers, gezondheidswerkers of beleidsmakers te 
verhogen, moeten onderzoekers belanghebbenden informeren over de relevantie van 
kosteneffectiviteitsanalyses voor het beleid en de praktijk, over de wijze waarop dergelijke analyses 
worden uitgevoerd, welke onzekerheden erin kunnen vervat zitten en hoe de resultaten moeten worden 
geïnterpreteerd in het licht van deze onzekerheden. Dit kan bereikt worden bijvoorbeeld door het 
organiseren van seminaries voor beleidsmakers evenals lunch-meetings met gezondheidswerkers. De 
resultaten van dit proefschrift zijn ook informatief voor gezondheidswerkers, vooral in het ontwikkelen 
en implementeren van interventies. Bij de ontwikkeling van een preventieve interventie moeten 
zorgverleners rekening houden met de factoren die  de grootste impact hebben op de kosteneffectiviteit, 
zoals blijkt uit de studies die zijn opgenomen in dit proefschrift. Meer specifiek raden we 
gezondheidswerkers aan om ook na te denken over de potentiële nadelige effecten van interventies 
door modules in de interventietrial te includeren die de impact nagaan op de kwaliteit van leven, maar 
ook de deelname en naleving van de participant. Bovendien is het verzamelen van informatie omtrent 
de levenskwaliteit van de participant ook aanbevolen om onze kennis te vergroten omtrent de waarde 
van intermediaire interventie-effecten voor de participant. Andere gemeenschappelijke parameters met 
een sterke invloed op het kosteneffectiviteit resultaat, waarmee gezondheidswerkers rekening kunnen 
houden, zijn de doeltreffendheid van de interventie evenals de duur van het effect en de kosten van de 
interventie. Meer longitudinaal onderzoek met een follow-up op de lange termijn wordt geadviseerd. 
Bovendien werd aangetoond dat tot nu toe rechtvaardigheid zelden wordt meegenomen in 
kosteneffectiviteitsanalyses. Om de integratie van dergelijke informatie te bevorderen, kunnen 
gezondheidswerkers rekening houden met heterogeniteit door het uitvoeren van subgroepanalyses 
tijdens de evaluatie van het effect interventie. Beleidsmakers moeten het gebruik van informatie over 
kosteneffectiviteit als een middel voor het identificeren van de meest waardevolle preventieve 
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interventies bevorderen door het financieren van onderzoek dat dergelijke informatie produceert, door 
de transfereerbaarheid van internationale kosteneffectiviteitsstudies naar de huidige context te 
onderzoeken, door training te volgen met het oog op een beter begrip van kosteneffectiviteitsanalyses, 
door verspreiding van de resultaten van de kosteneffectiviteitsstudies naar relevante belanghebbenden 
en door de informatie over kosteneffectiviteit mee te nemen in besluitvormingsprocessen. Bovendien 
kunnen beleidsmakers gezondheidseconomisch onderzoek ondersteunen, niet alleen door financiering 
van dergelijk onderzoek, maar ook door te investeren in het verbeteren en integreren van databases en 
door het vergemakkelijken van de toegang tot deze gegevens voor onderzoek. Verder moeten 
beleidsmakers er rekening mee houden dat kosteneffectiviteitsanalyses onzekerheden includeren. Of 
een model voldoende valide of accuraat is voor een bepaalde toepassing moet worden bepaald door 
degenen die de resultaten gebruiken. De vraag is niet of het wetenschappelijk is om beslissingen te 
nemen op basis van voorspellingen, maar hoeveel onzekerheid de beleidsmaker bereid is te 
accepteren. Er wordt aangenomen dat bij preventieve interventies die de volksgezondheid bevorderen 
meer onzekerheid is toegestaan, aangezien het moeilijker is om de effectiviteit van dergelijke 
interventies op lange termijn te beoordelen. Ten slotte is het van belang dat beleidsmakers meer 
transparant zijn in de criteria die worden meegenomen in de besluitvorming en het relatieve belang van 
de verschillende criteria in elke beslissing. 
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Dankwoord 
“Hoe voelt dat nu, zo vier jaar doctoreren?”, vragen mensen me soms. Ik heb er even over moeten 
nadenken, want er kwamen zoveel gevoelens aan te pas. “Als een rollercoaster”, zeg ik dan. Je kent 
het wel, je begint eraan zonder goed te weten wat er op je af komt of wat je staat te wachten. Vol goeie 
moed neem je plaats. Voor je het goed en wel beseft, bereik je in een sneltempo enkele hoogtes en 
laagtes en net wanneer je denkt dat het even rustiger begint te gaan, word je weer heen en weer 
geslingerd tussen zalige adrenalinestoten en het ‘ik wil hier uit’-gevoel. En achteraf ben je blij en trots 
dat je het volbracht hebt. Wel, ik denk dat dit een goede beschrijving is van het avontuur dat ik de 
voorbije 4,5 jaar heb mogen meemaken. Ik ben trots op het onderzoek dat ik vandaag kan presenteren, 
maar ook het proces erachter is belangrijk. Dit rollercoaster avontuur heb ik namelijk niet alleen beleefd, 
vele personen hebben me bijgestaan, zij het van aan de start, van op de zijlijn of bij de finish, zonder 
wie mijn doctoraat wellicht niet was geweest wat het nu is. Zoals de Dalai Lama het reeds zei: “The best 
things in life aren’t things”; daarom wil ik hier nog even tijd maken om enkele van deze personen in het 
bijzonder te bedanken.  
Lieven, bedankt voor het vertrouwen dat je 4,5 jaar geleden in me had toen je me als promotor onder je 
gezondheidseconomische vleugels nam. Bedankt om mij de kans te geven om aan dit doctoraat te 
beginnen en het te kunnen beëindigen. Het werken op verschillende projecten tegelijkertijd was niet 
altijd even makkelijk, maar ik heb erdoor leren plannen, leren omgaan met stress, en leren werken naar 
verschillende deadlines toe. Bedankt voor je begeleiding, voor het ontwarren van m’n hersenkronkels 
wanneer het nodig was, voor de kansen die ik kreeg om op buitenlandse congressen te gaan 
presenteren, voor de vrijheid die je me gaf. De voorbije jaren hebben me niet alleen op wetenschappelijk 
gebied heel veel bijgebracht, maar ook op persoonlijk vlak.  
Koen, ook jou wil ik bedanken om co-promotor te willen zijn van m’n werk. Bedankt voor je kritische blik 
en bijsturing waar nodig. Je stond (en staat nog steeds) altijd paraat om mee na te denken, om papers 
en rapporten na te lezen, om externe meetings bij te wonen en om te ondersteunen waar nodig. Bedankt 
voor je hartelijke telefoontjes en je humor, telkens een leuke uitlaatklep.  
Daarnaast wil ik de leden van de examencommissie bedanken. Dr. De Cocker, Prof. Dr. Deforche, Prof. 
Dr. Simoens, Prof. Dr. Vandijck, Prof. Dr. Uyl-de Groot, bedankt voor de tijd die jullie investeerden in 
het lezen en beoordelen van m’n proefschrift. Jullie vragen en commentaren, en de aanpassingen die 
ik maakte als gevolg ervan, zijn zeker een meerwaarde geweest voor de opbouw van m’n proefschrift.  
Ook een grote dankjewel aan mijn ‘buroomies’, wie ik de laatste jaren wellicht meer zag dan wie dan 
ook. Toen ik in maart 2012 startte, deelde ik een bureau met Jeroen, Nick en Delphine. Jeroen, ik 
apprecieer je directheid, ookal betekende dat dat het zich soms tegen me keerde. Ik zal de luchtige 
gesprekken, interessante discussies, je nuchtere blik op de zaken, maar ook impulsieve uitspraken 
missen. Nick, als ik een stressmomentje had, wist ik dat even een praatje met je moest komen maken, 
want jouw kalmte bracht me weer tot rust. Bedankt, want dat had ik soms nodig. Delphine, ik was heel 
blij dat er naast dat testosteron ook een vrouwelijke collega was. Ik heb veel hulp van je gekregen en 
ben je daar zeer dankbaar voor. Naast de werkgerelateerde zaken, kon/kan ik ook altijd bij je terecht 
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voor een praatje over de alledaagse dingen. Je bent niet alleen een collega, maar ook een vriendin en 
ik hoop dat ik je ook na december nog vaak hoor. Eind 2014, begin 2015 werd onze unit 
gezondheidseconomie versterkt met enkele nieuwe collega’s: Kristof, Sophie, Philip en Janne. En ik 
moet toegeven, Lieven weet ze goed te kiezen want jullie waren én een leuke uitbreiding van de unit én 
de balans West-Vlaming niet-West-Vlaming bleef positief. Het leuke is dat we allemaal verschillende 
karakters zijn, wat vaak tot boeiende, maar ook grappige gesprekken leidde, waarvan ik hoop dat ik ze 
nog via Whatsapp zal kunnen meevolgen. Het was heel fijn om jullie als collega’s te hebben en ik ben 
er zeker van dat ik binnenkort kan terugkomen om jullie hier te zien staan. Ruben, jij bent de jongste 
telg in de unit. Ik weet zeker dat er veel potentieel in je zit en wens je dan ook succes met je verdere 
onderzoek. Bedankt ook aan alle andere collega’s van de vakgroep Maatschappelijke 
Gezondheidkunde, voor de vele leuke praatjes de voorbije jaren.  
Verder wil ik de opdrachtgevers van de verschillende studies bedanken voor hun vertrouwen en de 
vlotte samenwerking. Prof. Brochez, Isabelle en Maaike, bedankt voor de fijne interne samenwerking 
aan de studies omtrent kankerscreening. 
Uiteraard wil ik ook een woordje van dank richten tot m’n vrienden van Gent, van 
Antwerpen/Hoogstraten en de schoolvriendinnen van de westhoek. Bedankt allemaal voor de  
uitstapjes, etentjes, feestjes en jullie onvoorwaardelijke steun! Ik besef dat ik mezelf gelukkig mag 
prijzen met jullie aan m’n zij.  
Minstens even belangrijk zijn mijn familie en schoonfamilie. Papa en mama, dankjewel voor jullie steun 
in alles wat ik doe, voor de kansen die jullie me al mijn hele leven bieden, voor jullie grenzeloos 
vertrouwen en begrip, zonder dewelke ik hier vandaag wellicht niet had gestaan. Marc en Karin, een 
dikke dankjewel voor de warme thuis die ook jullie me geven. Opa, oma, meme en pepe, bedankt voor 
jullie betrokkenheid en interesse in m’n onderzoeken. Meme en pepe, jullie hebben vorig jaar nog een 
lezing van Lieven bijgewoond, het motto ‘nooit te oud om bij te leren’ is iets wat ik graag van jullie 
overneem.  
Last but not least, wil ik heel graag m’n vriend Hans bedanken. Hans, m’n hansjepansje, ook voor jou 
was mijn doctoraat een hele beproeving. Ik nam m’n werk soms mee naar huis, en ik liet soms uitjes 
met je vallen in functie van m’n doctoraat, waarvoor een welgemeende sorry. Ik weet dat het in periodes 
moeilijk was om me te blijven steunen, maar desondanks ben je het wel blijven doen. Zeker in de 
eindfase heb je me helpen doorbijten, door je geloof in me op de nodige momenten te herhalen en je 
feedback te geven op bepaalde stukken die je hebt nagelezen. De combinatie van doctoraatstress en 
zwangerschapshormonen was niet altijd evident, maar bedankt om er voor me te zijn. We zijn een goed 
team en ik hoop dat we dat altijd zullen blijven. 
          
